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Many cellular events are regulated by G-protein coupled receptors (GPCRs). In order to maintain 
homeostasis, GPCR kinases (GRKs) selectively recognize and phosphorylate activated GPCRs for 
internalization. There is growing evidence that both GRK2 and GRK5 have roles in pathological 
heart failure. Previous work has demonstrated that targeting GRK2 can reduce the amount of 
receptor desensitization that occurs in cardiomyocytes and increase cardiac output. However, the 
close homologue GRK5 is equally well expressed in cardiac tissue. Herein, we describe our efforts 
toward developing selective GRK5 inhibitors using covalent engagement of a non-conserved 
cysteine to elucidate the role of GRK5 in cardiovascular diseases.  
Initially, we had identified a lead compound with a pyrrolopyrimidine scaffold 
(GSK2163632) from the GSK Published Kinase Inhibitor Set that had modest potency for GRK5 
and GRK2. Due to the similarity of the hinge region and binding pockets of GRK2 and GRK5, an 
approach towards building out GRK2 activity had to be based upon non-conserved residues such 
as Cys474. We used this approach to build covalent, and thereby selective, GRK5 inhibitors. Our 
initial designs allowed us to identify one strongly covalent inhibitor based on the 
pyrrolopyrimidine scaffold (CCG-265328) which features a weak electrophile and has 90-fold 
selectivity for GRK5 over GRK2. Previously, engagement of Cys474 was confirmed through 
tandem MS/MS, suggesting that this covalent interaction is driving selectivity. Structure-activity 
relationships (SAR) also revealed that linker length and degrees of freedom had less of an effect 
on covalent engagement than the reactivity of the electrophilic warhead. Additionally, SAR 
revealed that without a warhead, the modified pyrrolopyrimidine scaffold (CCG-264561) had only 
modest potency.  
We tried to improve potency through exploration of two separate scaffolds mined from a 
virtual screen and the literature respectively. From a virtual screen an aminopyridine compound 
(Chembl-1607632) was independently synthesized and a few analogues were created. We 




However, the indolinone scaffold derived from the literature proved a much more tractable 
option, with low nanomolar potency for the independently synthesized reference compound 
(CCG-271421). Interestingly, the warhead SAR developed in the pyrrolopyrimidine scaffold 
proved to be intractable. Indeed, the most reactive warheads, the haloketones (CCG-273220, 
CCG-273463) were considerably more potent and selective than the pyrrolopyrimidines (CCG-
265328). In fact, the haloketones (CCG-273441) proved to be the most potent and selective 
covalent GRK5 inhibitors (IC50 = 3.8 nM, 1300-fold selective over GRK2) to date. Thus, we have 
demonstrated through development of the pyrrolopyrimidine series (CCG-265328)  that Cys474 
can serve as a covalent handle to convey high levels of selectivity through covalent engagement 
with a warhead and that this covalent strategy is transferable to different scaffolds known in kinase 
drug discovery, provided these scaffolds have sufficient inherent potency.  
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Chapter 1: Building an Arsenal: The Need for Covalent GRK5 Inhibitors 
1.1 G Protein-Coupled Receptor Kinase 5 (GRK5) is Involved in Multiple Disease States 
G protein-coupled receptor kinases (GRKs) play a crucial role in cellular homeostasis, due to 
their ability to regulate G protein coupled receptor (GPCR) signaling. Given the importance of 
their functions, GRKs are often investigated in multiple clinically relevant disease states, such as 
neurodegenerative disorders, various cancers, diabetes, and cardiovascular diseases.  
1.1.1 GRK5 Plays a Dual Role in Neurodegenerative Diseases 
 G Protein-Coupled Receptor Kinase 5 (GRK5) has been traditionally studied within 
cardiovascular diseases. However, there is growing evidence the GRK5 is involved in 
neurodegenerative disorders, such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). 
 Parkinson’s Disease (PD) has hallmark symptoms including involuntary muscular 
contractions (tremors) and non-motor associated symptoms such as cognitive impairment.1 
Cognitive impairment in PD is associated with increased morbidity and mortality across patient 
samples.2 The pathological process of PD has been linked to development of dementia over time 
as patients experience degeneration of the basal forebrain cholinergic nuclei, degeneration of the 
brainstem dopaminergic neurons and the presence of cortical Lewis bodies (LBs).3 Deposition of 
LBs is strongly associated with α-synuclein (αSyn). αSyn is a soluble protein localized at the 
presynaptic terminals within the nervous system.4,5 Phosphorylation of αSyn at Serine 129 
(Ser129) has been identified as an essential step in producing a toxic environment for 
dopaminergic neurons and leads to aggregation of the protein and eventual deposition of LBs.. 
This series of events is key to the pathogenesis of sporadic PD (sPD). It has been reported that 
casein kinase 1 (CK1), CK2 and GRKs can control this event. Of the GRKs, GRK5 has been 
identified as one of the kinases .
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 Thus, GRK5 inhibition thereby eliminates the phosphorylation of αSyn which may present a new 
path towards PD treatment.  
 Similar to PD, Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by 
degeneration of neurons leading to progressive memory loss. However, AD is not associated with 
muscular tremors or loss of muscular tone. Given that the mechanisms which trigger this disorder 
are complex, treatments which target the underlying mechanisms of AD are rare. However, some 
of the underlying mechanism is understood. For example, GRK5 has been identified as the kinase 
responsible for regulating the desensitization of the M2/M4 receptors.6  
 However, it may not be advantageous to target GRK5 as an AD treatment. Recent studies 
have shown that reduced membrane bound GRK5 increases soluble β-amyloid in vitro.7,8 Studies 
have also shown that GRK5 dysfunction mediates tau hyperphosphorylation, leading to 
accumulation of neurofibrillary tangles within the hippocampus.9,10 Taken together, these studies 
suggest that GRK5 could be an attractive target for PD. However, this path should be approached 
with caution as its positive effects do not extend to AD.  
1.1.2 GRK5 Has Been Revealed to Affect Cancer Cell Migration and Treatment Sensitivity 
Various cancers have been some of the hottest targets within the pharmaceutical field for 
the past twenty years, since the release of the blockbuster drug Gleevec in 2001. Given the rise of 
drug resistance there is an urgent need to validate new targets and develop new therapeutic agents.  
 Unsurprisingly, the GRKs have recently become interesting targets for decreasing 
tumorigenesis and metastasis due to their ability to regulate cellular signaling pathways in a similar 
fashion to the receptor tyrosine kinases (RTKs). Given the complexity of each system, the exact 
effect of altering GRK functions must be determined on a case-by-case basis.11,12  
 Fortunately, there are some RTK inhibitors (RTKIs) which are also active against the 
GRKs. For example, Sunitinib, a FDA approved RTKI for use in cancer, has been shown to be 
active against GRK5.13 Recent studies have shown that when Sunitinib is used to inhibit GRK5 in 
triple negative breast cancer (TNBC) cells, lack of GRK5 function limits the migration of TNBC 
cells to unaffected areas.14 Such efforts illustrate that GRK5 inhibitors could be used to limit the 
progression of the cancer. This indirect effect on breast cancer cells extends to more than just 
metastasis.  
 In a separate study, GRK5 was studied for its ability to restore potency to Paclitaxel, a 
frontline cancer treatment, in drug resistant TNBC (MDA-MB-231) cells. GRK5  knockouts 
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(GRK5KO) were created and then treated with Paclitaxel whereby the cells were shown to have a 
susceptibility to treatment. This sensitivity to treatment is associated with increased levels of 
cellular acetylated α-tubulin thereby increasing sensitivity of the TNBC cells to the apoptotic 
effects of Paclitaxel. Increases in α-tubulin have been linked to decreased histone deacetylase 6 
(HDAC6) activity, thus providing evidence that decreases in HDAC6 activity may be key to 
sensitizing drug resistant TNBC cells to treatment. As GRK5 is known to phosphorylate HDAC5 
and HDAC6, there is evidence that GRK5 could be an interesting upstream target to control 
sensitization of TNBC cells to frontline treatments.15 Taken together, this evidence suggests that 
selective GRK5 inhibitors could be effective in multiple combination therapies. 
1.1.3 GRK5 Deficiencies Leads to Insulin Resistance 
 Diabetes is a metabolic disorder that induces hyperglycemia from defects in insulin release 
or insulin action. Due to complex factors (socio-economic status, genetic pre-disposition, and 
environment to name a few), this disorder has risen in prevalence worldwide. Experts attribute this 
public health crisis with the rise of obesity over the past 30 years.16,17 While obesity and diabetes 
are intimately linked, canonical pharmacological efforts to combat obesity have largely been 
ineffective. However, there is a thriving industry for new diabetes drugs, as long term exposure to 
second-generation diabetes medications has been linked to a higher risk for cardiovascular 
events.18  Other drugs, as part of the fourth-generation of the diabetes arsenal are known to target 
either the sodium-glucose co-transporter 2 (SLGT2) or glucagon-like peptide 1 (GLP1). Examples 
approved by the FDA include empagliflozin and liraglutide for use in diabetes patients to reduce 
cardiovascular risk.19 Thus, there is an urgent need for a new generation of diabetes drugs which 
can also treat co-morbid cardiovascular diseases.  
 Ullrich and coworkers have described a GRK5 inhibitor that has been shown to increase 
insulin release, thereby providing treatment of diabetes.13 As GRK5 is one of the protein kinases 
known to be highly expressed in cardiovascular tissues and is thought to control cardiomyocyte 
contractility, this study provides a possible new avenue to treating these two co-morbidities 
concurrently.  
1.1.4 GRKs Have a Critical Role in Cardiovascular Diseases 
Cardiovascular disease is the leading cause of death among men and women within the 
United States.20 Of those effected by cardiovascular disease, about 6.1 million have a type of 
cardiomyopathy and 6.2 million over the age of 20 years old have heart failure (HF) according to 
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the American Heart Association.21 Indeed, roughly 46% of the adult population have hypertension 
and 38.2% have high cholesterol, both of which indicate an increased risk for developing more 
serious CVDs such as heart failure. Currently, there are around 915,000 new cases of heart failure 
diagnosed each year, according to a 2019 AHA survey.21,22 Given these statistics, there is an 
incredible need to update the current strategies used to treat cardiovascular disease.  
 Current treatments for HF commonly include the use of angiotensin II converting enzyme 
inhibitors (ACE inhibitors) and beta blockers (β-blockers). These treatments options are effective 
for HF management; however, they do not address the underlying mechanism that cause 
progressive HF. ACE inhibitors work by acting within the Renin-Angiotensin-Aldosterone 
Secretion (RAAS) system that controls blood pressure. When a drop in blood pressure occurs, the 
RAAS system triggers a release in renin, which in turn causes ACE to convert Angiotensin I to 
Angiotensin II. Angiotensin II then goes on to trigger the release of vasopressin causing a 
restriction of the vasculature and subsequent increase in blood pressure. Thus, ACE inhibitors alter 
blood pressure by avoiding the release of vassopressins, however, this class of compounds do not 
counteract underlying contractile dysfunctions, which are key to progressive HF  (Figure 1.1).23 
 
Figure 1.1 Renin Aldosterone Angiotensin system (RAAS) that happens in response to a drop in blood pressure.  
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 In a properly functioning heart, cardiac performance increases as preload increases. 
Preloading, as measured by left ventricular pressure is linked to cardiac performance (measured as 
cardiac output) by the Frank-Starling Law.24,25 In HF, the heart can no longer access the proper 
Frank-Starling mechanism. Instead, at preload, the left ventricle stroke volume is lower than the 
level observed in a normal functioning left ventricle leading to incomplete ventricular emptying. 
Consequentially, this residual volume leads to progressive stretching of the myocardial fibers of 
the left ventricle. As this cycle continues, the volume preloaded for each successive stroke is higher 
in order to preserve cardiac output. Thus, the muscle workers harder  meanwhile the left ventricle 
fibers continue to stretch until the heart can no longer pump enough volume to maintain cardiac 
output.24,26 Therefore, to break this cycle of progressive ventricularly weakening would be an 
effective way to treat the underlying mechanism of HF and possibly help to strengthen the 
stretched left ventricle wall. 
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 Currently, there is a series of compounds, GRK2 inhibitors, which are known to increase 
cardiomyocyte contractility in this manner that could be used to strengthen the weakened left 
ventricle wall. Waldschmidt et. al. were able to show that GRK2 inhibitors, such as CCG-215022, 
can increase cardiomyocyte contractility following a treatment with isoproterenol.27,28 This study 
indicates that GRKs, which are involved in signal mediation within cardiomyocytes, are 
potentially potent targets for next generation of cardiovascular treatments. 
 Of the seven known GRKs, GRK2/3 and GRK5/6 are the most ubiquitously expressed, 
with GRK2 and GRK5 being the most highly expressed within cardiovascular tissues. GRK2 and 
GRK5 are known to phosphorylate the free C-terminal tail of G protein-coupled receptors 
(GPCRs) within cardiomyocytes. Cardiac GPCRs are activated by circulating catecholamines 
(norepinephrine and epinephrine), which causes the release of the heterotrimeric G-protein 
complex, thereby inducing signal amplification. The free tail of the GPCR is then phosphorylated 
 
Figure 1.2  Simplified diagram of GPCR desensitization. Catecholamines (purple) bind the GPCR (green), causing the 
release of the heterotrimeric g-protein complex (orange) thereby inducing cellular signaling. The free GPCR tail is 
then phosphorylated by GRK2 or GRK5 (lime) (4 phosphates shown here as one ball for simplicity, pink). The 
phosphorylated GPCR then recruits arrestins (yellow) causing endocytosis. Once endocytosed, the GPCR is then 
degraded, and therefore removed from the cellular surface. 
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by GRK2 or GRK5 triggering the recruitment of arrestins from the cytoplasm that promote 
receptor endocytosis. Once internalized, GPCRs can either be recycled back to the cellular 
membrane or degraded. In the case of HF, GPCRs tend to be degraded effectively lowering the 
number of receptors at the cell surface. A lack of receptors at the cell surface in turn leads to an 
increase in endogenous ligands (catecholamines) to result in maintained cardiac output (Figure 
1.2).29  
 The work done by Waldschmidt et. al. indicate that by targeting GRK2, cardiac 
contractility can be improved over time to restore ventricular function.27,28,30 However, there is a 
lack of knowledge as to the exact role of GRK5 within the cardiovascular system. GRK5 is known 
to act in a similar fashion to GRK2, phosphorylating GPCRs during desensitization. However, 
GRK5 is unique in that it can use a nuclear translocation domain to cross the nuclear membrane. 
Once inside the nucleus, GRK5 phosphorylates HDAC5 initiating the transcription of hypertrophic 
genes through myocyte enhancer factor 2 (MEF2). Thus, GRK5 is implicated in both progressive 
HF and hypertrophic cardiomyopathy.31  
 Given the role of GRK5 in multiple CVDs, development of a selective GRK5 inhibitor is 
of interest. Waldschmidt et. al. have tried to create GRK5 inhibitors with limited success. It was 
shown that GRK5 activity can easily be built out of GRK2 inhibitor scaffolds as GRK5 has a 
narrow and unaccommodating active site. For this reason, GRK2 activity has been a major block 
to developing GRK5 selective inhibitors. Canonical structure-based design efforts have failed to 
produce a truly GRK5 selective inhibitor. Therefore, a new approach is needed to create an arsenal 
of GRK5 selective inhibitors.  
1.2 Designing GRK5 Inhibitors Utilizing A Covalent Approach 
1.2.1 GRK Homology and Sequence Similarity Presents Challenges for Subfamily Selectivity 
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The seven mammalian GRKs are split into three distinct subfamilies. The GRK1 subfamily 
consists of GRK1 and GRK7, both of which are primarily expressed in ocular tissue. The GRK2 
subfamily, also known as the β-adrenergic receptor kinases, consists of GRK2 and GRK3, both of 
which are expressed ubiquitously. Finally, the GRK4 subfamily consists of GRK4, GRK5 and 
GRK6. Of these three kinases, GRK5 and GRK6 are expressed ubiquitously, while GRK4 is 
expressed primarily in sexual organs.32 GRK2 and GRK5 are the most highly expressed GRKs in 
cardiovascular tissues.33 Overall, the GRKs are highly similar, with a conserved structural core 
consisting of the RH domain and the kinase domain. The two domains work in tandem to 
phosphorylate GPCRs. The RH domain maintains the small lobe of the kinase domain in a state 
that allows phosphorylation by the kinase domain (Figure 1.3, reprinted with permission from 
Science Direct).34 The kinase domain itself contain contains the ATP binding pocket whereupon 
binding ATP, a phosphate can be transferred to the GPCR tail and ADP is released as a product. 
The C-terminal extension of the GRKs, characteristic of AGC kinases, are variable but these 
elements are thought to regulate kinase activity in a manner similar to other AGC kinases.35,36 
Kinase inhibition efforts generally focus on the inhibition of the orthosteric active site (kinase 
domain).  
1.2.2    GRK5 Structure – Annotated 
 
Figure 1.3 Sequence homology of the 7 mammalian GRKs, divided by subfamily.34 
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 Similar to other kinases, GRK5 has a large lobe and a small lobe that are connected via the 
hinge loop (Figure 1.4). Additionally, there is the activation loop, which does not need to be fully 
phosphorylated to achieve an active confirmation.34 Other key features include the active site tether 
(AST) loop, a piece of architecture that wraps down over the face of the kinase, passing over the 
ATP binding pocket when GRK5 adopts a closed, active confirmation.  
 The GRK5 orthosteric site features a narrow and slightly polar binding pocket, with the 
majority of the hydrophobicity located closest to the hinge loop. Within the binding pocket there 
are several key features, including the hinge donor and hinge acceptor. Interactions with these two 
amino acids are key to achieving binding for ATP. Also, within the binding pocket is the 
Gatekeeper residue, which resides just behind the hinge acceptor, and guards a secondary 
hydrophobic pocket, herein referred to as the back hydrophobic pocket or deeper hydrophobic 
pocket. The gatekeeper reside determines the size and shape of this deeper hydrophobic pocket in 
kinases.37  
1.2.3 Canonical and Non-Canonical Kinase Drug Design 
 
Figure 1.4 Annotated structure of GRK5 (cyan) shown with CCG-215022 (orange carbons) bound to the active site. AST 
loop highlighted in purple.  
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Before the introduction of Gleevec (May 2001) kinases were considered to be 
“undruggable” targets due to the highly conserved nature of the orthosteric binding pocket.38 Since 
the introduction of Gleevec, there has been a rapid expansion of kinase drug discovery campaigns 
leading to the creation of numerous kinase inhibitors that fall into four different types.  
Type I kinase inhibitors were the first-in-class examples of kinase targeted drugs. Type I 
kinase inhibitors bind in the orthosteric site and are ATP competitive. There are numerous 
examples of type I inhibitors that have been approved by the FDA. There is a majority of kinase 
inhibitors that adhere to this design template, possibly due to the initial bias set by use of 
phosphorylated kinases in biochemical assays that led the initial kinase drug discovery programs. 
These inhibitors interact with the hinge donor and acceptor residues in a pattern that mimics the 
binding pattern of ATP. It is important to note that although the binding pattern is similar to ATP, 
different scaffolds can be used to achieve this type I architecture. For example, Sunitinib, a FDA 
approved tyrosine kinase inhibitor (TKI) is a type I kinase inhibitor but features an indolinone 
scaffold in place of a purine scaffold.39  
Type II inhibitors are similar to Type I inhibitors, in that these compounds bind to the ATP 
site. However, Type II inhibitors exploit structural elements to boost potency and selectivity. Type 
II inhibitors bind a kinase in the inactive state, with the DFG-out conformation. Having the DFG 
residues in the “out” conformation results in an opening of the deeper hydrophobic pocket. Filling 
this secondary hydrophobic pocket with different pendants can lead to greater potency and 
selectivity for Type II inhibitors. The Type II inhibitor scaffold is exemplified in Gleevec, which 
features the hydrogen bonds to the αC-helix and the DFG-residues needed to unveil the secondary 
hydrophobic pocket.37,40,41 
Type III and Type IV kinase inhibitors are allosteric in nature.42 Type III kinase inhibitors 
are non-ATP competitive inhibitors as they bind outside the ATP binding pocket, in between the 
cleft of the large and small kinase lobes adjacent to the orthosteric site. Type IV inhibitors are also 
not known to bind the orthosteric site of a kinase. Rather, Type IV inhibitors bind outside the cleft 
and the phosphoacceptor sites.43 
These types of kinase inhibitors constitute the canonical set of design templates. Recently, 
given the rise of resistance-conveying mutations, the development of a new type of kinase 
inhibitors has appeared with the resurgence of covalent inhibition. These new covalent kinase 
inhibitors utilize one of the aforementioned design templates but exploit a piece of kinase 
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architecture prone to chemical interactions to afford ultra-selective compounds. This new strategy 
has opened the door to developing inhibitors for previously inaccessible targets.  
1.3 Covalent Inhibitors Offer a New Path Towards Selective GRK5 Inhibitors 
1.3.1 FDA Approved Tyrosine Kinase Inhibitors Provide a Plan for GRK5 Inhibitor        
Development 
A key point in this campaign is 
the lack of truly GRK5 specific 
inhibitors. However, there are 
strategies that can be pursued to 
achieve GRK5 selectivity, chief 
among them is covalent 
inhibition. There are more than 
40 FDA-approved covalent 
inhibitors currently on the market.44  Notable examples include the recent FDA approved Ibrutinib, 
a covalent inhibitor of BTK which treats non-small cell lung cancer and compounds such as 
Afatinib and Osimertinib which are FDA-approved inhibitors of EGFR and treat various types of 
cancer (Figure 1.5). The need for these new covalent inhibitors is driven primarily by the rise of 
clinical resistance to the original non-covalent inhibitors. For example, Osimertinib was developed 
from a known non-covalent EGFR inhibitor, and carries a covalent warhead to convey activity 
against EGFR T790M, the most clinically relevant mutation in EGFR. Osimertinib binds with 
Cys797, which exists on the hinge loop of the kinase domain, and has been proven to effectively 
reverse the loss of potency against the EGFR-T790M mutant.45–48 This covalent strategy, targeting 
a non-conserved cysteine residue within the binding pocket, has grown popular as it allows for 
minor modifications to an already optimized scaffold to convey large boosts in potency and 
selectivity as well offering the ability to lower the dose of compound needed to achieve a clinical 
effect.  
1.3.2 Cysteine as a  Handle for Selective Covalent Inhibition 
Cysteine plays critical roles in protein folding and establishing tertiary protein structure, 
despite this, the presence of cysteine codons within the genetic code (i.e.. coding genes) is 1.9%, 
making it a rare, and therefore, ideal handle for covalent interaction.44 Targeting a cysteine residue 
for covalent interaction is not straightforward as its pKa values are highly variable, making it 
 
Figure 1.5 Structures of FDA approved Covalent TKIs 
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uncertain whether solvent exposed cysteines will be available for engagement. This variability 
means that each inhibitor is designed to fulfill one set of conditions for reacting with a specific 
cysteine and is unlikely to interact with other surface cysteine residues.  
This level of selectivity allows the newly constructed covalent inhibitors to have a lower 
level of toxicity, which has traditionally been one of the most troubling side effects of covalent 
inhibitors. While idiosyncratic toxicity cannot be predicted a priori, the ability to lower the dose 
of a highly potent and selective inhibitor allows for less toxicity arising from hitting off-targets 
such as hERG, an ion channel which controls cardiomyocyte contractility (QT).49 Therefore, new 
classes of covalent inhibitors offer an alternative path towards optimized potency, selectivity and 
resilience against arising clinical resistance.  
Conveniently, the warhead design for cysteine engagement has already been fairly well 
studied by several groups. As hard-soft acid-base theory (HSAB) states that each nucleophile 
needs a matched electrophile, the warheads for each residue (Cys, Lys, Arg etc.)  is highly specific, 
and sensitive to changes in electrophilicity or strength of the nucleophile.50 Covalent warhead 
design also deals with vector length and angle, as there can be no covalent interaction if the 
warhead is not within striking distance of the nucleophile (generally between 2.5-5Å) or if the 
angle of approach does not match the ideal Bürgi-Dunitz angle (107°).51 Given the various 
parameters to keep in mind, multiple warheads must be tested for each individual scaffold. 
There are a few well known covalent warheads which commonly appear in known covalent 
inhibitors (Figure 1.6). The most common examples of cysteine specific warheads include classical 
Michael acceptors such as acrylamides and butynoic amides. Given the utility of the classic 
acrylamide, new warheads have been designed to act not only as a covalent modifier but also as 
internal bases. In the case of Afatinib, which features a N,N-dimethylaminobutenoic amide, the 
terminal dimethyl nitrogen acts as an intermolecular base designed to deprotonate the cysteine 
nucleophile of the protein to boost reactivity against the electrophile.47 This warhead, pioneered 
by Boehringer Ingelheim, has quickly gained traction as a popular warhead to test in covalent 
 
Figure 1.6 Selected cysteine targeting covalent modifiers, arranged by reactivity to nucleophiles. 
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inhibitor programs as it allows for a boost in reactivity of nucleophile rather than the electrophile. 
Highly electrophilic Michael acceptors are known to have promiscuous behavior which can lead 
to idiosyncratic toxicities. Other popular warheads include vinyl sulfones, epoxides and 
haloketones, which are some of the most reactive warheads designed yet but can offer the same 
levels of selectivity without altering the nucleophilicity of the targeted cysteine residue, which is 
useful in targeting cysteines located on flexible pieces of kinase architecture.52–58 
1.3.3 Other Amino Acid Handles for Covalent Inhibition 
Cysteine is not the 
only amino acid residue used 
in designing covalent 
inhibitors. In fact, any amino 
acid which features a potential 
nucleophile can be targeted for covalent engagement, including lysine and arginine, which both 
feature nitrogen nucleophiles. As these nucleophiles are generally less reactive than cysteine, they 
require different electrophiles to produce a covalent interaction. Similar to their cysteine 
counterpart, nitrogen and oxygen specific warheads exist as a common set to be used in developing 
covalent warheads in a case-by-case manner (Figure 1.7).44 
1.3.4 Reversible Covalent Inhibition is Expanding the Frontier of Covalent Kinase Drug Design 
Perhaps one of the biggest impacts in the revival of covalent inhibitors has been the 
development of reversible covalent inhibitors. Prior drug discovery efforts have focused on 
irreversible inhibition, but these compounds can have various issues. Irreversible inhibition means 
that residence time within the active site is limited by the turn-over time of the protein target. 
However, it may be advantageous to have a residence time that is shorter than the protein turn-
over time, thereby keeping the fraction of unbound drug high enough to increase exposure. In these 
cases, tunable reversible warheads offer a unique solution. Pioneered by Taunton and co-workers, 
these reversible warheads can form a covalent interaction with a cysteine residue, but over time 
 
Figure 1.7 Selected set of Lysine (nitrogen) targeting warheads. 
 
Figure 1.8  Selected set of reversible covalent warheads, as pioneered by Taunton et. al. 
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and with the addition of a second nucleophile such as water, can reverse this covalent interaction 
to release the inhibitor.59–61 This tunable residence time offers a solution to the problem of rapidly 
eliminating proteins labelled with irreversible covalent warheads and protein manufacturing, 
which is a common mechanism of resistance.62 
Taunton and co-workers have detailed the impact of various branching pendants on the 
residence time of reversible covalent warheads. There now exists a set of known tunable reversible 
warheads that can be employed within covalent inhibitor programs to further expand the arsenal 
of covalent inhibitors for each case (Figure 1.8).59 These reversible covalent warheads are of 
interest to us as they could be used to mitigate the potential pharmacokinetic toxicities.    
1.4 Using a Covalent Strategy GRK5 Selectivity over GRK2 Can Be Achieved 
1.4.1 GRK5 Inhibitor Design Strategy 
Previous work to validate GRK5 as a pharmacological target have been limited to genetic 
knockdown or knockout studies.63–65 Such studies have indicated that GRK5 has utility in many 
diseases, but a truly selective inhibitor has not been independently confirmed.66 Of the known 
GRK5 inhibitors, few are subfamily selective against GRK2.67,68 Perhaps the best example of a 
GRK5 inhibitor are the pan-GRK2/5 inhibitors, CCG-215022 and CCG-258747, created by 
Waldschmidt et. al.27,28  
 Much of the challenge of achieving a GRK5 selective inhibitor hinges on the high level of 
similarity between the GRK2 and GRK5 active sites. GRK2 and GRK5 share a similar hinge 
region and have the same residues as the hinge donor and acceptor, Met 266 and Thr 264 
respectively. The active site of GRK2 is larger and more hydrophobic than that of GRK5; for this 
reason, GRK5 activity is easily built out of GRK2 inhibitors.69  
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 The  aforementioned examples of covalent inhibition use cysteines within the ATP binding 
site (Figure 1.9). Typically, the sites of covalent engagement have been on the hinge loop (yellow), 
the roof of the ATP binding pocket (orange) or the P-loop (green). Other sites for covalent binding 
have included the DFG region (dusty blue). However, GRK5 does not feature a cysteine within 
the ATP binding pocket. Fortunately, GRK5 does have a non-conserved cysteine close to the ATP 
binding pocket, Cys474 which is found on the AST loop.70 The AST loop (cyan) where Cys474 is 
located is outside of these zones but is still predicted to be within reach. Additionally, Cys474 is 
only present in GRK4 subfamily members, making it an ideal candidate for a covalent handle. The 
easiest way to begin a campaign to build GRK5 covalent inhibitors is through a crystal structure 
of GRK5 with the covalent handle visualized. Although GRK5 has been crystallized a handful of 
times, there are no structures in which Cys474 is visualized.71,72 Fortunately, GRK6, a subfamily 
member, has been crystallized in what is believed to be an active conformation, and Cys474 is 
visible within this structure (Figure 1.10).71 This GRK6 structure reveals that the thiol group of 
Cys474 is located within the flexible active site tether (AST) loop of the kinase domain and is 
positioned adjacent to the ATP-binding site, at least when the kinase domain adopts a closed, active 
conformation. 
 
Figure 1.9  Cysteine Map, developed from the GRK5 structure (PDB: 4WNK). (a) full GRK5 structure, (b) ATP binding pocket  
with CCG-215022 bound (orange carbons), zoomed in view. Previously, covalent inhibitors have been designed to hit cysteines 
within the active site. Key areas of previous development have included the P-loop (green), the roof of the ATP pocket (orange), 
the hinge/front loop (yellow), and the DFG region (dusty blue). The AST loop where Cys474 is located is shown in cyan.  
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1.4.2 GRK5/6 Overlay Model Enables Rationale Design 
 An overlay model between GRK5 and GRK6 (PDB entries 4WNK and 3NYN 
respectively) can guide drug design until a crystal structure of GRK5 bound to a covalent inhibitor 
can be obtained.71,72 The model allows visualization of the covalent handle, Cys474, thereby filling 
in a crystallographic blind spot. From this point, initial drug discovery efforts could begin, from 
lead selection to development of advanced chemical probes. 
1.4.3 Known GRK5 Inhibitors Will Serve as Initial Lead Compounds in This Campaign 
With a model in hand, lead selection for the GRK5 inhibitor campaign can begin. The development 
of other covalent inhibitors traditionally begins with non-covalent inhibitors that can be modified 
to carry a covalent warhead.73 The most obvious choice for the GRK5 campaign is CCG-215022, 
the ligand that was used to obtain the GRK5 crystal structure. CCG-215022 is a known 
 
Figure 1.10 GRK5 (blue)/GRK6(purple) overlay model with CCG-215022 bound to GRK5 shown in dark blue. Cys474 (green carbons) is 
only visible in GRK6, as the AST in GRK5 is not visible. In a closed, active conformation the AST loop positions Cys474 within reach of 
the active site. 
17 
 
GRK2/GRK5 inhibitor with mild GRK2 selectivity (GRK2 Ki = 150 nM, GRK5 Ki = 350 nM, 2-
fold GRK2 selective).28 This particular inhibitor features an indazole as the main hinge binding 
motif and has an optimized pendant that extends into the deeper hydrophobic regions of GRK2 
and GRK5. Although this inhibitor has the intrinsic potency needed to run a successful discovery 
campaign, there remains the issue of appending a covalent warhead. Functionalization at the C3-
indazole position would be the ideal position, however the route to achieve this handle would be 
long and complicated, slowing the pace of design and discovery. Additionally, our initial designs 
placed these analogues outside the limits imposed by Lipinski’s rules.74 Although we acknowledge 
that there are examples of FDA approved drugs that fall outside Lipinski’s rule (Ibrutinib among 
them), these examples are still more the exceptions than the rule. Therefore, new scaffolds that are 
amenable to carrying a covalent modifier were needed. 
 Review of the current and historical literature surrounding GRK2 and GRK5 inhibitors 
gave rise to several new scaffolds that could be amenable to our GRK5 covalent campaign (Figure 
1.11).13,27,28,66,68 Of these scaffolds, the indazole series is a prominent member, as are the 
pyrrolopyrimidines (GSK2613632A), that were uncovered in a previous screen conducted by 
Homan et al. The pyrrolopyrimidine scaffold is known to be privileged in kinase drug discovery, 
and has been independently validated in have GRK1, GRK2 and GRK5 activity. GSK2613632A 
 
Figure 1.11 Current leads with known GRK2 or GRK5 activity.  
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is a potent inhibitor of GRK1 (Ki = 130 nM) with more modest potency against GRK2 and GRK5 
(logIC50 = -4.7, logIC50 = -5.5 respectively).68  
 Additional scaffolds with known activity against GRK2 or GRK5 include the 
aminopyridines (Chembl-1607632), natural product derived inhibitors (Balanol) and the 
indolinone scaffold (Ullrich-57). These scaffolds feature the desired activity, however, there are 
known drawbacks to these scaffolds. Firstly, the natural product scaffolds, including balanol have 
long synthetic sequences that are limit the production of potential analogues. The aminopyridine 
scaffold is known to be privileged in kinase drug discovery, making it a potentially good lead. 
However, the initial lead, Chembl-1607632 needs to be independently validated as it is known to 
possess activity against common kinase targets, including cMet. The same holds true for the 
indolinone scaffold lead, Ullich-57. The indolinone series is derived from a known receptor 
tyrosine kinase inhibitor (RTKI), Sunitinib. Sunitinib is known to be a pan-RTKI with an FDA 
black box warning. Thus, these particular lead scaffolds were deprioritized in order to avoid the 
potential issues that would come along with their development.  
1.5 Application of a Covalent Strategy May Yield Ultra Selective GRK5 Inhibitors 
1.5.1 Chapter Breakdowns and Project Flow 
As it stands, I have used both literature review and virtual screening to uncover three new scaffolds 
to develop a GRK5 covalent inhibitor program. In Chapter 2, I develop the pyrrolopyrimidines. In 
Chapter 3, I attempted validation of the aminopyridine scaffold. Chapter 4 describes the 
development of the indolinone series, wherein I describe the first examples of a nanomolar potency 
covalent, subfamily selective GRK5 inhibitor, and our efforts to expand this arsenal of GRK5 
inhibitors for the treatment of cardiovascular disease.  
1.6 References 
(1)  Nicoletti, G.; De Luca, V.; Tarantino, P.; Gagliardi, M.; Iannello, G.; Novellino, F.; 
Morelli, M.; Annesi, G.; Quattrone, A. Role of G-Protein Coupled Receptor Kinase 5 
Gene in Cognitive Impairment in Parkinson’s Disease. Psychiatry Res. 2015, 230 (3), 
975–977. https://doi.org/10.1016/j.psychres.2015.11.026. 
(2)  Aarsland, D.; Beyer, M. K.; Kurz, M. W. Dementia in Parkinson’s Disease. Curr. Opin. 
Neurol. 2008, 21 (6), 676–682. https://doi.org/10.1097/WCO.0b013e3283168df0. 
(3)  Harding, A. J.; Halliday, G. M. Cortical Lewy Body Pathology in the Diagnosis of 
Dementia. Acta Neuropathol. (Berl.) 2001, 102 (4), 355–363. 
https://doi.org/10.1007/s004010100390. 
(4)  Dev, K. K.; Hofele, K.; Barbieri, S.; Buchman, V. L.; van der Putten, H. Part II: Alpha-
Synuclein and Its Molecular Pathophysiological Role in Neurodegenerative Disease. 
Neuropharmacology 2003, 45 (1), 14–44. https://doi.org/10.1016/s0028-3908(03)00140-0. 
19 
 
(5)  Recchia, A.; Debetto, P.; Negro, A.; Guidolin, D.; Skaper, S. D.; Giusti, P. Alpha-
Synuclein and Parkinson’s Disease. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004, 18 
(6), 617–626. https://doi.org/10.1096/fj.03-0338rev. 
(6)  Liu, J.; Rasul, I.; Sun, Y.; Wu, G.; Li, L.; Premont, R. T.; Suo, W. Z. GRK5 Deficiency 
Leads to Reduced Hippocampal Acetylcholine Level via Impaired Presynaptic M2/M4 
Autoreceptor Desensitization. J. Biol. Chem. 2009, 284 (29), 19564–19571. 
https://doi.org/10.1074/jbc.M109.005959. 
(7)  He, M.; Singh, P.; Cheng, S.; Zhang, Q.; Peng, W.; Ding, X.; Li, L.; Liu, J.; Premont, R. 
T.; Morgan, D.; et al. GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic 
Neuronal Vulnerability. Sci. Rep. 2016, 6 (1), 1–12. https://doi.org/10.1038/srep26116. 
(8)  Lessel, D.; Muhammad, T.; Tena, T. C.; Moepps, B.; Burkhalter, M. D.; Hitz, M.-P.; 
Toka, O.; Rentzsch, A.; Schubert, S.; Schalinski, A.; et al. The Analysis of Heterotaxy 
Patients Reveals New Loss-of-Function Variants of GRK5. Sci. Rep. 2016, 6, srep33231. 
https://doi.org/10.1038/srep33231. 
(9)  Singh, P.; Peng, W.; Zhang, Q.; Ding, X.; Suo, W. Z. GRK5 Deficiency Leads to 
Susceptibility to Intermittent Hypoxia-Induced Cognitive Impairment. Behav. Brain Res. 
2016, 302, 29–34. https://doi.org/10.1016/j.bbr.2016.01.019. 
(10)  Cheng, S.; Li, L.; He, S.; Liu, J.; Sun, Y.; He, M.; Grasing, K.; Premont, R. T.; Suo, W. Z. 
GRK5 Deficiency Accelerates β-Amyloid Accumulation in Tg2576 Mice via Impaired 
Cholinergic Activity. J. Biol. Chem. 2010, 285 (53), 41541–41548. 
https://doi.org/10.1074/jbc.M110.170894. 
(11)  Nogués, L.; Palacios-García, J.; Reglero, C.; Rivas, V.; Neves, M.; Ribas, C.; Penela, P.; 
Mayor, F. G Protein-Coupled Receptor Kinases (GRKs) in Tumorigenesis and Cancer 
Progression: GPCR Regulators and Signaling Hubs. Semin. Cancer Biol. 2018, 48, 78–90. 
https://doi.org/10.1016/j.semcancer.2017.04.013. 
(12)  Penela, P.; Murga, C.; Ribas, C.; Tutor, A. S.; Peregrín, S.; Mayor, F. Mechanisms of 
Regulation of G Protein-Coupled Receptor Kinases (GRKs) and Cardiovascular Disease. 
Cardiovasc. Res. 2006, 69 (1), 46–56. https://doi.org/10.1016/j.cardiores.2005.09.011. 
(13)  Ullrich, A.; Falcenberg, M.; Örfi, Z.; Kéri, G.; ÖRFI, L.; Horváth, Z.; SZOKOL, B.; 
DOBOS, J.; NEMES, Z. Indolinone Derivatives as Grk5 Modulators. WO2015022437 A1, 
February 19, 2015. 
(14)  Sommer, A.-K.; Falcenberg, M.; Ljepoja, B.; Fröhlich, T.; Arnold, G. J.; Wagner, E.; 
Roidl, A. Downregulation of GRK5 Hampers the Migration of Breast Cancer Cells. Sci. 
Rep. 2019, 9 (1), 1–13. https://doi.org/10.1038/s41598-019-51923-1. 
(15)  Lagman, J.; Sayegh, P.; Lee, C. S.; Sulon, S. M.; Jacinto, A. Z.; Sok, V.; Peng, N.; Alp, 
D.; Benovic, J. L.; So, C. H. G Protein-Coupled Receptor Kinase 5 Modifies Cancer Cell 
Resistance to Paclitaxel. Mol. Cell. Biochem. 2019, 461 (1), 103–118. 
https://doi.org/10.1007/s11010-019-03594-9. 
(16)  Prasad, R. B.; Groop, L. Genetics of Type 2 Diabetes—Pitfalls and Possibilities. Genes 
2015, 6 (1), 87–123. https://doi.org/10.3390/genes6010087. 
(17)  International Diabetes Federation - Type 2 diabetes https://idf.org/aboutdiabetes/type-2-
diabetes.html (accessed Dec 30, 2019). 
(18)  O’Brien, M. J.; Karam, S. L.; Wallia, A.; Kang, R. H.; Cooper, A. J.; Lancki, N.; Moran, 
M. R.; Liss, D. T.; Prospect, T. A.; Ackermann, R. T. Association of Second-Line 
Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 
20 
 
Diabetes. JAMA Netw. Open 2018, 1 (8), e186125–e186125. 
https://doi.org/10.1001/jamanetworkopen.2018.6125. 
(19)  FDA’s Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm 
https://www.ajmc.com/newsroom/fdas-fast-track-designation-for-empagliflozin-in-heart-
failure-points-to-new-paradigm (accessed Dec 26, 2019). 
(20)  FastStats https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm (accessed Dec 26, 
2019). 
(21)  Benjamin Emelia J.; Muntner Paul; Alonso Alvaro; Bittencourt Marcio S.; Callaway 
Clifton W.; Carson April P.; Chamberlain Alanna M.; Chang Alexander R.; Cheng Susan; 
Das Sandeep R.; et al. Heart Disease and Stroke Statistics—2019 Update: A Report From 
the American Heart Association. Circulation 2019, 139 (10), e56–e528. 
https://doi.org/10.1161/CIR.0000000000000659. 
(22)  Mozaffarian, D.; Benjamin, E. J.; Go, A. S.; Arnett, D. K.; Blaha, M. J.; Cushman, M.; 
Das, S. R.; Ferranti, S. de; Després, J.-P.; Fullerton, H. J.; et al. Heart Disease and Stroke 
Statistics—2016 Update: A Report From the American Heart Association. Circulation 
2015, CIR.0000000000000350. https://doi.org/10.1161/CIR.0000000000000350. 
(23)  Orsborne, C.; Chaggar, P. S.; Shaw, S. M.; Williams, S. G. The Renin-Angiotensin-
Aldosterone System in Heart Failure for the Non-Specialist: The Past, the Present and the 
Future. Postgrad. Med. J. 2017, 93 (1095), 29–37. https://doi.org/10.1136/postgradmedj-
2016-134045. 
(24)  Delicce, A. V.; Basit, H.; Makaryus, A. N. Physiology, Frank Starling Law. In StatPearls; 
StatPearls Publishing: Treasure Island (FL), 2019. 
(25)  Sequeira, V.; van der Velden, J. Historical Perspective on Heart Function: The Frank–
Starling Law. Biophys. Rev. 2015, 7 (4), 421–447. https://doi.org/10.1007/s12551-015-
0184-4. 
(26)  Schwinger, R. H.; Böhm, M.; Koch, A.; Schmidt, U.; Morano, I.; Eissner, H. J.; Uberfuhr, 
P.; Reichart, B.; Erdmann, E. The Failing Human Heart Is Unable to Use the Frank-
Starling Mechanism. Circ. Res. 1994, 74 (5), 959–969. 
https://doi.org/10.1161/01.RES.74.5.959. 
(27)  Waldschmidt, H. V.; Homan, K. T.; Cruz-Rodríguez, O.; Cato, M. C.; Waninger-Saroni, 
J.; Larimore, K. M.; Cannavo, A.; Song, J.; Cheung, J. Y.; Kirchhoff, P. D.; et al. 
Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and 
Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. J. Med. Chem. 2016, 59 (8), 
3793–3807. https://doi.org/10.1021/acs.jmedchem.5b02000. 
(28)  Waldschmidt, H. V.; Homan, K. T.; Cato, M. C.; Cruz-Rodríguez, O.; Cannavo, A.; 
Wilson, M. W.; Song, J.; Cheung, J. Y.; Koch, W. J.; Tesmer, J. J. G.; et al. Structure-
Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 
Inhibitors Based on Paroxetine. J. Med. Chem. 2017, 60 (7), 3052–3069. 
https://doi.org/10.1021/acs.jmedchem.7b00112. 
(29)  Hanyaloglu, A. C.; von Zastrow, M. Regulation of GPCRs by Endocytic Membrane 
Trafficking and Its Potential Implications. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 537–
568. https://doi.org/10.1146/annurev.pharmtox.48.113006.094830. 
(30)  Brinks, H.; Koch, W. J. Targeting G Protein-Coupled Receptor Kinases (GRKs) in Heart 




(31)  Traynham, C. J.; Hullmann, J.; Koch, W. J. “Canonical and Non-Canonical Actions of 
GRK5 in the Heart.” J. Mol. Cell. Cardiol. 2016, 92 (Supplement C), 196–202. 
https://doi.org/10.1016/j.yjmcc.2016.01.027. 
(32)  Gurevich, E. V.; Tesmer, J. J. G.; Mushegian, A.; Gurevich, V. V. G Protein-Coupled 
Receptor Kinases: More than Just Kinases and Not Only for GPCRs. Pharmacol. Ther. 
2012, 133 (1), 40–69. https://doi.org/10.1016/j.pharmthera.2011.08.001. 
(33)  Lieu, M.; Koch, W. J. GRK2 and GRK5 as Therapeutic Targets and Their Role in 
Maladaptive and Pathological Cardiac Hypertrophy. Expert Opin. Ther. Targets 2019, 23 
(3), 201–214. https://doi.org/10.1080/14728222.2019.1575363. 
(34)  Homan, K. T.; Tesmer, J. J. Structural Insights into G Protein-Coupled Receptor Kinase 
Function. Curr. Opin. Cell Biol. 2014, 27, 25–31. 
https://doi.org/10.1016/j.ceb.2013.10.009. 
(35)  Huang, C.; Orban, T.; Jastrzebska, B.; Palczewski, K.; Tesmer, J. J. G. Activation of G 
Protein-Coupled Receptor Kinase 1 Involves Interactions between Its N-Terminal Region 
and Its Kinase Domain. Biochemistry 2011, 50 (11), 1940–1949. 
https://doi.org/10.1021/bi101606e. 
(36)  Sterne-Marr, R.; Leahey, P. A.; Bresee, J. E.; Dickson, H. M.; Ho, W.; Ragusa, M. J.; 
Donnelly, R. M.; Amie, S. M.; Krywy, J. A.; Brookins-Danz, E. D.; et al. GRK2 
Activation by Receptors: Role of the Kinase Large Lobe and Carboxyl-Terminal Tail. 
Biochemistry 2009, 48 (20), 4285–4293. https://doi.org/10.1021/bi900151g. 
(37)  Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation | Journal of 
Medicinal Chemistry https://pubs.acs.org/doi/10.1021/jm901443h (accessed Dec 30, 
2019). 
(38)  FDA-approved small-molecule kinase inhibitors: Trends in Pharmacological Sciences 
https://www.cell.com/trends/pharmacological-sciences/comments/S0165-6147(15)00077-
2 (accessed Sep 28, 2019). 
(39)  Sun, C. L.; Christensen, J. G.; McMahon, G. Discovery and Development of Sunitinib 
(SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and 
Angiogenesis. In Kinase Inhibitor Drugs; John Wiley & Sons, Ltd, 2009; pp 1–39. 
https://doi.org/10.1002/9780470524961.ch1. 
(40)  Noble, M. E. M.; Endicott, J. A.; Johnson, L. N. Protein Kinase Inhibitors: Insights into 
Drug Design from Structure. Science 2004, 303 (5665), 1800–1805. 
https://doi.org/10.1126/science.1095920. 
(41)  Knight, Z. A.; Shokat, K. M. Features of Selective Kinase Inhibitors. Chem. Biol. 2005, 12 
(6), 621–637. https://doi.org/10.1016/j.chembiol.2005.04.011. 
(42)  Fasano, M.; Della Corte, C. M.; Califano, R.; Capuano, A.; Troiani, T.; Martinelli, E.; 
Ciardiello, F.; Morgillo, F. Type III or Allosteric Kinase Inhibitors for the Treatment of 
Non-Small Cell Lung Cancer. Expert Opin. Investig. Drugs 2014, 23 (6), 809–821. 
https://doi.org/10.1517/13543784.2014.902934. 
(43)  Roskoski, R. Classification of Small Molecule Protein Kinase Inhibitors Based upon the 
Structures of Their Drug-Enzyme Complexes. Pharmacol. Res. 2016, 103, 26–48. 
https://doi.org/10.1016/j.phrs.2015.10.021. 
(44)  Gehringer, M.; Laufer, S. A. Emerging and Re-Emerging Warheads for Targeted Covalent 




(45)  Zhang, H. Osimertinib Making a Breakthrough in Lung Cancer Targeted Therapy. 
OncoTargets Ther. 2016, 9, 5489–5493. https://doi.org/10.2147/OTT.S114722. 
(46)  Harbeck, N.; Solca, F.; Gauler, T. C. Preclinical and Clinical Development of Afatinib: A 
Focus on Breast Cancer and Squamous Cell Carcinoma of the Head and Neck. Future 
Oncol. 2013, 10 (1), 21–40. https://doi.org/10.2217/fon.13.244. 
(47)  Keating, G. M. Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small 
Cell Lung Cancer. Drugs 2014, 74 (2), 207–221. https://doi.org/10.1007/s40265-013-
0170-8. 
(48)  Gayko, U.; Fung, M.; Clow, F.; Sun, S.; Faust, E.; Price, S.; James, D.; Doyle, M.; Bari, 
S.; Zhuang, S. H. Development of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib for B 
Cell Malignancies. Ann. N. Y. Acad. Sci. 2015, 1358, 82–94. 
https://doi.org/10.1111/nyas.12878. 
(49)  Danker, T.; Möller, C. Early Identification of HERG Liability in Drug Discovery 
Programs by Automated Patch Clamp. Front. Pharmacol. 2014, 5. 
https://doi.org/10.3389/fphar.2014.00203. 
(50)  LoPachin, R. M.; Gavin, T.; DeCaprio, A.; Barber, D. S. Application of the Hard and Soft, 
Acids and Bases (HSAB) Theory to Toxicant–Target Interactions. Chem. Res. Toxicol. 
2012, 25 (2), 239–251. https://doi.org/10.1021/tx2003257. 
(51)  Light, S. H.; Minasov, G.; Duban, M.-E.; Anderson, W. F. Adherence to Bürgi–Dunitz 
Stereochemical Principles Requires Significant Structural Rearrangements in Schiff-Base 
Formation: Insights from Transaldolase Complexes. Acta Crystallogr. D Biol. Crystallogr. 
2014, 70 (Pt 2), 544–552. https://doi.org/10.1107/S1399004713030666. 
(52)  Lonsdale, R.; A. Ward, R. Structure-Based Design of Targeted Covalent Inhibitors. Chem. 
Soc. Rev. 2018, 47 (11), 3816–3830. https://doi.org/10.1039/C7CS00220C. 
(53)  Ghosh, A. K.; Samanta, I.; Mondal, A.; Liu, W. R. Covalent Inhibition in Drug Discovery. 
ChemMedChem 0 (0). https://doi.org/10.1002/cmdc.201900107. 
(54)  Lonsdale, R.; Burgess, J.; Colclough, N.; Davies, N. L.; Lenz, E. M.; Orton, A. L.; Ward, 
R. A. Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. J. 
Chem. Inf. Model. 2017, 57 (12), 3124–3137. https://doi.org/10.1021/acs.jcim.7b00553. 
(55)  Jackson, P. A.; Widen, J. C.; Harki, D. A.; Brummond, K. M. Covalent Modifiers: A 
Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via 
Hetero-Michael Addition Reactions. J. Med. Chem. 2017, 60 (3), 839–885. 
https://doi.org/10.1021/acs.jmedchem.6b00788. 
(56)  Strelow, J. M. A Perspective on the Kinetics of Covalent and Irreversible Inhibition. SLAS 
Discov. Adv. Life Sci. RD 2017, 22 (1), 3–20. https://doi.org/10.1177/1087057116671509. 
(57)  Zhao, Z.; Bourne, P. E. Progress with Covalent Small-Molecule Kinase Inhibitors. Drug 
Discov. Today 2018, 23 (3), 727–735. https://doi.org/10.1016/j.drudis.2018.01.035. 
(58)  Chaikuad, A.; Koch, P.; Laufer, S. A.; Knapp, S. The Cysteinome of Protein Kinases as a 
Target in Drug Development. Angew. Chem. Int. Ed. 2018, 57 (16), 4372–4385. 
https://doi.org/10.1002/anie.201707875. 
(59)  Bradshaw, J. M.; Mcfarland, J. M.; Paavilainen, V. O.; Bisconte, A.; Tam, D.; Phan, V. T.; 
Romanov, S.; Finkle, D.; Shu, J.; Patel, V.; et al. Prolonged and Tunable Residence Time 
Using Reversible Covalent Kinase Inhibitors. Nat. Chem. Biol. Camb. 2015, 11 (7), 525–
531. http://dx.doi.org/10.1038/nchembio.1817. 
(60)  Krishnan, S.; Miller, R. M.; Tian, B.; Mullins, R. D.; Jacobson, M. P.; Taunton, J. Design 
of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and 
23 
 
Computational Analysis. J. Am. Chem. Soc. 2014, 136 (36), 12624–12630. 
https://doi.org/10.1021/ja505194w. 
(61)  Miller, R. M.; Taunton, J. Chapter Four - Targeting Protein Kinases with Selective and 
Semipromiscuous Covalent Inhibitors. In Methods in Enzymology; Shokat, K. M., Ed.; 
Protein Kinase Inhibitors in Research and Medicine; Academic Press, 2014; Vol. 548, pp 
93–116. https://doi.org/10.1016/B978-0-12-397918-6.00004-5. 
(62)  Finlay, M. R. V.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; 
Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; et al. Discovery of a Potent 
and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance 
Mutations That Spares the Wild Type Form of the Receptor. J. Med. Chem. 2014, 57 (20), 
8249–8267. https://doi.org/10.1021/jm500973a. 
(63)  Gold, J. I.; Martini, J. S.; Hullmann, J.; Gao, E.; Chuprun, J. K.; Lee, L.; Tilley, D. G.; 
Rabinowitz, J. E.; Bossuyt, J.; Bers, D. M.; et al. Nuclear Translocation of Cardiac G 
Protein-Coupled Receptor Kinase 5 Downstream of Select Gq-Activating Hypertrophic 
Ligands Is a Calmodulin-Dependent Process. PLOS ONE 2013, 8 (3), e57324. 
https://doi.org/10.1371/journal.pone.0057324. 
(64)  Gold Jessica I.; Gao Erhe; Shang Xiying; Premont Richard T.; Koch Walter J. 
Determining the Absolute Requirement of G Protein–Coupled Receptor Kinase 5 for 
Pathological Cardiac Hypertrophy. Circ. Res. 2012, 111 (8), 1048–1053. 
https://doi.org/10.1161/CIRCRESAHA.112.273367. 
(65)  Hendrickx, J. O.; van Gastel, J.; Leysen, H.; Santos-Otte, P.; Premont, R. T.; Martin, B.; 
Maudsley, S. GRK5 – A Functional Bridge Between Cardiovascular and 
Neurodegenerative Disorders. Front. Pharmacol. 2018, 9. 
https://doi.org/10.3389/fphar.2018.01484. 
(66)  Cho, S. Y.; Lee, B. H.; Jung, H.; Yun, C. S.; Ha, J. D.; Kim, H. R.; Chae, C. H.; Lee, J. H.; 
Seo, H. W.; Oh, K.-S. Design and Synthesis of Novel 3-(Benzo[d]Oxazol-2-Yl)-5-(1-
(Piperidin-4-Yl)-1H-Pyrazol-4-Yl)Pyridin-2-Amine Derivatives as Selective G-Protein-
Coupled Receptor Kinase-2 and -5 Inhibitors. Bioorg. Med. Chem. Lett. 2013, 23 (24), 
6711–6716. https://doi.org/10.1016/j.bmcl.2013.10.036. 
(67)  Thal, D. M.; Yeow, R. Y.; Schoenau, C.; Huber, J.; Tesmer, J. J. G. Molecular Mechanism 
of Selectivity among G Protein-Coupled Receptor Kinase 2 Inhibitors. Mol. Pharmacol. 
2011, 80 (2), 294–303. https://doi.org/10.1124/mol.111.071522. 
(68)  Homan, K. T.; Larimore, K. M.; Elkins, J. M.; Szklarz, M.; Knapp, S.; Tesmer, J. J. G. 
Identification and Structure–Function Analysis of Subfamily Selective G Protein-Coupled 
Receptor Kinase Inhibitors. ACS Chem. Biol. 2015, 10 (1), 310–319. 
https://doi.org/10.1021/cb5006323. 
(69)  Waldschmidt, H. V.; Bouley, R.; Kirchhoff, P. D.; Lee, P.; Tesmer, J. J. G.; Larsen, S. D. 
Utilizing a Structure-Based Docking Approach to Develop Potent G Protein-Coupled 
Receptor Kinase (GRK) 2 and 5 Inhibitors. Bioorg. Med. Chem. Lett. 2018, 28 (9), 1507–
1515. https://doi.org/10.1016/j.bmcl.2018.03.082. 
(70)  Barf, T.; Kaptein, A. Irreversible Protein Kinase Inhibitors: Balancing the Benefits and 
Risks. J. Med. Chem. 2012, 55 (14), 6243–6262. https://doi.org/10.1021/jm3003203. 
(71)  Boguth, C. A.; Singh, P.; Huang, C.; Tesmer, J. J. G. Molecular Basis for Activation of G 




(72)  Homan, K. T.; Waldschmidt, H. V.; Glukhova, A.; Cannavo, A.; Song, J.; Cheung, J. Y.; 
Koch, W. J.; Larsen, S. D.; Tesmer, J. J. G. Crystal Structure of G Protein-Coupled 
Receptor Kinase 5 in Complex with a Rationally Designed Inhibitor. J. Biol. Chem. 2015, 
290 (34), 20649–20659. https://doi.org/10.1074/jbc.M115.647370. 
(73)  Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. 
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. Chem. Biol. 2013, 
20 (2), 146–159. https://doi.org/10.1016/j.chembiol.2012.12.006. 
(74)  Lipinski’s Rule of Five - an overview | ScienceDirect Topics 
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-









Chapter 2: Structure-Based Design of Selective, Covalent G-Protein Coupled Receptor 
Kinase 5 Inhibitors 
2.1 Preface 
Ideas and conclusions presented in Chapter 2 appear verbatim in a publication.1 Design, synthesis 
and preliminary results for a select set of compounds (CCG258903, CCG258904, CCG262603, 
CCG264606, CCG263045 and CCG263115) have been published previously in the dissertation 
for the degree of Doctor of Philosophy (Medicinal Chemistry) from the University of Michigan by 
Helen Waldschmidt. I performed all additional design and synthesis of compounds CCG264099-
265648. In addition to these compounds designed and synthesized, I also generated the 
GRK5/GRK6 overlay model, performed virtual screening and docking experiments, as well as 
performed intact protein and tandem mass spectrometry experiments. GRK5 and GRK5-C474S 
were provided by Renee Bouley, and GRK6 was provided by Kristoff Homan. All other 
radiometric pharmacological assays including time-dependence experiments were performed by 
M. Claire Cato. Additional contributions to the analysis of structural-activity relationships were 
also performed by M. Claire Cato. 
2.2 Selectivity Presents a Massive Challenge for Developing GRK5 Inhibitors 
There is growing evidence that GRK2 and GRK5 have distinct pathological roles within the failing 
heart.2–6 Increased GRK2 levels are thought to mediate the decrease in cell-surface βARs and the 
prolonged sympathetic nervous system activation, leading to decreased contractility.3 GRK5 is 
unique among GRKs in that it undergoes Ca2+·calmodulin-dependent nuclear localization that 
allows GRK5 to translocate into the nucleus where it phosphorylates histone deacetylase 5 
(HDAC), turning on the transcription of hypertrophic genes.5 Indeed, cardiac-specific GRK2 
knockout mice have improved contractility and increased cell-surface βARs post-myocardial 
infarction, and GRK5 knockout mice are protected from cardiac hypertrophy following controlled 
cardiac stress.7 The extent of the functional differences in GRK2 and GRK5 within 
cardiomyocytes remains to be elucidated, but selective inhibition of each of these kinases would 
offer the opportunity to further understand their distinct roles in the progression of heart failure. In 
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addition, the selective inhibition of GRK2 or GRK5 presents the possibility of treating different 
aspects of heart failure without affecting the entire cardiac regulatory system. 
Despite high structural similarity in the active site among GRKs, we have had success in 
developing potent and selective small molecule inhibitors for the GRK2 subfamily that improve 
contractility in isolated adult mouse cardiomyocytes, in part because GRK2, and presumably 
GRK3, adopts a distinct inactive pose from other GRKs and other protein kinases.8–11 Comparison 
of GRK2 and GRK5 crystal structures revealed a more spacious ATP-binding pocket in GRK2/3 
that was able to accommodate bulkier chemical substituents, which allowed us to build out GRK5 
binding.8 We have also developed pan GRK-selective compounds (CCG-215022 and CCG-
258748) with high nanomolar potency for both GRK2 and GRK5 but thus far we have not been 
successful in developing GRK5 selective (or GRK4 subfamily selective) inhibitors using the 
canonical reversible binding model.8,9,11 Others have reported GRK4 subfamily selective 
compounds, but they are also potent inhibitors of other kinase families and have not been 
independently confirmed.12,13 
Examination of the crystal structure of GRK6 in what is believed to be an active conformation 
(PDB 3NYN) revealed that the thiol group of Cys474, located within the flexible active site tether 
(AST) loop of the kinase domain, is positioned adjacent to the ATP-binding site, at least when the 
kinase adopts a more closed conformation (Figure 2.1A).14 Because this cysteine is unique to 
GRK4 subfamily members it could be exploited as a handle for covalent inhibition to gain 
selectivity for GRK5 over GRK2.  
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In recent years, the popularity of covalent warheads has risen because they offer the possibility of 
more potency and selectivity than reversible inhibitors.15 In particular, specifically targeting non-
conserved cysteines in the ATP-binding pocket of kinases has demonstrated utility.15–17 The most 
successful irreversible modifiers have come from designing a reversibly-binding compound with 
low or sub-µM affinity to contain a covalent warhead that is within reach and in the proper 
orientation to interact with the free thiol of a nearby cysteine. The most widely used reaction to 
achieve irreversible covalent attachment onto a cysteine is a Michael addition using electrophilic 
warheads such as acrylamides, vinyl sulfones, and alkynes.17 Recent advances have also been 
Figure 2.1 GSK2163632A and related compounds suggest a route to selective inhibition of GRK5 via covalent modification of 
Cys474. (A) GSK2163632A (green) bound to GRK1 (yellow, PDB entry 4PNI) superimposed with the active conformation of 
GRK6 (blue, PDB entry 3NYN) (B) Previously identified pyrrolopyrimidine based GRK inhibitors and covalent inhibitor design 
rationale. Green ovals highlight the base of the scaffold that is generally conserved, and orange circles represent a basic nitrogen 
that was removed except in the case of analogs where it is replicated potentially by a N,N-dimethyl-butenoic amide. 
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made with the use of an N,N-dimethyl-butenoic amide, which improves solubility and contains an 
internal base that can deprotonate and activate the thiol group.17–19 
In a previous screen, GSK2163632A was identified as a modestly potent GRK5 inhibitor (IC50 = 
3.2 µM) with high potency for GRK1 (IC50 = 130 nM). Two related compounds, GSK1713088A 
and GSK1326255A (Figure 2.1B), were shown to have similar potency for GRK5 (IC50 = 3.2 and 
2.5 µM respectively), but also modest selectivity over both GRK1 and GRK2.20 All three GSK 
compounds share a common pyrrolopyrimidine core, which binds within the ATP pocket with the 
nitrogen from the core forming a hydrogen bonds with the hinge of the kinase domain in a donor-
acceptor-donor motif, as observed for GSK2163632A in complex with GRK1 (PDB entry 4PNI, 
Figure 2.1A).14 We therefore hypothesized that we could append covalent war-heads to the 
methoxyphenyl of GSK1713088A or GSK1326255A that could react with Cys474 (Figure 2.1B). 
To avoid a highly substituted ring, we replaced the tertiary amine appendages with our covalent 
warheads in hopes that the potency gained by the covalent bond would overcome the loss of a 
hydrogen bond accepted by the tertiary amine. The N,N-dimethyl-butenoic amide warhead would, 
however, place a basic tertiary amine in a similar position. 
2.3 Pyrrolopyrimidine Analogues can Achieve GRK5 Selectivity through Covalent Engagement 
We first rationally designed 6 different variants of the GSK inhibitor series with short amide 
linkers. We overlaid the GRK5 crystal structure (4WNK) with that of the active conformation of 
GRK6 (3NYN) (Figure 2.1A). Building a covalent warhead meta to the aniline (ring C) likely 
retains the hydrogen bond of the amide carbonyl that GSK2163632A forms with the backbone 
nitrogen of GRK1-Asp271 (GRK5-Asp270) but this may position the Michael acceptor too distant 
from Cys474. Alternatively, building the warhead para to the aniline would likely hinder the 
hydrogen bond with Asp271, but may put the Michael acceptor within 1.5 Å of the Cys474 thiol 
group. However, it is not possible to accurately model these interactions because the degree of 
kinase domain closure and the conformations of the flexible AST and P loops cannot be predicted 
a priori. Therefore, both para and meta substituents were synthesized, including unreactive 
saturated ethyl amide analogs as negative controls (Table 2.1).  
The para and meta ethyl amide controls, CCG-262604 and CCG-262606 respectively, showed 
substantially different biochemical results indicating a possible structure-activity-relationship 
(SAR) cliff. The para substituted ethyl amide CCG-262606 appears to saturate the assay, with 
activity ranging from 5.9 µM  at 1 hour to >100 µM at the 4 hour timepoint. This level of activity 
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at the four hour timepoint is consistent with the meta substituted ethyl amide CCG-262604 that 
showed >100 µM inhibition for GRK5 at all timepoints tested. The para substituted acrylamide, 
CCG-258903, exhibited an IC50 of 6.2 µM for GRK5 after one hour of preincubation on ice, with 
no potency against GRK1 or GRK2. After 4 hr, CCG-258903 showed a convincing increase in 
potency as a function of time consistent with covalent inhibition, with an IC50 of 0.2 µM (Table 
2.1, Figure 2). The >16-fold difference in GRK5 potency for CCG-258903 relative to its non-
covalent control CCG-262604 at 1 hour also suggests a covalent mechanism of action. The 
 
Experimental values derived from this report were run three times in duplicate with the exception of assays involving 5 against GRK5, GRK6, and GRK5-C474S 
with 4 hr incubations, which were performed two times in duplicate. Inhibitor incubation times are given in parentheses. 
‡From Homan K. et al.34. Note that these compounds were not assayed after 4 hr incubations and are listed here for comparison purposes only. 
§Selectivity for GRK5 over GRK2 based on IC50 ratio. The IC50 value for the longest incubation with GRK5 was used for the calculation. 
† Measured at 100 min. 
Table 1: IC50 Values for Pyrrolopyrimidine Compounds (µM ± SD) 
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compounds also exhibited >450 selectivity over GRK2. The meta acrylamide analog CCG-258904 
had similar potency for GRK5 at all incubation times with respect to its non-covalent control CCG-
262606 suggesting that it is not acting covalently. It also showed no inhibition of GRK1 but modest 
GRK2 inhibition (IC50 = 39 µM).  
Both CCG-263045 and CCG-263115, featuring the N,N-dimethyl-butenoic amide in para and 
meta positions, respectively, had increased potency for all three GRKs relative to the acrylamide 
inhibitors CCG-258903 and CCG-258904, indicating that addition of the basic nitrogen augments 
potency against all three kinases. The para substituted analog, CCG-263045, was predicted to be 
closer to the AST loop, and thus more likely to form a covalent bond with Cys474. In our time 
dependent inhibition of GRK5, it shows some improvement from 0 min to 1 hr (GRK5 IC50 from 
0.57 to 0.35 µM, respectively) but exhibits no selectivity over GRK1 or GRK2 (IC50 = 0.76 and 
0.68 µM, respectively). The meta substituted analog, CCG-263115, did not show time dependent 
GRK5 inhibition (IC50 range = 0.22 – 0.27 µM), although it showed ~10-fold selectivity for GRK5 
over GRK1 and GRK2 (IC50 = 2.1 and 2.7 µM, respectively). This difference in GRK selectivity 
between the meta and para substituted analogs CCG-263045 and CCG-263115 indicates that the 
position of the amide linked appendage from the methoxyphenyl ring is one route for gaining 
GRK5 selectivity. Despite their GRK5 potency CCG-263045 and CCG-263115 were not further 
pursued due to their lack of selectivity against GRK1 and 2.  
We then determined IC50 values of the homologated compounds after a 4 hour incubation for 
GRK2, GRK5, and GRK6 (Table 2.1). GRK6 was included as a positive control for GRK4 
subfamily selectivity. As in the non-homologated series, the ethylamide compounds (CCG-264561 
and CCG-265041) showed an SAR cliff, with the para ethyl amide unable to inhibit any of the 
GRKs tested. The reactive para-substituted series (CCG-264099-265328) were more selective for 
GRK5/6 over GRK2 than their meta analogs with the exception of CCG-265327. GRK5 tolerated 
both the small substituents of the acrylamide CCG-264099 (IC50 = 78 µM) and vinyl sulfone, 
CCG-265327 (IC50 = 19 µM) but also the large N,N-dimethyl-butenoic amide of CCG-264629 
(IC50 = 17 µM). The para-alkyne (CCG-265328) was the most potent and selective GRK5 
inhibitor from this series (IC50 = 1.1 µM, 90-fold selectivity over GRK2 after 4 hour incubation).  
Interestingly, potency for GRK2 was lost for all compounds with the para-substitution. It is 
possible that the slightly longer AST-loop in the GRK2 subfamily allows it to reach further in the 
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active site, as seen for residues 476-479 in the GRK2-Gβγ·GSK180736A co-crystal structure 
(PDB entry 4PNK), which would collide with substituents in the para-position. 
Overall, the meta-substituted compounds (CCG-265041-265268) tended to have higher potency 
against GRK5 but lower or even reversed selectivity versus GRK2 (the exception being the vinyl 
sulfone CCG-265267). Small polar groups, specifically those with hydrogen bond acceptor 
capability, were well tolerated in GRK5. For example, both CCG-265042 and CCG-265267 
inhibited GRK5, but the polar vinyl sulfone of CCG-265267 was more potent (IC50 = 7.1 μM) 
than the more lipophilic acrylamide of CCG-265042 (IC50 = 22 µM). The meta-alkyne (CCG-
265268) had no potency for GRK5, suggesting that this more rigid covalent modifier may collide 
with the P-loop or AST-loop. The CCG-265044 compound had low µM potency for GRK5.  
Of the homologated series, only CCG-265042, CCG-265044 and CCG-265041 showed activity 
















































































Figure 2.2 Time-dependent inhibition of GRK5 by CCG-265328 and CCG-265507 but not CCG-215022. 
Compounds were pre-incubated for times of 0 min (black), 100 min (magenta), and 240 min (green). (A) CCG-
215022, which has no covalent modifier, does not show a significant change in IC50 (380 nM) over time. (B) 5 and 
(C) CCG-265328 exhibit the expected leftward shift in IC50 for covalent inhibitors as pre-incubation times 
increase, as indicated by the blue arrows. Each curve is the average of either 3 (CCG-215022 and CCG-265328) or 
4 (5) experiments. Error bars are standard deviation. 
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within the shallow GRK2 ribose pocket. All the other meta-substituted materials have larger, less 
flexible warheads. As expected, inhibition of GRK6 was similar to that of GRK5 in most cases, 
the exception being CCG-265328, which was unable to inhibit GRK6. It is unclear whether this 
represents true intra-subfamily selectivity or a vagary of the experimental conditions for this 
combination. The most potent compound CCG-265328 was then additionally tested at 0 and 100 




Figure 2.3. Evidence from intact mass spectrometry for covalent modification of GRK5 by CCG-258903, CCG-
264099, and CCG-265328. (A) GRK5 only (black trace), GRK5·5 (purple). (B) MS traces for GRK5 (black trace), 




inhibition. Indeed, CCG-265328 displayed a marked increase in apparent potency as a function of 
time (Figure 2.2).  
Further confirmation of covalent inhibition of GRK5 was achieved through intact protein mass 
spectrometry (MS). Compounds CCG-258903 and CCG-264099-265328 were tested, but only 
CCG-258903, CCG-264099 and CCG-265328 showed significant amounts of covalent linkage 
after a three hour incubation (Figure 2.3), consistent with the results of our radiometric assays. 
Compounds CCG-265041-265268 were also tested but showed no covalent inhibition (Figure 2.4).  
For CCG-258903, CCG-264099 and CCG-265328, we also tested whether inhibition is affected 
when Cys474 is mutated to serine (GRK5-C474S). A decrease in GRK5-C474S potency relative 
to wild-type GRK5 would thus be consistent with a covalent inhibition mechanism. Compound 
CCG-258903 lost all potency against the mutant protein, whereas CCG-264099 and CCG-265328 
retained comparable activity. The reason is unclear, but it is possible that either the intrinsic 
66000 68000 70000 72000
daltons
 
Figure 2.4 MS traces for (a) CCG-265041, (b) CCG-265042, (c) CCG-265044, (d) CCG-265267 and (e) CCG-265268 
indicate that no meta-substituted material can make a covalent interaction with GRK5. 
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reactivity of these compounds is sufficient, or their reactive groups are more optimal oriented to 
engaged in a non-covalent interaction with an additional hydrogen bond donor on GRK5. 
However, the base scaffold may also simply bind with high affinity irrespective of covalent 
attachment. We next tested whether CCG-265328 engaged GRK5 in a covalent bond specifically 
at Cys474 using intact protein  MS and showed that GRK5-C474S mutant does not react (Figure 
2.5). Using tandem mass spectrometry (MS/MS) we further observed that CCG-265328 labels 
Cys474 but also a cysteine located in a solvent-exposed position in its regulator of G protein 
signaling homology domain, remote from the active site (Figure 2.6). The labeling of Cys54 is 
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Figure 2.5 Evidence for GRK5-Cys474 covalent engagement of CCG-265328. (A) MS trace for GRK5, (B) MS trace 
for GRK5 incubated with CCG-265328 indicating covalent modification, (C) MS trace for GRK5-C474S, (D) MS 
trace for GRK5-C474 incubated with CCG-265328 indicates that CCG-265328 cannot covalently modify GRK5-
C474S. Each peak shown is representative of n = 3 experiments. 
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more consistent with a concentration dependent labelling event than with a biologically relevant 
interaction. As the concentration of CCG-265328 needed to achieve a detectable amount of 
labelled Cys474 is above 1 mM, it is unsurprising that this extraneous labelling event occurred.  
In summary, we report the first examples of covalent inhibitors of GRK5, including the first 
examples of covalent, selective GRK5 inhibitors, CCG-258903 and CCG-265328, with high nM 
to low µM potency. We have leveraged the pyrrolopyrimidine scaffold to install para-substituted 
linkers that can interact covalently with the AST from GRK5 but not from GRK2. Additionally, 
we have shown that Cys474 is selectively targeted by our covalent warheads, validating our design 
strategy. Moving forward, we aim to further improve the potency of these compounds against 
GRK5 and GRK6, and to pursue crystal structures of the GRK5/6·258903 and CCG-265328 
complexes to confirm their binding poses and the effect of covalent modification on the overall 
conformation of GRK5. Before examining the effects of our compounds in vivo on cardiomyocyte 
contractility and, ultimately, to parse the role of GRK5 in heart failure, these compounds will also 
need to be tested for selectivity against other protein kinases. 
2.4 Initial Testing Suggests CCG-265328 Can Improve Contractility in Primary Cardiomyocytes 
 
Figure 2.6  GRK5 (gold) with CCG-265328 (pink) bound to the hinge. Cys474 (blue) was tagged by 265328, 
indicating it is a covalent handle. The more solvent exposed Cys54 (light blue) was also tagged, in a 
concentration-dependent labelling event.  
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Validation of CCG-265328 as a compound with high levels of selectivity, and a covalent 
interaction with Cys474 has opened the door to testing in various disease state models. While 
GRK5 has been implicated in multiple disease states, we are primarily concerned with 
understanding its role in heart failure. Previously, it has been shown that GRK2 inhibitors can 
reverse the contractility lose in cardiomyocytes following isoproterenol inducing transverse aortic 
constriction (TAC). Using this same assay, CCG-265328 was shown to also improve contractility 
in primary cardiomyocytes at a concentration of 100 µM. Following isoproterenol, CCG-265328 
was able to shorten cardiomyocyte length, indicating that contractility improvement in this model. 
Cardiomyocytes treated with CCG-265328 had a comparable cell length to those treated with 
paroxetine, an FDA-approved SSRI compound which is known to improve cardiac function in 
heart failure (Figure 2.7).9 While these results are preliminary, the data does suggest that GRK5 
may also play a role in improving cardiomyocyte contractility, independent of the effect seen by 
inhibiting GRK2. Further work with CCG-265328 can also help to elucidate the full role of GRK5 

















































































Figure 2.7 CCG-265328 can produce similar contractility improvements to that seen with paroxetine in primary 
cardiomyocytes following isoproterenol (100 nM) induced TAC. Each bar is an average of 3-4 experiments. 
Errors bars represent standard deviation. 
37 
 
2.5 SAR is Tractable to the 5-methylpyrimidine Series, but Does Not Offer Better Potency 
While the initial series of pyrrolopyrimidine based analogues offers moderate potency, it did allow 
for the validation of Cys474 as a covalent handle. However, there are pharmacokinetic issues with 
this series, such as poor solubility which may be limiting the intrinsic potency of these analogues. 
Our best compound, CCG-265328, had limited solubility (25.8 µM in water). This lack of 
solubility, when paired with the modest potency of the compound, creates concern about the 
overall utility of this series. Therefore, we chose to explore analogues which could either increase 
water solubility, or limit metabolic liabilities thereby increasing exposure time. Our initial change, 
the addition of a 3-pyridyl pendant, yielded CCG-265596 (Table 2.2). Such a change allows for 
the lowering of the solubility forecast index (SFI) by way of the cLogP. In this case, pyridyl 
pendant offer a decrease in cLogP while largely maintaining the properties of the lead compound, 
CCG-265328. CCG-265596 did display better water solubility (43.2 µM in water) by about 2-fold. 
 
Experimental values derived from this report were run three times in duplicate. Inhibitor incubation times are given in 
parentheses. Scaffold denotation given as Scaffold 1 (S1) or Scaffold 2 (S2). Activity against GRK5-C474S not determined. Error 
represents the standard deviation (data not shown).  
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However, we tested within our radiometric assay, this analogue and any analogue featuring a 
pyridyl pendant in this northern hemisphere are inactive (Ki >100 µM).  
 One of the other common ways to increase water solubility is to break planarity within the 
molecule. Following this rule, we synthesized CCG-265507, CCG-265508, CCG-265647 and 
CCG-265648. Interestingly, we found that CCG-265507, which is the 5-methylpyrimidine 
equivalent of CCG-265328, does maintain the same level of activity as the original lead compound. 
Better still, CCG-265507 demonstrated a 12-fold increase in water solubility, thereby validating 
our rationale design to increase solubility. Additionally, we were able to demonstrate that CCG-
265507 maintains the ability to form a covalent adduct with GRK5-C474 through intact and 
tandem MS (Figure 2.8). A number of cysteines were labeled by CCG-265507 within the tandem 
MS experiment, however, these labelling events are thought to be concentration dependent. CCG-
265507, was shown to label C54, C201, C144, and C297 in addition to the labelling event seen at 
C474. These cysteine residues are known to be placed at solvent exposed regions of GRK5, 
suggesting that when CCG-265507 is in excess, in this case there is a 100-fold excess of 
compound, then solvent exposed regions of the target are also labeled. These data are consistent 
with concentration dependent labeling event seen in a GRK5-CCG-265328 tandem MS 
experiment. When GRK5-C474S is used for tandem MS, CCG-265507 cannot form the covalent 
adduct seen in the GRK5-WT experiment (data not shown). This validates the applicability of our 
covalent strategy to other more intrinsically potent scaffolds.  
However, CCG-265508 and CCG-265647 are inactive, suggesting that potentially the activity of 
CCG-265507 is driven by covalent engagement of Cys474. Interestingly, CCG-265648, which 
features a 3-pyridyl in place of the methylbenzylamide featured in CCG-265507, has some 
intrinsic GRK5 activity, though it is poor (IC50= 22.1 µM). This poor activity could be due to low 
 
Figure 2.8 Tandem MS/MS data for CCG-265507 indicates that Cys474 is tagged and detected in multiple 
peptide fragments. Similar to 265328, 265507 also labels more solvent exposed cysteine residues, and due to 




intrinsic potency of the scaffold coupled with covalent interaction at Cys474. Together, these data 
suggest that the limiting factor for potency of these compounds may be the entropic cost of locking 
down the flexible AST-loop. We hypothesized that a more intrinsically potent non-covalent 
scaffold would be able to overcome this entropic cost, and our covalent strategy applied from there.  
2.6 Synthesis of Compounds 
 
Scheme 2.1 Synthetic route to CCG-264099-265328. 
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Synthesis of CCG-264099-CCG-265328 starts with the SEM-protection of common intermediate, 
2,4-dichloropyrrolopyrimidine, yielding intermediate 24. The northern hemisphere pendant is then 
introduced using an SNAr with 2-aminomethylbenzamide to give common intermediate 25. From 
25, the synthesis of these compounds diverge. For the para-substituted materials (CCG-264099-
CCG-265328), 25 is submitted to a Buchwald-Hartwig cross-coupling with 4-amino-3-
methoxybenzonitrile to give 26. The benzonitrile is then reduced with Raney nickel to give the 
free amine 27. The  free amine is then coupled to an appropriate warhead acid to yield 28-32. 
Finally, the SEM protecting group is removed to unveil the final products, CCG-264099-265328 
(33-37). 
 
Scheme 2.2 Synthetic route to CCG-265041-265268.  
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 In a similar fashion, CCG-265041-265268 are made through a Buchwald-Hartwig cross-
coupling of 25 with 50. 50 is made through a selective reduction of 3-amino-4-methoxybenzamide 
(51), and subsequent selective Cbz-protection of the diamine, 52. From 38, the Cbz-protecting 
group is then removed with hydrogen and palladium on carbon to give the free-amine, 39. The free 
amine then undergoes an amide coupling with an appropriate warhead acid to yield 40-44. The 
final products CCG-265041-265268 (45-49) are then unveiled through acid-catalyzed deprotecting 
of the SEM-group.  
 In an abbreviated synthesis, CCG-265507-CCG-265508 were made starting with an SNAr 
with 2,4-dichloro-5-methylpyrimidine and 2-aminomethylbenazamide to give 72. 72 is then 
submitted to an optimized Buchwald cross-coupling with 3-methoxy-4-aminobenzonitrile to give 
73. From 73, the free amine 74 is accessed through reduction with Raney Nickel. Finally, CCG-
265507 and CCG-265508 (75 and 76 respectively) are then accessed through an amide coupling 
catalyzed by HATU. In economical form, this synthetic route had no additional protecting groups 
to be removed, allowing a faster, stream-lined synthesis.  
Access to the starting materials for CCG-265647 and CCG-265648 proved more difficult due to 
the highly electron-rich nature of the pendants. 3-aminopyridine is used in a Buchwald cross-
coupling to produce 84. Then, a subsequent Buchwald cross-coupling is used to install the 3-
methoxy-4-aminobenzonitrile linker to give 85. The free amine, 86, is then accessed through 
reduction by Raney Nickel. Finally, CCG-265647 and CCG-265648 (88 and 89 respectively) are 
accessed through an amide coupling with an appropriate acid starting material.  
 
Scheme 2.4 Synthetic route to CCG-265647 and CCG-265648. 
 
Scheme 2.3 Synthetic route to CCG-265507 and CCG-265508. 
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2.7 Materials, Methods and Synthetic Experimental Data 
General Chemistry: All reagents from commercial sources were used without further purification unless 
otherwise noted. 1H-NMR spectra were taken in DMSO-d6, MeOD or CDCl3 at room temperature on 
Varian MR 400 MHz; Varian Vnmrs 500 MHz; and Varian Vnmrs 700 MHz instruments. The reported 
chemical shifts for the 1HNMR spectra were recorded in parts per million (ppm) on the δ scale from an 
internal tetramethylsilane (TMS) standard (0.0 ppm). Small molecule mass spectrometry data was measured 
using a Waters Corporation Micromass LCT or Agilent6230 Q-TOF instrument. HPLC was used to 
determine purity of compounds on an Agilent 1100 series with an Agilent Zorbax Eclipse Plus-C18 column. 
A gradient of 10-90% acetonitrile/water over 6 min followed by 90% acetonitrile/water for 7 min was used 
with detection at 254 nm.  
 
Intact Protein MS and Tandem MS/MS: Intact protein MS was acquired with a Phenomenex C4 column 
paired with an Agilent 6545 Q-TOF LC/MS. For intact MS and Tandem MS, all samples were prepared 
with 20 µM GRK in assay buffer (see below), 1 mM compound, and incubated at 4 ˚C for 3 hr before being 
quenched with 1.0 µL of formic acid. In Tandem MS/MS, we chose Glu-C as the restricting enzyme to 
avoid small fragments with mass-to-charge ratios below the limit of detection of our instrument.1 All 
samples were digested with Glu-C sequencing enzyme, procured from Sigma Aldrich (Roche Life Sciences 
subsidiary) and used without further purification. MS/MS experiments were run on a nano-LC (Dionex 
RSLC-nano) with an Orbitrap Fusion Tribrid ETD mass spectrometer. This work was conducted by the 
Proteomics Resource Facility at the University of Michigan. 
 
Inhibition Assays: For compounds 10-23, IC50 values for human GRK5, bovine GRK2, and bovine GRK1 
were determined using a radiometric assay as follows. 50 nM GRK was incubated with 500 nM porcine 
brain tubulin (Cytoskeleton) and 0 - 333 μM inhibitor in 20 mM HEPES pH 7.0, 2 mM MgCl2, 0.025% 
dodecylmaltoside (DDM), 3% DMSO for 20-30 min for GRK1 and 2 and 0-1 hr for GRK5, as denoted in 
Table 1, on ice, prior to initiation with the addition of 5 µM ATP supplemented with radioactive [ -32P]-
ATP (PerkinElmer Life Sciences). Reactions were quenched at 5 min by addition of 6 μL of 4X SDS gel 
loading dye to the 6 μL reactions. 8 μL samples were separated on a 4-15% Criterion TGX precast gel (Bio-
Rad). Experiments were performed with an n = 3 in duplicate. 
 
For the remaining compounds CCG-264099-265328, IC50 values for human GRK5, bovine GRK2, bovine 
GRK6, and bovine GRK5-C474S were similarly determined with the following differences. Inhibitors were 
assessed over the range of 1 nM–1 mM in 20 mM HEPES pH 7.5, 10 mM NaCl, 10 mM MgCl2, 2 mM 
DTT after a 4 hr incubation at room temperature prior to reaction initiation with ATP. Reactions were 
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quenched at 8 min by transferring 10 μL reaction into 5 μL 4X SDS gel loading dye. 10 μL samples were 
separated on a 4-15% Criterion TGX precast gel. These conditions were also used to assess compound 10 
for GRK5 (4 hr), GRK2, and GRK5-C474S but with the addition of 3% DMSO (final) to the incubation 
buffer. Experiments were performed with an n = 3 except for assays involving 5 against GRK5, GRK6, and 
GRK5-C474S with 4 hr incubations, which were performed 4 times. 
 
For compounds CCG-258903 and CCG-265328, IC50 values were also determined when opsin was used as 
the substrate. 50 nM of GRK5 were preincubated with 0-750 µM inhibitor in buffer containing 20 mM 
HEPES pH 7.0, 2 mM MgCl2, 0.025% dodecylmaltoside (DDM), 3% DMSO for 0, 30, 60 or 240 min. 
Rhodopsin in the rod outer segment was exposed to the light for approximately 3 min right before 
phosphorylation. 5 µM ATP supplemented with radioactive [ -32P]-ATP (PerkinElmer Life Sciences) was 
added to initiate the reaction. Reactions were quenched at 5 min by addition of 10 μL of 4X SDS gel loading 
dye to the 20 μL reactions. 12 μL samples were separated on a 4-15% Criterion TGX precast gel (Bio-Rad). 
Experiments were performed with an n = 2 for compound 5 an n=3 for compound 16d. 
 
Gels were dried, exposed to a storage phosphor screen overnight, and scanned using a Typhoon scanner. 
Bands corresponding to phosphorylated tubulin were quantified using ImageQuant, plotted as a function of 
log[inhibitor], and fit to the three-parameter log(inhibitor) vs. response model in GraphPad Prism 7.03 to 
determine the IC50., and mean and standard deviation values were calculated using the column statistics 
function of GraphPad Prism 7.03. 
 
Standard control compounds are run during each assay to assess consistency across time, experimenters, 
and subtle changes in assay conditions that are sometimes required to keep some of the compounds soluble 
and disperse (such as through addition of DDM or 3% DMSO). Paroxetine, GSK180736A, and CCG215022 







Scheme 2.5: Synthesis of non-homologated para-substituted analogues 10 and 11. 
2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (5): To a 100 mL round bottom flask was added 2,4-
dichloro-7H-pyrrolo[2,3-d]pyrimidine 4 (1.0 g, 5.32 mmol), 4 – methylbenzene – 1 – sulfonyl chloride 
(1.12 g, 5.85 mmol), tetra – butyl ammonium chloride (0.07 g, 0.27 mmol), and dichloromethane (20 mL). 
Then 6N sodium hydroxide (2.66 mL, 15.96 mmol) was added dropwise. The slurry was stirred at room 
temperature vigorously for 1.5 hours going from cloudy to clear. The reaction was then diluted with water 
and the layers were separated. The organic layer was washed with NaCl (1x), and then dried with MgSO4. 
The MgSO4 was filtered off and the filtrate was then concentrated. The resulting off white solid was purified 
using 100% dichloromethane to give the title compound as a white solid (1.64 g, 4.79 mmol, 89% yield). 
1H NMR (500 MHz, DMSO-d6) δ 8.13 (d, J = 4.0 Hz, 1H), 8.07 – 8.01 (m, 2H), 7.51 (d, J = 8.2 Hz, 2H), 
6.99 (d, J = 4.1 Hz, 1H), 2.39 (s, 4H). HPLC (gradient A): retention time = 8.207 min; purity = 98%. 
2-((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide (6): To a 100 mL round bottom 
flask was added 2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine 5 (0.93 g, 2.72 mmol) and 2 – 
aminobenzamide S7 (1.48 g, 10.88 mmol). Isopropanol (16 mL) and di-isopropylethylamine (2.38 mL, 13.6 
mmol) were then added and the reaction was heated to reflux at 85 ˚C. All solids went into solution upon 
heating. After refluxing overnight, the reaction was cooled down and the resulting white precipitate was 
filtered off and washed with additional isopropanol to give the title compound (1.10 g, 2.49 mmol, 92% 
yield). 1H NMR (400 MHz, DMSO-d6) δ 12.34 (s, 1H), 8.50 – 8.43 (m, 1H), 8.32 (s, 1H), 8.00 (d, J = 8.2 
Hz, 2H), 7.85 (d, J = 7.9 Hz, 1H), 7.81 (s, 1H), 7.77 (d, J = 3.9 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.49 (d, J 
45 
 
= 8.1 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H), 6.70 (d, J = 4.0 Hz, 1H), 2.38 (s, 3H). HPLC (gradient A): retention 
time = 7.890 min; purity = 99%. 
5-((4-amino-2-methoxyphenyl)amino)-3-tosylpyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one (7): 
To a 100 mL pressure vessel was added 2-((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide 6 (0.221 g, 0.500 mmol), (9H-fluoren-9-yl)methyl (4-amino-3-
methoxyphenyl)carbamate 13 (0.189 g, 0.525 mmol), 4M HCl in dioxanes (0.50 mL, 2.0 mmol), potassium 
iodide (0.01 g, 0.06 mmol), and trifluoroethanol (10 mL). The sealed reaction was then heated overnight at 
90 ˚C. The following day the reaction was cooled to room temperature and then a light yellow/orange solid 
was filtered off and taken as is to the next step. 
2-((2-((4-amino-2-methoxyphenyl)amino)-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (8): To a 50 mL pressure vessel was added crude 5-((4-amino-2-
methoxyphenyl)amino)-3-tosylpyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one 7 (0.264 g, 0.50 
mmol), 28% ammonium hydroxide in water (10 mL), and THF (10mL). The sealed reaction was heated to 
60 ˚C overnight. After cooling the reaction was diluted with dichloromethane and water. The layers were 
separated, and the organic layer was washed with NaCl (2x) and then dried over sodium sulfate. The sodium 
sulfate was filtered off and the filtrate was concentrated. The resulting orange solid was purified using 0-
10% MeOH/DCM to give the title compound as a white solid (0.120 g, 0.065 mmol, 44% yield over two 
steps). 1H NMR (400 MHz, DMSO-d6) δ 12.12 (s, 1H), 8.80 (s, 1H), 8.31 (s, 1H), 7.93 (d, J = 7.8 Hz, 2H), 
7.84 – 7.80 (m, 1H), 7.75 (s, 1H), 7.36 (d, J = 8.1 Hz, 3H), 7.33 (d, J = 4.0 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 
6.46 (d, J = 4.0 Hz, 1H), 6.38 (d, J = 2.2 Hz, 1H), 6.32 – 6.24 (m, 1H), 5.02 (s, 2H), 3.70 (s, 3H), 2.36 (s, 
3H). HPLC (gradient A): retention time = 5.711 min; purity = 94%.  
2-((2-((4-amino-2-methoxyphenyl)amino)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4- 
yl)amino)benzamide (9): To a 50 mL round bottom flask was added 2-((2-((4-amino-2- 
methoxyphenyl)amino)-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 
8 (0.315 g, 0.579 mmol) followed by THF (10 mL), MeOH (2 mL), and 3N potassium hydroxide (6.0 mL). 
The reaction was stirred, refluxing, at 65 ̊ C overnight. After cooling the organic solvents were concentrated 
off and then the reaction was diluted with ethyl acetate. The layers were then separated, and the organic 
layer was washed with NaCl (1x) and dried over sodium sulfate. The sodium sulfate was then filtered off 
and the resulting filtrate was concentrated and purified using 0% - 8% MeOH/DCM to give the title 
compound as a slightly grey solid (0.132 g, 0.339 mmol, 59% yield). 1HNMR (400 MHz, DMSO-d6) δ 
11.95 (s, 1H),11.19 (s, 1H), 8.97 (d, J = 8.5 Hz, 1H), 8.28 (s, 1H), 7.88 – 7.77 (m, 1H), 7.77 – 7.65 (m, 1H), 
7.52 (d, J = 8.3 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.29 (s, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.91 (dd, 
J = 3.4, 2.2 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 6.22 (dd, J = 3.5, 1.9 Hz, 1H), 6.18 (dd, J = 8.4, 





CCG-258903)): In a 25 mL flask 2-((2-((4-amino-2- 
methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 9 (0.10 g, 0.257 
mmol) was dissolved in THF (6.0 mL). Diisopropylethylamine (0.134 mL, 0.770 mmol) and 1- 
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.098 g, 0.512 mmol) were then 
added and the reaction was stirred ten minutes and cooled to 0 ˚C. Acrylic acid (0.02 mL, 0.282 
mmol) was then added and the reaction was allowed to warm to room temperature and stir overnight. Water 
was added to quench the reaction and then ethyl acetate was added to extract the organics. The layers were 
separated, and the organic layer was washed with NaHCO3 (1x), dried over magnesium sulfate, and 
concentrated. The resulting residue was purified using flash chromatography (0 – 10% MeOH/DCM) to 
give a light yellow solid as the desired compound 
(0.0107 g, 0.024 mmol, 10% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.99 (s, 1H), 11.36 (s, 
1H), 10.10 (s, 1H), 8.93 (d, J = 8.5 Hz, 1H), 8.30 (s, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.83 (d, J = 
7.7 Hz, 1H), 7.74 (s, 1H), 7.56 – 7.43 (m, 3H), 7.24 – 7.16 (m, 1H), 7.07 – 6.97 (m, 2H), 6.44 
(dd, J = 17.0, 10.1 Hz, 1H), 6.32 – 6.20 (m, 2H), 5.78 – 5.70 (m, 1H), 3.85 (s, 3H). HPLC 
(gradient A): retention time = 4.987 min; purity = 95%. Molecular formula: C23H21N7O3, Mass Calc: 443.17, 
ESI-MS Found: 444.1626 [M+1] 
(E)-2-((2-((4-(4-(dimethylamino)but-2-enamido)-2-methoxyphenyl)amino)-7H-pyrrolo[2,3- 
d]pyrimidin-4-yl)amino)benzamide (11, CCG-263045): In a 25 mL flask 2-((2-((4- 
amino-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 9 (0.137 
g, 0.352 mmol) was dissolved in THF (6.0 mL). Diisopropylethylamine (0.246 mL, 0.1.41 
mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.108 g, 0.563 
mmol) were then added and the reaction was stirred ten minutes and cooled to 0 ˚C. Trans–4–
dimethylaminocrotonic acid hydrochloride (0.070 g, 0.422 mmol) was then added and the reaction was 
allowed to warm to room temperature and stir overnight. Water was added to quench the reaction and then 
ethyl acetate was added to extract the organics. The layers were separated, and the organic layer was washed 
with NaCl (1x), dried over magnesium sulfate, and concentrated. The resulting residue was purified using 
flash chromatography (5 – 10% MeOH/DCM) to give a light brown solid as the desired compound (0.017 
g, 0.034 mmol, 10% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.99 (s, 1H), 11.36 (s, 1H), 10.02 (s, 1H), 
8.94 (dd, J = 8.4, 1.2 Hz, 1H), 8.30 (s, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.83 (dd, J = 8.1, 1.6 Hz, 1H), 7.75 (s, 
1H), 7.56 – 7.42 (m, 3H), 7.17 (dd, J = 8.7, 2.1 Hz, 1H), 7.07 – 6.96 (m, 2H), 6.72 (dt, J = 15.4, 5.9 Hz, 
1H), 6.31– 6.24 (m, 2H), 3.84 (s, 3H), 3.10 – 3.03 (m, 2H), 2.19 (s, 6H). HPLC (gradient A): retention time 
47 
 




Scheme 2.6: Synthesis of non-homologated meta-substituted analogues. 
(9H-fluoren-9-yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-
b]quinazolin-5-yl)amino)phenyl)carbamate (14): To a 100 mL pressure vessel was added 2-((2-chloro-7-
tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 6 (0.60 g, 1.36 mmol), (9H-fluoren-9-yl)methyl 
(3-amino-4-methoxyphenyl)carbamate 19 (0.515 g, 1.43 mmol), 4M HCl in dioxanes (1.36 mL, 5.44 
mmol), potassium iodide (0.04 g, 0.24 mmol), and trifluoroethanol (40 mL). The sealed reaction was then 
heated overnight at 90 ˚C. The following day the reaction was cooled to room temperature and then diluted 
with water and an excessive amount of dichloromethane (~100 mL, otherwise an emulsion will form). The 
layers were separated and the organic was washed with NaCl (1x) and dried with sodium sulfate. The 
sodium sulfate was then filtered off and the filtrate was concentrated to give a light yellow/orange solid 
which was taken as is to the next step. 
(9H-fluoren-9-yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-
b]quinazolin-5-yl)amino)phenyl)carbamate (15): To a 100 mL pressure vessel was added (9H-fluoren-9-
yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-5-
yl)amino)phenyl)carbamate 14 (1.02 g, 1.36 mmol), 28% ammonium hydroxide in water (20 mL), and THF 
(20mL). The reaction was heated in a sealed pressure vessel to 60 ˚C overnight. After cooling the reaction 
was diluted with ethyl acetate and water. The layers were separated, and the organic layer was washed with 
NaCl (2x) and then dried of sodium sulfate. The sodium sulfate was filtered off and the filtrate was 
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concentrated. The resulting orange solid was triturated in dichloromethane to give the title compound as an 
off white solid (0.378 g, 0.70 mmol, 51% yield over two steps). 1H NMR (400 MHz, DMSO-d6) δ 12.13 
(s, 1H), 8.76 (dd, J = 8.5, 1.1 Hz, 1H), 8.31 (s, 1H), 8.03 – 7.97 (m, 2H), 7.93 (s, 1H), 7.83 (dd, J = 8.0, 1.5 
Hz, 1H), 7.76 (s, 1H), 7.49 (ddd, J = 8.6, 5.7, 1.5 Hz, 2H), 7.41 (d, J = 4.0 Hz, 1H), 7.38 (d, J = 8.2 Hz, 
2H), 7.09 – 7.02 (m, 1H), 6.81 (d, J = 8.6 Hz, 1H), 6.53 (d, J = 4.0 Hz, 1H), 6.37 (dd, J = 8.5, 2.7 Hz, 1H), 
4.55 (s, 2H), 3.72 (s, 3H), 2.34 (s, 3H). HPLC (gradient A): retention time = 5.850 min; purity = 88%. 
2-((2-((5-amino-2-methoxyphenyl)amino)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (16): To a 25 mL round bottom flask was added (9H-fluoren-9-yl)methyl (4-methoxy-
3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-5-yl)amino)phenyl)carbamate 
15 (0.158 g, 0.291 mmol), methanol (2 mL), 3N potassium hydroxide (2 mL) and THF (4.5 mL). The 
reaction was heated to 65 ˚C and stirred overnight for two days. The reaction was then cooled, and the 
organic layers were concentrated off. The resulting suspension in the aqueous layer was then filtered off to 
give adequately pure compound (0.082 mg, 72% yield). 1H NMR (500 MHz, DMSO-d6) δ 11.99 (s, 1H), 
11.33 (s, 1H), 8.97 (d, J = 8.1 Hz, 1H), 8.28 (s, 1H), 7.83 (dd, J = 8.0, 1.5 Hz, 1H), 7.72 (s, 1H), 7.59 – 7.49 
(m, 2H), 7.39 (s, 1H), 7.06 – 6.97 (m, 2H), 6.73 (d, J = 8.6 Hz, 1H), 6.29 (dd, J = 3.5, 1.9 Hz, 1H), 6.21 
(dd, J = 8.5, 2.7 Hz, 1H), 4.47 (s, 2H), 3.74 (s, 3H). HPLC (gradient A): retention time = 4.166 min; purity 
= 91%. 
2-((2-((5-acrylamido-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide (17, 
CCG-258904): In a 25 mL flask 2-((2-((5-amino-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-
4-yl)amino)benzamide  16 (0.088 g, 0.226 mmol) was dissolved in THF (6.0 mL). Diisopropylethylamine 
(0.12 mL, 0.678 mmol) and 1-Ethyl-3-(3 dimethylaminopropyl)carbodiimide hydrochloride (0.087 g, 0.452 
mmol) were then added and the reaction was stirred ten minutes and cooled to 0 ˚C. Acrylic acid (0.017 
mL, 0.249 mmol) was then added and the reaction was allowed to warm to room temperature and stir 
overnight. Water was added to quench the reaction and then ethyl acetate was added to extract the organics. 
The layers were separated, and the organic layer was washed with NaCO3 (1x), dried over magnesium 
sulfate, and concentrated. The resulting residue was subjected to flash chromatography (5 – 10% 
MeOH/DCM) and then purified using reverse phase chromatography (30 – 60% Acetonitrile/Water) to give 
the desired compound as a light yellow solid (0.012 g, 0.026 mmol, 12% yield). 1H NMR (500 MHz, 
DMSO-d6) δ 12.05 (s, 1H), 11.44 (s, 1H), 10.05 (s, 1H), 8.94 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 2.8 Hz, 2H), 
7.82 (dd, J = 7.9, 1.6 Hz, 1H), 7.73 (s, 1H), 7.59 (s, 1H), 7.44 – 7.36 (m, 2H), 6.98 (q, J = 7.1, 5.9 Hz, 3H), 
6.45 (dd, J = 17.0, 10.2 Hz, 1H), 6.29 (d, J = 3.5 Hz, 1H), 6.22 (dd, J = 17.0, 2.1 Hz, 1H), 5.71 (dd, J = 10.0, 
2.1 Hz, 1H), 3.84 (s, 3H). HPLC (gradient A): retention time = 4.921 min; purity = 93%. Molecular 




4-yl)amino)benzamide (18, CCG-263115): In a 25 mL flask 2-((2-((5-amino-2-methoxyphenyl)amino)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 16 (0.073 g, 0.187 mmol) was dissolved in THF (4.0 
mL). Diisopropylethylamine (0.10 mL, 0.561 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (0.047 g, 0.243 mmol) were then added and the reaction was stirred ten minutes and cooled 
to 0 ˚C. Trans–4–dimethylaminocrotonic acid hydrochloride (0.034 g, 0.206 mmol) was then added and the 
reaction was allowed to warm to room temperature and stir three hours. Water was added to quench the 
reaction and then ethyl acetate was added to extract the organics. The layers were separated, and the organic 
layer was washed with NaCl (1x), dried over magnesium sulfate, and concentrated. The resulting residue 
was purified using flash chromatography (5 – 10% MeOH/DCM) to give a light brown solid as the desired 
compound (0.012 g, 0.024 mmol, 13% yield). 1H NMR (500 MHz, DMSO-d6) δ 12.07 (s, 1H), 11.34 (s, 
1H), 9.88 (s, 1H), 8.94 (dd, J = 8.6, 1.2 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J = 2.5 Hz, 1H), 7.82 (dd, J = 7.9, 
1.6 Hz, 1H), 7.74 (s, 1H), 7.60 (s, 1H), 7.43 – 7.34 (m, 2H), 7.05 – 6.94 (m, 3H), 6.75 – 6.65 (m, 1H), 6.30 
– 6.22 (m, 2H), 3.83 (s, 3H), 3.04 (dd, J = 6.1, 1.6 Hz, 2H), 2.18 (s, 6H). HPLC (gradient A): retention time 




Scheme 2.7 Synthesis of saturated analogs 22 and 23. 
2-((2-((2-methoxy-4-propionamidophenyl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (20): To a 25 mL round bottom flask was added 2-((2-((4-amino-2-
methoxyphenyl)amino)-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide  8 (0.070 
g, 0.128 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.049 g, 0.258 mmol), 
diisopropylethylamine (0.068 mL, 0.387 mmol), and THF (4.0 mL). The reaction was cooled to 0 ˚C and 
then stirred for ten minutes before adding propionic acid (0.012 mL, 0.155 mmol).  The reaction was further 
50 
 
stirred overnight. Water was added to quench the reaction and then the reaction was further diluted with 
ethyl acetate. The two layers were separated. The organic layer was washed with 10% citric acid (1x), NaCl 
(2x), and then dried with sodium sulfate. The sodium sulfate was then filtered off and the filtrate was 
concentrated. The resulting residue was purified using 0 – 5% methanol/dichloromethane to give the title 
compound as a light pink solid (0.022 g, 0.041 mmol, 32% yield). 1H NMR (400 MHz, DMSO-d6) δ 12.12 
(s, 1H), 9.88 (s, 1H), 8.75 (d, J = 8.4 Hz, 1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.94 (d, J = 8.1 Hz, 3H), 7.82 (dd, 
J = 8.0, 1.6 Hz, 1H), 7.76 (s, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.48 – 7.34 (m, 4H), 7.20 (dd, J = 8.6, 2.1 Hz, 
1H), 7.10 – 7.02 (m, 1H), 6.52 (d, J = 4.0 Hz, 1H), 3.81 (s, 3H), 2.41 – 2.30 (m, 5H), 1.12 (t, J = 7.6 Hz, 
3H). HPLC (gradient A): retention time = 7.312 min; purity = 94%. 
2-((2-((2-methoxy-5-propionamidophenyl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (21): To a 25 mL round bottom flask was added (9H-fluoren-9-yl)methyl (4-methoxy-
3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-5-yl)amino)phenyl)carbamate  
15 (0.100 g, 0.184 mmol), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.071 g, 0.368 
mmol), diisopropylethylamine (0.096 mL, 0.552 mmol), and THF (4.0 mL). The reaction was cooled to 0 
˚C and then stirred for ten minutes before adding propionic acid (0.017 mL, 0.221 mmol).  The reaction 
was further stirred overnight. Water was added to quench the reaction and then the reaction was further 
diluted with ethyl acetate. The two layers were separated. The organic layer was washed with 10% citric 
acid (1x), NaCl (2x), and then dried with sodium sulfate. The sodium sulfate was then filtered off and the 
filtrate was concentrated. The resulting residue was purified using 0 – 5% isopropanol/dichloromethane to 
give the title compound as a white solid (0.065 g, 0.108 mmol, 59% yield). 1H NMR (400 MHz, DMSO-
d6) δ 12.20 (s, 1H), 9.71 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.97 (d, J = 8.2 Hz, 
2H), 7.93 (d, J = 2.5 Hz, 1H), 7.82 (dd, J = 8.0, 1.5 Hz, 1H), 7.77 (s, 1H), 7.39 (d, J = 4.0 Hz, 1H), 7.38 – 
7.28 (m, 4H), 7.07 – 6.99 (m, 2H), 6.50 (d, J = 4.0 Hz, 1H), 3.79 (s, 3H), 2.34 (s, 3H), 2.29 (q, J = 7.6 Hz, 
2H), 1.07 (t, J = 7.6 Hz, 3H). HPLC (gradient A): retention time = 7.195 min; purity = 93%.  
2-((2-((2-methoxy-4-propionamidophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4- 
yl)amino)benzamide (22, CCG-262604): In a 25 mL round bottom flask a suspension of 
2-((2-((2-methoxy-4-propionamidophenyl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4- 
yl)amino)benzamide (0.022 g, 0.037 mmol), MeOH (1.0 mL), THF (4.0 mL), and 2N NaOH (4.0mL) was 
stirred overnight becoming clearer. The reaction was diluted with ethyl acetate and 
water. The layers were separated and the organic was washed with NaCl (1x), dried over MgSO4, and 
concentrated. The resulting crude residue was purified using 5% - 10% MeOH/DCM and then further 
purified by recrystallizing from 15% MeOH/DCM overnight (~ 1.5 mL) to give the title compound as an 
off white solid (0.013 g, 0.029 mmol, 78% yield). 1H NMR (400 MHz,DMSO-d6) δ 11.99 (s, 1H), 11.34 
(s, 1H), 9.79 (s, 1H), 8.93 (d, J = 8.5 Hz, 1H), 8.30 (s, 1H), 8.13 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.0 Hz, 
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1H), 7.75 (s, 1H), 7.53 – 7.40 (m, 3H), 7.10 (d, J = 8.7 Hz, 1H), 7.05 – 6.95 (m, 2H), 6.28 (s, 1H), 3.82 (s, 
3H), 2.31 (q, J = 8.5, 7.5 Hz, 2H), 1.09 (t, J = 7.5 Hz, 3H). HPLC (gradient A): retention time = 4.906 min; 
purity = 95%. Molecular Formula: C23H23N7O3, Mass Calc: 445.19, ESI-MS Found: 446.1926 [M+1] 
2-((2-((2-methoxy-5-propionamidophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 
(23, CCG-262606): In a 25 mL flask 2-((2-((2-methoxy-5- propionamidophenyl)amino)-7-tosyl-7H-
pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 128 (0.062 g, 0.104 mmol) was suspended in 1,4 – 
dioxanes (5.0 mL) and 2N NaOH (5.0 mL) and the reaction was stirred vigorously. After 2 hours the 
reaction was still cloudy and THF (3 mL) and MeOH (1 mL) were then added and the reaction was stirred 
overnight. The organics were then concentrated off and the pH was lowered with concentrated HCl at which 
point a new side product formed. Assuming it was the cyclized lactam the compound was then stirred in a 
sealed reaction vessel with 28% NH4OH (4 mL) and THF (4 mL) at 40 ˚C for four hours, concentrated, 
and extracted with ethyl acetate (disappearance of the side product was observed confirming likelihood of 
it being the cyclized lactam). The organic was then washed with NaCl (1x), dried over MgSO4, and 
concentrated. The resulting residue was then purified on flash chromatography using a gradient of 0 – 5% 
MeOH/DCM to afford the desired product as a pale yellow solid (0.036 mg, 0.081 mmol, 78% yield). 1H 
NMR (400 MHz, DMSO-d6) δ 12.07 (s, 1H), 11.33 (s,1H), 9.65 (s, 1H), 8.97 – 8.90 (m, 1H), 8.30 (s, 1H), 
8.15 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 7.9 Hz,1H), 7.75 (s, 1H), 7.58 (s, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.30 
(dd, J = 8.8, 2.5 Hz, 1H), 7.04 –6.92 (m, 3H), 6.29 (dd, J = 3.5, 1.9 Hz, 1H), 3.82 (s, 3H), 2.27 (q, J = 7.6 
Hz, 2H), 1.07 (t, J =7.6 Hz, 3H). HPLC (gradient A): retention time = 4.927 min; purity = 95% Molecular 











To a flame dried flask were added 5.0002 g (30 mmol) of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (4), 
dissolved in 60 mL of DMF. The solution was cooled to 0 ˚C, and 666.3 mg of NaH (60% dispersion in 
mineral oil, 27.76 mmol, 0.9 equiv) were added portion wise. The solution was allowed to stir at room 
temperature for 30 min, then cooled back to 0 ̊ C and 6.0 mL of SEM-Cl (30 mmol) then added. The solution 
was then allowed to warm to rt and stirred for 6 h. The reaction was quenched with 500 mL of brine and 
then extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with brine (1 x 150 
mL) and then dried over MgSO4. The solvent was removed under pressure, and the yellow residue was 
taken up in hexanes. The solution was run through a silica plug, eluting with a gradient of hexanes to 5% 
EtOAc/hexanes. The solvent was removed under pressure to yield a white solid. Yield: 6.9200 g, 70% 
HPLC: 8.948 min, Molecular Formula: C12H17Cl2N3OSi, Mass Calc: 317.05, ESI MS-Found: 318 [M+1], 
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purity: 99% 1H NMR (500 MHz, Chloroform-d) δ 7.38 (d, J = 3.7 Hz, 1H), 6.68 (d, J = 3.7 Hz, 1H), 5.61 
(s, 2H), 3.67 – 3.59 (m, 2H), 1.00 – 0.88 (m, 2H), -0.03 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 160.97, 




methylbenzamide (25)  
A flask was charged with 1.000 g of 24 (3 mmol, 1 equiv.), 501.1 mg of 2-amino-N-methylbenzamide (3 
mmol, 1 equiv.), and 16 mL of THF. The resulting solution was cooled to 0 ˚C and 702.1 mg of KOtBu 
(6.0 mmol, 2 equiv.) were added to form an orange solution which was heated to 120 ̊ C for 3 h. The solution 
was cooled to rt and quenched with water,  extracted with EtOAc (3 x 100 mL) and the combined organic 
layers were washed with brine (1 x 50mL). The  organic layer was dried over Na2SO4 , filtered and 
concentrated in vacuo and purified by column chromatography eluting with 60% EtOAc/Hexanes to afford 
an off white solid. Yield:  802.0 mg, 60% HPLC: 8.96 min, Molecular Formula: C20H26ClN5O2Si, Mass 
Calc: 431.15, ESI-MS-Found: 432 [M+1], purity: 92% 1HNMR (500 MHz, DMSO-d6) δ 12.06 (s, 1H), 
8.80 (d, J = 5.0 Hz, 1H), 8.63 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.51 (d, 
J = 3.5 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 6.56 (d, J = 3.5 Hz, 1H), 5.51 (s, 2H), 3.52 (t, J = 8.0 Hz, 2H), 
2.82 (d, J = 4.4 Hz, 3H), 0.84 (t, J = 8.1 Hz, 2H), -0.08 (s, 9H). 13CNMR (126 MHz, dmso) δ 169.60, 153.90, 
152.61, 151.34, 140.04, 132.42, 128.62, 127.74, 122.56, 121.28, 121.13, 103.84, 98.70, 72.98, 66.03, 40.50, 





Compound 26 was prepared using protocols described in the literature.2 A  flame dried three neck flask was 
charged with 201.1 mg of 25 (0.463 mmol,1 equiv), 795.6 mg of Cs2CO3 (2.32 mmol,5 equiv.), 60.3 mg of 
BINAP, racemic (0.00927 mmol, 0.2 equiv.), Pd(OAc)2 (0.1 equiv., 5 mol%), and 84.1 mg of 4-amino-3-
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methoxybenzonitrile (0.555 mmol 1.2 equiv.). The mixture  was degassed with three cycles of evacuation 
and back filled with nitrogen and 4 mL of dioxanes added. The solution was further degassed with an 
additional 4 cycles of evacuation and back filled with nitrogen, then heated to 110 ˚C for 20 h. The reaction 
mixture was passed through a pad of celite, washing with EtOAc and purified by column chromatography 
eluting with 50% EtOAc/Hexanes to afford a dark red solid 56.2 mg, 22.3% HPLC: 8.912 min, Molecular 
Formula: C28H33N7O3Si, Mass Calc: 543.24 ESI-MS-Found: 544.17 [M+1], purity: 90% 1H NMR (500 
MHz, Chloroform-d) δ 11.19 (s, 1H), 8.86 (dd, J = 8.5, 5.7 Hz, 2H), 7.78 (s, 1H), 7.56 – 7.49 (m, 2H), 7.10 
– 7.05 (m, 2H), 7.01 (d, J = 3.6 Hz, 1H), 6.64 (d, J = 3.7 Hz, 1H), 5.56 (s, 2H), 3.62 – 3.57 (m, 2H), 3.05 
(d, J = 4.8 Hz, 3H), 0.98 – 0.92 (m, 2H), -0.07 (d, J = 1.0 Hz, 9H).13CNMR (126 MHz, dmso) δ 169.62, 
163.07, 158.90, 153.91, 152.63, 151.36, 140.05, 132.42, 128.63, 127.73, 123.88, 122.57, 118.65, 117.79, 






To a dried flask were added 270.2 mg of 26 and10 mL (13 mmol) of  7N methanolic ammonia.3 The solution 
was degassed with three rounds of evacuation and back filled with nitrogen. RaNi (slurry in water) was 
added and the mixture was further degassed with three rounds of evacuation and back filled with nitrogen. 
The atmosphere was then replaced with hydrogen and allowed to stir under H2 for 6 h. Once complete, H2 
atmosphere was removed and the solution was passed through a pad of celite, washing with methanolic 
ammonia. The solvent was removed under pressure to give a light green solid, 250 mg, 92%. HPLC: 6.331 
min, Molecular Formula: C28H37N7O3Si, Mass Calc: 547.27 ESI-MS-Found: 548.2719 [M+1], purity: 97%. 
1HNMR (500 MHz, DMSO-d6) δ 11.76 (s, 1H), 8.82 (dq, J = 30.6, 7.9 Hz, 2H), 8.41 (dd, J = 32.4, 24.4 
Hz, 1H), 7.81 (q, J = 15.7, 10.9 Hz, 1H), 7.70 – 7.59 (m, 1H), 7.54 (dt, J = 25.5, 12.4 Hz, 1H), 7.21 (s, 1H), 
7.15 – 7.05 (m, 2H), 6.93 (dt, J = 22.3, 10.2 Hz, 1H), 6.46 (s, 1H), 5.49 (d, J = 18.2 Hz, 2H), 4.08 – 4.04 
(m, 2H), 3.90 (d, J = 25.2 Hz, 3H), 3.62 – 3.54 (m, 3H), 2.86 (s, 3H), 0.93 – 0.87 (m, 2H), -0.08 (d, J = 10.4 
Hz, 9H).13CNMR (126 MHz, dmso) δ 170.66, 169.78, 155.97, 153.45, 152.36, 148.46, 141.03, 134.79, 
132.16, 128.36, 126.19, 124.07, 121.24, 121.13, 119.91, 119.23, 117.65, 113.43, 108.23, 99.45, 98.55, 







A dried flask was charged with 0.02 mL of propionic acid (0.0913 mmol, 1 equiv), 2 drops of DMF, and 2 
mL of DCM (40 mmol). The mixture was cooled to 0 ˚C and 0.04 mL of oxalyl chloride (5 equiv., 0.5 
mmol) were added. The mixture was allowed to warm to rt and stir for 1 h.  Once complete, the solvent was 
removed under pressure and the light green residue was rinsed with DCM (3 x 10 mL). The green residue 
was then taken up in DCM (2 mL, 40 mmol), and the mixture was cooled back to 0 ˚C. At 0 ˚C were added 
0.1 mL of DIPEA (0.0913 mmol,1.0 equiv.), and 50.4 mg of 27 (1 equiv, 0.09 mmol). The solution was 
warmed to rt for 3 h. Once complete the solvent was removed. The dark yellow residue was purified by 
preparatory TLC plate (EtOAc/1% MeOH). The band containing the desired material was collected, and 
the material was eluted off silica gel with acetone. The solvent was removed to give a light yellow solid, 5 
mg, 9%. HPLC: 7.04 min, Molecular Formula: C31H41N7O4Si, Mass Calc: 603.30 ESI-MS-Found: 604 
[M+1], purity: 90%. 1HNMR (700 MHz, DMSO-d6) δ 11.69 (s, 1H), 8.82 – 8.78 (m, 1H), 8.75 (d, J = 4.8 
Hz, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.22 (t, J = 5.8 Hz, 1H), 7.95 (s, 1H), 7.75 (dd, J = 7.9, 1.6 Hz, 1H), 7.63 
(s, 1H), 7.52 – 7.46 (m, 1H), 7.18 (d, J = 3.6 Hz, 1H), 7.07 (td, J = 7.7, 1.2 Hz, 1H), 6.94 (d, J = 1.8 Hz, 
1H), 6.83 (dd, J = 8.2, 1.8 Hz, 1H), 6.41 (d, J = 3.6 Hz, 1H), 5.47 (s, 2H), 4.24 (d, J = 5.9 Hz, 2H), 3.87 (s, 
3H), 3.57 – 3.51 (m, 2H), 2.82 (d, J = 4.5 Hz, 3H), 2.15 (q, J = 7.6 Hz, 2H), 1.04 (t, J = 7.6 Hz, 3H), 0.89 – 
0.84 (m, 2H), -0.10 (s, 9H).13CNMR (176 MHz, dmso) δ 173.25, 169.89, 162.79, 156.06, 153.56, 152.46, 
148.64, 141.08, 133.36, 132.27, 128.68, 124.24, 121.39, 120.11, 119.49, 118.29, 110.20, 99.53, 98.65, 







methylbenzamide (33, CCG-264561) 
A dried flask was charged with 5 mg of 28 (8 µmol, 1.0 equiv), and 2 mL of DCM. The solution was cooled 
to 0 ˚C, and 0.08 mL of TFA (25 equiv., 0.2 mmol) were added in one portion. The solution was warmed 
to 80 ˚C  and stirred until complete. Once complete, the solvent was removed, and the residue was rinsed 
with DCM ( 3 x 5 mL). The yellow residue was then purified by preparatory TLC plate (1% MeOH/EtOAc). 
The band containing the desired material was collected, and the material was washed off silica gel with 
MeOH. The solvent was removed to give a light yellow oil, 2.0 mg, 50%. HPLC: 4.99 min, Molecular 
Formula: C25H27N7O3, Mass Calc: 473.22 ESI-MS-Found: 474 [M+1], purity: 92% 1HNMR (700 MHz, 
DMSO-d6) δ 11.68 (s, 1H), 8.80 (d, J = 8.3 Hz, 1H), 8.75 (d, J = 5.1 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 8.23 
(s, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.60 (s, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 3.6 Hz, 1H), 7.06 (t, J = 
7.5 Hz, 1H), 6.93 (s, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.46 (t, J = 7.3 Hz, 1H), 6.38 (d, J = 3.6 Hz, 1H), 4.24 
(d, J = 5.9 Hz, 2H), 3.86 (d, J = 4.3 Hz, 3H), 2.82 (d, J = 4.5 Hz, 3H), 2.16 (dd, J = 10.7, 4.7 Hz, 2H), 1.05 
(t, J = 7.6 Hz, 3H). 13CNMR (176 MHz, dmso) δ 173.25, 169.89, 162.79, 156.06, 153.56, 152.46, 148.64, 






A dried flask was charged with 0.05 mL of acrylic acid (0.219 mmol, 1 equiv), 2 drops of DMF and 2 mL 
of THF (0.1 molar).The mixture was cooled to 0 ˚C and 0.1 mL of oxalyl chloride (1.14 mmol, 5.1 equiv) 
were added. The solution was allowed to warm to rt for 1 h. Once complete, the solvent was removed under 
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pressure and the light green residue was rinsed with DCM (3 x 10 mL). The light green residue was then 
taken up in DCM ( 5 mL, 40 mmol) and cooled to 0 ˚C. At 0 ˚C, 120 mg of 27 (0.219 mmol, 1 equiv) and 
0.1 mL of DIPEA (0.57 mmol, 2.6 equiv) were added. The solution warmed to rt and stirred until reaction 
was complete. Once complete, the solvent was removed, evaporating product onto silica gel. The material 
was purified by column chromatography (EtOAc/Hex). The major product was eluted in MeOH  and 
collected to give a light yellow solid, 70.6 mg, 53.6%. HPLC: 7.24 min, Molecular Formula: C31H39N7O4Si, 
Mass Calc: 601.28 ESI-MS-Found: 674 [M+Acrylic Acid], purity: 90%. 1HNMR (700 MHz, DMSO-d6) δ 
11.71 (d, J = 4.9 Hz, 1H), 8.80 (dt, J = 8.5, 3.0 Hz, 1H), 8.75 (q, J = 4.4 Hz, 1H), 8.55 (t, J = 5.9 Hz, 1H), 
8.35 (d, J = 8.0 Hz, 1H), 7.95 (s, 1H), 7.76 (dt, J = 8.0, 2.0 Hz, 1H), 7.64 (s, 1H), 7.49 (ddd, J = 8.5, 7.1, 
1.5 Hz, 1H), 7.20 – 7.17 (m, 1H), 7.10 – 7.04 (m, 1H), 6.97 (d, J = 1.8 Hz, 1H), 6.86 (dd, J = 8.2, 1.8 Hz, 
1H), 6.42 (dd, J = 3.6, 1.6 Hz, 1H), 6.33 – 6.27 (m, 1H), 6.17 – 6.12 (m, 1H), 5.47 (s, 2H), 4.34 (t, J = 6.0 
Hz, 2H), 3.87 (d, J = 4.5 Hz, 3H), 3.58 – 3.51 (m, 2H), 2.82 (d, J = 4.4 Hz, 3H), 0.88 – 0.84 (m, 2H), -0.10 
(s, 9H).13CNMR (176 MHz, dmso) δ 169.38, 164.43, 162.26, 155.53, 153.05, 151.94, 148.15, 140.58, 
132.31, 131.76, 128.36, 127.95, 125.19, 123.73, 120.87, 120.76, 119.57, 119.28, 119.10, 109.93, 99.06, 
98.14, 72.04, 65.29, 55.67, 42.21, 26.29, 17.08, -1.46. 
 
 2-((2-((4-(acrylamidomethyl)-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-
methylbenzamide (34, CCG-264099) 
A dried flask was charged with 10 mg of 29 (0.008 mmol, 1.0 equiv), and 2 mL of DCM (4 mmol).  The 
solution was cooled to 0 ˚C, and 0.20 mL of TFA (150 equiv.) were added in one portion. The dark red 
solution warmed to 80 ˚C for 3 h. Once complete, the mixture was cooled to rt and quenched with saturated 
K2CO3 in MeOH. The mixture was then extracted with DCM (3 x 30 mL) and the combined organic layers 
were washed with brine (1 x 30 mL). The organic layer was dried over MgSO4 and then purified by 
preparatory TLC plate (50% EtOAc/Hex with 5% MeOH) to yield a white solid, 4.7 mg, 60%. HPLC: 5.750 
min, Molecular Formula: C25H25N7O3, Mass Calc: 471.20 ESI-MS-Found: 472 [M+1], purity: 96%. 
1HNMR (700 MHz, DMSO-d6) δ 11.43 (s, 1H), 10.72 (s, 1H), 8.78 (d, J = 8.8 Hz, 1H), 8.55 (t, J = 5.8 Hz, 
1H), 8.22 (d, J = 8.1 Hz, 1H), 7.97 (dd, J = 8.0, 1.6 Hz, 1H), 7.61 – 7.56 (m, 2H), 7.10 (t, J = 7.9 Hz, 1H), 
7.03 (dd, J = 3.5, 2.2 Hz, 1H), 6.96 (d, J = 1.8 Hz, 1H), 6.85 (dd, J = 8.2, 1.8 Hz, 1H), 6.40 (dd, J = 3.5, 1.9 
Hz, 1H), 6.33 – 6.24 (m, 1H), 6.14 (dd, J = 17.1, 2.3 Hz, 1H), 5.62 (dd, J = 10.2, 2.2 Hz, 1H), 4.33 (d, J = 
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5.9 Hz, 2H), 3.86 (d, J = 8.8 Hz, 6H).. 13CNMR (176 MHz, dmso) δ 168.98, 164.94, 155.90, 153.28, 152.97, 
149.14, 142.41, 134.50, 133.02, 132.25, 131.05, 128.99, 125.74, 121.55, 121.40, 121.11, 119.83, 116.30, 






A dried flask was charged with 29.7 mg of (E)-4-(dimethylamino)but-2-enoic acid (1.0 equiv., 0.219 
mmol), 3 drops of DMF, and 2 mL of THF (0.1 molar). . The mixture  was cooled to 0 ˚C and 0.02 mL of 
oxalyl chloride (1.1 equiv., 0.241 mmol) were added. The solution was warmed to rt and allowed for 1 h. 
Once complete, the solvent was removed under pressure and the light green residue was rinsed with DCM 
(3 x 10 mL). The light green residue was then taken up in THF ( 5 mL, 40 mmol) and cooled to 0 ˚C. At 0 
˚C were added 120.0 mg of 27 (0.219 mmol, 1.0 equiv) and 0.1 mL of DIPEA (2.6 equiv., 0.57 mmol). The 
mixture was warmed to rt and stirred until reaction was complete. Once complete, the solvent was removed, 
evaporating product onto silica gel. The material was purified by column chromatography (30-50% 
EtOAc/Hex). The major product was collected, and the solvent was removed under pressure to give a light 
yellow solid, 53.2 mg, 36.9% HPLC: 7.288 min, Molecular Formula: C34H46N8O4Si, Mass Calc: 658.34 
ESI-MS-Found: 659.3460 [M+H], purity: 80%. 1HNMR (700 MHz, Chloroform-d) δ 8.91 (dd, J = 11.7, 
8.4 Hz, 2H), 8.64 – 8.60 (m, 2H), 8.10 (dd, J = 20.4, 7.9 Hz, 1H), 7.66 (s, 1H), 7.64 (d, J = 8.1 Hz, 2H), 
7.28 (d, J = 1.9 Hz, 1H), 7.20 (t, J = 7.3 Hz, 2H), 7.00 (s, 1H), 6.99 (d, J = 2.0 Hz, 1H), 6.98 (s, 1H), 6.83 
(d, J = 1.7 Hz, 1H), 6.32 (d, J = 7.7 Hz, 1H), 5.97 (d, J = 15.3 Hz, 1H), 5.53 (s, 2H), 4.47 (d, J = 5.6 Hz, 
2H), 3.91 (s, 3H), 3.55 (dt, J = 8.3, 2.2 Hz, 3H), 3.07 (dd, J = 6.2, 1.6 Hz, 2H), 3.02 (d, J = 4.7 Hz, 3H), 
2.18 (s, 6H), 0.88 (t, J = 6.9 Hz, 2H), -0.09 (s, 9H). 13CNMR (176 MHz, cdcl3) δ 168.97, 167.63, 166.29, 
155.12, 151.63, 147.90, 143.92, 143.34, 132.23, 130.15, 128.90, 122.70, 121.88, 120.48, 118.89, 117.88, 







Compound 16c was synthesized using the protocol described for 30. Yields a bright yellow solid, 40.5 mg, 
84%. HPLC: 4.72 min, Molecular Formula: C28H32N8O3, Mass Calc: 528.26 ESI-MS-Found: 559 
[M+MeOH], purity: 95%. 1HNMR (700 MHz, DMSO-d6) δ 11.69 (s, 2H), 8.81 (d, J = 8.4 Hz, 1H), 8.75 
(s, 1H), 8.32 – 8.28 (m, 2H), 7.76 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.14 (d, J = 3.3 
Hz, 1H), 7.07 (t, J = 7.3 Hz, 1H), 6.94 (s, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.46 (s, 1H), 6.39 (d, J = 3.4 Hz, 
1H), 4.25 – 4.21 (m, 2H), 3.87 (s, 3H), 3.06 (m, 2H), 2.83 (d, J = 4.4 Hz, 3H), 2.18 (s, 6H).13CNMR (176 
MHz, dmso) δ 168.73, 167.68, 166.40, 155.97, 150.40, 147.03, 144.02, 143.35, 132.93, 130.30, 128.36, 






Compound 31 was synthesized using the protocol described for 28. Yields a yellow solid, 15 mg, 64%. 
HPLC: 7.163 min, Molecular Formula: C30H39N7O5SSi, Mass Calc: 637.25, ESI-MS-Found: 638 [M+1], 
purity: 95% 1HNMR (700 MHz, Chloroform-d) δ 11.61 (s, 1H), 8.93 (d, J = 8.5 Hz, 1H), 8.29 (s, 1H), 8.10 
(d, J = 7.2 Hz, 1H), 8.05 (s, 2H), 7.75 (m, 1H), 7.54 (m, 1H), 7.42 (m, 1H), 7.36 (s, 1H), 7.22 (d, J = 8.2 
Hz, 1H), 7.05 (d, J = 9.2 Hz, 2H), 6.97 (m, 2H), 6.25 (m, 2H), 6.05 (d, J = 9.0 Hz, 1H), 5.80 (d, J = 10.0 
Hz, 1H), 5.57 (s, 2H), 3.87 (d, J = 13.2 Hz, 3H), 3.54 (m, 2H), 3.36 (s, 2H), 3.04 (d, J = 5.1 Hz, 3H), 0.85 
(m, 2H), -0.08 (s, 9H).13CNMR (176 MHz, cdcl3) δ 168.42, 167.74, 154.59, 151.23, 147.52, 144.10, 135.80, 
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133.05, 132.47, 130.63, 128.35, 123.63, 119.80, 119.02, 117.86, 117.16, 116.42, 110.90, 103.45, 100.62, 






Compound 32 was synthesized using the protocol described for 28. Yields a light yellow solid, 15 mg, 38%. 
HPLC: 7.15 min, Molecular Formula: C32H39N7O4Si, Mass Calc: 613.28, ESI-MS-Found: 614 [M+1], 
purity: 80% 1HNMR (700 MHz, Chloroform-d) δ 11.09 (s, 1H), 8.91 (d, J = 8.4 Hz, 1H), 8.64 (d, J = 8.2 
Hz, 1H), 8.21 (s, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.49 (t, J = 6.2 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 6.94 (d, J 
= 3.6 Hz, 1H), 6.87 (dd, J = 8.3, 1.8 Hz, 1H), 6.82 (d, J = 1.9 Hz, 1H), 6.60 (d, J = 3.5 Hz, 1H), 6.49 (d, J 
= 5.6 Hz, 1H), 6.39 (d, J = 5.4 Hz, 1H), 5.53 (s, 2H), 4.42 (d, J = 5.7 Hz, 1H), 3.92 (s, 3H), 3.51 – 3.43 (m, 
3H), 2.99 (s, 3H), 1.93 (s, 3H), 0.94 (t, J = 8.2 Hz, 2H), -0.08 (s, 9H). 13CNMR (176 MHz, cdcl3) δ 170.35, 
156.89, 155.81, 153.79, 152.77, 149.75, 147.90, 141.29, 132.28, 130.27, 129.29, 126.79, 122.71, 121.86, 





Compound 37 was synthesized using the protocol described for 34.  Yields a yellow solid, 6 mg, 50% 
HPLC: 5.7 min, Molecular Formula: C24H25N7O4S, Mass Calc: 507.17 ESI-MS-Found: 508 [M+1], purity: 
95%1H NMR (700 MHz, Chloroform-d) δ 11.60 (d, J = 18.4 Hz, 2H), 9.47 (d, J = 2.3 Hz, 1H), 9.10 (s, 1H), 
8.91 (d, J = 9.1 Hz, 1H), 8.44 (d, J = 7.7 Hz, 1H), 7.85 (s, 1H), 7.80 (d, J = 8.6 Hz, 1H), 7.56 (s, 1H), 7.50 
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– 7.47 (m, 1H), 7.45 (s, 1H), 7.19 (s, 2H), 7.14 (s, 2H), 7.10 (s, 1H), 7.06 (s, 2H), 6.67 (d, J = 19.8 Hz, 1H), 
6.28 (s, 1H), 5.65 (s, 1H), 3.86 (s, 3H), 3.35 (d, J = 2.7 Hz, 2H), 3.04 (d, J = 4.4 Hz, 3H).13CNMR (176 
MHz, dmso) δ 168.35, 167.93, 155.05, 150.76, 147.84, 143.92, 135.24, 132.83, 132.37, 130.53, 128.35, 






Compound 36 was synthesized using the protocol described for 34. Yields a white solid, 10 mg, 25% HPLC: 
5.3 min, Molecular Formula: C26H25N7O3, Mass Calc: 483.20 ESI-MS-Found: 484 [M+1], purity: 
95%.1HNMR (700 MHz, DMSO-d6) δ 11.64 (s, 1H), 11.37 (s, 1H), 8.95 (t, J = 6.2 Hz, 1H), 8.84 (d, J = 
8.4 Hz, 1H), 8.73 (d, J = 4.6 Hz, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.53 (s, 1H), 7.49 
(t, J = 7.9 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 3.3 Hz, 1H), 6.93 (s, 1H), 6.81 (d, J = 8.1 Hz, 1H), 
6.33 (s, 1H), 4.25 (d, J = 6.1 Hz, 2H), 3.86 (s, 3H), 2.83 (d, J = 4.4 Hz, 3H), 1.97 (d, J = 1.1 Hz, 3H). 
13CNMR (176 MHz, cdcl3) δ 170.17, 156.71, 155.63, 153.61, 153.23, 152.59, 149.57, 147.72, 141.11, 
132.10, 130.09, 129.11, 126.61, 122.53, 121.68, 120.93, 120.35, 120.02, 118.04, 109.65, 99.41, 55.76, 
44.03, 26.83, 3.66.  
 










A flame dried three neck flask was charged with 90.0 mg of 25 (0.21 mmol, 1.0 equiv), 68.2 mg of K2CO3 
(0.42 mmol, 2 equiv.), 5.5 mg of XPhos (0.012 mmol, 0.055 equiv), 2.1 mg of Pd2(dba)3 (0.002 mmol,0.01 
equiv) and 4 mL of tBuOH. The mixture was degassed with 8 cycles of evacuation and back filled with 
nitrogen.  The solution was heated to 110 ˚C for 20 h. Once complete, the solution was passed through a 
pad of celite, and  purified by column chromatography (eluting with 50% EtOAc/Hexanes). The solvent 
was removed under pressure to give a dark red solid, 120.0 mg, 82% HPLC: 8.109 min, Molecular Formula: 
C36H43N7O5Si, Mass Calc: 681.31 ESI-MS-Found: 682 [M+1], purity: 97% 1HNMR (700 MHz, CDCl3-d) 
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δ 11.03 (s, 1H), 8.84 (d, J = 8.4 Hz, 1H), 8.69 (s, 1H), 7.55 (s, 1H), 7.46 (t, J = 8.1 Hz, 1H), 7.42 (d, J = 7.8 
Hz, 1H), 7.33 (dd, J = 13.1, 5.8 Hz, 4H), 7.31 – 7.27 (m, 1H), 6.96 – 6.91 (m, 2H), 6.82 (q, J = 8.5 Hz, 2H), 
6.59 (d, J = 3.7 Hz, 1H), 6.41 (q, J = 4.6 Hz, 1H), 5.49 (s, 2H), 5.13 (s, 2H), 4.33 (d, J = 5.7 Hz, 2H), 3.90 
(s, 3H), 3.59 – 3.54 (m, 2H), 2.96 (d, J = 4.8 Hz, 3H), 0.93 (t, J = 8.2 Hz, 2H), -0.09 (s, 9H). 13CNMR (176 
MHz, CDCl3) δ 170.45, 156.52, 155.88, 153.86, 152.88, 147.15, 141.32, 136.93, 132.19, 130.89, 128.72, 
128.28, 128.23, 127.02, 122.90, 121.81, 121.24, 120.55, 119.57, 117.59, 109.96, 100.38, 99.59, 66.33, 





A dried flask was charged with 120 mg of 38 (0.176 mmol, 1.0 equiv) and 3 mL of 7N NH3 in MeOH. The 
solution was degassed with three rounds of evacuation and back filled with nitrogen, and then RaNi (slurry 
in water), was added. The solution was further degassed by three cycles of evacuation and back fill with 
nitrogen. The atmosphere was replaced with hydrogen, and the mixture was stirred for 12 hours. Once 
complete, the atmosphere was removed and then solution was passed through a pad of celite. The solvent 
was removed to yield a green solid, 91.8 mg, 93.5%. Molecular Formula: C28H37N7O3Si, Mass Calc: 547.27 
ESI-MS-Found: 548 [M+1], HPLC: 6.241min, purity: 98.2%. 1HNMR (500 MHz, Chloroform-d) δ 10.61 
(s, 1H), 8.55 – 8.48 (m, 1H), 8.44 (d, J = 8.0 Hz, 1H), 8.36 (s, 1H), 7.56 (d, J = 10.3 Hz, 1H), 7.50 (s, 1H), 
7.42 (d, J = 8.6 Hz, 1H), 7.10 (d, J = 7.5 Hz, 1H), 7.03 (s, 1H), 7.01 – 6.96 (m, 1H), 6.91 (dd, J = 10.3, 7.4 
Hz, 2H), 6.80 (d, J = 8.1 Hz, 1H), 6.71 (t, J = 9.6 Hz, 1H), 6.47 (d, J = 9.9 Hz, 1H), 5.51 (s, 2H), 3.89 – 
3.84 (m, 3H), 3.55 (t, J = 8.4 Hz, 2H), 3.03 – 2.93 (m, 3H), 0.96 – 0.89 (m, 2H), -0.07 (d, J = 2.7 Hz, 9H). 
13CNMR  (176 MHz, cdcl3) δ 169.94, 155.53, 153.31, 152.31, 140.77, 131.64, 126.52, 122.13, 121.28, 
120.51, 119.78, 117.79, 109.92, 99.67, 99.06, 77.03, 77.00, 76.84, 76.82, 76.66, 76.64, 72.21, 65.78, 55.36, 
26.43, 17.33, 13.86, -0.33, -1.75, -1.78. (126 MHz, cdcl3) δ 168.39, 167.61, 155.35, 153.84, 147.88, 144.63, 
140.11, 133.00, 131.50, 130.70, 128.22, 121.92, 120.22, 119.20, 118.07, 116.49, 114.73, 103.48, 99.40, 







Compound 41 was synthesized using the protocol described for 28. Yields a light yellow residue, 13.9 mg, 
19%. HPLC: 7.104 min, Molecular Formula: C31H39N7O4Si, Mass Calc: 601.28  ESI-MS-Found: 602.2900 
[M+1], purity: 74.4%. 1HNMR (700 MHz, CDCl3) δ 11.03 (s, 1H), 8.81 (s, 1H), 8.65 (s, 1H), 7.50 – 7.45 
(m, 2H), 7.01 (q, J = 8.1, 7.6 Hz, 1H), 6.93 (t, J = 3.7 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 6.83 (d, J = 8.2 Hz, 
1H), 6.60 – 6.55 (m, 2H), 6.31 (dd, J = 3.0, 1.8 Hz, 1H), 6.28 (dd, J = 2.8, 1.8 Hz, 1H), 5.66 (dd, J = 10.5, 
2.0 Hz, 1H), 5.62 (dd, J = 10.3, 1.6 Hz, 1H), 5.51 (s, 2H), 4.44 (dd, J = 9.8, 5.6 Hz, 2H), 3.91 (d, J = 2.7 
Hz, 3H), 3.59 – 3.55 (m, 2H), 3.01 (d, J = 3.7 Hz, 3H), 0.96 – 0.89 (m, 2H), -0.08 (d, J = 9.7 Hz, 9H). 
13CNMR (176 MHz, cdcl3) δ 170.30, 165.28, 155.82, 153.81, 150.34, 147.14, 143.85, 132.16, 131.02, 
130.18, 127.82, 127.71, 126.58, 122.87, 121.85, 119.99, 118.04, 117.18, 116.36, 110.04, 99.67, 86.17, 





Compound 40 was synthesized using the protocol described for 28. Yields aa light yellow residue,20 mg, 
40%. HPLC: 6.781 min, Molecular Formula: C31H41N7O4Si, Mass Calc: 603.30 ESI-MS-Found: 603.3219 
[M+1], purity: 99% 1HNMR (500 MHz, Chloroform-d) δ 11.13 (s, 1H), 8.88 (d, J = 8.4 Hz, 1H), 8.61 (d, J 
= 8.2 Hz, 1H), 7.99 (s, 1H), 7.54 (s, 1H), 7.50 (d, J = 7.9 Hz, 2H), 7.00 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 3.6 
Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H), 6.82 (s, 1H), 6.71 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 1.9 Hz, 1H), 6.62 (s, 
1H), 6.60 (t, J = 3.8 Hz, 2H), 6.53 (d, J = 5.7 Hz, 1H), 5.53 (s, 2H), 4.28 (d, J = 5.5 Hz, 3H), 3.91 (s, 3H), 
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3.59 (t, J = 8.2 Hz, 2H), 3.01 (d, J = 4.7 Hz, 3H), 2.80 (s, 2H), 2.24 (dq, J = 18.6, 7.6 Hz, 2H), 1.18 (dt, J = 
15.0, 7.6 Hz, 3H), 0.94 (t, J = 8.2 Hz, 2H), -0.07 (s, 9H).13CNMR (126 MHz, cdcl3) δ 173.53, 170.13, 
162.56, 153.57, 152.35, 147.76, 146.72, 140.95, 136.35, 132.00, 130.94, 130.38, 129.69, 126.73, 122.55, 
121.67, 121.03, 120.14, 118.19, 117.76, 114.49, 110.29, 109.65, 100.00, 99.45, 72.58, 66.11, 55.52, 43.36, 






Compound 42 was synthesized using the protocol described for 28. Yields a light yellow residue, 20 mg, 
28%. HPLC: 7.65 min, Molecular Formula: C34H46N8O4Si, Mass Calc: 658.34 ESI-MS-Found: 662 [M+4], 
purity: 85%. 1HNMR (700 MHz, Chloroform-d) δ 10.87 (s, 1H), 8.78 (d, J = 8.3 Hz, 1H), 8.70 – 8.65 (m, 
1H), 7.57 (s, 1H), 7.49 (d, J = 7.7 Hz, 2H), 7.23 (d, J = 6.5 Hz, 1H), 7.03 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 
3.6 Hz, 1H), 6.85 (d, J = 3.0 Hz, 2H), 6.60 (d, J = 3.5 Hz, 1H), 6.44 (d, J = 5.5 Hz, 1H), 5.54 (s, 2H), 4.40 
(d, J = 5.8 Hz, 2H), 3.93 (s, 3H), 3.60 – 3.55 (m, 2H), 3.03 (d, J = 4.8 Hz, 3H), 0.94 (ddd, J = 10.9, 7.6, 3.2 
Hz, 2H), -0.08 (s, 9H).13CNMR (176 MHz, cdcl3) δ 169.99, 160.06, 156.21, 155.36, 153.45, 152.51, 
146.93, 140.68, 131.63, 130.59, 128.68, 126.62, 122.54, 121.86, 120.99, 120.81, 119.65, 117.58, 109.60, 







Compound 43 was synthesized using the protocol described for 28. Yields a light yellow residue, 10 mg, 
34%. HPLC: 7.534 min, Molecular Formula: C30H39N7O5SSi, Mass Calc: 637.25 ESI-MS-Found: 638 
[M+1], purity: 85%. 1HNMR (400 MHz, Chloroform-d) δ 8.37 (s, 1H), 8.04 (s, 1H), 7.50 (s, 1H), 6.89 (s, 
3H), 6.50 (s, 1H), 6.22 (s, 1H), 5.91 (s, 1H), 5.57 (s, 2H), 4.23 (m, 2H), 3.95 (s, 3H), 3.61 (s, 2H), 3.37 (d, 
J = 16.6 Hz, 2H), 2.96 – 2.81 (m, 3H), 0.88 (d, J = 24.2 Hz, 2H), -0.07 (s, 9H). 13CNMR (176 MHz, cdcl3) 
δ 169.98, 165.69, 155.06, 150.31, 147.80, 143.19, 135.08, 133.85, 131.70, 128.59, 122.86, 121.52, 120.55, 







Compound 44 was synthesized using the protocol described for 28. Yields a light yellow residue, 10 mg, 
36%. HPLC: 8.610 min, Molecular Formula: C32H39N7O4Si, Mass Calc: 613.28 ESI-MS-Found: 623, 
purity: 65%. 1HNMR (500 MHz, Chloroform-d) δ 11.10 (s, 1H), 8.92 (d, J = 8.4 Hz, 1H), 8.65 (d, J = 8.3 
Hz, 1H), 7.52 (d, J = 7.1 Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.02 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 3.6 Hz, 
1H), 6.88 (d, J = 8.4 Hz, 1H), 6.83 (s, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.65 (d, J = 2.0 Hz, 1H), 6.63 (d, J = 
2.3 Hz, 1H), 6.62 – 6.60 (m, 2H), 5.55 (d, J = 7.9 Hz, 2H), 4.32 (d, J = 5.7 Hz, 3H), 3.93 (s, 2H), 3.60 (t, J 
= 8.1 Hz, 2H), 3.03 (d, J = 4.7 Hz, 3H), 1.93 (s, 4H), 0.95 (t, J = 8.1 Hz, 2H), -0.06 (d, J = 4.0 Hz, 9H). 
13CNMR (126 MHz, cdcl3) δ 170.42, 155.90, 153.88, 153.48, 152.86, 148.01, 147.13, 141.38, 136.74, 
132.34, 130.24, 129.42, 126.86, 122.79, 121.95, 121.19, 120.60, 120.30, 118.34, 118.09, 114.70, 110.58, 








Compound 46 was synthesized using the protocol described for 34. Yields a light yellow solid, 2 mg, 10%. 
HPLC: 5.114 min, Molecular Formula: C25H25N7O3, Mass Calc: 471.20 ESI-MS-Found: 471 [M], purity: 
90%. 1HNMR (700 MHz, DMSO-d6) δ 11.70 (s, 1H), 8.80 (dd, J = 8.0, 3.3 Hz, 1H), 8.75 (t, J = 4.6 Hz, 
1H), 8.57 (t, J = 6.0 Hz, 1H), 8.40 (d, J = 2.1 Hz, 1H), 7.76 (dd, J = 8.0, 1.5 Hz, 1H), 7.63 (d, J = 3.9 Hz, 
1H), 7.52 – 7.49 (m, 1H), 7.16 (d, J = 3.5 Hz, 1H), 7.06 (t, J = 7.6 Hz, 1H), 6.99 (d, J = 4.5 Hz, 1H), 6.87 – 
6.83 (m, 1H), 6.51 (t, J = 7.3 Hz, 1H), 6.40 (d, J = 3.6 Hz, 1H), 5.60 (ddd, J = 10.3, 4.3, 2.1 Hz, 1H), 4.31 
(d, J = 6.0 Hz, 2H), 3.87 (d, J = 2.5 Hz, 3H), 2.82 (d, J = 4.5 Hz, 3H).13CNMR (176 MHz, dmso) δ 169.63, 
167.25, 164.75, 155.43, 153.21, 147.32, 143.98, 134.27, 132.08, 131.91, 128.25, 125.52, 121.04, 120.71, 
119.73, 118.62, 117.83, 116.41, 110.45, 99.58, 90.85, 56.10, 42.56, 26.55. 
 
2-((2-((2-methoxy-5-(propionamidomethyl)phenyl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-
pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-methylbenzamide (45)  
Compound 45 was synthesized using the protocol described for 34. Yields a light yellow residue, 5 mg, 
30%. HPLC: 4.99 min, Molecular Formula: C25H27N7O3, Mass Calc: 473.22 ESI-MS-Found: 474 [M+1], 
purity: 95% 1HNMR (700 MHz, DMSO-d6) δ 11.64 (s, 1H), 11.37 (s, 1H), 8.85 (d, J = 8.6 Hz, 1H), 8.74 
(s, 1H), 8.26 – 8.19 (m, 2H), 8.11 – 8.04 (m, 2H), 7.75 (d, J = 8.1 Hz, 1H), 7.53 (s, 1H), 7.50 – 7.44 (m, 
1H), 7.08 – 7.03 (m, 1H), 7.03 – 6.98 (m, 1H), 6.93 (s, 1H), 6.82 (d, J = 8.4 Hz, 1H), 4.24 (d, J = 6.6 Hz, 
2H), 3.86 (d, J = 5.5 Hz, 3H), 2.83 (d, J = 4.6 Hz, 3H), 2.16 (q, J = 7.7 Hz, 2H), 1.05 (t, J = 7.6 Hz, 3H). 
13CNMR(176 MHz, dmso) δ 172.87, 169.81, 163.15, 161.80, 159.33, 155.89, 153.30, 152.61, 148.82, 
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145.71, 141.27, 137.80, 133.24, 132.28, 128.79, 128.34, 120.96, 119.90, 119.67, 119.40, 115.42, 113.37, 





Compound 47 synthesized using the protocol  described for 34. Yields a bright yellow solid, 8 mg, 50%. 
HPLC: 5.485 min, Molecular Formula: C28H32N8O3, Mass Calc: 528.26 ESI-MS-Found: 562 
[M+H+MeOH], purity: 95%. 1HNMR (700 MHz, DMSO-d6) δ 11.71 (s, 1H), 9.34 (t, J = 6.3 Hz, 1H), 8.80 
(d, J = 8.4 Hz, 1H), 8.78 – 8.71 (m, 1H), 8.39 – 8.36 (m, 1H), 7.76 (dd, J = 7.9, 1.6 Hz, 1H), 7.64 (s, 1H), 
7.53 – 7.48 (m, 1H), 7.16 (d, J = 3.5 Hz, 1H), 7.08 – 7.04 (m, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.86 (dd, J = 
8.2, 2.2 Hz, 1H), 6.42 (t, J = 7.3 Hz, 1H), 6.40 (d, J = 3.6 Hz, 1H), 5.48 (d, J = 7.2 Hz, 2H), 4.29 (d, J = 6.3 
Hz, 2H), 3.87 (s, 3H), 2.83 (d, J = 4.4 Hz, 3H), 1.26 (dd, J = 6.3, 3.7 Hz, 6H).13CNMR (176 MHz, dmso) δ 
169.63, 160.56, 157.59, 155.46, 153.20, 147.55, 143.59, 140.93, 132.65, 132.09, 130.54, 128.22, 123.46, 






Compound 48 was synthesized using the protocol  described for 34. Yields a white residue, 2 mg, 20%. 
HPLC: 6.13 min, Molecular Formula: C24H25N7O4S, Mass Calc: 507.17 ESI-MS-Found: 508 [M+1], purity: 
95%. 1HNMR (700 MHz, Chloroform-d) δ 10.82 (s, 1H), 8.63 (s, 1H), 8.51 (s, 1H), 7.58 (s, 1H), 7.53 (s, 
1H), 7.47 (s, 1H), 6.92 (s, 1H), 6.83 (s, 1H), 6.58 (s, 1H), 5.81 (s, 1H), 4.17 – 4.07 (m, 2H), 3.92 (s, 3H), 
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3.03 (s, 3H). 13CNMR (176 MHz, cdcl3) δ 169.98, 165.69, 155.06, 150.31, 147.80, 143.19, 135.08, 133.85, 






Compound 49 was synthesized using the protocol described for 34. Yields a white residue, 4 mg, 40%. 
HPLC: 5.67 min, Molecular Formula: C26H25N7O3, Mass Calc: 483.20 ESI-MS-Found: 484 [M+1], 506 
[M+Na], purity: 92% 1H NMR (700 MHz, DMSO-d6) δ 12.05 (s, 1H), 11.68 (s, 1H), 8.96 (s, 1H), 8.83 (s, 
3H), 8.74 (s, 1H), 8.62 (d, J = 8.1 Hz, 1H), 8.28 (s, 1H), 7.75 (s, 1H), 7.61 (s, 1H), 7.51 (t, J = 3.4 Hz, 1H), 
7.07 (s, 2H), 6.94 (s, 1H), 4.25 (d, J = 5.8 Hz, 2H), 3.86 (d, J = 3.4 Hz, 3H), 2.84 – 2.80 (m, 7H), 1.95 – 
1.94 (m, 12H). 13CNMR (176 MHz, dmso) δ 162.92, 162.46, 161.19, 156.25, 152.67, 147.87, 145.77, 
137.82, 134.02, 131.84, 131.51, 127.00, 122.23, 121.19, 121.07, 119.79, 119.58, 118.60, 116.58, 115.41, 





5-(aminomethyl)-2-methoxyaniline (52)  
A flame dried flask was charged with 995.4 mg of 3-amino-4-methoxybenzamide (51) (6 mmol, 1.0 equiv) 
and 30 mL of dry THF (0.1 molar). The solution was cooled to 0 °C and 6.1 mL of LAH (10 mmol, 2 equiv) 
were added dropwise over 5 min. The bright yellow solution was allowed to continue stirring at 0 °C for 
30 min. After 30 min, the solution was  warmed to 65 °C for 6-8 hours. Once complete, the reaction was 
cooled back to 0 °C and worked up with the Feiser Method: 0.457 mL water, followed by 0.457 mL of 
freshly prepared 15% NaOH, and 1.371 mL of water. The resultant brown solution was allowed to stir at rt 
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for 15 min. Then  MgSO4 was added and the solution was allowed to stir for additional 15 min. The MgSO4 
was filtered off and the solvent was removed to yield a yellow oil, 0.900 g, 100%. Molecular Formula: 
C8H12N2O, Mass Calc: 152.09 ESI-MS-Found: 152 [M] HPLC: 0.96 min, purity: > 95% 1HNMR (400 
MHz, DMSO-d6) δ 6.69 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 6.46 (dd, J = 8.1, 2.1 Hz, 1H), 4.59 




benzyl (3-amino-4-methoxybenzyl)carbamate (50)  
A flame dried flask was charged with 900.0 mg of 52 (5.91 mmol, 1.0 equiv) and 40 mL of dry THF (0.19 
molar). The solution was cooled to 0 °C and 0.92 mL of TEA (6.6 mmol, 1.1 equiv), and 0.94 mL of Cbz-
Cl (6.6 mmol, 1.1 equiv) were added in one portion, respectively. Once complete, the reaction was quenched 
with water and then extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with 
brine (1 x 30 mL) and then dried over Na2SO4. The crude oil was purified by column chromatography (0-
100% EtOAc/Hex) to give a light yellow oil, 1.14 g, 67.3%. HPLC: 4.871 min,  Molecular Formula: 
C16H18N2O3 Mass Calc: 286.13 ESI-MS-Found: 287, purity: 85%  1HNMR (500 MHz, Chloroform-d) δ 
7.34 (dd, J = 21.0, 4.5 Hz, 5H), 6.72 (d, J = 8.1 Hz, 1H), 6.65 (s, 1H), 6.62 (d, J = 7.8 Hz, 1H), 5.13 (s, 2H), 
4.25 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.79 (s, 2H). 
2-chloro-N-methyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (53, RAR-5-
75) 
To a flask were added 249 mg of RAR-5-70 (SEM-protected dichloropyrrolopyrimidine) which was 
dissolved in 4 mL of MeOH. To this solution were added 0.1 mL of methylamine, and the solution was 
heated to 70 °C for 2 hours. Once complete, the solvent was removed under pressure to yield to desired 
product. Yields a white solid, 240 mg, 98%.  1H NMR (500 MHz, Chloroform-d) δ 7.03 (t, J = 3.8 Hz, 
1H), 6.41 (s, 1H), 5.52 (d, J = 3.1 Hz, 2H), 3.52 (t, J = 8.2 Hz, 2H), 0.90 (td, J = 8.2, 3.2 Hz, 2H), -0.06 (t, 
J = 3.5 Hz, 9H). 
3-methoxy-4-nitrobenzoyl chloride (54, RAR-5-81) 
To a dried flask were added 252.4 mg of 3-methoxy-4-nitrobenzoic acid, dissolved in 8 mL of dry THF. 
The solution was cooled to 0 °C and 0.02 mL of oxalyl chloride were added. The solution was allowed to 
stir at 0 °C for 1 hour or until complete. Once complete, the solvent was removed, and the acid chloride 
was rinsed with DCM (3 x 30 mL) before being used directly in the next step. HPLC: 6.43, 92% 
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(3-methoxy-4-nitrophenyl)(morpholino)methanone (55, RAR-5-82) 
To a dried flask were added 273 mg of RAR-5-81, dissolved in 5 mL of THF. The solution was cooled to 
0 °C and then 0.44 mL of DIPEA and 0.166 mL of morpholine were added respectively. The solution was 
allowed to stir at 0 °C for 1 h, and then the reaction was quenched with water and extracted with EtOAc (3 
x 30 mL). The combined organic layers were then dried over Na2SO4 and the solvent was removed to yield 
a crude product. The crude yellow product was purified by column chromatography to give the desired 
product as a yellow oil, 306.7 mg, 91%. 1H NMR (400 MHz, DMSO-d6) δ 7.93 (d, J = 8.2 Hz, 1H), 7.37 
(d, J = 1.5 Hz, 1H), 7.11 (dd, J = 8.2, 1.5 Hz, 1H), 3.94 (s, 3H), 3.75 – 3.39 (m, 8H). 
(4-amino-3-methoxyphenyl)(morpholino)methanone (56, RAR-5-83) 
To a flask were added 153 mg of RAR-5-82, dissolved in 3 mL of MeOH. The solution was degassed with 
3 cycles of evacuation and backfill with nitrogen before Pd/C was added. The solution was then further 
degassed with an additional 3 cycles of evacuation and backfill with nitrogen, at which point hydrogen 
atmosphere was introduced. The reaction was allowed to run for 12-18 hours. Once complete, the hydrogen 
atmosphere was removed, and the solution was passed through a pad of celite. The solvent was removed to 
yield the desired product as a yellow solid, 57.2 mg, 43.0%. 1H NMR (400 MHz, DMSO-d6) δ 6.85 (d, J 
= 1.7 Hz, 1H), 6.80 (dd, J = 7.9, 1.8 Hz, 1H), 6.61 (d, J = 7.9 Hz, 1H), 5.15 (s, 1H), 3.77 (s, 3H), 3.61 – 
3.55 (m, 4H), 3.50 (t, J = 4.6 Hz, 4H). 
(3-methoxy-4-((4-(methylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
yl)amino)phenyl)(morpholino)methanone (57, RAR-5-89) 
To a three neck flask were added 57.2 mg of RAR-5-83, dissolved in 4.7 mL of dry and degassed nBuOH. 
To this solution were added 50 mg of RAR-5-75, 47.0 mg of K2CO3, XPhos, and Pd2(dba)3. The solution 
was degassed with 6 cycles of evacuation and backfill with nitrogen before a reflux condenser was fitted to 
the flask.  The solution was then heated to 100 °C for 6-12 h. Once complete, the reaction was cooled to 
room temperature and then passed through a pad of celite. The filtrate was then purified by column 
chromatography to yield the desired product as a yellow oil, 49.8 mg, 60%. MS: 513, HPLC: 5.994, 1H 
NMR (400 MHz, Chloroform-d) δ 8.79 (d, J = 8.1 Hz, 1H), 7.62 (s, 1H), 7.01 (d, J = 8.1 Hz, 1H), 6.94 (d, 
J = 1.8 Hz, 1H), 6.89 – 6.81 (m, 1H), 6.64 (d, J = 7.9 Hz, 1H), 5.51 (s, 1H), 3.94 (s, 3H), 3.86 (s, 3H), 3.72 
– 3.61 (m, 8H), 3.17 (d, J = 5.0 Hz, 2H), 0.96 – 0.88 (m, 2H), -0.09 (s, 9H). 
(3-methoxy-4-((4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)(morpholino)methanone 
(58, RAR-5-93, CCG-264018) 
To a flask were added 49.8 mg of RAR-5-89, which was dissolved in 5 mL of DCM. To this solution were 
added 1.0 mL of TFA and the resultant bright orange solution was heated to 50 °C for 3 h. Once complete, 
the reaction was cooled to room temperature and then quenched with saturated NaHCO3 and was extracted 
with EtOAc (3 x 30 mL). The combined organic layer was then washed with brine (1 x 30 mL) and dried 
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over Na2SO4. The crude material was purified by column chromatography to yield the final product, 30 mg, 
80%. 1H NMR (700 MHz, DMSO-d6) δ 6.97 (d, J = 1.7 Hz, 1H), 6.92 (dd, J = 8.0, 1.7 Hz, 1H), 6.73 (d, J 
= 7.9 Hz, 1H), 5.27 (s, 2H), 3.90 (s, 3H), 3.70 (t, J = 4.7 Hz, 4H), 3.62 (t, J = 4.7 Hz, 4H). 13C NMR (176 
MHz, dmso) δ 169.80, 145.35, 139.75, 121.96, 121.15, 112.14, 110.31, 66.15, 55.30, 48.44, 28.96. 
tert-butyl 4-(3-methoxy-4-nitrobenzoyl)piperazine-1-carboxylate (59, RAR-5-99) 
This material was made using the same protocol described for the preparation of RAR-5-82. Yields the 
desired product as a dark brown oil, 785.1 mg, 80% 1H NMR (400 MHz, Chloroform-d) δ 7.85 (d, J = 8.2 
Hz, 1H), 7.13 (d, J = 1.5 Hz, 1H), 6.99 (dd, J = 8.2, 1.5 Hz, 1H), 3.97 (s, 3H), 3.52 (s, 4H), 3.38 (s, 4H), 
1.46 (s, 9H). 13C NMR (100 MHz, cdcl3) δ 168.34, 154.60, 153.39, 126.04, 118.46, 112.76, 80.79, 56.90, 
28.51. 
tert-butyl 4-(4-amino-3-methoxybenzoyl)piperazine-1-carboxylate (60, RAR-5-100) 
This material was prepared using the same protocol described for the preparation of RAR-5-83. Yields a 
white residue, 100 mg, 50%. 1H NMR (400 MHz, Chloroform-d) δ 6.94 (d, J = 1.7 Hz, 1H), 6.85 (dd, J = 
7.9, 1.8 Hz, 1H), 6.65 (d, J = 7.9 Hz, 1H), 4.04 (s, 2H), 3.86 (s, 3H), 3.61 (t, J = 5.1 Hz, 4H), 3.45 (dd, J = 
6.7, 3.9 Hz, 4H), 1.47 (s, 9H). 
(3-methoxy-4-((4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)(piperazin-1-
yl)methanone (61, RAR-6-4, CCG-264078) 
This material was prepared using the same protocol described for the preparation of RAR-5-89. The final 
product is obtained as a white solid, 78.7 mg, 90%. LRMS: 401 [M+ H2O], HPLC: 8.91. 1H NMR (400 
MHz, Chloroform-d) δ 11.54 (s, 1H), 8.80 (dd, J = 8.5, 1.1 Hz, 1H), 7.50 (ddd, J = 8.6, 7.4, 1.6 Hz, 1H), 
7.39 (dd, J = 7.9, 1.5 Hz, 1H), 7.19 (d, J = 3.6 Hz, 1H), 6.92 (td, J = 7.6, 1.2 Hz, 1H), 6.71 (d, J = 3.6 Hz, 
2H), 5.60 (s, 1H), 3.63 – 3.55 (m, 2H), 3.07 (d, J = 4.9 Hz, 3H), 1.01 – 0.93 (m, 1H). 13C NMR (100 MHz, 
cdcl3) δ 170.22, 153.96, 151.76, 140.29, 132.33, 126.84, 125.41, 121.84, 121.34, 120.15, 104.16, 99.59, 
72.97, 66.58, 26.96, 17.83. 
N-(tert-butyl)-2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (62, 
RAR-6-18) 
This material was prepared using the same protocol to prepare RAR-5-75. The product is yielded as a 
yellow oil, 99.4 mg, 35%. 1H NMR (400 MHz, Chloroform-d) δ 7.00 (dd, J = 3.7, 1.6 Hz, 1H), 6.29 (dd, J 
= 3.6, 1.4 Hz, 1H), 5.49 (d, J = 1.5 Hz, 2H), 4.93 (s, 1H), 3.55 – 3.47 (m, 2H), 1.55 (s, 9H), 0.94 – 0.87 (m, 
2H). 
(4-((4-(tert-butylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-
methoxyphenyl)(morpholino)methanone (63, RAR-6-29) 
This material was prepared using the same protocol described for the construction of RAR-5-89. Yields the 
desired product as a light yellow solid, 40.2 mg, 60%. HPLC: 8.14.  1H NMR (500 MHz, Chloroform-d) δ 
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8.38 (s, 1H), 7.05 (d, J = 3.6 Hz, 1H), 6.98 (s, 1H), 6.87 (d, J = 3.6 Hz, 1H), 6.32 (d, J = 3.6 Hz, 1H), 5.56 
(s, 2H), 4.79 (s, 1H), 4.34 (d, J = 7.6 Hz, 4H), 3.53 (t, J = 8.2 Hz, 4H), 1.58 (s, 9H), -0.05 (s, 9H). 
(4-((4-(tert-butylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-
methoxyphenyl)(morpholino)methanone (64, RAR-6-37, CCG-264141) 
This material was prepared using the same protocol described for the preparation of RAR-5-93. Yields the 
desired product as a dark yellow oil, 2 mg, 10%. HPLC: 5.9, MS: 425. 1H NMR (700 MHz, DMSO-d6) δ 
11.06 (s, 1H), 7.94 (d, J = 8.2 Hz, 1H), 6.93 (d, J = 3.5 Hz, 2H), 6.82 (s, 1H), 4.23 (t, J = 6.7 Hz, 4H), 4.18 
(t, J = 6.8 Hz, 4H), 3.95 (s, 3H), 1.49 (s, 9H). 
2-chloro-N-cyclopropyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (65, 
RAR-6-24) 
This material is prepared using the same protocol described for the preparation of RAR-5-75. Yields the 
desired product as a yellow oil, 67.1 mg, 25.1%. HPLC: 8.20, MS: 339.  1H NMR (400 MHz, Chloroform-
d) δ 7.06 (d, J = 3.7 Hz, 1H), 6.74 (s, 1H), 5.86 (s, 1H), 5.53 (s, 2H), 3.53 (dd, J = 9.1, 7.4 Hz, 2H), 3.01 – 
2.93 (m, 1H), 0.98 – 0.87 (m, 4H), 0.76 – 0.67 (m, 2H), -0.06 (s, 9H). 
(4-((4-(cyclopropylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-
3-methoxyphenyl)(morpholino)methanone (66, RAR-6-32) 
This material was prepared using the protocol described for RAR-5-89. Isolated product could not be 
separated from oxidized XPhos, telescoped through after crude NMR indicated product was in sample. 
Yields the desired product as a yellow solid, 44.8 mg, 83%. MS: 539, HPLC: 7.991. 1H NMR (500 MHz, 
Chloroform-d) δ 7.58 (q, J = 3.3, 2.8 Hz, 1H), 7.45 – 7.44 (m, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.31 (s, 1H), 
7.03 (s, 1H), 5.55 (s, 2H), 4.36 (t, J = 6.6 Hz, 4H), 3.64 – 3.56 (m, 4H), 3.30 – 3.24 (m, 2H), 2.95 (q, J = 
7.3 Hz, 1H), 0.98 – 0.94 (m, 4H), 0.74 (dd, J = 6.8, 4.1 Hz, 2H), 0.05 (s, 9H). 
tert-butyl 4-(4-((4-(cyclopropylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-
2-yl)amino)-3-methoxybenzoyl)piperazine-1-carboxylate (67, RAR-6-43)  
This material was prepared using the protocol described for RAR-5-89 by using RAR-5-99. Yields the final 
product as a dark brown solid, 24.9 mg, 42%. HPLC: 7.17, MS: 638 [M+1]. 1H NMR (700 MHz, 
Chloroform-d) δ 8.76 (d, J = 8.2 Hz, 1H), 7.66 (s, 1H), 7.01 (s, 2H), 6.97 (s, 1H), 6.89 (d, J = 3.6 Hz, 1H), 
6.66 – 6.64 (m, 1H), 5.52 (s, 2H), 3.93 (s, 3H), 3.64 (t, J = 6.6 Hz, 4H), 3.58 (dd, J = 8.8, 7.5 Hz, 4H), 2.95 
(d, J = 5.0 Hz, 1H), 1.47 (d, J = 4.6 Hz, 9H), 0.98 (t, J = 7.4 Hz, 2H), 0.87 (t, J = 7.0 Hz, 2H), -0.08 (d, J = 
0.9 Hz, 9H). 13C NMR (176 MHz, cdcl3) δ 171.02, 159.34, 154.63, 150.57, 147.24, 132.37, 127.05, 122.01, 
116.28, 112.19, 109.47, 99.38, 84.16, 80.28, 66.25, 55.85, 50.52, 48.84, 28.37, 26.70, 8.79, -1.45. 
(4-((4-(cyclopropylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(piperazin-1-
yl)methanone (68, RAR-6-46, CCG-264159) 
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This material was prepared using the protocol described for CCG-264078. Yields the final product as a 
yellow solid, 3 mg, 20%. HPLC: 3.93, MS: 406 [M-1] negative mode. 1H NMR (500 MHz, DMSO-d6) δ 
8.87 (s, 1H), 7.60 (s, 1H), 7.39 (s, 1H), 7.00 (d, J = 4.4 Hz, 2H), 6.97 (d, J = 4.0 Hz, 2H), 3.93 (d, J = 3.9 
Hz, 3H), 3.47 (s, 4H), 2.74 (s, 4H), 2.28 (t, J = 7.4 Hz, 1H), 0.81 (d, J = 5.4 Hz, 2H), 0.60 – 0.56 (m, 2H). 
tert-butyl 4-(4-((4-(tert-butylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
yl)amino)-3-methoxybenzoyl)piperazine-1-carboxylate (69, RAR-6-41) 
This material was prepared using the protocol described for RAR-6-43. Yields the desired product as dark 
yellow solid, 80 mg, 97%. HPLC: 7.90, MS: 658 [M+1]. 1H NMR (700 MHz, Chloroform-d) δ 8.78 (d, J 
= 8.1 Hz, 1H), 7.53 (s, 1H), 7.27 (s, 1H), 7.02 (s, 2H), 6.97 (s, 1H), 6.84 (d, J = 3.6 Hz, 1H), 6.23 (d, J = 
3.6 Hz, 1H), 5.50 (s, 2H), 3.95 (s, 3H), 3.63 (t, J = 6.6 Hz, 6H), 3.59 – 3.56 (m, 4H), 3.49 – 3.45 (s, 1H), 
1.57 (s, 9H), 1.47 (s, 9H), -0.07 (s, 9H). 13C NMR (176 MHz, cdcl3) δ 171.17, 156.36, 154.64, 151.53, 
147.03, 132.79, 125.79, 123.48, 121.37, 116.18, 109.38, 103.67, 98.46, 80.27, 66.11, 62.62, 55.79, 52.04, 
51.85, 29.44, 28.35, 24.03. 
2-chloro-N-cyclobutyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (70, 
RAR-6-44) 
This material was prepared using the protocol described for RAR-5-75. Yields the desired product as a 
yellow oil, 50 mg, 9.0%. HPLC: 8.79, MS (neg mode): 351. 1H NMR (500 MHz, Chloroform-d) δ 7.03 (d, 
J = 3.6 Hz, 1H), 6.41 (s, 1H), 5.50 (s, 2H), 3.51 (t, J = 8.2 Hz, 2H), 2.52 – 2.44 (m, 2H), 2.01 – 1.90 (m, 
3H), 1.78 (td, J = 10.4, 4.9 Hz, 2H), -0.05 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 156.50, 154.25, 151.92, 
124.34, 103.16, 99.70, 72.96, 66.54, 31.97, 17.89, 15.21, -1.25. 
(4-((4-(cyclobutylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-
methoxyphenyl)(morpholino)methanone (71, RAR-6-49) 
This material was prepared using the protocol described for RAR-5-89. Yields the desired product as a 
yellow solid, 32.2 mg, 82%. Note that some oxidized XPhos carried through with product. HPLC: 7.60, 
MS: 652. 1H NMR (400 MHz, Chloroform-d) δ 8.79 (d, J = 8.5 Hz, 1H), 7.59 (s, 1H), 7.04 (dd, J = 6.6, 1.6 
Hz, 2H), 7.00 – 6.93 (m, 1H), 6.87 (dd, J = 8.1, 5.0 Hz, 2H), 6.66 (d, J = 7.9 Hz, 1H), 6.33 (d, J = 3.6 Hz, 
1H), 5.52 (s, 2H), 3.95 (s, 3H), 3.69 – 3.56 (m, 4H), 3.53 – 3.41 (m, 6H), 2.41 (p, J = 6.8 Hz, 1H), 2.05 – 
1.95 (m, 3H), 1.89 – 1.79 (m, 3H), 0.98 – 0.90 (m, 2H), -0.07 (d, J = 1.2 Hz, 9H). 
2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-methylbenzamide (72, RAR-9-8) 
To a flask were added 0.22 mL of 2,4-dichloro-5-methylpyrimidine, and 304.5 mg of 2-amino-N-
methylbenzamide, all of which were dissolved in 10 mL of dry DMF. The solution was cooled to 0 °C and 
then 2.6 mL of NaHMDS were added over five minutes. The solution was stirred at 0 °C for 4 h. Once 
complete, the reaction was quenched with brine and then extracted with EtOAc (4 x 30 mL). The combined 
organic layer was then washed with brine (1 x 30 mL) and dried over MgSO4. The crude material was 
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purified by column chromatography to yield the desired product, 200 mg, 39%. HPLC: 5.952, LRMS: 277, 
1H NMR (500 MHz, Chloroform-d) δ 11.19 (s, 1H), 8.80 (dd, J = 8.5, 1.1 Hz, 1H), 8.03 (d, J = 1.0 Hz, 
1H), 7.55 (ddd, J = 8.7, 7.4, 1.6 Hz, 1H), 7.49 (dd, J = 7.9, 1.5 Hz, 1H), 7.08 (td, J = 7.7, 1.2 Hz, 1H), 6.34 
(s, 1H), 3.03 (d, J = 4.8 Hz, 3H), 2.27 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 170.21, 160.12, 156.26, 
146.57, 140.25, 132.83, 126.78, 122.49, 121.87, 120.61, 115.33, 27.14, 13.86. 
2-((2-((4-cyano-2-methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)-N-methylbenzamide (73, RAR-
9-13) 
To a microwave flask were added 121.4 mg of RAR-9-8, 711.1 mg of Cs2CO3, 100.7 mg of nitrile amine, 
XantPhos (2 mol %), and Pd2(dba)3 (1-5 mol%). All materials were then dissolved in 3 mL of nBuOH. The 
solution was degassed with five cycles of evacuation and backfill with nitrogen before the flask was sealed. 
The reaction was heated to 160 °C for 15 mins. Once complete, the reaction was quenched with brine (1 x 
25 mL) and extracted with EtOAc (3 x 25 mL). The crude material was purified by column chromatography 
to yield the desired product as a yellow solid, 33 mg, 12%. LRMS: 389, HPLC: 5.244. 1H NMR (500 MHz, 
Chloroform-d) δ 10.65 (s, 1H), 8.65 (dd, J = 8.3, 5.9 Hz, 2H), 8.00 (s, 1H), 7.92 (dd, J = 7.8, 1.5 Hz, 1H), 
7.72 (d, J = 6.4 Hz, 1H), 7.52 (dd, J = 8.9, 6.8 Hz, 2H), 7.13 – 7.08 (m, 1H), 7.06 (d, J = 1.8 Hz, 1H), 3.95 
(s, 3H), 3.09 (s, 3H), 2.27 – 2.23 (m, 3H). 13C NMR (126 MHz, cdcl3) δ 169.93, 167.41, 166.52, 159.02, 




To a flask were added 33 mg of RAR-9-13, dissolved in 5 mL of 7N NH3 in MeOH. The solution was 
degassed with three cycles of evacuation and back fill with nitrogen before RaNi was added in one portion. 
The solution was then degassed with an additional 3 cycles of evacuation and backfill with nitrogen before 
the hydrogen atmosphere was introduced. Once complete, the atmosphere was removed, and the solution 
was passed through a pad of celite. The solvent was removed to yield the desired product as a light yellow 
solid, 30 mg, 90%. HPLC: 4.094, HRMS: 393.2027. 1H NMR (500 MHz, Chloroform-d) δ 10.55 (s, 1H), 
8.77 (d, J = 8.4 Hz, 1H), 8.38 (d, J = 8.1 Hz, 1H), 7.96 (s, 1H), 7.54 – 7.45 (m, 2H), 7.42 (s, 1H), 7.04 (t, J 
= 7.5 Hz, 1H), 6.85 (d, J = 10.7 Hz, 2H), 6.31 (s, 1H), 3.91 (s, 3H), 3.02 (d, J = 4.8 Hz, 3H), 2.22 (s, 3H). 
13C NMR (126 MHz, cdcl3) δ 170.03, 167.95, 166.11, 158.23, 155.77, 147.93, 140.67, 131.93, 131.28, 
126.61, 120.69, 119.10, 118.66, 108.95, 107.35, 55.75, 48.03, 26.89, 13.63. 
2-((2-((4-(but-2-ynamidomethyl)-2-methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)-N-
methylbenzamide (75, RAR-9-17, CCG-265507) 
To a flask were added 13.9 mg of butynoic acid, 33.8 mg of HATU, 30 mg of RAR-9-16, and 0.05 mL of 
DIPEA. All materials were dissolved in 3 mL of DMF to yield a light yellow solution. This solution was 
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allowed to stir at room temperature for 5 hours. Once complete, the reaction was quenched with brine  and 
extracted with EtOAc ( 3 x 30 mL). The combined organic layer was washed with brine (2 x 30 mL) and 
then dried over MgSO4 before being purified by column chromatography. Yields a light yellow solid. 
LRMS: 459, HPLC: 4.943. 1H NMR (700 MHz, Chloroform-d) δ 10.59 (s, 1H), 8.71 (d, J = 8.5 Hz, 1H), 
8.36 (d, J = 8.1 Hz, 1H), 7.93 (s, 1H), 7.52 (s, 1H), 7.48 (d, J = 7.9 Hz, 2H), 7.04 (t, J = 7.5 Hz, 1H), 6.80 
(d, J = 7.6 Hz, 1H), 6.36 (s, 1H), 4.41 (d, J = 5.7 Hz, 1H), 3.88 (s, 3H), 3.01 (d, J = 4.7 Hz, 3H), 1.93 (s, 
2H). 13C NMR (176 MHz, cdcl3) δ 170.02, 167.45, 166.15, 159.01, 155.47, 153.23, 146.36, 132.59, 
131.80, 129.91, 126.59, 122.45, 121.46, 120.90, 118.80, 109.81, 104.44, 100.24, 80.64, 55.75, 43.98, 26.81, 
13.56, 3.63. 
2-((2-((4-(acrylamidomethyl)-2-methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)-N-
methylbenzamide (76, RAR-9-20, CCG-265508) 
This material was prepared using the protocol described for CCG-265507. Yields the product as a light 
yellow solid, 2 mg, 9%. LRMS: 449, HPLC: 5.095. 1H NMR (700 MHz, Chloroform-d) δ 8.64 (s, 1H), 
8.32 (s, 1H), 8.30 – 8.25 (m, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.62 (d, J = 8.3 Hz, 
1H), 7.57 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 6.84 (s, 1H), 6.64 (d, J = 8.1 Hz, 1H), 6.56 – 6.50 (m, 1H), 6.18 
(d, J = 17.2 Hz, 1H), 3.64 (d, J = 3.1 Hz, 3H), 3.08 (d, J = 3.2 Hz, 3H), 2.64 (d, J = 3.1 Hz, 3H). 
2-chloro-N-(pyridin-3-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (77, 
RAR-9-21) 
 To a three neck flask were added 500 mg of SEM-protected 2,4-dichloropyrrolopyrimidine, 208.2 mg of 
3-aminopyridine, 469.0 mg of NaOtBu, XPhos (4 mol%) and Pd2(dba)3 (1 mol%). All materials were then 
dissolved in 8 mL of toluene, and then solution was degassed with 8 cycles of evacuation and backfill with 
nitrogen. The reaction was then heated to 90 °C for 2.5 h or until complete. Once complete, the reaction 
was cooled to rt and then passed through a pad of celite. The crude material was evaporated onto silica gel 
and then purified by column chromatography. Yields the desired product as a pale yellow solid, 195.4 mg, 
32%. LRMS: 376, HPLC: 6.133. 1H NMR (700 MHz, Chloroform-d) δ 8.72 (d, J = 2.9 Hz, 1H), 8.44 (s, 
1H), 8.27 (d, J = 8.5 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.14 (t, J = 3.2 Hz, 2H), 6.95 (s, 2H), 6.27 (s, 1H), 5.57 
(d, J = 2.7 Hz, 2H), 3.57 – 3.53 (m, 2H), 2.21 (s, 3H), 0.01 (d, J = 2.7 Hz, 9H). 
3-methoxy-4-((4-(pyridin-3-ylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
yl)amino)benzonitrile (78, RAR-9-24) 
This material was prepared using the protocol described for RAR-9-13. Yields the desired product as a light 
brown solid, 75 mg, 58%. LRMS: 488, HPLC: 6.924. 1H NMR (500 MHz, Chloroform-d) δ 8.92 (d, J = 
2.6 Hz, 1H), 8.81 (d, J = 8.5 Hz, 1H), 8.43 (d, J = 5.0 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.78 (s, 1H), 7.36 
(dd, J = 8.3, 4.6 Hz, 1H), 7.09 (d, J = 1.8 Hz, 1H), 7.02 (d, J = 3.7 Hz, 1H), 6.70 (s, 1H), 6.33 (d, J = 3.7 




pyrrolo[2,3-d]pyrimidine-2,4-diamine (79, RAR-9-26) 
This material was prepared using the protocol described for RAR-9-16. Yields the desired product as a light 
yellow solid, 15.6 mg, 51.6%. HPLC: 5.334, HRMS: 492.2535. 1H NMR (500 MHz, Chloroform-d) δ 8.86 
(s, 1H), 8.52 (d, J = 8.0 Hz, 1H), 8.36 (s, 1H), 8.15 (s, 1H), 7.47 (s, 1H), 7.31 (s, 3H), 6.95 (d, J = 3.3 Hz, 
2H), 6.92 (d, J = 8.4 Hz, 1H), 6.69 (s, 1H), 6.30 (d, J = 3.4 Hz, 1H), 5.55 (s, 2H), 3.94 (s, 3H), 3.91 (s, 2H), 
3.64 – 3.59 (m, 2H), 0.98 – 0.93 (m, 2H), -0.06 (s, 9H). 
N-(3-methoxy-4-((4-(pyridin-3-ylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-yl)amino)benzyl)acrylamide (80, RAR-9-29) 
This material was prepared using the protocol described for CCG-265507. Yields the desired product as 
bright green solid, 10 mg, 45%. HRMS: 546.2641, HPLC: 6.287. Moved forwards without further 
characterization, is unstable in air. 
N-(3-methoxy-4-((4-(pyridin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)benzyl)acrylamide (81, 
RAR-9-30, CCG-265595) 
This material was prepared using the protocol described for CCG-265328. Yields a white residue, 2 mg, 
20%. LRMS: 416, HPLC: 4.2700. 1H NMR (700 MHz, Chloroform-d) δ 8.87 (d, J = 2.6 Hz, 1H), 8.45 (d, 
J = 8.2 Hz, 1H), 8.39 (d, J = 4.4 Hz, 1H), 8.29 (s, 1H), 8.15 (d, J = 8.5 Hz, 1H), 7.33 (dd, J = 8.1, 4.7 Hz, 
1H), 6.90 (d, J = 5.8 Hz, 2H), 6.86 (s, 1H), 6.67 (s, 1H), 6.34 (d, J = 17.0 Hz, 1H), 6.29 (t, J = 2.8 Hz, 1H), 
6.12 (dd, J = 17.0, 10.3 Hz, 1H), 5.84 (s, 1H), 5.68 (d, J = 11.4 Hz, 1H), 4.50 (d, J = 5.6 Hz, 2H), 3.92 (s, 
3H). 
N-(3-methoxy-4-((4-(pyridin-3-ylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-yl)amino)benzyl)but-2-ynamide (82, RAR-9-33) 
This material was prepared using the protocol described for CCG-265507. Yields the desired product as 
light yellow solid, 10 mg, 44%. LRMS: 558, HPLC: 6.2800. 1H NMR (700 MHz, Chloroform-d) δ 8.88 (s, 
1H), 8.56 (d, J = 8.2 Hz, 1H), 8.38 (d, J = 4.6 Hz, 1H), 8.15 (d, J = 8.1 Hz, 1H), 7.50 (s, 1H), 7.33 (dd, J = 
8.3, 4.7 Hz, 1H), 6.96 (dd, J = 3.6, 0.9 Hz, 1H), 6.90 – 6.86 (m, 1H), 6.84 (s, 1H), 6.70 (s, 1H), 6.30 (dd, J 
= 3.6, 0.9 Hz, 1H), 6.05 (s, 1H), 5.57 – 5.54 (m, 2H), 4.44 (d, J = 5.7 Hz, 2H), 3.93 (d, J = 0.9 Hz, 3H), 
3.63 – 3.58 (m, 2H), 1.95 (d, J = 0.9 Hz, 3H), 0.97 – 0.93 (m, 2H), -0.06 (d, J = 0.9 Hz, 9H). 
N-(3-methoxy-4-((4-(pyridin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)benzyl)but-2-ynamide 
(83, RAR-9-11, CCG-265596) 
This material was prepared using the protocol described for CCG-265328. Yields the desired product as a 
white solid, 2.0 mg, 26%. HRMS: 428.1824, HPLC: 4.223. 1H NMR (700 MHz, Chloroform-d) δ 8.86 (s, 
1H), 8.43 (s, 1H), 8.37 (d, J = 25.9 Hz, 2H), 8.14 (s, 1H), 7.41 (s, 1H), 7.33 (s, 1H), 6.88 (d, J = 13.6 Hz, 
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2H), 6.84 (s, 1H), 6.69 (s, 1H), 6.29 (s, 1H), 6.08 (s, 1H), 4.44 (s, 2H), 3.91 (d, J = 4.9 Hz, 3H), 1.95 (t, J = 
3.8 Hz, 3H). 
2-chloro-5-methylpyrimidin-4-amine (84, RAR-9-38) 
To a pressure vessel were added 1.1 mL of 2,4-dichloro-5-methylpyrimidine dissolved in 2.2 mL of 
NH3(aq). All materials were then further dissolved in 35 mL of EtOH, and the tube was sealed. The reaction 
was heated to 100 °C for 16 h, then cooled to room temperature. The desired product was filtered off as a 
white solid and washed with cold EtOH. Moved forward without further characterization. HRMS: 
144.0321, HPLC: 2.100.  
2-chloro-5-methyl-N-(pyridin-3-yl)pyrimidin-4-amine (85, RAR-9-43) 
This material was prepared using the protocol described for RAR-9-21. Yields the desired product as a 
yellow solid, 38.3 mg, 50%. HRMS: 221.0584, HPLC: 3.909. 1H NMR (401 MHz, Chloroform-d) δ 8.48 
(d, J = 8.4 Hz, 1H), 8.30 (d, J = 4.9 Hz, 1H), 8.09 (s, 1H), 7.81 – 7.75 (m, 1H), 7.05 (dd, J = 7.3, 5.0 Hz, 
1H), 2.23 (s, 3H). 
3-methoxy-4-((5-methyl-4-(pyridin-3-ylamino)pyrimidin-2-yl)amino)benzonitrile (86, RAR-9-44) 
This material was prepared using the protocol described in RAR-9-24. Yields the desired product as a dark 
red solid, 44.7 mg, 59%. HRMS: 333.1455, HPLC: 5.022. 1H NMR (500 MHz, Chloroform-d) δ 7.76 (s, 
1H), 7.73 (s, 1H), 7.62 (dd, J = 6.6, 2.9 Hz, 4H), 7.42 (dd, J = 5.0, 1.9 Hz, 7H), 7.13 (d, J = 1.7 Hz, 1H), 
7.11 (d, J = 1.9 Hz, 2H), 7.08 (s, 1H), 6.96 (d, J = 1.7 Hz, 2H), 6.65 (d, J = 8.1 Hz, 2H), 4.29 (s, 2H), 3.87 
(s, 3H).  
N2-(4-(aminomethyl)-2-methoxyphenyl)-5-methyl-N4-(pyridin-3-yl)pyrimidine-2,4-diamine (87, RAR-9-
46) 
This material was prepared using the protocol described in RAR-9-16 and was moved forward without 
further characterization due to instability. Yields the desired product as dark yellow oil. HPLC: 3.520.  
N-(3-methoxy-4-((5-methyl-4-(pyridin-3-ylamino)pyrimidin-2-yl)amino)benzyl)acrylamide (88, RAR-9-47, 
CCG-265647) 
This material was prepared using the protocol described for CCG-265507. Yields the final product as a 
light yellow solid. MS: 359 [M-OMe], HPLC: 5.062. 1H NMR (700 MHz, Chloroform-d) δ 7.94 (s, 1H), 
7.79 (d, J = 7.6 Hz, 2H), 7.71 (dd, J = 5.7, 3.3 Hz, 3H), 7.54 (dd, J = 5.7, 3.3 Hz, 3H), 7.42 (s, 1H), 7.14 (d, 
J = 7.8 Hz, 2H), 7.12 (s, 1H), 6.42 (m, 1H), 6.12 (m, 1H), 5.86 (s, 2H), 3.88 (s, 3H), 2.21 (m, 3H). 
N-(3-methoxy-4-((5-methyl-4-(pyridin-3-ylamino)pyrimidin-2-yl)amino)benzyl)but-2-ynamide (89, RAR-
9-48, CCG-265648) 
This material was prepared using the protocol described for CCG-265507. Yields the final product as a 
light yellow solid, 3.0 mg, 25%. MS: 420 [M+H2O], HPLC: 4.539. 1H NMR (700 MHz, Chloroform-d) δ 
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8.76 (s, 1H), 8.72 (s, 2H), 8.43 (s, 1H), 7.80 (s, 1H), 7.48 (d, J = 3.9 Hz, 1H), 7.42 (s, 1H), 7.14 (d, J = 8.1 
Hz, 1H), 7.12 (s, 1H), 3.91 (s, 3H), 2.72 – 2.67 (m, 3H), 1.98 (s, 3H). 
2-((2-chloro-5-methylpyrimidin-4-yl)amino)benzoic acid (90, RAR-10-24) 
To a pressure vessel were added 0.360 mL of 2,4-dichloro-5-methylpyrimidine, 431.8 mg of 2-
aminobenzoic acid and 10 mL of IPA. To this solution were added 2.7 mL of DIPEA, and the tube was 
sealed and heated to 80 °C for 36 h. Once complete, the reaction was cooled to rt and then the solvent was 
removed. The white solid was taken back up in EtOAc and then washed with 1N HCl, and saturated 
NaHCO3 (1 x 30 mL, respectively). The combined organic layer was dried over MgSO4 and then purified 
by column chromatography. Yields the desired product as a white solid, 310 mg, 38%. LRMS: 264, HPLC: 
6.078 1H NMR (500 MHz, DMSO-d6) δ 13.79 (s, 1H), 11.31 (s, 1H), 8.77 (d, J = 8.5 Hz, 1H), 8.21 (s, 
1H), 8.06 (d, J = 7.9 Hz, 1H), 7.69 (t, J = 7.9 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 2.22 (s, 3H).  
2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-(pyridin-3-ylmethyl)benzamide (91, RAR-10-25) 
This material was prepared using the protocol described for CCG-265507. Yields a white solid, 17 mg, 
13%. LRMS: 449 [M+Na, with DMF], HPLC: 6.378. 1H NMR (700 MHz, Chloroform-d) δ 11.09 (s, 1H), 
8.89 – 8.71 (m, 1H), 8.59 (d, J = 45.0 Hz, 3H), 8.10 – 7.95 (m, 1H), 7.72 (d, J = 10.3 Hz, 1H), 7.61 – 7.43 
(m, 2H), 7.14 – 6.98 (m, 1H), 6.87 (s, 1H), 4.75 – 4.56 (m, 2H), 2.26 (ddd, J = 15.1, 9.8, 5.1 Hz, 3H). 13C 
NMR (176 MHz, cdcl3) δ 169.51, 156.23, 149.36, 149.26, 140.29, 135.66, 133.02, 126.70, 123.75, 122.28, 
121.72, 119.80, 115.12, 41.53, 13.62. 
2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-((3-(methoxymethyl)-1,2,4-oxadiazol-5-
yl)methyl)benzamide (92, RAR-10-26) 
This material is prepared using the protocol described for the creation of CCG-265507. Yields a white solid. 
LRMS: 389 [M+1], HPLC: 6.770. 1H NMR (700 MHz, Chloroform-d) δ 10.73 (s, 1H), 8.31 (t, J = 6.2 Hz, 
1H), 7.81 (q, J = 6.7 Hz, 1H), 7.70 (d, J = 6.8 Hz, 1H), 7.42 (q, J = 5.9, 5.0 Hz, 2H), 4.96 – 4.92 (m, 2H), 
4.60 (q, J = 2.9 Hz, 2H), 3.49 (q, J = 3.0 Hz, 2H), 2.23 (d, J = 4.4 Hz, 3H). 
2-((2-((4-cyano-2-methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)-N-(pyridin-3-
ylmethyl)benzamide (93, RAR-10-27) 
This material is prepared using the protocol described for RAR-9-13. Yields a pale yellow solid, 7 mg, 
30%. HRMS: 466.1986, HPLC: 4.590. 1H NMR (700 MHz, Chloroform-d) δ 10.57 (s, 1H), 8.70 – 8.62 
(m, 3H), 8.59 (s, 1H), 8.02 (d, J = 3.4 Hz, 1H), 7.76 – 7.70 (m, 2H), 7.55 (dd, J = 8.1, 3.3 Hz, 2H), 7.33 – 
7.29 (m, 1H), 7.26 – 7.22 (m, 1H), 7.11 (d, J = 2.9 Hz, 1H), 7.08 – 7.04 (m, 1H), 6.56 (s, 1H), 4.69 (t, J = 
4.7 Hz, 2H), 3.95 (d, J = 3.5 Hz, 3H), 2.25 (d, J = 3.4 Hz, 3H). 
2-((2-((4-(aminomethyl)-2-methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)-N-(pyridin-3-
ylmethyl)benzamide (94, RAR-10-29) 
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This material was prepared using the protocol described for RAR-9-16. Moved forward without further 
characterization due to instability in air. Yields the product as a white residue, 6.3 mg, 90%. HPLC: 3.742, 
LRMS: 470 [M+1], 492 [M+Na]. 
3-((2-chloro-5-methylpyrimidin-4-yl)amino)benzoic acid (95, RAR-10-33) 
This material was prepared using the protocol described in RAR-10-24. Yields a white solid, 310 mg, 20%. 
MS: 264, HPLC: 5.77. 1H NMR (500 MHz, DMSO-d6) δ 9.19 (d, J = 25.3 Hz, 1H), 8.75 (s, 1H), 8.22 (s, 
0H), 8.07 (d, J = 9.3 Hz, 0H), 7.94 (s, 1H), 7.67 (d, J = 7.8 Hz, 0H), 7.43 (s, 1H). 
3-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-(pyridin-3-ylmethyl)benzamide (96, RAR-10-35) 
This material was prepared using the protocol described for CCG-265507. Yields a yellow oil, 30 mg, 14%. 
MS: 360, HPLC: 2.84.  1H NMR (500 MHz, Chloroform-d) δ 8.64 (s, 1H), 8.56 (d, J = 5.0 Hz, 1H), 8.02 
(s, 3H), 7.88 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.34 – 7.28 (m, 1H), 4.75 (d, J = 5.7 Hz, 2H), 2.81 (d, J = 1.3 
Hz, 3H). 
3-((2-((4-cyano-2-methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)-N-(pyridin-3-
ylmethyl)benzamide (97, RAR-10-37) 
This material was prepared using the protocol described for RAR-9-21. Yields a light yellow solid, 10 mg, 
25%. MS: 501 [M+Cl] from solvent, HPLC: 2.48  1H NMR (500 MHz, Chloroform-d) δ 8.65 (d, J = 11.0 
Hz, 2H), 8.57 (s, 2H), 8.48 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H), 7.85 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.70 (d, 
J = 8.1 Hz, 2H), 7.31 (d, J = 6.2 Hz, 2H), 7.19 (d, J = 8.5 Hz, 1H), 4.75 (d, J = 5.7 Hz, 2H), 3.92 (s, 3H), 
2.03 (s, 3H). 
2-chloro-5-methyl-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (98, RAR-10-44) 
This material was prepared using the protocol described in CCG-265507. Yields a yellow solid, 100 mg, 
30%. HPLC: 5.497. 1H NMR (700 MHz, Chloroform-d) δ 8.69 (dt, J = 4.7, 1.6 Hz, 1H), 8.48 – 8.41 (m, 
2H), 7.96 (s, 2H), 7.47 (ddd, J = 8.5, 4.5, 1.6 Hz, 1H), 2.52 – 2.46 (m, 3H). 13C NMR (176 MHz, cdcl3) δ 
167.62, 161.45, 157.54, 152.02, 140.51, 134.98, 129.79, 121.19, 115.35, 11.76. 
3-methoxy-4-((5-methyl-4-((pyridin-3-ylmethyl)amino)pyrimidin-2-yl)amino)benzonitrile (99, RAR-10-48) 
This material was prepared using the protocol described in RAR-9-21. Yields a light yellow solid, 14.4 mg, 
43%. MS: 493.35 [3M + Na], HPLC: 6.546. 1H NMR (500 MHz, Chloroform-d) δ 8.74 (d, J = 4.7 Hz, 1H), 
8.58 (d, J = 8.4 Hz, 1H), 8.35 (s, 1H), 7.68 (s, 1H), 7.54 (dd, J = 8.0, 4.3 Hz, 1H), 7.12 (s, 1H), 3.83 (d, J = 
4.2 Hz, 3H), 2.48 (s, 3H). 
2-((2-chloro-5-methylpyrimidin-4-yl)amino)-6-fluorobenzoic acid (100, RAR-10-64) 
This material was prepared using the protocol described in RAR-10-24. Yields an off-white solid, 430 mg, 
50%.  HPLC: 6.04. 1H NMR (400 MHz, DMSO-d6) δ 13.55 (s, 1H), 8.75 (q, J = 0.8 Hz, 2H), 8.37 – 8.31 
(m, 1H), 8.06 (d, J = 1.0 Hz, 1H), 7.33 – 7.24 (m, 1H), 6.80 – 6.71 (m, 1H), 2.31 (d, J = 0.8 Hz, 3H). 
2-((2-chloro-5-methylpyrimidin-4-yl)amino)-6-fluoro-N-(pyridin-2-ylmethyl)benzamide (RAR-10-81, 101) 
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This material was prepared using the protocol described in CCG-265507. Yields a white solid, 60 mg, 5%. 
MS: 372.0951, HPLC: 5.075. 1H NMR (400 MHz, Chloroform-d) δ 11.46 (s, 1H), 8.68 (d, J = 8.6 Hz, 1H), 
8.63 (dd, J = 11.1, 2.4 Hz, 1H), 8.54 (dd, J = 9.6, 4.6 Hz, 1H), 8.07 – 8.04 (m, 1H), 7.75 – 7.66 (m, 1H), 
7.49 (td, J = 8.4, 4.1 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.13 – 7.05 (m, 1H), 4.67 (dd, J = 19.4, 5.9 Hz, 2H), 
2.24 (s, 3H). 
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Chapter 3. Expanding the Arsenal: Virtual Screening & Validation of the Aminopyridine 
Scaffold 
3.1 Preface 
Ideas and conclusions from Chapter 3 are in preparation for publication and may appear verbatim 
in a future publication. I planned, executed and evaluated hits from the virtual screening efforts. I 
synthesized all compounds within this chapter. Pharmacological assays were performed by M. 
Claire Cato, Renee Bouley and me. GRK5 and GRK2 were provided by Renee Bouley.  
3.2 Virtual Screening Mined New Scaffolds for GRK5 Inhibitors 
In Chapter 2, Cys474 was established as a viable handle for selective inhibition of GRK5 through 
covalent modification.1 However, the original pyrrolopyrimidine scaffold was unable to be 
improved upon despite our best efforts. While CCG-265328 did show modest potency, the lack 
of tractable SAR meant another lead was urgently needed.  
As the scaffold hop preformed in Chapter 2 did not yield a more potent or selective 
analogue, the known scaffolds that target GRK5 were further dwindled. Of the known and 
confirmed lead options there were two: the indazole scaffold, exemplified by CCG-215022, and 
the paroxetine scaffold, exemplified by the pan-GRK2/GRK5 inhibitor, CCG-258748.2,3 However, 
both options present a similar barrier to development: the scaffolds are not amenable to 
modification to carry a covalent warhead. In our GRK5/GRK6 model neither CCG-215022 nor 
CCG-258748 have a position where a vector could be created to carry the covalent warhead. As 
non-covalent strategy has failed to produce a GRK5 selective inhibitor, these leads were 
deprioritized.  
To generate a lead for this project, we chose to mine chemical space for an entirely new 
scaffold. Known chemical space is vast and searching for a lead with novel IP through traditional 
High-Throughput Screening (HTS) efforts can be expensive. Most novel leads are found through 
HTS, however, there are serious considerations such as reagent cost, instrumentation and assay 
development that can make HTS cost prohibitive. Additionally, HTS libraries are built of a discrete 
set of real compounds. Therefore, only those compounds available within a given collection may 
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be screened, thereby limiting the amount of novel chemical space that can be mined for a 
new lead.4–6 Fortunately, there has been rapid advancement in the field of virtual screening that 
has allowed medicinal chemists to mine novel chemical space using real, synthetically feasible 
lead compounds in silico.7 For these reasons, we chose to pursue virtual screening, utilizing a 
pharmacophore-based screening filter to mine new scaffolds for this project. 
For our virtual screening effort a knowledge-based library was compiled, using compounds 
reported to have known GRK2, GRK5 and ROCK1 activity.8,9 This compiled library was then 
filtered using PipelinePilot to remove pan assay interfering compounds (PAINS).10 PAINS are 
compounds with apparent biochemical activity conveyed through interference with the assay 
readout or through an alternative mechanism. Common reasons a compound may be classified as 
a PAIN include: redox capability, chemical aggregation, chelation, sample impurities and non-
selective interactions with proteins, to name a few.11 By removing these compounds the risk of 
identifying leads with promiscuous activity is reduced. However, we were careful to leave 
compounds with the potential to covalently interact with our target protein, as we are searching for 
a lead compound to be developed into a covalent inhibitor.5,12 
A 3D pharmacophore screening method was pursued to further increase our chances of 
mining leads which would be active against our kinase target.8,13,14 For this particular screen, we 
chose to use the GRK5/GRK6 model that was developed in Chapter 2, as GRK5 is thought to be 
in a closed, active conformation in this structure.15,16    
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For the virtual screen, an 
appropriate model of the 
target protein was needed. In 
the GRK5 structure 
previously published by the 
Tesmer group, the desired 
covalent handle, Cys474, is 
missing from the assigned 
structure (PDB: 4WNK).15 
This is due to the flexibility 
of piece of architecture where 
Cys474 is located. The 
active-site tether (AST)-loop 
is a highly flexible piece of 
architecture that runs along 
the face of the kinase, 
connecting the large and small lobes of the kinase. When the kinase interacts with a substrate, such 
as ATP, it adopts a closed-active conformation in which the AST-loop wraps over the front of the 
kinase domain (Figure 3.1). This flexibility allows the kinase to adopt different conformations, 
which is critical to the regulation of downstream signaling cascades. However, this flexibility often 
means that in crystal structures the AST-loop can adopt several conformations within one crystal. 
Thus, the exact position of the highly flexible loop is impossible to fully determine.17,18 This effect 
produces a crystallographic “blind spot” in which it is assumed that the AST-loop is present but 
cannot be modeled in space with any degree of reasonable certainty.  
Resolving a crystallographic blind spot requires that a crystal structure of a highly related 
protein, in this case the GRK4-family member GRK6, has a partially or fully resolved AST-loop. 
 
Figure 3.1 Overlay model of GRK5 (blue) and GRK6 (purple). Cys474, located on the 
AST loop is highlighted in green. CCG-215022 (orange) is bound to the hinge, within 
the kinase domain. 
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In this overlay model, 
GRK6 (PDB: 3NYN) has a 
partially resolved AST-
loop, which does display 
Cys474.16 As GRK5 and 
GRK6 are subfamily 
members that share 
sequence homology (72.6% 
overall) as well as a kinase 
domain which is conserved 
among all GRKs, our 
overlay model was 
constructed using these two 
proteins (GRK5-4WNK, 
GRK6-3NYN).15,16,19–21 Having filled in the crystallographic blind spot, determining parameters 
for virtual screening was next determined. 
In order to obtain a series of potential leads that are reasonable, and increase the attrition 
rate of our virtual screen, a training set and experimental set of compounds were created (Figure 
3.2).8 The test-set, which is used to validate the model and screening parameters consisted of 
known GRK2 and GRK5 inhibitors as well as known FDA-approved kinase inhibitors, such as 
ROCK1 inhibitor Fasudil.22 The experimental set was consisted of compounds pulled from both 
Figure 3.2 Screening funnel used for compilation, filtering and screening of 
in silico library of enriched compounds. Eventually, the “hit” compounds are 
redocked to validate through replication, and the individual “lead” is then 
either purchased or synthesized and tested for affinity data.  
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the Maybridge chemical library and the Chembl compound library.23,24 These libraries were 
collated and filtered to include compounds that either had existing GRK5 or GRK2 activity data, 
or had a scaffold known to be privileged in kinase drug discovery.25 Both sets of compounds were 
then subjected to an additional filtering system (Pipeline Pilot), which eliminated PAINs and other 
potentially reactive compounds.10 The final sets were then imported into Molecular Operating 
Environment (MOE 2018.01) in preparation for the virtual screen.26 
For the initial training set, the virtual screen had a number of parameters set to give 
potential leads that adopt an appropriate binding mode. In this instance, the key interaction for all 
compounds to contain was a hydrogen-bond acceptor that was congruent with the hinge hydrogen-
bond donor on the hinge loop (Met266).27,28 Additionally, the pharmacophore was set to include a 
hydrogen bond-donor (blue) adjacent to the hydrogen-bond acceptor (purple) and at least one 
aromatic ring (orange) connecting the two hydrogen bond elements. This pharmacophore was 
based upon the binding pattern observed for CCG-215022, which was crystallized in GRK5 (PDB: 
4WNK) (Figure 3.3). Once the pharmacophore had been set, the training set was run to validate 
the screening parameters. From this test, the screen returned a number of potential hits, including 
Fasudil, the known ROCK1 inhibitor, thereby validating that this method would produce 
potentially valid lead compounds. 
 
Figure 3.3 (a) binding mode for CCG-215022 as seen when crystallized with GRK5 (PDB: 4WNK). (b) 
pharmacophore generated from CCG-215022 to use in virtual screen. Hydrogen bond donors (magenta sphere), 
hydrogen bond acceptors (turquoise spheres) and aromatic rings (orange spheres) are selected as the 
pharmacophoric features required for virtual screening hits. Annotation points, automatically calculated by MOE, 




Once validated, the same pharmacophore was used to screen the experimental set of 
compounds. In order to avoid an unmanageable amount of hit data, the number of poses generated 
for each compound was limited to five poses. Each hit from the virtual screen was evaluated by 
visual inspection, and top hits were then independently re-docked into the original model, forgoing 
the pharmacophore requirements for binding.29 From this screen, four scaffolds were identified, 
the oxaindole scaffold, the thiopyrimidine scaffold, the pyrimidine scaffold and the aminopyridine 
scaffold. In total 11 compounds from the 3 former scaffolds were commercially available. Those 
compounds that were commercially available were purchased and evaluated. In total, none of the 
11 compounds evaluated for biologically activity were found to be active. Therefore, we chose to 
evaluate the aminopyridines, all of which seemed to bind the hinge region in the desired fashion 
 
Figure 3.4 Lead compound Chembl-1607632 bound to GRK5 (blue)/GRK6 (purple) overlay model. Shows that the 
aminopyridine scaffold binds to the hinge region (Met266 and Thr264) with a two pronged hydrogen bonding pattern. 
Also shows that the southern piperidine ring could be removed and a warhead could be put there, and still maintain the 
correct vector for covalent engagement. Also, the eastern pyrrolidine ring has filled a deeper section of the hydrophobic 
back pocket, with a matched polar side chain. 
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(Figure 3.4).  Given its optimal binding mode, feasibility of modification to accommodate covalent 
warheads and excellent reported GRK5 activity data (GRK5 = 59 nM for lead compound Chembl-
1607632), we chose to continuing validating Chembl-1607632 as our lead compound for a new 
series of GRK5 inhibitors.30  
3.3 Independent Synthesis of Chembl-1607632 Required Route Optimization 
An authentic standard of Chembl-1607632 was commercially unavailable, however in the 
literature that described its activity, there is also a brief synthetic scheme.30 Thus, we set out to 
independently synthesis Chembl-1607632 for final validation of this lead compound and potential 
series of compounds. The original route for synthesis of this compound is described in Scheme 
3.1.  
The original synthetic route to the lead compound begins with a SNAr of pyrrolidine with 
starting material 102 to yield intermediate 103. The free aminophenol, 104 is revealed following 
a zinc catalyzed nitro-reduction, and it is immediately condensed with 105 to give the benzoxazole 
core seen in 106.31 The yield for the production of 106 is severely limited for a few reasons. First, 
upon reduction of the nitro-group seen in 103, a diamine, with a high level of resonance, is created 
(104). This diamine begins to immediately oxidize upon contact with air.31 As this reaction is run 
in the open atmosphere, these conditions yield an oxidized product and desired product (104) as 
an inseparable mixture. Only intermediate 104 is usable in the next step to create the benzoxazole 
ring, and therefore, the limited quantity of usable 104 limits the efficacy of the ring formation. 
Scheme 3.1 Original synthetic route proposed for Chembl-1607632A (109) and related compounds. 
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Also, the transformation from 104 to 106 occurs in one pot, starting with 105 undergoing an amide 
coupling. However, it is well known that the acid starting material of 105 is light sensitive and can 
undergo a UV-catalyzed decarboxylation. Therefore, special care was needed to form the 
intermediate 104 and use it in the ring formation of 106 (light protection and argon atmosphere). 
Given these challenges, we were never able to produce 106 in more than 30% yield.  
Then the aminopyridine moiety was installed using a SNAr with tert-butyl amine to give 
107. While the installation of the aminopyridine core through SNAr proceeded smoothly, it also 
yielded inconsistent results with yields of 50-75%.  This limited yield was due to steric hinderance 
from the tert-butyl amine in the 2-aminopyridine position. This exceptionally large group limited 
the rotational degrees of freedom for the compound and thus could only be produced in small 
batches. Additionally, there are multiple positions that can react with tert-butylamine to produce 
an undesired isomer of the desired product, 107. Interestingly, we were unable to exchange this 
protecting group for a more conventional amine protecting group. The most common Boc-
protecting group would have come off in our down-stream chemistry that features strongly acid 
conditions and metal catalyzed coupling reactions. Other allyl groups would have proved difficult 
to remove as well. This tert-butyl group is theorized to be removed by releasing a tert-butyl cation, 
other allyl groups would have to be removed by harsh boronic conditions. Therefore, we chose to 
keep this protecting group, despite its obvious limitations.  
According to Cho. et al. attaching the southern hemisphere of the compound, constructed 
in a separate line of synthesis, could be achieved using a Suzuki-Miyara cross-coupling.30 
However, in our hands, we were never able to achieve this transformation. This failure to complete 
intermediate 108 may be due to the highly electron rich system of the starting material 107. It is 
well known that highly electron rich, deactivated systems are rarely good participants in cross-
coupling methods.32 Additionally, the bromine-leaving group of 107 is not the most ideal leaving 
group for these transformations, which typically prefer chlorines as leaving groups.33,34 Well it has 
been well established that bromine can be used in palladium catalyzed transformations, clearly, in 
this case, it is not an appropriate match under these conditions. As 108 could not be produced, we 
were unable to establish that the removal of the tert-butyl group by TFA was a legitimate way to 
produce the final product, 109.  
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 Given the amount of difficulty with this highly electron-rich and sensitive system, we chose 
to redesign the route to achieve the lead compound and derivatives. Ideally, the modified route 
avoids the unveiling of highly sensitive or reactive pendants, though certain precautions were taken 
to optimize the efficiency of each reaction. The actual route used to achieve CCG-265649 is 
described in Scheme 3.2. Synthesis begins with an amide coupling between 110 and 2-amino-4-
chlorophenol to yield the open intermediate, 111. It was initially thought that an acid catalyzed 
ring closure would achieve 112, however, we were only ever able to isolate 10-25% of the desired 
compound and the open intermediate 111 with those procedures.35–37 Through a Mitsunobu 
reaction with DEAD, 111 was successfully converted to the benzoxazole core, 112 in moderate 
yields (70%) allowing us to operate the next few difficult steps at a higher scale. The installation 
of the aminopyridine core is then accomplished through a SNAr, yielding common intermediate 
113.38 While we did attempt to optimize this SNAr, we found that the conditions initially suggested 
by Cho et.al. proved to be the most effective, if erratic in yield (10-80%). Intermediate 113 is then 
submitted to the Suzuki-Miyara coupling conditions described by Thompson, thereby yielding the 
second common intermediate 114.34,39,40 One advantage of this route is that it allowed us to rapidly 
generate a series of analogues using optimized Buchwald-Hartwig coupling conditions. One of the 
major issues with this is that Buchwald-Hartwig are often optimized case-by-case due to the 
sensitivity of the catalysts and the coupling partners.32 Despite these challenges we were able to 
Scheme 3.2 Optimized synthetic route to CCG-265649. 
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produce our own authentic sample of Chembl-1607632 (now known as CCG-265649) and an 
initial series of compounds produced while trying to validate our synthetic route.41  
3.4 CCG-265649 Invalidates Chembl-1607632 Lead Compound in Radiometric Assays 
With an authentic sample of Chembl-1607632 (CCG-265649) in hand, the next step was 
to validate the activity of the lead and by extension the series. We also chose to test a few 
compounds which were produced as part of the synthetic route validation process.  
 CCG-265649 was reported in the literature as having nanomolar potency against GRK5 
(IC50 = 59 nM), with relatively low-selectivity against GRK2 (IC50 = 460 nM, 7-fold selective for 
GRK5). However, in our hands, this compound was found to have little to no activity against 
GRK5 with an IC50 = >100 µM. Interestingly, compounds that were produced during route 
 
Table 3.1: IC50 Values for Aminopyridine Route Development 
Compounds (µM ± SD) 
                                              







 Br H tBu >100 ND 
CCG† 
264222 
  H tBu >100 ND 
CCG† 
264240 
  Cl H >100 ND 
CCG† 
264485 





H H >100 >100 
CCG 
265176 
  H H >100 >100 
Experimental values derived from this report were run in triplicate with n=3 experiments against GRK5. 




optimization showed a similar level of inactivity. Unsurprisingly CCG-264187, and CCG-264222 
do not show any level of appreciable activity, as the tert-butyl amine moiety blocks the ability of 
the amine to hydrogen bond with the hinge of GRK5. The inactivity of CCG-264240 and CCG-
264485, is surprising as that moiety is not blocked from engaging with the hinge region of GRK5. 
As these compounds are smaller fragments, it is possible that an alternative binding mode, wherein 
the aminopyridine moiety doesn’t bind to the hinge of GRK5 is possible, accounting for the lower 
levels of activity observed.  However, in a separate single dose experiment, conducted at 1 mM, 
CCG-265176 was found to strongly inhibit both GRK5 and GRK2 (data not shown). Given this 
discrepancy, it is clear that further investigation of key compounds, CCG-265175 and CCG-
265176 is needed to better understand the relationship between GRK5 and this series. 
Data from the initially developed compounds suggested that CCG-265649 may be an 
anomaly, as it shows no inhibitory activity with an IC50 > 100 µM (Table 3.2) despite the reported 
literature data. To further investigate, compounds CCG-270957-CCG-270964 were created. CCG-
270957 and CCG-270958 were designed to have some activity against GRK5 or GRK2, as the 
Table 3.2: IC50 Values for Aminopyridine Compounds (µM ± SD) 
                                              

















  H >100 >100 
CCG 
270958 









  H >100 >100 
Experimental values derived from this report were run three times in duplicate against GRK5 and GRK2. 






pyridyl pendant is known to have activity against GRK2. However, their lack of activity suggests 
that otherwise, implying that these pyridyl pendants might not be positioned in the same 
hydrophobic pocket as the pyridyl pendant in the well known GRK2/GRK5 inhibitor, CCG-
215022.  Given the lack of activity from these compounds, further investigation is needed, and 
potentially a new scaffold may need to be pursued.  
In an effort to expand our covalent arsenal of GRK5 inhibitors, we created CCG-265175 
that features an acrylamide warhead. While this warhead demonstrated lower reactivity in our 
initial pyrrolopyrimidine series, we were able to observe covalent labeling. Given the knowledge 
that less potent compounds have a slower Kon which can then extend the timeframe needed to 
observe a covalent engagement, we tested CCG-265175 in intact protein mass spectrometry with 
a 24 h incubation period (Figure 3.5). However, even with ample amount of time to form a covalent 
adduct CCG-265175 did not have any observable amount of labelled GRK5, instead only a GRK5 
aggregate with a much higher weight than anticipated was observed, suggesting CCG-265175 may 







Figure 3.5 Intact protein mass spectrometry of CCG-265649 (coral), and CCG-265175 (lavender). All traces 
indicate that none of the compounds tested are capable of forming a covalent bond with GRK5.  
MS traces are an average of n=1 experiments.  
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fashion.  Thus, we concluded that while the model suggested this scaffold would be amenable to 
carrying covalent modifiers, this is not the case.  
 Other rationally 
designed compounds, 
CCG-270957-270964, 
display a similar level of 
inactivity. Interestingly, 
we thought that the free 
pyrazole compound, 
CCG-270964, could 
adopt a different binding, 
one that is more similar to 
that seen in the crystal 
structure of GRK5 bound 
to CCG-215022 (Figure 
3.6). In this model, we 
assumed that the free-
pyrazole pendant could 
bind the hinge and the 
benzoxazole core could 
then fill the deeper hydrophobic pocket, similar to other known Type II kinase inhibitors. However, 
the inactivity of this compound suggests that this binding event does not occur.   
3.5 Invalidation of CCG-265649 Means Abandoning the Series 
 
Figure 3.6 Alternate binding mode for CCG-270964 (gray) bound to the 
GRK5(blue)/GRK6 (purple) homology model. Changes in binding motif and 
solvent exposure are denoted in red and blue respectively. Key residues: Thr264, 
Met266 and Cys474 (green) indicated by arrows.   
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While CCG-265649 originally seemed like an ideal candidate for a new series of covalent GRK5 
inhibitors, this is sadly not 
the case. We were unable to 
replicate the data set out in 
the literature, suggesting 
two possibilities. First, as 
Cho et. al. did not provide 
experimental data for 
Chembl-1607632, it is 
possible that CCG-265649, 
was not the active ingredient 
in their sample. Second, it is 
possible that a contaminant 
was present in their sample 
that conveyed activity 
making it appear as if Chembl-1607632 was a potent compound.  
None of the compounds made as part of the series yielded any appreciable level of activity. 
We can attribute this lack of activity to one of two reasons. Either these compounds do not bind as 
we predicted they would, or the aminopyridine scaffold does not have a sufficient amount of 
intrinsic potency to allow for binding. In independent docking experiments, we did observe that 
the original lead compound (and all other in the series with the southern piperidine pendant) could 
adopt a secondary binding mode. This secondary binding mode shows the piperidine ring forming 
a hydrogen bond with the hinge hydrogen bond-donor, but this is the only key interaction with the 
hinge in this binding mode (Figure 3.7). This alternate binding mode also indicates new types of 
interactions being made with Val200 and Asn316 which are not shown in the original binding 
mode posited by the virtual screening docking experiment. These new interactions are suggestive 
of overall better binding mode however, their presence is not enough to suggest strong binding, 
which is consistent with the data for CCG-265649.  
 
Figure 3.7 Alternate binding mode for CCG-265649 (orange) shown with the 
lipophilic pocket of GRK5 (blue). The more polar groups are seen to be situated 
ideally in this binding mode, and additional interactions with Asn316. 
97 
 
 As the aminopyridine scaffold is known in kinase drug-discovery to be a privileged 
scaffold (with appearances in known FDA-approved kinase inhibitors such as Crizotinib) it seems 
unlikely that the intrinsic potency of the aminopyridine scaffold wouldn’t be enough to enable 
some low-activity level binding event.25,42 However, it is entirely possible that the electronics of 
CCG-265649 and its series members make an inexact match with the binding pocket. Potentially 
these molecules are too electron-rich causing an electronic repulsion with residues within the 
binding site (Figure 3.8). Indeed, when looking at the electrostatic map of GRK5 (Figure 3.8a) 
against the electronic map of CCG-265649 (Figure 3.8b), we see that deeper in the hydrophobic 
pocket there is an inexact match occurring around the aminopyridine and pyrrolidine moiety. In 
fact, these two areas of CCG-265649 have almost the exact same properties of that seen in the 
GRK5 active site electrostatic map. This kind of mismatch is indicative of an electronic repulsion 
(in this case, blue shading matching with red shading indicates a strong electronic attraction). 
Therefore, this binding mode, while attractive when looking at just lipophilicity and hinge binding, 
is not ideal for high affinity compounds. This is consistent with the low affinity seen in this series, 
suggesting that potentially, this alternate binding mode is closer to what is actually occurring in 
vivo.  
 Despite this reasoning, we still have deep misgivings about this series due to the 
discrepancy between our data and the data reported in the literature.  Given the large discrepancy 
Figure 3.8 (a) Electrostatic map shown for alternate binding mode of CCG-265649 shown in blue and red. (b) 
Electronic density of CCG-265649, as shown in the alternate binding mode. (c) CCG-265649 (orange) in alternate 
binding mode indicates that additional hydrogen bonds can be achieved with Asn316 and the aminopyridine moiety. 
Hinge donor and acceptor are indicated in respective order (back to front) via bracket.  
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in data we have determined that unless the authentic third-party sample of Chembl-1607632 can 
be obtained and validated, this series is not worth pursuing further.  
3.6 Materials, Methods and Synthetic Experimental Data 
Computational Modeling General Information: 
GRK5/GRK6 Overlay Model: 
GRK5 (4WNK) and GRK6 (3NYN) were loaded into Molecular Operating Environment 2018.01 
(Molecular Operating Environment (MOE), 2018.01; Chemical Computing Group ULC, 1010 
Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018) and proteins were 
prepared using QuickPrep function. Once preparation was complete, the sequences of both 
proteins were aligned. The alignment was used to create a super-position of the two proteins within 
3D space. This super-position is herein referred to as the “GRK5/GRK6 overlay model” and serves 
as the basis for computational work described throughout this text.  
Database Creation: 
From Chembl database were downloaded compounds with activity for GRK2, GRK5 and ROCK1 
(https://www.ebi.ac.uk/chembl/) . These results were then collated with screening compounds from 
the Maybridge Chemical Library 
(https://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__177/DesktopDefault.aspx). 
Compounds with known GRK2, GRK5 and ROCK1 activity were added to test if the virtual 
screening could find these compounds as hits. The collated library of compounds were then sorted 
using Pipeline Pilot to remove compounds that contain: nitro groups, Michael acceptors and other 
chemically reactive moieties, and may have redox potential (PAINS). The refined list of 
compounds were imported into MOE, washed and converted from 2D to 3D space. The resultant 
MDB file, with 2408 compounds, was saved and used in the virtual screening efforts described 
below. 
Building a Pharmacophore Model: 
For the virtual screen, a pharmacophore was built around the known GRK5 ligand, CCG-215022, 
as shown in the GRK5 crystal structure (4WNK). The pharmacophore query included the two 
aromatic rings that form the indazole core of the CCG-215022 scaffold, and the hydrogen bond 
donor and acceptor from the indazole core. This query was saved and used to determine potential 
hits within the virtual screening efforts described below. For additional details, see Figure 3.3 
Running the Virtual Screen: 
With the screening database and pharmacophore model in hand, the virtual screen was conducted. 
In the MOE docking protocol, the following parameters were used: Amber10:EHT as the force 
field, the above-mentioned pharmacophore as the placement, rigid receptor refinement, and 
London dG, GBVI/WSA dG as the scoring method. All results from the screen were then refined 
by visual inspection, and compounds with desired binding modes were duplicated for later 
examination and identification of commercially available sources. As validation of our method, 
our screen drew Fasudil, a known ROCK1 inhibitor, as a hit. Further visual inspection produced 
four novel scaffolds, the oxaindoles, the thiopyrimidines, the pyrimidines and the aminopyridines. 
To evaluate hits, 11 commercially available compounds were purchased, see list below, and 
evaluated by radiometric assay (described below). Of the compounds tested, none were found to 
be active (data not shown).  
Virtual Screening Compounds Purchased: 
- Oxaindoles, sourced from Sigma Aldrich and used without further purification 
Z1213677549, Z1119386706, 477862-37-6 
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- Thiopyrimidines, sourced from Enamine Building Blocks and used without further 
purification 
Z5676559, Z1699857079, Z11263716020, Z1575308464 
- Pyrimidines, sourced from Sigma Aldrich and used without further purification 
B0241956, B0241957, B0241958, B02410012 
 
Chemistry General Information: All reagents from commercial sources were used without further 
purification unless otherwise noted. 1HNMR spectra were taken in DMSO-d6, MeOD or CDCl3 at 
room temperature on Varian MR 400 MHz, Varian Vnmrs 500 MHz and Varian Vnmrs 700 MHz 
instruments. Reported chemical shifts for the 1HNMR spectra were recorded in parts per million 
(ppm) on the δ scale from an internal tetramethylsilane (TMS) standard (0.0 ppm). Small molecule 
mass spectrometry data was measured using a Waters Coporation Micromass LCT or Agilent6230 
Q-TOF instrument. HPLC was used to determine purity of biologically tested compounds on an 
Agilent 1100 series with an Agilent Zorbax Eclipse Plus-C18 column. A gradient of 10-90% 
acetonitrile/water over 6 minutes followed by 90% acetonitrile/water for 7 minutes was used with 
detection at 254 nm.  
 
Intact Protein MS Information: Intact Protein mass spectrometry was acquired with a Phenomenex 
C4 column paired with an Agilent 6545 Q-TOF LC/MS. For intact MS all samples were prepared 
with 20 µM GRK in assay buffer (see below), 1 mM compound, and incubated at 4 ˚C for 3-24 
hours before being quenched with 1.0 µL of formic acid.  
 
Biology General Information: IC50s for human GRK5, bovine GRK2, bovine GRK6, and bovine 
GRK5-C474S were determined using a radiometric assay as follows. 50 nM GRK was incubated 
with 500 nM porcine brain tubulin (Cytoskeleton) and 1 nM–1 mM inhibitor in Reaction Buffer 
(20 mM HEPES pH 7.5, 10 mM NaCl, 10 mM MgCl2, 2 mM DTT) for 4 h at room temperature 
prior to initiation with the addition of 5 μM ATP supplemented with radioactive [γ-32P]-ATP 
(PerkinElmer Life Sciences). Reactions were quenched at 8 min by transferring 10 μL reaction 
into 5 μL 4X SDS gel loading dye. 10 μL samples were separated on a 4-15% Criterion TGX 
precast gel (Bio-Rad), and gels were dried, exposed to a storage phosphor screen overnight, and 
scanned using a Typhoon scanner. Bands corresponding to phosphorylated tubulin were quantified 
using ImageQuant, plotted as a function of log[inhibitor], and fit to the three-parameter 
log(inhibitor) vs. response model in GraphPad Prism 7.03 to determine IC50s. Experiments were 
performed with an n = 3, and mean and standard deviation values were calculated using the column 




2-nitro-5-(pyrrolidin-1-yl)phenol (103, RAR-5-7) 
To a sealed tube were added 2.0012 g of 5-bromo-2-nitrophenol, dissolved in 45 m of MeCN. To 
this solution were added 4 mL of pyrrolidine, and the tube was sealed and heated to 80 °C for 12-
18 h. Once complete, the reaction was cooled to rt and the solvent was removed under pressure. 
The crude material was purified by column chromatography (80% DCM/Hex) to yield the desired 
product. 1H NMR (500 MHz, Chloroform-d) δ 10.61 (s, 2H), 7.97 (dt, J = 9.3, 2.6 Hz, 2H), 7.96 
– 7.91 (m, 1H), 7.37 (q, J = 2.9, 2.4 Hz, 2H), 7.14 (dt, J = 8.6, 1.9 Hz, 2H), 6.20 – 6.13 (m, 1H), 
6.01 (d, J = 2.9 Hz, 1H), 3.41 (d, J = 5.9 Hz, 4H), 2.07 (td, J = 5.9, 3.3 Hz, 4H). 13C NMR (126 
MHz, cdcl3) δ 128.01, 126.57, 124.40, 123.52, 109.85, 106.92, 97.89, 48.57, 25.84. 
 
2-amino-5-(pyrrolidin-1-yl)phenol (104, RAR-5-18) 
To a flask were added 50 mg of 2-nitro-5-(purrolidin-2-yl)phenol, dissolved in 3 mL of 1:1 
MeOH/EtOAc. The solution was degassed with three rounds of evacuation and back fill with 
nitrogen before Pd/C catalyst was introduced. The solution was then degassed with an additional 
3 cycles of evacuation and back fill with nitrogen. The atmosphere was replaced with hydrogen 
gas, and the resultant solution was allowed to stir at rt until complete (about 12 h). Once complete, 
the hydrogen atmosphere was removed, and the solution was passed through a pad of celite. The 
solvent was removed under pressure and the crude material was taken forward without further 
characterization due to instability in open atmosphere. 
 
5-bromo-2-chloronicotinoyl chloride (105, RAR-5-17) 
To a dried flask were added 50.1 mg of 5-bromo-2-chloronicotinic acid. All materials were then 
dissolved in 3 mL of dry DCM, and the flask was wrapped in foil (to prevent light catalyzed 
decarboxylation). The solution was cooled to 0 °C and 0.1 mL of DMF as well as 0.02 mL of  
 
Scheme 3.3. Original synthetic route to CCG-265649. 
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Oxalyl chloride were added sequentially. The solution was allowed to gently warm to rt and run 
for 2 h. Once complete, the solvent was removed under pressure and the crude material was further 
rinsed with DCM (3 x 15 mL). Due to instability in air, this product was moved forward without 
further characterization. 
 
2-(5-bromo-2-chloropyridin-3-yl)-6-(pyrrolidin-1-yl)benzo[d]oxazole (106, RAR-4-100) 
To a flask were 50 mg of freshly prepared 5-bromo-2-chloronicotinoyl chloride, and 30 mg of 2-
amino-5-(pyrrolidine-1-yl)phenol, dissolved in 3 mL of NMP. The solution was cooled to 0 °C 
and 0.1 mL of pyridine were added in one portion before being stirred for 20 mins. The solution 
was then slowly warmed to 120 °C for 4 hours. Once complete, the reaction was quenched with 
brine and the aqueous layer was extracted with EtOAc (4 x 30 mL). The combined organic layer 
was then washed with brine (1 x 30 mL) and then dried over Na2SO4. The crude material was then 
purified by column chromatography to yield the desired product as a light yellow solid, 46.6 mg, 
60%.  1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H), 9.34 (s, 1H), 8.65 (d, J = 2.5 Hz, 1H), 8.32 
(d, J = 2.5 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 6.08 (d, J = 2.6 Hz, 1H), 6.04 (dd, J = 8.7, 2.5 Hz, 




To a sealed tube were added 220 mg of (106) dissolved in 5 mL of dry DMF. To this solution were 
added 0.06 mL of tert-butylamine and the tube was sealed. The solution was then heated to 120 
°C for 18 h. Once complete, the reaction was cooled to rt and diluted with 50% EtOAc/Hex. The 
organic layer was washed with water (1 x 30 mL) and brine (1 x 30 mL) before being dried over 
Na2SO4. The solvent was removed under pressure, evaporating the product onto silica gel. The 
crude material was purified by column chromatography to yield the product as a white solid, 100 
mg, 50%. 1H NMR (500 MHz, Chloroform-d) δ 8.31 (d, J = 2.4 Hz, 1H), 8.23 (d, J = 2.5 Hz, 1H), 
8.15 (d, J = 2.4 Hz, 1H), 7.78 (dd, J = 5.9, 3.3 Hz, 1H), 7.58 (dt, J = 7.3, 3.7 Hz, 1H), 7.47 (dd, J 
= 9.0, 2.4 Hz, 1H), 7.39 – 7.36 (m, 2H), 6.25 (d, J = 9.0 Hz, 1H), 3.45 – 3.37 (m, 4H), 2.97 (d, J = 
1.1 Hz, 7H), 2.04 – 1.97 (m, 4H). 13C NMR (126 MHz, cdcl3) δ 150.45, 142.66, 125.53, 124.95, 
120.36, 77.50, 77.25, 76.99, 47.06, 41.48, 25.79, 0.24.  
 
2-(5-bromo-2-chloropyridin-3-yl)benzo[d]oxazole (116, RAR-8-3) 
To a flask were added 1.5 g of 5-bromo-2-chloronicotinoyl chloride, dissolved in 30 mL of toluene. 
To this solution were added 694.0 mg of aminophenol and 1.7 mL of triethylamine. The solution 
was then stirred at rt for 2 h. After 2 h, 1.6 g of PPTS were added to the solution in one portion, 
and the reaction was heated to 170 °C for 24-48 h. Once complete, the reaction was cooled to rt 
and the solvent was removed under pressure. The material was then diluted with EtOAc and 
washed with water (1 x 50 mL) and brine (2 x 50 mL). The organic layer was dried over Na2SO4 
and the solvent was removed. The crude product was purified using a silica plug, eluting with 5% 
EtOAc/Hexanes. The solvent was removed to give the desired product as a yellow solid, 420 mg, 
21% LRMS: 310 [M+1], HPLC: 8.053. 1H NMR (700 MHz, Chloroform-d) δ 8.75 – 8.54 (m, 2H), 
7.87 (s, 1H), 7.65 (s, 1H), 7.45 (s, 3H). 
3-(benzo[d]oxazol-2-yl)-5-bromo-N-(tert-butyl)pyridin-2-amine (117, RAR-8-4) 
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To a sealed tube were added 202.4 mg of RAR-8-3 which was dissolved in 6 mL of DMF. To this 
solution were added 1.0 mL of tert-butylamine and then the tube was sealed. The reaction was 
heated to 120 °C for 20 h. Once complete, the reaction was cooled to rt and then the reaction was 
quenched with brine. The aqueous layer was extracted with EtOAc/Hex (50%, 3 x 30 mL). The 
combined organic layer was then washed with brine (2 x 25 mL), and then dried over Na2SO4. The 
solvent was removed under pressure, and the crude material was purified by column 
chromatography yielding 186.9 mg, 80%. MS: 348, HPLC: 8.215. 1H NMR (500 MHz, 
Chloroform-d) δ 8.77 (s, 1H), 8.30 (dd, J = 40.5, 21.9 Hz, 3H), 7.73 (d, J = 6.1 Hz, 1H), 7.62 – 
7.53 (m, 2H), 7.37 (d, J = 8.0 Hz, 4H), 3.06 – 2.92 (m, 3H), 1.59 (s, 9H). 
tert-butyl 4-(4-(5-(benzo[d]oxazol-2-yl)-6-(tert-butylamino)pyridin-3-yl)-1H-pyrazol-1-
yl)piperidine-1-carboxylate (118, RAR-8-7) 
This material was prepared using the protocol described for RAR-9-45. LRMS: 517 [M+1], HPLC: 
9.060. 1H NMR (700 MHz, Chloroform-d) δ 8.75 (s, 1H), 8.45 (d, J = 2.4 Hz, 1H), 8.36 – 8.32 
(m, 1H), 7.79 (s, 1H), 7.74 (dd, J = 5.9, 3.2 Hz, 1H), 7.67 (s, 1H), 7.58 (dd, J = 5.9, 3.3 Hz, 1H), 
7.53 – 7.51 (m, 2H), 7.42 (d, J = 2.3 Hz, 2H), 7.37 – 7.35 (m, 2H), 6.27 (t, J = 2.2 Hz, 2H), 3.71 
(s, 1H), 3.31 (ddd, J = 13.6, 8.1, 3.7 Hz, 1H), 2.22 – 2.17 (m, 2H), 2.02 – 1.95 (m, 4H), 1.86 – 1.79 
(m, 2H), 1.62 (s, 10H), 1.50 (s, 9H).13C NMR (176 MHz, cdcl3) δ 161.90, 155.00, 154.58, 149.49, 
148.33, 141.45, 138.93, 135.89, 133.56, 126.39, 125.03, 124.46, 122.65, 119.89, 119.57, 115.83, 
110.18, 105.26, 103.94, 79.86, 77.18, 59.48, 59.15, 51.82, 38.85, 32.44, 29.27, 28.41. 
3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine (119, CCG-
265176, RAR-8-15) 
To a flask were added 8.1 mg of tert-butyl 4-(4-(5-(benzo[d]oxazol-2-yl)-6-(tert-
butylamino)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (0.019 mmol) and 2 mL of 
xylenes. To this solution were added 0.2 mL of TFA (1.9 mmol) and the solution was heated to 70 
°C for 3-12 h. Once complete, the solution was cooled to room temperature and then quenched 
with saturated Na2CO3 and then extracted with EtOAc (3 x 10 mL). The combined organic layer 
was then dried over Na2SO4 and the crude product was purified by column chromatography. 
Product is a yellow solid, 1.0 mg, 14%. MS: 549 [M+Toluene], HPLC: 5.997. 1H NMR (700 MHz, 
Chloroform-d) δ 8.75 (s, 1H), 8.45 (d, J = 2.5 Hz, 1H), 8.35 (d, J = 2.4 Hz, 1H), 7.79 (s, 1H), 7.74 
(dd, J = 5.9, 3.2 Hz, 1H), 7.69 (s, 1H), 7.59 (dd, J = 5.8, 3.3 Hz, 1H), 7.36 (dt, J = 6.0, 3.4 Hz, 2H), 
4.35 – 4.29 (m, 1H), 3.34 (d, J = 12.9 Hz, 2H), 2.86 (t, J = 12.2 Hz, 2H), 2.27 (d, J = 13.3 Hz, 2H), 
2.03 (dd, J = 12.4, 3.5 Hz, 2H). 13C NMR (176 MHz, cdcl3) δ 161.93, 155.00, 149.51, 141.47, 
141.11, 137.86, 135.77, 133.58, 129.02, 128.21, 125.02, 124.46, 122.59, 119.84, 110.20, 106.37, 






Scheme 3.4 Synthetic route to lead compound 109. Modification to the route for derivation are 





5-bromo-2-chloro-N-(4-chloro-2-hydroxyphenyl)nicotinamide (111, RAR-9-88) 
To a dried flask were added 1.009 g of 5-bromo-2-chloronicotinic acid (1 eq), 1.9997 g of HATU 
(2 eq), 802.0 mg of 2-amino-4-chlorophenol (1 eq). All materials were dissolved in 30 mL of 
DMF, and 2.2 mL of DIPEA were added. Bright red solution was protected under foil and allowed 
to stir at room temperature (rt) for 12 hours. Once complete, reaction was quenched with brine 
(200 mL) and then extracted with EtOAc (3 x 150 mL). The combined organic layers were washed 
with brine (2 x 100 mL) and then dried over MgSO4. The material was then purified by column 
chromatography (20-100% EtOAc/Hex) and the major product was collected as the final product. 
Result: bright red solid, 1 g, 75%. HRMS: 362.9121, HPLC: 6.880, purity: 85%. 1H NMR (700 
MHz, Chloroform-d) δ 9.06 (s, 1H), 8.83 (s, 1H), 8.66 (d, J = 9.6 Hz, 1H), 8.56 – 8.50 (m, 3H), 
7.97 (s, 2H), 7.93 (d, J = 8.6 Hz, 1H), 7.36 (d, J = 8.9 Hz, 1H), 6.88 (d, J = 8.5 Hz, 1H). 13C NMR 






2-(5-bromo-2-chloropyridin-3-yl)-6-chlorobenzo[d]oxazole (112, RAR-9-94) 
To a dried flask were added 2.0044 g of 111, dissolved in 30 mL of THF. To this solution were 
added 2.5 mL of DIAD, and 5.0 g of triphenylphosphine. The bright red mixture was allowed to 
stir at 65 °C for 18 hours. Once complete, reaction was cooled to rt and solvent was removed under 
pressure. Resultant pink solid was then titrated in absolute EtOH and a light pink solid was filtered 
off as the final product. Result: light pink solid, 1.300 g, 70%. HRMS: 343.99, HPLC: 8.597, 
Purity: 95% 1H NMR (700 MHz, Chloroform-d) δ 8.63 (d, J = 2.5 Hz, 1H), 8.61 (d, J = 2.6 Hz, 
1H), 7.77 (dd, J = 8.4, 2.3 Hz, 1H), 7.67 (d, J = 2.1 Hz, 1H), 7.41 (dd, J = 8.6, 2.0 Hz, 1H). 13C 
NMR (176 MHz, cdcl3) δ 158.50, 152.22, 150.93, 148.00, 142.25, 140.19, 132.35, 128.51, 126.13, 
124.15, 121.43, 119.02, 111.68. 
 
5-bromo-N-(tert-butyl)-3-(6-chlorobenzo[d]oxazol-2-yl)pyridin-2-amine (113, RAR-9-99) 
To a pressure vessel were added 86.0 mg (1 eq) of 112, 0.32 mL of tert-butylamine (12 eq) with 
all materials dissolved in 3 mL of DMF. The tube was sealed and heated to 120 °C for 18 hours. 
Once complete, the solution was cooled to rt, quenched with brine and extracted with EtOAc:Hex 
(1:1, 3 x 50 mL). The combined organic layers were then washed with brine (1 x 30 mL) and then 
dried over MgSO4. The bright orange residue was purified by column chromatography (0-50% 
EtOAc/Hex) and the product was collected to give a pale yellow solid. Result: pale yellow solid, 
34.7 mg, 36%. HRMS: 384.00, HPLC: 8.990, Purity: > 95%. 1H NMR (700 MHz, Chloroform-d) 
δ 8.62 (s, 1H), 8.29 – 8.25 (m, 2H), 7.67 (d, J = 8.6 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.36 – 7.31 
(m, 2H), 1.57 (s, 9H).13C NMR (176 MHz, cdcl3) δ 161.38, 157.76, 151.72, 140.01, 128.45, 





To a three neck flask were added 150 mg of 113, 0.05 mL of pyrrolidine (2 equiv), 126.4 mg of 
NaOtBu (3 equiv), XPhos (2 mol%) and Pd2(dba)3 (1 mol%). All materials were dissolved in 3 mL 
of Dioxanes and the solution was degassed with 8 cycles of evacuation and back fill with nitrogen. 
The reaction was then heated to 110 °C for 18 h. Once complete, the reaction was cooled to rt and 
then passed through a pad of celite. The filtrate was then purified by column chromatography to 
yield the desired product as a bright yellow residue. MS: (des tBu) 371, HPLC: 8.273. 1H NMR 
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(500 MHz, Chloroform-d) δ 8.64 (s, 1H), 8.29 (s, 1H), 8.24 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 8.4 
Hz, 2H), 7.57 (t, J = 2.8 Hz, 2H), 6.62 (dd, J = 7.8, 4.8 Hz, 1H), 3.32 (s, 4H), 2.06 (s, 4H), 1.60 (s, 
9H). 
tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)pyridin-3-yl)-1H-
pyrazol-1-yl)piperidine-1-carboxylate (115, RAR-9-45) 
To a three neck flask were added 50 mg of 114, 44.7 mg of tert-butyl 4-(4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (RAR-9-36),  Pd(PPH3)2Cl2 
(1 mol%). All materials were then dissolved in 3 mL of dry dioxanes. The bright yellow solution 
was then degassed (3 cycles of evac./back fill). After 10 mins, 0.5 mL of Na2CO3 (1M) were 
added. The solution was then further degassed (3 cycles of evac./backfill) and  heated to 110 °C 
(reflux) for 3-6 h. Once complete, the reaction was cooled to rt and then passed through a pad of 
celite. The filtrate was then purified by column chromatography to yield the desired product and 
the starting material as an inseparable mixture. MS: 586 (with Cl starting material still present at 
551), HPLC: 5.376. 1H NMR (700 MHz, Chloroform-d) δ 8.63 (s, 1H), 8.46 (d, J = 2.4 Hz, 1H), 
8.30 (d, J = 2.5 Hz, 1H), 8.08 (s, 1H), 7.79 (d, J = 9.0 Hz, 2H), 7.67 (d, J = 7.7 Hz, 2H), 7.64 (d, J 
= 8.5 Hz, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.53 (d, J = 1.8 Hz, 3H), 7.48 (d, J = 7.6 Hz, 2H), 7.43 (d, 
J = 2.3 Hz, 3H), 7.39 – 7.33 (m, 3H), 6.27 (d, J = 2.2 Hz, 3H), 4.30 (tdt, J = 11.6, 8.0, 4.1 Hz, 
12H), 2.90 (s, 12H), 2.19 (d, J = 5.5 Hz, 5H), 2.13 (d, J = 12.2 Hz, 8H), 1.96 – 1.88 (m, 9H), 1.61 
(s, 9H). 13C NMR (176 MHz, cdcl3) δ 162.75, 159.51, 155.10, 154.74, 149.85, 148.90, 140.43, 
139.11, 136.64, 136.06, 133.74, 132.74, 130.72, 129.02, 126.57, 125.63, 125.33, 123.68, 122.85, 
120.15, 119.90, 116.12, 111.05, 105.44, 103.57, 80.04, 59.68, 59.63, 59.33, 52.08, 43.40, 42.65, 
32.63, 29.42, 28.59. 
5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3-(6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)pyridin-2-
amine (109, CCG-265649 RAR-9-49, RAR-13-44) 
To a flask were added 20 mg of 115, and 1.2 mL of TFA. The neat solution was heated to 80 °C 
fir 3 hours. Once complete, the solvent was removed, and the orange residue was purified by 
preparatory TLC plate (5% DCM/MeOH). Result: dark orange residue, 2 mg, 9%. HRMS: 
430.2343, HPLC: 5.029. 1H NMR (700 MHz, DMSO-d6) δ 8.63 (s, 1H), 8.54 (s, 1H), 8.23 (t, J = 
3.1 Hz, 1H), 7.90 – 7.82 (m, 1H), 7.69 (s, 1H), 7.43 (s, 1H), 6.22 (s, 1H), 3.76 (s, 1H), 3.38 (d, J 
= 13.5 Hz, 4H), 3.06 (s, 2H), 2.93 (t, J = 10.4 Hz, 2H), 2.15 (d, J = 9.5 Hz, 4H), 2.10 (d, J = 2.4 





pyrazol-4-yl)pyridin-2-amine (RAR-10-41, 121) 
To a dried flask were added 1.7 g of compound 120, dissolved in 26 mL of dry THF. The solution 
was cooled to 0 °C and 220.4 mg of NaH were added in one portion. The solution was allowed to 
stir at 0 °C for 30 mins, before 0.90 mL of SEM-Cl were added. The yellow solution was then 
allowed to warm to rt for 2.5 hours. Once complete, the reaction was quenched with water, and 
then extracted with EtOAc (3 x 30 mL). The combined organic layers were then washed with brine 
(1 x 30 mL) and dried over MgSO4. The resultant material was purified by column chromatography 
to yield a light yellow solid, 700 mg, 50%. HPLC: 8.280, HRMS: 498.1980, Purity: 90%. 1H NMR 
(500 MHz, Chloroform-d) δ 8.65 (s, 1H), 8.48 (d, J = 2.4 Hz, 1H), 8.33 (d, J = 2.5 Hz, 1H), 7.82 
(d, J = 4.8 Hz, 2H), 7.64 (d, J = 8.7 Hz, 1H), 7.60 – 7.57 (m, 1H), 7.37 – 7.32 (m, 1H), 5.49 (s, 
2H), 3.65 – 3.61 (m, 2H), 1.62 (s, 9H), 0.95 (t, J = 8.2 Hz, 9H). 
N-(tert-butyl)-3-(6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)-5-(1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-pyrazol-4-yl)pyridin-2-amine (RAR-10-43, 122) 
This material was prepared using the protocol described in RAR-9-25. Yields the desired product 
as a fluorescent yellow solid, 32 mg, 60%. HRMS: 533.3050, HPLC: 9.870. 1H NMR (700 MHz, 
Chloroform-d) δ 8.74 (d, J = 5.2 Hz, 1H), 8.41 (dd, J = 5.4, 2.5 Hz, 1H), 8.30 (dd, J = 5.4, 2.5 Hz, 
1H), 7.82 (dd, J = 17.1, 5.5 Hz, 2H), 7.54 (dd, J = 8.9, 5.4 Hz, 1H), 6.70 (dd, J = 5.4, 2.3 Hz, 1H), 
6.61 (dt, J = 8.4, 3.7 Hz, 1H), 5.48 (d, J = 5.5 Hz, 2H), 3.67 – 3.59 (m, 2H), 3.37 (q, J = 6.3 Hz, 
4H), 2.11 – 2.05 (m, 4H), 1.62 (s, 9H). 13C NMR (176 MHz, cdcl3) δ 146.77, 136.72, 132.50, 
124.89, 119.32, 115.12, 109.53, 92.00, 80.23, 66.59, 51.48, 47.98, 29.08, 25.36, 17.65, -1.61. 
 





To a flask were added 97.0 mg of RAR-10-43, dissolved in 2 mL of MeOH. To this yellow solution 
were added 3 mL of 4 N HCl (in dioxanes/water). The resulting orange solution was allowed to 
stir at rt for 12 hours. Once complete, the solvent was removed and the residue was purified by 
column chromatography (0-10% DCM/MeOH) to give an orange residue, 70 mg, quant. HPLC: 
7.591, HRMS: 403.2233, purity: 90%. 1H NMR (700 MHz, Methanol-d4) δ 8.75 (t, J = 20.0 Hz, 
1H), 8.25 (s, 1H), 8.12 (s, 2H), 7.69 – 7.63 (m, 1H), 7.58 (d, J = 8.6 Hz, 2H), 6.85 (s, 1H), 6.77 (d, 
J = 9.0 Hz, 1H), 3.40 (s, 4H), 2.11 (s, 4H), 1.69 (s, 9H). 
3-(benzo[d]oxazol-2-yl)-5-bromo-N-(tert-butyl)pyridin-2-amine (CCG-264187, RAR-6-56) 
To a sealed tube were added 160 mg of 2-(5-bromo-2-chloropyridin-3-yl)benzo[d]oxazole (0.517 
mmol), and 0.28 mL of tert-butylamine (2.58 mmol). All materials were then dissolved in 3 mL 
of dry DMF, and the solution was heated to 120 °C for 12-18 h. Once complete, the reaction was 
cooled to room temperature and quenched with brine (30 mL). The aqueous layer was extracted 
with EtOAc:Hexanes (1:1) (3 x 30 mL). The combined organic layer was then dried over Na2SO4 
and solvent was removed to give the desired product. Yields a fluffy yellow solid, 179 mg, 80%. 
HPLC: 8.010, LRMS: 288. 1H NMR (500 MHz, Chloroform-d) δ 8.36 (d, J = 2.6 Hz, 1H), 8.28 
(d, J = 2.3 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.73 (dd, J = 7.0, 2.6 Hz, 2H), 7.38 – 7.35 (m, 2H), 
1.59 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 163.02, 160.90, 151.62, 151.19, 141.50, 138.48, 
124.87, 123.02, 119.94, 110.58, 104.62, 59.10, 29.30, 0.25. 
5-bromo-2-(tert-butylamino)-N-(4-chloro-2-hydroxyphenyl)nicotinamide (CCG-264221, RAR-6-
59) 
To a sealed tube were added 274.1 mg of 5-bromo-2-chloro-N-(5-chloro-2-
hydroxyphenyl)nicotinamide (0.76 mmol), and 0.400 mL of tert-butylamine (3.8 mmol). All 
materials were then dissolved in 5 mL of dry DMF, and the solution was heated to 120 °C for 12-
18 h. Once complete, the solution was cooled to room temperature, and quenched with brine (30 
mL). The aqueous layer was then extracted with EtOAc (3 x 30 mL). The combined organic layer 
was washed with brine (1 x 30 mL) and then dried over Na2SO4. The solvent was then removed 
under pressure to give the crude product, which was purified by column chromatography (0-100% 
EtOAc/Hexanes). Yields an orange solid, 90.0 mg, 30%. HPLC: 6.800, LRMS: 412 [M+MeOH]. 
1H NMR (500 MHz, Chloroform-d) δ 8.54 (d, J = 2.9 Hz, 1H), 8.46 (d, J = 2.5 Hz, 1H), 8.30 (d, 
J = 12.2 Hz, 1H), 7.68 (s, 1H), 7.08 (s, 1H), 6.96 (d, J = 8.2 Hz, 1H), 1.35 (s, 9H). 
3-(benzo[d]oxazol-2-yl)-N-(tert-butyl)-5-(1H-pyrrol-3-yl)pyridin-2-amine (CCG-264222, RAR-7-
5) 
To a three neck flask were added 100 mg of Cs2CO3 (0.289 mmol), 43.7 mg of tert-butyl 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (0.14 mmol), and 
tetrakis(triphenylphosphine)palladium(0) (0.014 mmol). The materials were degassed with 3 
cycles of evacuation and back fill with nitrogen. To the flask were added 56.0 mg of 3-
(benzo[d]oxazol-2-yl)-5-bromo-N-(tert-butyl)pyridin-2-amine (0.144 mmol) and dissolved in 4 
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mL of 3:1 Dioxanes:Water. The solution was then degassed with an additional 6 cycles of 
evacuation and backfill with nitrogen. The three neck flask was fitted with a reflux condenser, and 
the solution was heated to 100 °C for 12-24 h. Once complete, the solution was cooled to room 
temperature, and then passed through a pad of celite. The mother liquor was then diluted with 
water and extracted with EtOAC (2 x 25 mL). The combined organic layer was washed with brine 
(1 x 15 mL) and then dried over Na2SO4 and the product was evaporated onto silica gel. The crude 
material was purified by column chromatography to yield the final product. Product is a bright 
yellow solid, 7.5 mg, 30%. MS: 333 [M+1], HPLC: 6.900. 1H NMR (700 MHz, Chloroform-d) δ 
8.79 (s, 1H), 8.49 (s, 1H), 8.39 (s, 1H), 7.87 (s, 2H), 7.74 (s, 1H), 7.59 (s, 1H), 7.37 (s, 2H), 1.64 
(d, J = 4.6 Hz, 9H). 
N-(tert-butyl)-3-(6-chlorobenzo[d]oxazol-2-yl)-5-(1H-pyrrol-3-yl)pyridin-2-amine (CCG-
264223, RAR-6-67) 
To a three neck flask were added 90.2 mg of Cs2CO3 (0.236 mmol), 46.0 mg of (1-
(triisopropylsilyl)-1H-pyrrol-3-yl)boronic acid (0.177 mmol), 45.0 mg of 5-bromo-N-(tert-butyl)-
3-(6-chlorobenzo[d]oxazol-2-yl)pyridin-2-amine (0.118 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.014 mmol). All materials dissolved in 4 mL of 3:1 
Dioxanes:Water. The solution was then degassed with 8 cycles of evacuation and backfill with 
nitrogen. The three neck flask was fitted with a reflux condenser, and then the solution was heated 
to 100 °C for 12 h. Once complete, the solution was cooled to room temperature and passed 
through a pad of celite. The mother liquor was then diluted with water and extracted with EtOAc 
(3 x 30 mL). The combined organic layer was then dried over Na2SO4 and the crude material was 
purified by column chromatography. Yields a white solid, 11.5 mg, 26.5%. HPLC: 6.8, LRMS: 
371. 1H NMR (500 MHz, Chloroform-d) δ 8.54 (t, J = 3.3 Hz, 1H), 8.46 (t, J = 2.3 Hz, 1H), 7.43 
(d, J = 9.2 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.23 – 7.20 (m, 2H), 7.07 – 7.03 (m, 1H), 6.98 (d, J 
= 8.4 Hz, 1H), 1.60 (s, 9H). 
2-amino-N-(4-chloro-2-hydroxyphenyl)-5-(1H-pyrrol-3-yl)nicotinamide (CCG-264240, RAR-6-
72) 
To a flask were added 11 mg of 2-(tert-butylamino)-N-(5-chloro-2-hydroxyphenyl)-5-(1H-pyrrol-
3-yl)nicotinamide (0.029 mmol) and 0.46 mL of TFA (5.7 mmol) dissolved in 2 mL of toluene. 
The solution was heated to 70 °C for 3 h. Once complete, the reaction was quenched with saturated 
Na2CO3 and extracted with DCM (3 x 30 mL). The combined organic layer was dried over Na2SO4 
and purified by column chromatography. Product is a yellow solid, 3 mg, 30%. HPLC: 7.199. 1H 
NMR (500 MHz, DMSO-d6) δ 10.94 (s, 1H), 10.86 (s, 1H), 8.65 (dt, J = 11.3, 3.4 Hz, 1H), 8.38 
(dd, J = 5.1, 2.6 Hz, 1H), 7.47 (t, J = 3.3 Hz, 1H), 7.39 – 7.33 (m, 2H), 7.23 – 7.16 (m, 3H). 
2-amino-5-bromo-N-(4-(dimethylamino)-2-hydroxyphenyl)nicotinamide (CCG-264241, RAR-6-
74-p1) 
To a three neck flask were added 218.3 mg of Cs2CO3 (0.5 mmol), 80 mg of tert-butyl 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (0.3mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.014 mmol) and 100 mg of 5-bromo-N-(tert-butyl)-3-
(6-chlorobenzo[d]oxazol-2-yl)pyridin-2-amine (0.3 mmol). All materials were dissolved in 4 mL 
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of 3:1 Dioxanes:Water, and the solution was degassed with 7 cycles of evacuation and backfill 
with nitrogen. The solution was heated to 100 °C for 12 h. Once complete, the solution was cooled 
to  room temperature, and passed through a pad of celite. The mother liquor was diluted with water 
and extracted with EtOAc (3 x 30 mL). The combined organic layer was dried over Na2SO4 and 
the crude product was purified by column chromatography. Light orange solid, 79.2 mg, 79%. 
HPLC: 7.199, LRMS: 371. 1H NMR (500 MHz, Chloroform-d) δ 11.47 (s, 1H), 9.36 (s, 1H), 8.53 
(dt, J = 14.5, 2.3 Hz, 2H), 7.08 (d, J = 2.2 Hz, 1H), 7.00 – 6.97 (m, 1H), 6.90 (dd, J = 8.5, 2.2 Hz, 
1H), 2.92 (d, J = 1.8 Hz, 6H).  
2-amino-N-(4-chloro-2-hydroxyphenyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide 
(CCG-264262, RAR-6-75) 
To a flask were added 21.5 mg of tert-butyl 4-(4-(6-(tert-butylamino)-5-((5-chloro-2-
hydroxyphenyl)carbamoyl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (0.0378 
mmol) and 2 mL of toluene. To this dark red solution were added 0.46 mL of TFA (7.56 mmol) 
and the solution was heated to 70 °C for 3 h. Once complete, the solution was cooled to room 
temperature and quenched with saturated Na2CO3 and then extracted with EtOAc (3 x 30 mL). The 
combined organic layer was dried over Na2SO4 and purified by column chromatography. Product 
is a yellow solid44, 1 mg, 6%. MS: 413 [M+1], HPLC: 6.800. 1H NMR (700 MHz, DMSO-d6) δ 
8.25 (s, 1H), 8.11 (d, J = 5.8 Hz, 1H), 7.85 – 7.80 (m, 1H), 7.77 (s, 1H), 7.72 (s, 1H), 7.44 – 7.38 
(m, 2H), 6.90 (s, 1H), 6.21 (d, J = 6.6 Hz, 2H), 5.02 (s, 2H), 2.11 – 2.03 (m, 2H), 1.96 (s, 3H), 1.93 
– 1.86 (m, 5H), 1.76 – 1.69 (m, 6H). 
3-(benzo[d]oxazol-2-yl)-5-(1H-pyrazol-4-yl)pyridin-2-amine (CCG-264485, RAR-7-9) 
To a flask were added 35.5 mg of 3-(benzo[d]oxazol-2-yl)-N-(tert-butyl)-5-(1H-pyrazol-4-
yl)pyridin-2-amine (0.106 mmol), and 1.5 mL of toluene. To this light blue solution were added 
0.16 mL of TFA (2.13 mmol), and the solution was heated to 70 °C for 3 h. Once complete, the 
solution was cooled to room temperature and quenched with saturated Na2CO3 and then extracted 
with EtOAc (3 x 10 mL). The combined organic layer was then dried over Na2SO4 and the crude 
product was purified by column chromatography. Product is a bright yellow solid, 2.5 mg, 8.5%. 
MS: 278 [M+1], HPLC: 4.77. 1H NMR (700 MHz, DMSO-d6) δ 8.55 (d, J = 2.3 Hz, 1H), 8.49 (d, 
J = 2.1 Hz, 1H), 8.12 (s, 2H), 7.85 (d, J = 7.7 Hz, 1H), 7.81 (d, J = 7.5 Hz, 1H), 7.49 – 7.41 (m, 
3H). 
3-(benzo[d]oxazol-2-yl)-N-(tert-butyl)-5-(1H-pyrazol-4-yl)pyridin-2-amine (RAR-8-6) 
To a flask were added 84.2 mg of RAR-8-4, 65.3 mg of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate, 156.7 mg of Cs2CO3 and cat. Palladium tetrakis. 
All materials were then dissolved in 3 mL of dioxanes, and the solution was degassed with six 
cycles of evacuation and backfill with nitrogen. Once degassed, the reaction was heated to 110 °C 
for 18-24 h. Once complete, the solution was cooled to rt and passed through a pad of celite. The 
filtrate was then washed with brine (1 x 30 mL) and then dried over Na2SO4. The crude material 
was purified by column chromatography to yields a yellow solid, 24.5 mg, 30%. 1H NMR (500 
MHz, Chloroform-d) δ 8.78 (s, 1H), 8.52 – 8.47 (m, 1H), 8.39 (dd, J = 5.1, 2.5 Hz, 1H), 7.87 (s, 
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To a dried flask were added 0.05 mL of acrylic acid, dissolved in 2 mL of DCM. The solution was 
cooled to 0 °C where upon 0.01 mL of DMF and 0.05 mL of oxalyl chloride were added 
consecutively. The solution was then warmed to rt for 1 h. Once complete, the solvent was 
removed, and the crude material was moved forward without characterization. This acid chloride 
was then dissolved in DCM (3 mL) and the solution was cooled to  0 °C and 24.5 mg of RAR-8-6 
were added in one portion. Then 0.04 mL of DIPEA were added to the solution and then reaction 
was run for 2 h. Once complete, the reaction was quenched with water and extracted with EtOAc 
(3 x 30 mL). The combined organic layer was washed with brine (1 x 25 mL) and then dried over 
Na2SO4. The crude material was then purified by column chromatography to yield the product as 
a yellow solid, 15 mg, 52%. LRMS: 388, HPLC: 10.48. 1H NMR (700 MHz, Chloroform-d) δ 
8.90 (s, 1H), 8.56 (s, 1H), 8.54 (d, J = 2.5 Hz, 1H), 8.44 (d, J = 2.5 Hz, 1H), 8.08 (s, 1H), 7.76 – 
7.73 (m, 1H), 7.64 – 7.58 (m, 2H), 7.39 – 7.37 (m, 2H), 6.79 (dd, J = 17.3, 1.4 Hz, 1H), 6.13 (dd, 
J = 10.5, 1.5 Hz, 1H), 1.63 (s, 9H). 13C NMR (176 MHz, cdcl3) δ 162.91, 161.51, 155.50, 149.51, 
148.59, 141.78, 141.33, 133.91, 133.42, 126.18, 125.25, 124.58, 124.19, 122.94, 119.64, 113.64, 
110.31, 106.61, 104.21, 52.05, 29.20. 
1-(4-(6-amino-5-(benzo[d]oxazol-2-yl)pyridin-3-yl)-1H-pyrazol-1-yl)prop-2-en-1-one (CCG-
265175, RAR-8-12) 
To a flask were added 10 mg of 1-(4-(5-(benzo[d]oxazol-2-yl)-6-(tert-butylamino)pyridin-3-yl)-
1H-pyrazol-1-yl)prop-2-en-1-one (0.026 mmol) and 2 mL of xylenes. To this solution were added 
0.200 mL of TFA (2.6 mmol) and the solution was heated to 70 °C overnight. Once complete, the 
solution was cooled to room temperature and then quenched with saturated NasCO3 and then 
extracted with EtOAc (3 x 10 mL). The combined organic layer was then dried over Na2SO4 and 
the crude product was purified by column chromatography. Product is a yellow solid, 1.0 mg, 12%. 
MS: 334 [M+1], HPLC: 4.40. 1H NMR (700 MHz, Chloroform-d) δ 8.45 (s, 1H), 8.39 (s, 1H), 
7.89 (s, 2H), 7.79 – 7.73 (m, 1H), 7.64 – 7.58 (m, 1H), 7.41 – 7.38 (m, 2H), 6.46 – 6.39 (m, 1H), 
6.12 (ddd, J = 17.3, 14.2, 10.5 Hz, 1H), 5.86 – 5.81 (m, 1H). 
3-(6-(4-ethylpiperazin-1-yl)benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-
2-amine (CCG-270962, RAR-10-46) 
To a flask were added 42.0 mg of tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-(4-ethylpiperazin-1-
yl)benzo[d]oxazol-2-yl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (0.067 mmol) 
and 2 mL of toluene. To this solution were added 0.3 mL of TFA (3 mmol) and the solution was 
heated to 70 °C for 3 h. Once complete, the reaction was cooled to room temperature and the 
toluene was removed by azeotrope with MeOH to give the product as a TFA salt. The crude 
product was then purified by preparatory plate. MS: 633, 1H NMR (700 MHz, Chloroform-d) δ 
8.56 (s, 1H), 8.50 (s, 1H), 7.99 (d, J = 13.0 Hz, 1H), 7.36 (s, 1H), 6.72 (s, 1H), 3.66 (d, J = 2.9 Hz, 
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1H), 3.36 (d, J = 2.9 Hz, 8H), 3.03 – 3.00 (m, 2H), 2.75 (td, J = 8.0, 7.6, 3.0 Hz, 2H), 2.35 (d, J = 
13.4 Hz, 2H), 2.05 (d, J = 3.2 Hz, 2H), 1.77 (s, 2H), 1.12 – 1.10 (m, 3H). 
5-(1H-pyrazol-4-yl)-3-(6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)pyridin-2-amine (CCG-270964, 
RAR-10-58) 
To a flask were added 82 mg of N-(tert-butyl)-3-(6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)-5-(1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyridin-2-amine (0.15 mmol), 0.4 mL of TFA 
(5.3 mmol) all of which are dissolved in 5 mL of DMF. The bright orange solution was allowed to 
stir overnight or until complete. Once complete, the solvent was removed under pressure and the 
crude material was purified by column chromatography (5% EtOAc/MeOH). The final product 
was collected, and the solvent was removed to give the product as a bright yellow solid. MS: 
347.1717 [M+1], HPLC: 5.229. 1H NMR (500 MHz, DMSO-d6) δ 8.54 (m, 1H), 8.44 (m, 1H), 
8.35 (m, 2H), 7.95 (m, 2H), 7.55 (m, 1H), 7.02 (s, 1H), 6.61 (s, 1H), 3.50 (m, 4H), 2.11-2.05 (m, 
4H).  
2-(2-amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-(pyridin-4-
ylmethyl)benzo[d]oxazol-6-amine (CCG-270957, RAR-10-11) 
To a flask were added 20 mg of tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-((pyridin-4-
ylmethyl)amino)benzo[d]oxazol-2-yl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
(0.032 mmol) and 0.05 mL of TFA (0.39 mmol) all of which were dissolved in 2 mL of toluene. 
The solution was heated to 70 °C for 3 hours or until complete. Once complete, the solution was 
cooled to room temperature and then the toluene was removed under pressure. The crude oil was 
then purified by preparatory TLC plate (5% EtOAc/MeOH) to give the final product as a yellow 
solid.  HPLC: 5.006   MS: 467.2297 [free base] and 695.2556 [M+2TFA] 11H NMR (500 MHz, 
Chloroform-d) δ 8.84 (d, J = 13.5 Hz, 2H), 8.74 (d, J = 5.5 Hz, 1H), 8.06 (d, J = 5.1 Hz, 1H), 7.97 
(d, J = 5.2 Hz, 1H), 7.81 (d, J = 5.4 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.48 (s, 1H), 6.09 (s, 1H), 4.71 
(d, J = 6.3 Hz, 1H), 3.65 (d, J = 20.8 Hz, 1H), 3.27 (s, 1H), 3.06 (s, 1H), 2.64 (s, 1H), 2.05 (s, 2H), 
1.89 (s, 2H). 
2-(2-amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-(pyridin-3-
ylmethyl)benzo[d]oxazol-6-amine (CCG-270958, RAR-10-21) 
To a flask were added 32 mg of tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-((pyridin-3-
ylmethyl)amino)benzo[d]oxazol-2-yl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
(0.032 mmol), dissolved in 2 mL of toluene. To this solution were added 0.05 mL of TFA (0.39 
mmol) and the solution was heated to 70 °C until complete. Once complete, the reaction was cooled 
to room temperature and the solvent was removed under pressure. The crude oil was then purified 
by preparatory TLC plate, to give the product as yellow solid. HPLC: 4.072   MS: 468.1769, 1H 
NMR (500 MHz, Chloroform-d) δ 8.64 (s, 1H), 8.57 (s, 1H), 8.49 (s, 1H), 8.34 (s, 1H), 7.94 (m, 
2H), 7.86 (s, 1H), 7.47 (m, 2H), 7.05 (m, 2H), 4.53 (s, 2H), 3.74 (s, 1H), 3.15 (m, 2H), 3.02 (m, 
2H), 2.06 (m, 2H), 1.83 (m, 2H). 
tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-chlorobenzo[d]oxazol-2-yl)pyridin-3-yl)-1H-pyrazol-1-
yl)piperidine-1-carboxylate (RAR-10-2, RAR-13-31) 
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To a three neck flask were added 149.1 mg of RAR-9-99 (0.525 mmol), 234 mg of RAR-9-54 
(1.05 mmol), 192.0 mg of Na2CO3 (1.58 mmol), and Pd(PPh3)2Cl2 (0.0014 mmol). All materials 
were then dissolved in 7.5 mL of Dioxanes:Water (3:1). The solution was then degassed with 9 
cycles of evacuation and backfill with nitrogen. The solution was then heated to 112 °C for 3-12 
h. Once complete, the solution was cooled to room temperature and then passed through a pad of 
celite before being purified by column chromatography. Yields a fluorescent yellow residue, 76.1 
mg, 25%. HRMS: 551.2528, HPLC: 8.34. 1H NMR (500 MHz, Chloroform-d) δ 8.62 (s, 1H), 8.27 
(dd, J = 4.8, 2.0 Hz, 1H), 8.22 (dd, J = 7.8, 2.0 Hz, 1H), 7.72 (ddt, J = 13.3, 6.9, 1.4 Hz, 3H), 7.55 
(d, J = 2.0 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.31 (t, J = 1.7 Hz, 1H), 3.88 (s, 1H), 3.71 – 3.65 (m, 
2H), 3.31 (ddd, J = 13.6, 7.7, 3.6 Hz, 2H), 2.31 (dd, J = 9.2, 5.9 Hz, 2H), 1.97 – 1.90 (m, 2H), 1.46 
(s, 9H). 13C NMR (126 MHz, cdcl3) δ 151.64, 136.94, 132.55, 131.78, 128.79, 125.29, 120.13, 
111.11, 110.84, 62.35, 52.07, 49.75, 29.95, 29.45, 28.66. 
tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-((pyridin-4-ylmethyl)amino)benzo[d]oxazol-2-
yl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (RAR-10-10) 
To a microwave vessel were added 25.4 mg of RAR-10-2 (0.045 mmol), Pd2(dba)3 (0.0014 mmol), 
XPhos (0.007 mmol), 15.6 mg of NaOtBu (0.14 mmol) and 0.01 mL of 4-picolylamine (0.064 
mmol). The materials were dissolved in 3 mL of toluene, and the solution was degassed with 5 
cycles of evacuation and back fill with nitrogen. The solution was heated to 160 °C for 30-40 mins. 
Once complete, the solution was rinsed through a pad of celite and the filtrate was purified by 
column chromatography to yield the desired product. Yields a fluorescent yellow solid, 10 mg, 
35%. HRMS: 623.3444, HPLC: 6.809. 1H NMR (500 MHz, Chloroform-d) δ 8.64 (s, 1H), 8.59 
(s, 8H), 8.56 (s, 7H), 8.39 (s, 1H), 8.22 (s, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.34 (s, 2H), 6.67 (s, 2H), 
4.47 (s, 2H), 4.30 (s, 1H), 3.93 (s, 2H), 3.36 (s, 1H), 2.13 (s, 2H), 1.95 (s, 2H), 1.62 – 1.59 (m, 
9H), 1.50 (d, J = 1.7 Hz, 9H). 
tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-((pyridin-3-ylmethyl)amino)benzo[d]oxazol-2-
yl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (RAR-10-16) 
To a microwave vessel were added 48 mg of RAR-10-2 (0.087 mmol), Pd2(dba)3 (0.0014 mmol), 
XPhos (0.007 mmol), 39.2 mg of NaOtBu (0.35 mmol) and 0.05 mL of 3-picolylamine (0.12 
mmol). The materials were then dissolved in 3 mL of toluene, and then degassed with 5 cycles of 
evacuation and backfill with nitrogen. The solution was then heated to 160 °C for 30-45 mins. 
Once complete, the reaction was cooled to room temperature, and then passed through a pad of 
celite. The filtrate was then purified by column chromatography to give the desired product.  Yields 
a light yellow fluorescent solid, 19 mg, 35%. HRMS: 623.34, HPLC: 6.513.  1H NMR (700 MHz, 
Chloroform-d) δ 8.57 (s, 2H), 8.39 (d, J = 2.4 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.98 – 7.95 (m, 
2H), 7.83 – 7.79 (m, 1H), 7.49 (s, 1H), 7.36 (d, J = 7.2 Hz, 2H), 6.68 (dd, J = 8.6, 2.2 Hz, 2H), 
5.14 (s, 1H), 4.33 (s, 2H), 3.74 (m, 1H), 3.60-3.56 (m, 1H), 3.46 – 3.44 (m, 2H), 2.22 (m, 2H), 
1.97 (m, 2H), 1.61 (s, 9H), 1.50 (s, 9H). 
N-(tert-butyl)-3-(6-chlorobenzo[d]oxazol-2-yl)-5-(1H-pyrazol-4-yl)pyridin-2-amine (RAR-10-18) 
To a flask were added 250 mg of RAR-10-2 (0.657 mmol), 420.6 mg of tert-butyl 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (1.31 mmol), Pd(PPh3)2Cl2 
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(0.065 mmol) and 246.3 mg of Na2CO3 (2 mmol). All materials were then dissolved in 7 mL of 
Dioxanes:Water (3:1). The solution was then degassed with 8 cycles of evacuation and back fill 
with nitrogen before being heated to 110 °C for 12 h. once complete, the solution was cooled to 
room temperature, and then passed through a pad of celite. The filtrate was then purified by column 
chromatography to give the desired product. Yields a fluorescent yellow solid, 161 mg, 67%. 
HRMS: 368.1268, HPLC: 8.517. 1H NMR (500 MHz, Chloroform-d) δ 8.65 (s, 1H), 8.50 (s, 1H), 
8.35 (s, 1H), 7.87 (d, J = 4.1 Hz, 2H), 7.53 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.25 (s, 
1H), 1.62 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 162.75, 159.16, 154.61, 140.42, 139.84, 135.45, 
133.85, 128.87, 126.63, 125.78, 121.83, 119.98, 110.91, 104.62, 59.09, 29.25. 
tert-butyl 4-(6-(tert-butylamino)-5-(6-chlorobenzo[d]oxazol-2-yl)pyridin-3-yl)-1H-pyrazole-1-
carboxylate (RAR-10-20) 
To a flask were added 161 mg of RAR-10-18 (0.435 mmol), cat. DMAP and 0.12 mL of Boc2O 
(0.478 mmol). All materials were dissolved in 20 mL of THF and allowed to stir at room 
temperature for 1 h. Once complete, the solvent was removed under pressure, and the crude product 
was brought back up in EtOAc. The organic layer was rinsed with water (1 x 30 mL) and brine (1 
x 50 mL) before drying the organic layer over Na2SO4. The solvent was removed under pressure 
to give the desired product. Product was moved forward without further characterization. Yields 
a yellow solid, 171.1 mg, 84%. HRMS: 468.17, HPLC: 7.385 
tert-butyl 4-(4-(6-(tert-butylamino)-5-(6-(4-ethylpiperazin-1-yl)benzo[d]oxazol-2-yl)pyridin-3-
yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (RAR-10-40) 
To a three necked flask were added 61 mg of RAR-10-2 (0.09 mmol), 37.8 mg of NaOtBu (0.27 
mmol), 0.04 mL of ethylpiperazine (0.13 mmol), XPhos (2 umol) and Pd2(dba)3 (1 umol). All 
materials were dissolved in 4 mL of dioxanes and then the solution was degassed with 8 cycles of 
evacuation and backfill with nitrogen. The solution was then heated to 110 °C for 18 h. Once 
complete, the reaction was cooled to room temperature, and then passed through a pad of celite. 
The filtrate was then purified by column chromatography to give the desired product. Yields a 
light yellow solid, 42.0 mg, 66%. HRMS: 629.3915, HPLC: 6.700. 1H NMR (700 MHz, 
Chloroform-d) δ 8.67 (s, 1H), 8.40 (d, J = 2.4 Hz, 1H), 8.27 (d, J = 2.5 Hz, 1H), 7.77 (s, 1H), 7.64 
(s, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.10 (d, J = 2.2 Hz, 1H), 7.00 (dd, J = 8.7, 2.2 Hz, 1H), 4.31 (tt, 
J = 11.6, 4.1 Hz, 2H), 3.31 (t, J = 5.0 Hz, 4H), 2.72 (t, J = 5.0 Hz, 4H), 2.55 (q, J = 7.2 Hz, 2H), 
2.21 – 2.16 (m, 2H), 1.97 (tt, J = 11.7, 6.2 Hz, 2H), 1.61 (s, 9H), 1.17 (t, J = 7.2 Hz, 3H). 13C 
NMR (176 MHz, cdcl3) δ 160.85, 154.74, 150.97, 150.24, 147.71, 136.03, 134.89, 133.15, 122.76, 
120.19, 119.56, 115.89, 114.73, 104.64, 97.74, 80.07, 59.61, 52.67, 52.33, 51.89, 49.88, 29.44, 
28.60, 11.79. 
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Chapter 4. Indolinone-Based Covalent, Selective Inhibitors of GRK5 
4.1 Preface 
Ideas and conclusions from Chapter 4 are in preparation for publication and may appear verbatim 
in a future publication or patent. Design and synthesis for compounds presented in Chapter 4, as 
well as intact protein and tandem mass spectrometry experiments, I performed. Pharmacological 
evaluation of compounds was performed by Renee Bouley (CCG-271421, CCG-271423, CCG-
271424), Qiuyan Chen and Larisa Avramova (all remaining compounds). Any additional efforts 
towards modeling and docking experiments, I performed.  
4.2 Validation of Indolinone-Ullrich 57 Provides a New Scaffold for GRK5 Inhibitor Development 
There is still a need for an ultra-selective GRK5 inhibitor as the pyrrolopyrimidine scaffold 
developed in Chapter 2 could not be further improved upon. Considering the inability to validate 
the reported Chembl-1607632 lead, there remains a need to develop new scaffolds for GRK5 
inhibition. There exists a limited set of known GRK inhibitors, only one of which is reported to be 
GRK5 selective. Balanol and Takeda 103 are known GRK2 inhibitors, are were not initially 
developed in the previous GRK2 inhibitor campaign within the Tesmer group. Given the 
difficulties that were faced in building in GRK5 activity through canonical means, any new 
scaffold must be amenable to modification to carry a covalent warhead. Balanol, a natural product, 
is complex and would require a serious undertaking to identify and develop the chemistry needed 
to create a covalent analogue; thus, it will not serve as an appropriate scaffold. Takeda 103 is a 
known pharmaceutical agent that has optimized pharmacokinetic properties. However, the scaffold 
itself is not amenable to modification to carry a covalent warhead. Thus, these two known 
inhibitors are deprioritized choices for new scaffolds. 
 The last of the known scaffolds was initially developed as a GRK5 modifiers for use in 
diabetes.1,2 However, there is limited specific data available for this new scaffold. The lead 
compound Ullrich-57, which features an indolinone scaffold, was reported as having IC50 < 0.1 
µM activity against GRK5. Unfortunately, the originally reported data did not give a definitive 
IC50 for any compound but rather gave ranges of activity against GRK5. In terms of selectivity, 
little is known about this series as there was no reported data for GRK2 or other related kinases. 
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This indolinone scaffold is originally derived from the FDA approved receptor tyrosine kinase 
inhibitor (RTKI) Sunitinib.3 Sunitinib was originally approved for use in various cancers and 
features an optimized scaffold. Additionally, Sunitinib and the originally designed analogues from 
Ullrich and co-workers are easily amenable to modification to carry a covalent warhead.  
 However, the indolinone scaffold is not without its own problems. The indolinone scaffold 
is known to undergo a liquid state photoisomerization. This isomerization produces an active (Z-
conformer) and an inactive (E-conformer) configuration.4 Restriction of the molecular 
conformation can limit this isomerization but cannot completely eliminate the reaction. 
Additionally, Sunitinib has been known to induce cardiotoxicity in large doses.3,5 It was 
hypothesized that if a ultra-potent compound could be produced this issue could be overcome. 
Sunitinib is also approved as a pan-RKTI.3 Thus, special care must be taken to examine the extent 
of kinome-wide selectivity. As the covalent strategy developed in Chapter 2 will be applied to this 
new scaffold, we expected these new compounds to be subfamily selective. However, if an ultra-
selective compound could be produced through this method, then kinome-wide selectivity could 
be less of a liability. Despite these known issues, this scaffold presents the best option to continue 
developing a second generation of covalent, selective GRK5 inhibitors.  
 The original lead, CCG-271421 (previously Ullrich-57), was shown in our assays to have 
exceptional potency against GRK5 (IC50 = 15 nM) with a minimal intrinsic amount of selectivity 
for GRK2 (IC50 = 1100 nM), about 74-fold selective (Table 4.1). This data was indicative of the 
fact that this series can definitely serve as lead for the second generation of our GRK5 covalent 
inhibitors. We predicted that if these compounds could be modified to carry a covalent warhead, 
the selectivity could be improved by 100-fold or greater while potency could also potentially be  
in the picomolar range.  
4.3 Haloketones Produce a Rapid Covalent Interaction with Cys474 
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First and foremost, the focus for this series was establishing the appropriate warhead for covalent 
engagement with Cys474. Initially, the linkage for the warhead was maintained and simple 
alkynyl-amine and alkenyl-amines were appended to the pyrrole ring through the free carboxylic 
acid.6 These compounds, CCG-271423-CCG-271442, demonstrated reasonable but lower potency 
that the initial lead, CCG-271421. Interestingly, CCG-271423, which features a propargyl group, 
has the highest level of selectivity among the compounds made, with a 2100-fold selectivity 
Table 4.1: IC50 Values for Indolinones With Various Warheads (µM ± SD) 
 




Sunitinib  NA 
 
N/A 
0.83 ± 0.7 
(3) 








0.015 ± 0.02 
(7) 
1.1 ± 0.7 
(4) 






0.021 ± 0.01 
(7) 








0.048 ± 0.008 
(3) 
22 ± 10 
(3) 






0.091 ± 0.04 
(3) 
130 ± 50 
(3) 






1.9 ± 0.4 
(2) 








2.5 ± 0.8 
(3) 


















0.74 ± 0.6 
(5) 





 H NO2 CH3 
0.73 ± 0.5 
(3) 








0.22 ± 0.04 
(3) 
350 ± 100 
(2) 






0.36 ± 0.2 
(3) 








0.08 ± 0.03 
(3) 
6.7 ± 5 
(3) 
 
















0.0086 ± 0.003 
(7) 
12 ± 20 
(3) 






0.28 ± 0.1 
(3) 
120 ± 80 
(2) 
430 >250 (2) 
CCG 
215022 
    
0.28 ± 0.1 
(6) 
ND  >250 (2) 
paroxetine     ND 
0.78 ± 0.3 
(3) 
 
850 ± 400  
(4) 
All data were fit to a log([Inhibitor]) versus response model with variable slope and automatic outlier rejection in GraphPad Prism. 
Curves that had R squared values less than 0.8 after fitting were omitted. ND, not determined. Numbers in parentheses indicate the 
number of independent experimental curves.   
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against GRK2. Such an increase activity indicates that there is a clear interaction between the 
propargyl group and the GRK5 P-loop that is not present in GRK2. Indeed, it is known that the 
GRK2 P-loop extends farther down over the face of the active site, and therefore may cause a steric 
clash with the propargyl group of CCG-271423.7 However, we were able to rule out the idea that 
this warhead engages C474 covalently through intact protein mass spectrometry (MS).  
Additionally, compounds with longer linker length, CCG-271441 and CCG-271442 
respectively, were shown to have variable potency from 0.91 µM to 1.9 µM. Interestingly, the 
selectivity trends between the alkyne and alkene warheads remained consistent in these two 
analogues, suggesting that linker flexibility does not allow the propargyl group to avoid a steric 
clash with the GRK2 P-loop. These data suggest that linker lengths for our warhead cannot be 
extended beyond one methylene unit without causing a steric clash with either the GRK2 or GRK5 
P-loop. Thus, the key to maintaining potency may be to maintain the initial linker length of CCG-
271421, but selectivity necessitates a different covalent modifier be present. 
Given that the initial warheads developed in Chapter 2 were inaccessible via the initial 
route, a new strategy was used. The pyrrole-amide was reversed so that the warheads used in 

















developing CCG-265328 could be tested within this scaffold. Immediately, the most desired 
compound was CCG-273221, which features the N,N-dimethylethylenediamine warhead that has 
a basic terminal amine.8,9 Since the original lead, CCG-271421, also features a terminal amine we 
anticipated that this warhead would be highly effective. However, CCG-273221 has modest 
potency against GRK5 (IC50 = 0.36 µM) with only 47-fold selectivity over GRK2. This level of 
selectivity indicates that CCG-273221 may not be covalent, which indeed was found to be the case 
in intact protein mass spectrometry experiments. A drop in potency, as compared to CCG-271421, 
indicates that the terminal amine on the warhead may be making an interaction with the P-loop, as 
was observed in CCG-264629 in Chapter 2.  
Interestingly, CCG-273180, which features the 2-methylbutyne warhead from CCG-
265328, has very limited potency against GRK5 (IC50 = 2.5 µM), but still retains selectivity against 
GRK2 (61-fold selective). Therefore, we concluded that while this warhead was initial useful in 
the pyrrolopyrimidine series, there must be a type of steric repulsion happening between the 2-
methyl portion of this warhead and the GRK5 P-loop. This data also indicates that the steric clash 
originally observed in CCG-271423 is still prevalent despite having a reversed linker orientation. 
Thus, our previously most reactive warhead is no longer useful in this scaffold, suggesting that 
SAR for covalent warheads is case-specific, and must be optimized with each new scaffold.  
Other traditional Michael acceptor warheads such as acrylamides and vinyl sulfones, 
featured in CCG-273181 (IC50 = 0.81 µM) and CCG-273182 (IC50 = 0.74 µM), show lower levels 
of activity to that seen in CCG-273221. Interestingly, of the original warheads tested, only the 
vinyl sulfone in CCG-273182 was able to form a covalent interaction (Figure 4.1). In intact protein 
MS, CCG-273182 took three hours to form a covalent interaction with GRK5, which was 
consistent with the development of the CCG-265328.10  However, this delay in covalent 
engagement does suggest that there is a slower Kon for CCG-273182 than other compounds in this 
series. This slower Kon rate may be due to a potential steric clash between the GRK5 P-loop and 
the vinylsulfone, before C474 is engaged, which ultimately realigns the spent warhead into a more 
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favorable position. Additionally, the vinyl sulfone is one of the more polar warheads tested within 
the series, potentially causing a slower Kon rate, as our model suggests that the warhead is 
positioned directly beneath the P-loop in a more highly lipophilic area while the acrylate piece of 
the warhead is solvent exposed.  
The most reactive warhead, the chloroketone featured in CCG-273220, did demonstrate 
covalent interaction with GRK5 within 30 minutes, has a reasonable potency (IC50 = 0.22 µM) and 
excellent selectivity against GRK2 (IC50 = 350 µM, 1500-fold selective for GRK5) (Figure 4.2). 
Unsurprisingly given the covalent engagement, CCG-273220 has a 1500-fold selectivity for GRK5 
over GRK2. Similarly, the bromoketone seen in CCG-273463, is shown to have better potency 
than its chloroketone counterpart, but with 50% labelling of GRK5 within 30 minutes. However, 
the bromoketone CCG-273463 is one of the most potent and selective compounds from the series. 
Indeed, with 8.6 nM potency and 1400-fold selectivity for GRK5, CCG-273463 is unique. Such 
data indicates that two main factors may be a play. Firstly, the bromoketone may be fulfilling some 















Figure 4.2 Intact protein MS for haloketones. CCG-273220 (purple) shows labelling in 30 mins. CCG-273441 (light blue) 
also shows labelling at 30 mins, but the other analogues show no labeling at that time point. As labeling events are controlled 
by kinetics, this data suggests that other analogues have a slower Kon rate.  
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kind of lipophilic pocket fill within the area where the warhead of these compounds is modeled to 
sit. Additionally, the bromine of the warhead is known to be a softer electrophile than its chlorine 
counterpart.11,12 In hard-soft acid-base (HSAB) theory, soft electrophiles are most effective when 
paired with equally soft nucleophiles.13 As cysteine (in this case, C474 specifically) is a 
particularly soft nucleophile, it is possible that the bromoketone is a HSAB match for C474, 
making this compound exceptionally potent and selective. However, the bromoketone warhead is 
more labile than its chlorine based counterpart, making it less ideal in the further development of 
this series. 
In keeping with what was learned from CCG-271441 and CCG-271442, the homologated 
chloroketone seen in CCG-273464 had a two-fold reduced potency and was unable to make a 
covalent engagement with GRK5. The epoxide warhead, seen in CCG-273462 was similarly 
unable to make a covalent engagement with GRK5, though it has a moderate level of potency (IC50 
= 0.74 µM). Interestingly, this result is consistent with what other groups have observed when 
testing epoxides for labeling in proteomic experiments.6,14 As CCG-273462 does not form a 
covalent interaction in intact MS and has less than 100-fold selectivity for GRK5 over GRK2, it 
can safely be assumed that this analogue is not making the desired interaction with Cys474. Thus, 
we were able to determine, that while the intrinsic potency of the scaffold is good (between 10-
500 nM), only the haloketone and vinyl sulfone warheads were able to form a covalent interactions 
and improve both potency and selectivity.  
4.4 Filling Lipophilicity Pockets Increases Potency, But Electronics Also Plays a Critical Role 
Having determined the best warhead for covalent interaction for this scaffold, the next focus was 
on improving solubility and intrinsic potency of this scaffold. Initial changes focused on the most 
amenable sites for removing or adding pendants. The phenyl ring pendant was the easiest to modify 
and served as the primary point for SAR expansion. 
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 Interestingly, GRK5 has a strong preference for para substitutions on the phenyl ring. As 
seen in CCG-273441, CCG-273442  and CCG-273583, possessing a para pendant gains a small 
boost in potency. CCG-273445, which features the 4-methyl pendant, has the worst activity of any 
of the compounds from this series (Table 4.2). This drop in potency could be a function of 
electronic mismatches between the compound and the deeper hydrophobic pocket of GRK5 or a 
clash between the 4-methyl pendant and the floor of the GRK5 active site. Interestingly, the 3-
methyl analogue, CCG-273261 shows low nanomolar activity, suggesting that either there are less 
steric clashes with the GRK5 pocket. Similarly, CCG-273442 demonstrates that even the position 
of a heteroatom within a ring matters in terms of potency. CCG-273442, which features a 4-pyridyl 
pendant, has improved potency over its 2-pyridyl counterpart, CCG-273443, by 2-fold. Looking 
Table 4.2: Expanded SAR for Indolinone Series (µM ± SD) 
                                                                         




Sunitinib  NA 
 
N/A 
0.83 ± 0.7 
(3) 








0.029 ± 0.03 
(5) 
11 ± 6 
(3) 






1.30 ± 0.1 
(3) 








0.0038 ± 0.001 
(7) 
4.8 ± 3 
(3) 






0.13 ± 0.05 
(3) 





     2-Py 
 
CH3 
0.45 ± 0.1 
(3) 








0.14 ± 0.04 
(3) 
19 ± 10 
(3) 






0.78 ± 03 
(3) 








0.13 ± 0.09 
(4) 
13 ± 3 
(3) 





12 ± 5 
(3) 








0.11 ± 0.05 
(3) 







0.087 ± 0.02 
(3) 
23 ± 20 
(4) 





0.095 ± 0.03 
(3) 
15 ± 7 
(3) 
160 69 ± 10 (6) 
All data were fit to a log([Inhibitor]) versus response model with variable slope and automatic outlier rejection in 
GraphPad Prism. Curves that had R squared values less than 0.8 after fitting were omitted. ND, not determined. Numbers 




at the model, it is clear that GRK5 can accommodate a more polar pendant within this deeper 
hydrophobic pocket (Figure 4.3). What is less clear at first glance, is that CCG-273442 may be 
fulfilling an electronic deficit which is not filled by CCG-273443. Comparison of the electrostatic 
map of the GRK5 binding site with the electrostatic map of CCG-273442, it is clear that CCG-
273442 has an appropriate match with the electrostatics of the binding site. Meanwhile, CCG-
273443 does not have an electrostatic match. Indeed, this electrostatic effect also seems to come 
into play with CCG-273441. CCG-273441, which is one of the most potent, but not the most 
selective GRK5 inhibitor of the series, does have an exact electrostatic match within the deeper 
hydrophobic pocket of the active site. Thus, the subtle electrostatics that control the deeper 
hydrophobic pocket when combined with a softer electrophile yield the best results from this 
series. This principle is reinforced by CCG-359090, featuring a 4-fluoro pendant and a 
bromoketone warhead, which has exceptional potency against GRK5 (IC50 = 20 nM) but lower 
selectivity over GRK2 than CCG-273441 (CCG-359090 has 233-fold subfamily selectivity). As 
these two functionalities afforded the highest levels of potency and selectivity seen in the series, it 
was assumed that the combination would have a synergistic effect producing a potentially sub-
nanomolar analogue. However, the need to balance the subtle electrostatic effects of the ligand 
and the GRK5 binding pocket combined with a less reactive haloketone warhead resulted in an 
analogue that sees an additive effect of these efficacious pendants.   
 
Figure 4.3 Electrostatic map comparison between GRK5 (Blue) and CCG-273442 (Gold carbons). (a) GRK5/GRK6 with CCG-
273442 in the active site, an electronic map for the GRK5 active site is shown in blue/red shading, (b) electronic map of CCG-
273442 shown in blue/red shading, (c) CCG-273442 represented in 3D (gold carbons).  
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Pleasingly, we were able to demonstrate that classic medicinal chemistry strategy can 
improve the solubility of these compounds. Indeed, CCG-273443 is the most soluble of the limited 
set tested, with an aqueous solubility of 261.7 µM (Table 4.3). While this level of aqueous 
solubility is not optimal, it is certainly still more advantageous than that of CCG-273220 (Aq. Sol.: 
75.1 µM). Interestingly, there was an increase in solubility with every change to the base scaffold 
of CCG-273220. The addition of either a 4-fluoro or a 4-methyl pendant resulted in highly levels 
of aqueous solubility (90.7 µM and 252.1 µM, respectively). However, there was a drop in the pH 
of each sample following thermodynamic solubility testing, indicating that potentially the 
chloroketone warhead is hydrolyzing during testing conditions. If true, the corresponding alpha-
hydroxy ketone would most certainly be more water soluble than its counterpart. Interestingly, the 
addition of a terminal amine, as in CCG-273221, improves aqueous solubility by 1.6-fold, 
compared to CCG-273220. This improvement in solubility implies that by building in a terminal 
amine to our warhead or linker, solubility could be increased in an atom economic fashion. We 
were able to increase the aqueous solubility of these compounds and also found that in some cases, 
CCG-273443 being a prime example, this does not help to optimize potency. Indeed, there seems 
to be a sensitive electronic balance underlying the intrinsic reactivity of each analogue. Therefore, 
compounds which are more soluble can also be less potent, potentially due to loss of the 
electrophilic warhead due to higher reactivity of the modifier which is supported by the more 
highly electron-rich scaffold.  
4.5 The Stereocenter Cannot Be Replaced or Activity Will Be Lost 
Table 4.3 Thermodynamic Solubility of Indolinone Series Analogues 
Compound 






273220 water 75.1 35.7 5.6 5 
CCG-
273221 water 125.3 64 3 5 
CCG-
273441 water 90.7 44.8 4 3 
CCG-
273443 water 261.7 124.9 7.6 4 
CCG-
273445 water 252.1 123.6 7.6 2.5 
CCG-
273583 water 205.4 104.8 6 4 




One of the biggest challenges we faced was the stereocenter that is prominently featured in the 
original lead CCG-271421. While some stereocenters cannot be removed from lead compounds, 
it is generally advisable to attempt to uncover whether or not a stereocenter can be removed or 
racemized. Large scale or preparative synthesis of lead compounds is known to be cheaper, and 
less complex without the inclusion of such structural elements, making their removal ideal.  
From our model, it is clear 
that the (R) configuration has the 
effect of positioning the phenyl 
pendant into a lipophilic pocket 
beyond the gatekeeper (Figure 4.4). 
When the (S) enantiomer is 
featured, however, potency is 
drastically limited, as seen in CCG-
273262 which has an IC50 = 1.3 µM 
(43-fold less potent than CCG-
271421). Removal of the 
stereocenter entirely in CCG-273561 demonstrated 130 nM level of potency, which is still highly 
potent, but about 10-fold less potent than our best compounds. While expanding the pendant from 
an (R)-methyl to an (R)-isopropyl group, demonstrated in CCG-273564 causes a steric repulsion 
deeper in the hydrophobic pocket, leading to a subsequent loss of potency. Replacing the 
stereocenter with a geminal di-methyl group, shown in CCG-273562, has moderate potency and 
was generally well tolerated. The same proved to be true of using an oxetane ring at the benzyl 
position (CCG-273563). This effect suggests that the positioning of the methyl pendant in the (R)-
configuration provides a great boost in potency and can even negate the effects of simultaneously 
positioning a secondary pendant in the (S)-configuration. Thus, we have been able to show that 
the key to selectivity and potency for GRK5 lies in not only a covalent interaction with Cys474 
but also in placement of pendants deep in the hydrophobic pocket in the correct orientation. Thus, 
we determined that while we cannot remove the stereocenter completely without a loss in potency, 
some changes to the benzylic position are well tolerated. As the oxetane ring and the geminal 
dimethyl groups were meant to protect against metabolic instability, it is encouraging that these 
changes were moderately tolerated by GRK5.  
 
Figure 4.4 CCG-273220 (gold carbons) docked into the GRK5 
(blue)/GRK6 (purple) model. The (R)-methyl group is positioned in a more 
spacious pocket, instead of directly underneath the P-loop/roof of the kinase.  
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4.6 Tandem Mass Spectrometry Confirms Cys474 Engagement  
Similar to what was seen in Chapter 2, we chose to further explore the exact location of covalent 
engagement by both CCG-273182 and CCG-273220. As demonstrated by initial intact protein 
mass spectrometry experiments, these compounds were found to have covalent interactions, but 
the exact location of engagement cannot be determined by those methods. Thus, tandem mass 
spectrometry was used to definitively determine sites of covalent engagement. 
 In the case of CCG-273182, when incubated for three hours with GRK5, the predominantly 
labelled residue was Cys474 (Figure 4.5). However, even at 100 µM concentrations, some 
concentration dependent labelling events were observed.15,16 Cys145 and Cys520 were also 
 
 
Figure 4.5 Tandem MS data shown in the table above indicates that Cys474 is the most predominantly labeled cysteine. Sites of 
labeling are shown in magenta in the GRK5 model (gold). Shown in the active site is CCG-273182 (blue carbons). 
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labelled in this sample, but they constitute some of the most solvent exposed cysteine residues in 
GRK5. Due to the level of solvent exposure, these extra labelling events are not considered to be 
biologically relevant. Pleasingly, this data confirms that our initially targeted residue, Cys474, is 
the site of covalent engagement for this new series. 
 Given that CCG-273220 served as a lead for the covalent warheads in the indolinone series, 
it was also tested with tandem MS. After a three hour incubation with GRK5, tandem MS of this 
sample was not able to detect a covalent label from CCG-273220 on any GRK5 cysteine. As it is 
known that GRK5 is labelled by the less reactive CCG-273182 at Cys474, this data seemed 
incongruent. However, the chloroketone of CCG-273220 is more labile than the vinyl sulfone of 
CCG-273182 and could have undergo hydrolysis within the three hour incubation, causing a lack 
of covalent engagement. Further examination of the peptide fragments from the CCG-273220-
GRK5 sample also appear to be cut into fragments at the upper weight limit for tandem mass 
spectrometry detection. With the addition of the covalent label, it is possible that fragments would 
be above the upper limit for tandem MS detection. If this proves true, then covalent labels on 
Cys474 exist it simply cannot be detected in these tandem MS conditions. 
 Given the ambiguous results of the tandem MS for CCG-273220, we chose to return to 
intact protein MS utilizing a mutant GRK5-C474S strain. This replacement of the nucleophile to 
a less reactive serine should prevent covalent engagement. Indeed, this effect is observed in the 
CCG-273220-GRK5-C474S sample. Pleasingly, this data further confirms our suspicions that 
 
Figure 4.6 Intact MS of GRK5 and GRK5-C474S with CCG-273220. (a) GRK5 incubated with CG-273220, shows covalent 
engagement, (b) GRK5-C474S shows unlabeled peak at 68,921 Da, (c) GRK5-C474S incubated with CCG-273220 shows an 
unlabeled peak at 68,921 Da, indicating that covalent engagement is lost if the C474 nucleophile is replaced.  
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CCG-273220 and all other covalent analogues from this series are engaging Cys474, as designed 
(Figure 4.6).  
4.7 Screening of CCG-273463 and CCG-271423 against a Kinase Panel Indicates High Selectivity 
for This Series 
 Given the high potency and subfamily selectivity of this series their limitation may prove 
to be kinome-wide selectivity. The indolinone series was originally derived from a RTKI 
(Sunitinib) therefore it is possible that multiple side target liabilities remain.3,4,17 The introduction 
of the covalent warhead is intended to remove these liabilities, as Cys474 is not conserved among 
all kinases rather it is only found in GRK5 and GRK6.  
 The use of a covalent warhead may prove to be a sufficient deterrent to activity against 
multiple targets, however, the haloketone warhead is known to be one of the most reactive 
warheads used in covalent drug discovery.11 For this reason, the currently developed indolinone 
series could have activity against multiple targets, not just those kinases within the AGC kinase 
family. Therefore, to determine the exact utility of this series, a kinome-wide selectivity screen 
was pursued. 
 As the most developed compounds in the series feature a haloketone, the most active and 
subfamily selective compound, CCG-273463, was selected for testing. Additionally, as CCG-
271423 was the most selective non-covalent compound developed in this series, this compound 
was also submitted for selectivity screening. Thus, the samples that were screened for kinome 
 
Figure 4.7 Kinase selectivity panel for CCG-271423 and CCG-273463. Inhibition values are an average of n=2 experiment. 
Levels of inhibition are indicated by gradient color, with higher levels of protein inhibition labeled as red. (A) Kinome 
selectivity map for CCG-271423 indicates subfamily selectivity levels are not maintained across the kinome.. (B) Kinome 
selectivity map for CCG-273463 indicates that subfamily selectivity levels are not maintained across the kinome.  
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selectivity represent the two most selective and potent covalent and non-covalent inhibitors 
developed, respectively.  
 Against a panel of 300 kinases, CCG-273463 was found to be promiscuous, hitting kinases 
across all families within the panel (Figure 4.7). Indeed, while CCG-273463 does show incredible 
subfamily selectivity this level of selectivity is not extended to the entire kinome. As the original 
scaffold was derived from a promiscuous RTKI, this lack of selectivity is not altogether surprising. 
Especially since known targets of Sunitinib, platelet-derived growth factor receptor (PDGFR) and 
vascular endothelial growth factor receptor (VEGFR), are also major off-targets for CCG-273463. 
However, it is possible that the highly reactive warhead has contributed to this lack of selectivity 
across the kinome. Should that prove to be true, a lower concentration of CCG-273463 tested 
against this kinase panel would yield more selectivity.  
 Against the same panel of 300 kinases, CCG-271423 was found to be equally as 
promiscuous as CCG-273463. As CCG-261423 is non-covalent, it is not predicted to suffer 
promiscuity within this screening panel. These data indicate that the base scaffold is sufficiently 
potent against multiple kinases across several families to produce a non-selective inhibitor. Again, 
as the original scaffold is derived from a pan-RKTI these data are not surprising. Thus, we have 
demonstrated that changes to our scaffold are sufficient to produce subfamily selectivity but not 
kinome selectivity, suggesting further changes are needed for a truly ultra-selective GRK5 
inhibitor.  
 From this screening data it is clear that the haloketone warhead does bestow ultra-
selectivity for GRK4 subfamily members but does not convey that same level of selectivity against 
all kinases. Given the lack of kinome-wide selectivity, a new utility for these compounds has 
arisen. The covalent GRK5 inhibitors may be used to investigate the role of GRK5 within various 
cancers, where the activity against multiple targets, including classic cancer targets such as 
PDGFR and VEGFR might prove advantageous.  
4.8 Indolinones Do Not Increase Cardiomyocyte Contractility, But They Do Alter Ca2+ Flow 
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 With ultra-selectivity against GRK4 subfamily members, and reasonable selectivity across 
the kinome, this indolinone series was used to investigate the role of GRK5 in cardiomyocyte 
contractility. Originally, it was thought that selective GRK5 inhibitors would act similarly to 
GRK2 inhibitors in that they would increase cardiomyocyte contractility, as demonstrated by 
Waldschmidt et. al.18,19  
 A survey of a representative sample of covalent, and non-covalent selective, potent GRK5 
inhibitors in cardiomyocytes indicated that these inhibitors do not act in the same manner as 
described for GRK2 inhibitors. Rather, these compounds do not alter cardiomyocyte contractility 
significantly, when compared to a negative control (DMSO). Even the non-covalent CCG-271423 
did not show a significant increase in cardiomyocyte contractility when compared with the DMSO 
negative control (Figure 4.8). Similarly, CCG-273220, a forerunner to CCG-273463, does not 
increase cardiomyocyte contractility when compared to the negative control. This data suggests 
 
Figure 4.8 (top) Fractional shortening of cardiomyocytes, both without and with an isoproterenol challenge. Data shown are an 
average of n 1-3 experiments. (bottom) Measurements of the calcium transience in cardiomyocytes without and with an 
isoproterenol challenge. Data shown are an average of n 1-3 experiments.  
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that the mechanism of action, regardless of covalency, for these compounds does not directly 
impact cardiomyocyte contractility in the same fashion as GRK2 inhibitors such as CCG-215022. 
 Interestingly, these indolinone samples were found to affect Ca2+ transience in negative 
fashion. This is an intriguing discovery, as GRK5 is not known to affect Ca2+ transience in 
cardiomyocytes. However, this study does shed some light on why the indolinone series does not 
affect cardiomyocyte contractility. Ca2+ transience is known to be linked in a positive feedback 
loop with cardiomyocyte contractility.20–22 With inhibitors such as CCG-271423 and CCG-273220 
showing a decrease in Ca2+ transience when compared with the negative control (DMSO) it is not 
surprising that these compounds do not increase contractility. Additionally, the remaining 
compounds in the tested set also show a drastic decrease in Ca2+ transience when compared to the 
negative control, indicating that they too may not increase cardiomyocyte contractility. Indeed, 
this proves to be the case, as CCG-273221 and CCG-273445 do not increase cardiomyocyte 
contractility in the same manner that CCG-273220 and CCG-271423 do not increase contractility. 
While it remains unclear how GRK5 affects cardiomyocyte contractility, it is clear that the effect 
of GRK5 is different than GRK2 in the cardiovascular system.  
4.9 Concluding Thoughts on the Indolinone Series 
With the development of this new series, there now exists a suitable selective GRK5 inhibitor. In 
this series I have shown how a scaffold with a high affinity can be made ultra-subfamily selective 
using the same covalent strategy applied in Chapter 2. Given the high levels of selectivity and 
potency for key compounds, CCG-271423, CCG-273441 and CCG-359090, these new probes will 
serve as excellent tools to further study the role of GRK5 in various disease states.  
4.10 Synthesis of Compounds 
Synthesis of the original compound CCG-273421 and its analogues begins with a divergent route.2 
In the first line of synthesis, the free indolinone carboxylic acid, 2, undergoes an amide coupling 
with (R)-phenylethylamine to give the intermediate, 3. In the second line of synthesis, the pyrrole 
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carbaldehyde starting material 6 undergoes an amide coupling with an amine of choice to give the 
intermediate 4a-e. Intermediate 3 is then condensed with 4a-e using standard Knovenagel 
conditions to yield the desired products 271421-271442 (Scheme 4.1).  
 In a similar route, the final analogues of 273180-273583 can be achieved. Starting from 
the common intermediate 3, a Knovenagel condensation with 3,5-dimethyl-4-nitro-
 
Scheme 4.1 Synthetic route to CCG-27421-271442.  
 
     Scheme 4.2 Synthetic route to 273180-359090. 
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pyrrolocarbaldehyde gives the common intermediate 7 (Scheme 4.2). Compound 7 can then 
undergo a zinc catalyzed nitro group reduction to give the free amine, 8. Free amine 8 can then be 
immediately used in an amide coupling with a chosen acid to give the final compounds. For almost 
all compounds, the final step involved the inclusion of the chloroacetic acid warhead. For those 
final compounds that include a different warhead, DMTMM was used to couple the free warhead 
acid with the free amine 8. For variations in the phenyl ring substituent or in the benzylic position, 
all modifications start back at the amide coupling with 2, and use the appropriate amine to yield 
the intermediate 3a-h. From 3a-h the rest of the route remains unchanged yielding the final 
compounds 273441-359090.  
4.11 Materials, Methods and Synthetic Experimental Data 
General Chemistry: All reagents from commercial sources were used without further purification 
unless otherwise noted. 1H-NMR spectra were taken in DMSO-d6, MeOD or CDCl3 at room 
temperature on Varian MR 400 MHz; Varian Vnmrs 500 MHz; and Varian Vnmrs 700 MHz 
instruments. The reported chemical shifts for the 1HNMR spectra were recorded in parts per 
million (ppm) on the δ scale from an internal tetramethylsilane (TMS) standard (0.0 ppm). Small 
molecule mass spectrometry data was measured using a Waters Corporation Micromass LCT or 
Agilent6230 Q-TOF instrument. HPLC was used to determine purity of compounds on an Agilent 
1100 series with an Agilent Zorbax Eclipse Plus-C18 column. A gradient of 10-90% 
acetonitrile/water over 6 min followed by 90% acetonitrile/water for 7 min was used with detection 
at 254 nm.  
Intact Protein MS and Tandem MS/MS: Intact protein MS was acquired with a Phenomenex C4 
column paired with an Agilent 6545 Q-TOF LC/MS. For intact MS and Tandem MS, all samples 
were prepared with 20 µM GRK in assay buffer (see below), 1 mM compound, and incubated at 4 
˚C for 3 hr before being quenched with 1.0 µL of formic acid. In Tandem MS/MS, we chose Glu-
C as the restricting enzyme to avoid small fragments with mass-to-charge ratios below the limit of 
detection of our instrument. All samples were digested with Glu-C sequencing enzyme, procured 
from Sigma Aldrich (Roche Life Sciences subsidiary) and used without further purification. 
MS/MS experiments were run on a nano-LC (Dionex RSLC-nano) with an Orbitrap Fusion Tribrid 
ETD mass spectrometer. This work was conducted by the Proteomics Resource Facility at the 
University of Michigan. 
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Inhibition Assays: For compounds CCG-271421-359090, IC50 values for human GRK5, bovine 
GRK2, and bovine GRK1 were determined using a radiometric assay as follows. 50 nM GRK was 
incubated with 500 nM porcine brain tubulin (Cytoskeleton) and 0 - 333 μM inhibitor in 20 mM 
HEPES pH 7.0, 2 mM MgCl2, 0.025% dodecylmaltoside (DDM), 3% DMSO for 20-30 min for 
GRK1 and 2 and 0-1 hr for GRK5, as denoted in Table 1, on ice, prior to initiation with the addition 
of 5 µM ATP supplemented with radioactive [γ-32P]-ATP (PerkinElmer Life Sciences). Reactions 
were quenched at 5 min by addition of 6 μL of 4X SDS gel loading dye to the 6 μL reactions. 8 
μL samples were separated on a 4-15% Criterion TGX precast gel (Bio-Rad). Experiments were 
performed with an n = 3 in duplicate. 
Gels were dried, exposed to a storage phosphor screen overnight, and scanned using a 
Typhoon scanner. Bands corresponding to phosphorylated tubulin were quantified using 
ImageQuant, plotted as a function of log[inhibitor], and fit to the three-parameter log(inhibitor) vs. 
response model in GraphPad Prism 7.03 to determine the IC50., and mean and standard deviation 
values were calculated using the column statistics function of GraphPad Prism 7.03. 
Standard control compounds are run during each assay to assess consistency across time, 
experimenters, and subtle changes in assay conditions that are sometimes required to keep some 
of the compounds soluble and disperse (such as through addition of DDM or 3% DMSO). 
CCG215022 was used as controls for CCG-271421-359090.  
 
 
Scheme 4.3. Synthetic route to indolone materials. 
 
 (R)-2-oxo-N-(1-phenylethyl)indoline-5-carboxamide (132, RAR-11-87) 
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To a round bottom flask were added 297.7 mg (1.69 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.244 mL (1.88 mmol) of 
(S)-1-phenylethan-1-amine, 0.300 mL (1.69 mmol) of DIPEA and 746.1 mg (1.95 mmol) of 
HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 mL 
of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed 
with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography (0-15% 
DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 401.9 mg, 84% 
Molecular Formula: C17H16N2O2  ESI-MS calc: 280.12  ESI-MS found: 281.1283 [M+1]  HPLC: 
5.198 1H NMR (400 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 7.0 
Hz, 2H), 7.39 – 7.35 (m, 2H), 7.31 (dd, J = 8.4, 6.8 Hz, 2H), 7.23 – 7.18 (m, 1H), 6.88 – 6.83 (m, 
1H), 5.15 (p, J = 7.2 Hz, 1H), 3.53 (s, 2H), 1.46 (d, J = 7.1 Hz, 3H). 13C NMR (100 MHz, dmso) 
δ 177.17, 165.76, 146.85, 145.65, 129.29, 128.67, 126.52, 126.06, 108.90, 48.85, 36.09, 22.84. 
N-(2-(diethylamino)ethyl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide (127, RAR-11-93) 
To a round bottom flask were added 200.9 mg (1.20 mmol) of 5-formyl-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid, 365.8 mg (1.79 mmol) of EDCI, 277.7 mg (1.79 mmol) of HOBt, 7 mL of dry 
DMF, 0.200 mL (1.44 mmol) of N1,N1-diethylethane-1,2-diamine and 0.34 mL (2.39 mmol) of 
TEA. The dark red solution was allowed to stir at rt for 12 h before being quenched with water 
and extracted with DCM ( 3 x 30 mL). The combined organic layer was washed with brine (2 x 
20 mL) and then washed with 10% Citric acid (3 x 50 mL), drawing the desired product into the 
water layer.23 The organic layer was discarded. The aqueous layer was basified with Na2CO3, 
bringing the pH up to 10, and then extracted with DCM (4 x 50 mL). The combined organic layers 
were dried over MgSO4 and then evaporated onto silica gel and purified by column 
chromatography (5-15% MeOH/DCM). The solvent was removed under pressure to give a yellow 
solid. Result: light yellow solid, 90 mg, 27%  Molecular Formula: C14H23N3O2, ESI-MS Calc: 
265.18 ESI-MS found: 266.1749    HPLC: 2.681 1H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 
9.54 (s, 1H), 7.95 (s, 2H), 2.34 (d, J = 20.8 Hz, 7H), 0.99 (s, 6H). 
5-formyl-2,4-dimethyl-N-(prop-2-yn-1-yl)-1H-pyrrole-3-carboxamide (128, RAR-11-97) 
To a round bottom flask were added 199.4 mg (1.20 mmol) of 5-formyl-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid, 688.0 mg (1.79 mmol) of HATU, 6 mL of dry DMF, 0.100 mL (1.44 mmol) of 
propargylamine and 0.34 mL (2.39 mmol) of TEA. The dark red solution was allowed to stir at rt 
for 12 h before being quenched with water and extracted with DCM ( 3 x 30 mL). Took the 
combined organic layers and washed with brine (2 x 20 mL) and then washed with 10% Citric acid 
(3 x 50 mL), taking the desired product into the aqueous layer. Discarded the organic layer. The 
aqueous layer was basified with Na2CO3, bringing the pH up to 10, and then extracted with DCM 
(4 x 50 mL). The combined organic layer was dried over over MgSO4 and then removed solvent 
to give the final product as a light orange oil. Result: light orange oil, 61 mg, 25% Molecular 
Formula: C11H12N2O2 ESI-MS calc: 204.09 ESI-MS found: 205.0873 [M+1], 242.1167 
[M+K]   HPLC: 3.625 1H NMR (700 MHz, DMSO-d6) δ 11.87 (s, 1H), 9.55 (s, 1H), 7.95 (s, 
16H), 3.97 (ddd, J = 12.7, 5.7, 2.5 Hz, 3H), 3.08 (t, J = 2.4 Hz, 1H), 2.36 (s, 3H), 2.31 (s, 3H). 13C 
NMR (176 MHz, dmso) δ 177.82, 164.77, 139.11, 138.51, 128.26, 119.20, 89.92, 82.16, 72.95, 
55.38, 40.24, 38.71, 28.42, 12.90, 10.00. 
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N-allyl-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide (129, RAR-11-99) 
To a round bottom flask were added 204.4 mg (1.20 mmol) of 5-formyl-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid, 350.3 mg of EDCI (1.79 mmol), 275.3 mg (1.79 mmol) of HOBt, 6 mL of dry 
DMF, 0.110 mL (1.44 mmol) of allylamine and 0.34 mL (2.39 mmol) of TEA. The dark red 
solution was allowed to stir at rt for 12 h before being quenched with water and extracted with 
DCM ( 3 x 30 mL). Took combined organic layers and washed with LiCl 3 x 20 mL) and then 
washed with 10% Citric acid (3 x 50 mL), drawing the desired product into the aqueous 
layer. Discarded the organic layer. The aqueous layer was basified with Na2CO3, bringing the pH 
up to 8, and then extracted with DCM (4 x 50 mL) The combined organic layer was dried over 
MgSO4 and then removed solvent to give a yellow solid. Result: light yellow solid, 64 mg, 
25% Molecular Formula: C11H14N2O2 ESI-MS calc: 206.11 ESI-MS: 246.1621 [M+ 
MeCN]   HPLC: 3.885 1H NMR (500 MHz, DMSO-d6) δ 11.38 (s, 1H), 9.54 (s, 1H),8.17 (s, 1H), 
6.01 (tt, J = 10.8, 5.4 Hz, 1H), 5.87 (ddt, J = 16.4, 10.6, 5.3 Hz, 2H), 5.18 (t, J = 15.7 Hz, 3H), 
5.08 (dd, J = 16.5, 10.2 Hz, 3H), 4.14 (d, J = 5.5 Hz, 2H), 3.82 (t, J = 5.7 Hz, 3H), 2.31 (s, 5H), 
2.23 (s, 3H). 13C NMR (126 MHz, dmso) δ 161.78, 150.29, 135.45, 135.21, 115.01, 114.35, 
114.20, 40.54, 40.50, 39.50, 39.33, 39.17, 39.00, 38.83, 38.67, 38.50, 35.26, 30.25, 11.95, 9.27. 
 
N-(but-3-yn-1-yl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide (130, RAR-12-2) 
To a round bottom flask were added 199.6 mg (1.20 mmol) of 5-formyl-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid, 684.3 mg (1.79 mmol) of HATU, 6 mL of dry DMF, 0.100 mL (1.44 mmol) of 
1-amino-3-butyne and 0.30 mL (2.39 mmol) of DIPEA. The dark red solution was allowed to stir 
at rt for 12 h before being quenched with water and extracted with DCM ( 3 x 30 mL). The 
combined organic layers were washed with LiCl (2 x 20 mL) and then washed with 10% Citric 
acid (3 x 50 mL), drawing the desired product into the water layer. Discarded the organic layer. 
The aqueous layer was basified with Na2CO3, bringing the pH up to 10, and then extracted with 
DCM (4 x 50 mL). The combined organic layer was dried over MgSO4 and then removed solvent 
under pressure to give the final product as a yellow solid. Result: light yellow solid, 99.6 mg, 
38.1%  Molecular Formula: C12H14N2O2  ESI-MS calc: 218.11  ESI-MS found: 219.1129   HPLC: 
3.997 1H NMR (700 MHz, DMSO-d6) δ 11.83 (s, 1H), 2.83 (s, 1H), 2.69 (d, J = 1.0 Hz, 1H), 2.60 
(d, J = 2.4 Hz, 3H), 2.37 (s, 4H), 2.32 (s, 3H). 13C NMR (176 MHz, dmso) δ 178.94, 164.54, 
160.23, 152.56, 147.04, 146.58, 126.55, 115.31, 88.48, 82.43, 72.02, 55.77, 37.85, 18.85, 13.97, 
10.55. 
N-(but-3-en-1-yl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide (131, RAR-12-3) 
To a round bottom flask were added 197.8 mg (1.20 mmol) of 5-formyl-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid, 685.8 mg (1.79 mmol) of HATU, 6 mL of dry DMF, 107.1 mg (1.44 mmol) of 
but-3-en-1-amine and 0.45 mL (2.40 mmol) of DIPEA. The dark red solution was allowed to stir 
at rt for 12 h before being quenched with water and extracted with DCM ( 3 x 30 mL). The 
combined organic layers were washed with brine (2 x 20 mL) and then washed with 10% Citric 
acid (3 x 50 mL), drawing the desired material in to the aqueous layer. Discarded the organic 
layer. The aqueous layer was basified with Na2CO3, bringing the pH up to 10, and then extracted 
with DCM (4 x 50 mL). The combined organic layer was dried over MgSO4 and then removed 
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solvent. Result: light orange oil, 106.1 mg, 37.2%  Molecular Formula: C12H16N2O2 ESI-MS calc: 
220.12 MS: 221.1304   HPLC: 5.554 1H NMR (500 MHz, DMSO-d6) δ 9.77 (s, 1H), 8.84 (d, J = 
4.5 Hz, 1H), 8.73 (d, J = 8.4 Hz, 1H), 7.95 (s, 4H), 7.66 (dd, J = 8.7, 4.6 Hz, 1H), 5.12 – 4.99 (m, 
1H), 2.59 (s, 7H). 13C NMR (126 MHz, dmso) δ 179.37, 165.02, 162.73, 152.99, 146.27, 140.66, 




To a dried sealed tube were added 97.9 mg (0.371 mmol) of (133), 107.0 mg (0.357 mmol) of 
(127) all of which were dissolved in abs. EtOH (3.5 mL). To this solution were added 2 drops of 
piperidine and heated to reflux (95 °C) for 4 h. Once complete, cooled to room temperature and 
then filtered off the product as an orange solid. Yield: orange solid, 38.3 mg, 22% Molecular 
Formula: C31H37N5O3 ESI-MS calc: 527.29 ESI-MS found: 528.2955    HPLC: 5.621 1HNMR 
(500 MHz, DMSO-d6) δ 13.59 (s, 1H), 11.13 (s, 1H), 8.59 (d, J = 8.1 Hz, 1H), 8.25 (s, 1H), 7.71 
(d, J = 6.8 Hz, 2H), 7.44 (d, J = 6.0 Hz, 1H), 7.41 (d, J = 7.9 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.22 
(t, J = 7.7 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 5.19 (t, J = 7.5 Hz, 1H), 3.28 (d, J = 7.0 Hz, 2H), 2.44 
(d, J = 6.7 Hz, 6H), 1.51 (d, J = 7.1 Hz, 3H), 0.97 (t, J = 7.1 Hz, 7H). 13CNMR (176 MHz, dmso) 
δ 169.90, 165.95, 164.71, 145.11, 140.64, 136.48, 129.93, 128.30, 127.78, 126.64, 126.37, 126.18, 
125.86, 125.28, 124.09, 120.76, 117.69, 114.37, 108.94, 51.72, 48.55, 46.59, 45.44, 39.86, 39.74, 
39.62, 39.50, 39.38, 39.26, 39.14, 37.06, 22.35, 13.40, 11.92, 10.79. 
(R,Z)-3-((3,5-dimethyl-4-(prop-2-yn-1-ylcarbamoyl)-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (135,RAR-11-98) 
To a dried sealed tube were added 75.1 mg (0.27 mmol) of (133), 50 mg (0.28 mmol) of  (128) all 
of which were dissolved in abs. EtOH (1.8 mL).  To this solution were added 0.05 mL of piperidine 
and heated to reflux (95 °C) for 4 h. Once complete, cooled to room temperature and filtered off 
an orange solid. The solid was rinsed with cold EtOH to give the final product. Yield: bright orange 
solid, 58.6 mg, 46% Molecular Formula: C28H26N4O3 ESI-MS calc: 466.20 ESI-MS found: 
467.2037    HPLC: 6.360 1H NMR (700 MHz, DMSO-d6) δ 13.61 (s, 1H), 11.15 (s, 1H), 8.61 (d, 
J = 8.0 Hz, 1H), 8.26 (s, 1H), 8.06 (t, J = 5.5 Hz, 1H), 7.71 (d, J = 9.0 Hz, 2H), 7.41 (d, J = 7.8 Hz, 
2H), 7.33 (q, J = 5.8, 3.9 Hz, 2H), 7.23 (t, J = 7.2 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 5.20 (t, J = 7.7 
Hz, 1H), 4.02 (d, J = 5.5 Hz, 2H), 3.14 – 3.08 (m, 1H), 2.44 (d, J = 9.2 Hz, 7H), 1.51 (d, J = 7.1 
Hz, 3H). 13C NMR (176 MHz, dmso) δ 170.30, 166.26, 145.52, 141.06, 136.92, 130.46, 128.67, 
128.29, 127.00, 126.82, 126.58, 126.28, 124.49, 120.45, 118.23, 115.03, 109.28, 82.17, 73.04, 
48.87, 28.49, 22.77, 13.76, 11.13. 
(R,Z)-3-((4-(allylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (136, RAR-11-100) 
To a dried sealed tube were added 53.6 mg (0.27 mmol) of (133), 50 mg (0.28 mmol) of (129) all 
of which were dissolved in abs. EtOH (3 mL). To this solution were added 2 drops (0.05 mL) of 
piperidine and heated to reflux (95 °C) for 4 h. Once complete, the reaction was cooled to room 
temperature and then an orange solid was filtered off. The solid was washed with cold EtOH to 
give the final product.  Result: orange solid, 79.5 mg, 63% Molecular Formula: C28H28N4O3 ESI-
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MS calc: 468.22 ESI-MS found: 469.2224    HPLC: 6.450 1H NMR (700 MHz, DMSO-d6) δ 
13.60 (s, 1H), 11.14 (s, 1H), 8.60 (d, J = 8.0 Hz, 1H), 8.25 (d, J = 1.6 Hz, 1H), 7.83 (t, J = 5.8 Hz, 
1H), 7.73 – 7.68 (m, 2H), 7.41 (d, J = 7.6 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 7.3 Hz, 
1H), 6.94 (d, J = 8.1 Hz, 1H), 5.90 (ddt, J = 15.7, 10.3, 5.2 Hz, 1H), 5.22 – 5.18 (m, 2H), 5.10 (dd, 
J = 10.3, 1.8 Hz, 1H), 3.87 (t, J = 5.6 Hz, 2H), 2.44 (d, J = 7.8 Hz, 6H), 1.51 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, dmso) δ 170.50, 145.29, 135.97, 130.84, 129.65, 128.44, 128.02, 126.34, 
115.20, 108.42, 103.80, 91.16, 59.93, 22.53, 13.55, 10.93. 
(R,Z)-3-((4-(but-3-yn-1-ylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (137, RAR-12-4) 
To a dried sealed tube were added 99.9 mg (0.357 mmol) of (133), 82 mg of RAR-12-2 (130) all 
of which were dissolved in abs. EtOH (3.5 mL). To this solution were added 2 drops (0.05 mL) of 
piperidine and heated to reflux (95 °C) for 4 h. Once complete, the solution was cooled to room 
temperature and then an orange solid was filtered off. The solid was washed with cold EtOH to 
give the final product. Yield: orange solid, 19 mg, 10% Molecular Formula: C29H28N4O3 ESI-MS 
calc: 480.22 ESI-MS found: 481.2226   HPLC: 6.444 1H NMR (700 MHz, DMSO-d6) δ 13.60 (s, 
1H), 11.15 (s, 1H), 8.62 (d, J = 8.0 Hz, 1H), 8.25 (s, 1H), 7.79 (t, J = 5.8 Hz, 1H), 7.71 (d, J = 6.3 
Hz, 2H), 7.41 (d, J = 7.6 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 7.23 (t, J = 7.3 Hz, 1H), 6.94 (d, J = 8.2 
Hz, 1H), 5.19 (p, J = 7.3 Hz, 1H), 2.86 (t, J = 2.5 Hz, 1H), 2.45 (d, J = 12.0 Hz, 6H), 2.42 (td, J = 
7.1, 2.4 Hz, 2H), 1.51 (d, J = 7.0 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.83, 165.81, 164.71, 
145.08, 140.56, 136.34, 130.00, 128.23, 127.80, 126.55, 126.12, 125.79, 125.18, 124.08, 120.61, 
117.76, 82.50, 72.12, 48.42, 37.95, 22.33, 13.33, 10.70. 
(R,Z)-3-((4-(but-3-en-1-ylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (138, RAR-12-5) 
To a dried sealed tube were added 94.8 mg (0.27 mmol) of (133), 87.2 mg (0.28 mmol) of RAR-
12-3 (131) all of which were dissolved in abs. EtOH (2.2 mL). To this solution were added 2 drops 
(0.07 mL) of piperidine and heated to reflux (95 °C) for 4 h. Once complete, solution was cooled 
to room temperature and then purified by column chromatography. Fractions were collected and 
solvent was removed under pressure to give the desired product, as an orange solid. Yield: orange 
solid, 103 mg, 59% Molecular Formula: C29H30N4O3 ESI-MS calc: 482.23 ESI-MS found: 
483.2382 [M+1]    HPLC: 6.720 1H NMR (700 MHz, DMSO-d6) δ 13.54 (s, 1H), 11.13 (s, 1H), 
8.61 (d, J = 8.2 Hz, 2H), 8.27 – 8.18 (m, 2H), 7.73 – 7.71 (m, 1H), 7.68 (s, 1H), 7.42 (d, J = 8.3 
Hz, 3H), 7.35 – 7.31 (m, 4H), 7.25 – 7.21 (m, 2H), 6.94 (d, J = 8.1 Hz, 1H), 5.21 (p, J = 7.3 Hz, 
2H), 2.43 (d, J = 9.0 Hz, 2H), 2.29 (d, J = 11.4 Hz, 7H), 1.63 – 1.59 (m, 3H), 1.51 (d, J = 7.1 Hz, 
6H). 13C NMR (176 MHz, dmso) δ 169.79, 165.81, 165.04, 145.07, 140.57, 133.90, 128.74, 
128.19, 127.78, 126.52, 126.11, 125.22, 123.96, 120.71, 117.70, 116.21, 114.09, 108.74, 48.41, 
35.77, 33.74, 22.26, 12.40, 10.15. 
(S)-2-oxo-N-(1-phenylethyl)indoline-5-carboxamide (139)  
To a round bottom flask were added 201.8 mg (1.13 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.160 mL (1.24 mmol) of 
(S)-1-phenylethan-1-amine, 0.200 mL (1.13 mmol) of DIPEA and 492.4 mg (1.30 mmol) of 
HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 mL 
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of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was 
washed with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography 
(0-15% DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 280 mg, 84% 
Molecular Formula: C17H16N2O2 ESI-MS calc: 280.12 ESI-MS found: 281.0903 [M+1]  HPLC: 
5.249 1H NMR (500 MHz, DMSO-d6) δ 10.67 (s, 1H), 8.66 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 7.2 
Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.20 (t, J = 7.3 Hz, 1H), 6.86 (d, J = 
8.2 Hz, 1H), 5.15 (p, J = 7.2 Hz, 1H), 3.53 (s, 2H), 1.46 (d, J = 7.1 Hz, 3H). 13C NMR (176 
MHz, dmso) δ 176.83, 165.50, 146.49, 145.22, 128.27, 127.77, 127.54, 126.60, 126.14, 125.64, 




To a dried sealed tube were added 91.2 mg (0.325 mmol) of (139), 79.9 mg (0.299 mmol) of (127) 
all of which were dissolved in abs. EtOH (2.5 mL). To this solution were added 2 drops of 
piperidine and heated to reflux (95 °C) for 4 h. Once complete, cooled to room temperature and 
then filtered off the product as an orange solid. Yield: orange solid, 38.3 mg, 22%  Molecular 
Formula: C31H37N5O3 ESI-MS calc: 527.29 ESI MS found: 528.2043    HPLC: 5.753  1H NMR 
(500 MHz, DMSO-d6) δ 13.59 (s, 1H), 11.16 (s, 1H), 8.67 (s, 1H), 8.32 (d, J = 5.5 Hz, 1H), 7.75 
– 7.68 (m, 2H), 7.48 (s, 1H), 7.42 (d, J = 7.7 Hz, 3H), 7.32 (t, J = 7.6 Hz, 3H), 7.22 (t, J = 7.3 Hz, 
1H), 6.94 (d, J = 8.1 Hz, 1H), 5.19 (p, J = 7.2 Hz, 1H), 2.45 (d, J = 3.4 Hz, 8H), 2.37 (s, 1H), 2.32 
(s, 1H), 2.08 (s, 1H), 1.51 (d, J = 7.1 Hz, 4H), 0.99 (t, J = 7.5 Hz, 8H). 13C NMR (126 MHz, dmso) 
δ 170.28, 147.82, 141.01, 130.32, 128.66, 127.23, 126.98, 126.61, 126.26, 125.66, 124.60, 118.30, 





carboxamide (141, RAR-12-6) 
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To a dried sealed tube were added 91.2 mg (0.892 mmol) of (133), 79.9 mg (1.39 mmol) of 3,5-
dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (2.5 
mL). To this solution were added 2 drops (0.05 mL) of piperidine and heated to reflux (95 °C) for 
4 h. Once complete, the reaction was cooled to room temperature and an orange solid was filtered 
off. The solid was washed with cold EtOH to give the desired product.  Result: orange solid, 269.3 
mg, 69%  Molecular Formula: C24H22N4O4 ESI-MS calc: 430.16 ESI-MS found: 
431.1715    HPLC: 7.400 1H NMR (700 MHz, DMSO-d6) δ 8.63 (d, J = 8.0 Hz, 1H), 8.36 (d, J = 
1.6 Hz, 1H), 7.83 (s, 1H), 7.76 (dd, J = 8.1, 1.7 Hz, 1H), 7.41 (d, J = 7.5 Hz, 2H), 7.33 (t, J = 7.6 
Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 6.97 (d, J = 8.1 Hz, 1H), 5.19 (p, J = 7.2 Hz, 1H), 2.08 (d, J = 
1.0 Hz, 1H), 1.50 (d, J = 7.1 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.90, 165.69, 144.98, 
142.47, 136.80, 132.12, 130.48, 129.11, 128.20, 127.74, 126.10, 125.56, 123.33, 121.76, 115.38, 
53.66, 22.28, 18.23, 10.50. 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-phenylethyl)indoline-5-
carboxamide (142, RAR-12-7) 
To a flask were added 90.7 mg of (141), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 226.8 mg (14 equiv) of Zn powder and 2 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid.24 *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: orange solid, 66.7 mg, 79.0% Molecular Formula: C24H24N4O2 
ESI-MS calc: 400.19 ESI-MS found: 401.1955   HPLC: 5.177 1H NMR (700 MHz, DMSO-d6) δ 
13.45 (s, 1H), 10.88 (s, 1H), 8.56 (d, J = 8.0 Hz, 1H), 8.12 (d, J = 1.6 Hz, 1H), 7.62 (dd, J = 8.1, 
1.6 Hz, 1H), 7.46 (s, 1H), 7.41 (d, J = 7.6 Hz, 3H), 7.33 (t, J = 7.6 Hz, 3H), 7.22 (t, J = 7.3 Hz, 
1H), 6.89 (d, J = 8.1 Hz, 1H), 5.20 (q, J = 7.4 Hz, 1H), 4.02 (d, J = 14.5 Hz, 2H), 2.26 (s, 3H), 2.17 
(s, 3H), 1.51 (d, J = 7.1 Hz, 3H). 
 
(R,Z)-3-((4-(but-2-ynamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (143, RAR-12-17) 
To a flask were added 22.3 mg (0.37 mmol) of butynoic acid, 157.5 mg (0.37 mmol) of HATU, 
cat. DMAP and 50 mg (0.19 mmol) of RAR-12-15 dissolved in 1 mL of DMF. To this bright red 
solution were added 0.25 mL (1.3 mmol) of DIPEA, and the solution was allowed to stir at rt for 
2 h. Once complete, the reaction mixture was diluted with EtOAc and washed with sat. LiCl and 
then dried over MgSO4. The crude material was purified by prepatory TLC with 50% 
Acetone/Hexanes. The desired band was collected, and the material was rinsed off the silica gel 
with acetone and then solvent was removed under pressure to give the desired product. Result: 
yellow solid, 17.5 mg, 20% Molecular Formula: C28H26N4O3 ESI-MS calc: 466.20 ESI-MS found 
467.2071    HPLC: 6.336 1H NMR (700 MHz, DMSO-d6) δ 13.53 (s, 1H), 11.07 (s, 1H), 9.78 (s, 
1H), 8.86 (d, J = 4.5 Hz, 2H), 8.68 (d, J = 8.8 Hz, 2H), 8.60 (d, J = 7.7 Hz, 2H), 8.21 (s, 1H), 7.69 
(d, J = 8.9 Hz, 2H), 7.65 – 7.62 (m, 3H), 7.41 (d, J = 7.9 Hz, 5H), 7.33 (t, J = 7.3 Hz, 7H), 7.23 
(d, J = 7.0 Hz, 3H), 6.93 (d, J = 8.1 Hz, 1H), 6.59 (s, 3H), 5.21 – 5.17 (m, 1H), 2.19 (s, 4H), 2.17 
(s, 4H), 2.03 (s, 3H), 1.52 (s, 2H). 13C NMR (176 MHz, dmso) δ 170.28, 167.22, 165.79, 149.50, 
148.74, 145.19, 139.73, 135.08, 130.24, 128.98, 128.19, 127.41, 126.55, 125.97, 125.02, 122.58, 





phenylethyl)indoline-5-carboxamide (144, RAR-12-32) 
To a round bottom flask that contained RAR-12-31 (50 mg, 0.12 mmol) were added 0.01 mL (0.12 
mmol) of acrylic acid, 58.8 mg (0.12 mmol) of HATU, cat. DMAP and 0.50 mL (0.87 mmol) of 
TEA. All materials were dissolved in 2 mL of DMF and sonicated to give a homogenous solution. 
The solution was allowed to stir at 56 °C for two hours. Once complete, quenched with sat. LiCl 
and then extracted with EtOAc (3 x 30 mL). The combined organic layers were then dried over 
MgSO4 and the material was purified by preparatory TLC (50% Acetone/Hexanes) collecting the 
baseline product, which was washed off the silica gel with acetone. The solvent was removed to 
give the final product as an orange solid, 13.9 mg, 24%. Molecular Formula: C27H26N4O3 ESI-MS 
calc: 454.20 ESI-MS found: 455.1632 [M+1]   HPLC: 6.147 1H NMR (700 MHz, DMSO-d6) δ 
13.53 (s, 1H), 11.07 (s, 1H), 9.41 (s, 1H), 8.60 (d, J = 8.1 Hz, 2H), 8.21 (d, J = 9.5 Hz, 1H), 7.69 
(d, J = 8.3 Hz, 2H), 7.66 (s, 1H), 7.41 (d, J = 7.8 Hz, 5H), 7.33 (t, J = 7.5 Hz, 5H), 7.22 (t, J = 7.4 
Hz, 3H), 6.93 (dd, J = 8.1, 3.6 Hz, 1H), 6.45 (dd, J = 17.1, 10.3 Hz, 1H), 6.23 – 6.19 (m, 1H), 5.72 
(dd, J = 10.7, 1.9 Hz, 1H), 5.19 (t, J = 7.3 Hz, 2H), 2.21 (s, 3H), 2.20 (s, 3H), 1.50 (d, J = 7.1 Hz, 
3H).   13C NMR (176 MHz, dmso) δ 180.81, 169.69, 169.00, 167.87, 165.86, 153.99, 145.07, 
141.22, 140.27, 136.23, 131.78, 129.29, 128.18, 127.56, 126.86, 126.49, 126.09, 124.16, 120.41, 
109.40, 108.64, 53.84, 22.28. 
 
(R,Z)-3-((3,5-dimethyl-4-(vinylsulfonamido)-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (145, RAR-12-34)  
Step 1: To a dried flask were added 0.03 mL (0.12 mmol) of vinyl sulfonic acid, 2 drops of DMF 
and 2 mL of DCM. The solution was cooled to 0 °C and then 0.02 mL (0.14 mmol) of oxalyl 
chloride were added in one portion. The solution was warmed to rt and allowed to stir until 
complete (1 hour). Once complete, then solvent was removed, and the resultant clear oil was rinsed 
with DCM (3 x 15 mL) and dried under high pressure until ready for second step 
Step 2: To the flask holding the acid chloride were added RAR-12-33 (50 mg, 0.12 mmol) 
dissolved in 3 mL of THF. To this murky orange solution were added 0.50 mL (7 equiv) of TEA, 
and the solution was allowed to stir at rt for 5 hours. Once complete, removed solvent under 
pressure and brought yellow residue back up in EtOAc. The organic layer was washed with sat. 
Na2CO3 and then brine (1 x 30 mL) respectively. Purified by prepatory TLC plate (40% 
Acetone/Hexanes), collecting secondary spot (Rf = 0.2-0.3). The material was rinsed off silica 
with acetone and the solvent was removed to give a dark orange solid as the desired product. 
Result: orange solid,16 mg, 27%  Molecular Formula: C26H26N4O4S ESI-MS calc: 490.17 ESI-MS 
found: 491.1249   HPLC: 6.43 1H NMR (400 MHz, DMSO-d6) δ 13.50 (s, 1H), 11.38 (s, 1H), 
11.09 (s, 1H), 8.98 (s, 1H), 8.64 – 8.57 (m, 2H), 8.36 (s, 1H), 8.20 (s, 1H), 7.84 (s, 1H), 7.77 (d, J 
= 8.3 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.63 (s, 1H), 7.41 (d, J = 7.8 Hz, 5H), 7.33 (t, J = 7.6 Hz, 
5H), 7.21 (d, J = 7.3 Hz, 2H), 6.98 (s, 1H), 6.93 (d, J = 8.1 Hz, 1H), 6.84 (dd, J = 16.5, 9.8 Hz, 
1H), 5.93 (d, J = 8.0 Hz, 1H), 5.19 (t, J = 7.4 Hz, 2H), 2.29 (s, 4H), 2.26 (s, 3H), 1.50 (d, J = 7.1 
Hz, 6H). 13C NMR (176 MHz, dmso) δ 169.90, 165.56, 145.07, 141.33, 136.84, 133.74, 128.32, 
128.19, 127.65, 126.53, 126.15, 125.20, 124.79, 124.46, 123.83, 119.49, 119.12, 109.21, 48.52, 





phenylethyl)indoline-5-carboxamide (146, RAR-12-52) 
To a dried round bottom flask were added RAR-12-51(60 mg, 0.15 mmol) dissolved in 3 mL of 
THF. The yellow solution was cooled to 0 °C and 0.01 mL (0.18 mmol) of chloroacetylchloride 
was added dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, 
quenched with water and extracted with EtOAc. The solvent was removed, and the crude material 
was purified by prep plate (50% Acetone/Hexanes) collecting the major product. The desired 
product was rinsed off of silica gel and then the solvent was removed to give a bright yellow solid. 
The yellow solid was washed with DCM and sonicated to give a red solid. The red solid was then 
pulped in water:acetone (30:1) to give the final product. Result: red solid, 25.1 mg, 35% Molecular 
Formula: C26H25ClN4O3 ESI-MS calc: 476.16 ESI-MS found: 477.0999  HPLC: 6.388 
1H NMR 
(700 MHz, DMSO-d6) δ 11.08 (s, 1H), 9.53 (s, 1H), 8.60 (d, J = 8.0 Hz, 1H), 8.22 (s, 1H), 7.69 
(d, J = 8.2 Hz, 1H), 7.65 (s, 1H), 7.41 (d, J = 7.8 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.4 
Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 5.19 (t, J = 7.5 Hz, -1H), 2.20 (d, J = 12.1 Hz, 7H), 2.08 (s, 3H), 
1.50 (d, J = 7.1 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.67, 168.51, 156.78, 145.12, 140.30, 
131.64, 129.98, 128.13, 127.50, 126.89, 126.44, 126.11, 124.45, 122.62, 121.01, 117.42, 116.93, 




N-((R)-1-phenylethyl)indoline-5-carboxamide (147, RAR-12-54) 
To a round bottom flask were added RAR-12-53 (50 mg, 0.12 mmol), 20.2 mg (0.12 mmol) of 
N,N-dimethylaminobutenoic acid and 36 mg (0.12 mmol) of DMTMM and 0.20 mL (0.24 mmol) 
of TEA. All materials were brought up in 2 mL of DMF, and the resulting solution was allowed to 
stir at rt for 12 h. Once complete, the reaction was quenched with Sat. NaCl, and extracting with 
EtOAc (3 x 50 mL). The organic layer was washed with sat. Na2CO3 and brine (1 x 50 mL) 
respectively and then dried over MgSO4. The solvent was removed under pressure, evaporating 
the material onto silica gel. Purified by column chromatography 5-100% Acetone/Hexanes. 
Flushed the column with 7N NH3 in MeOH to yield the final product as a bright yellow oil. 
Result: yellow oil, 13 mg, 20% Molecular Formula: C30H33N5O3 ESI-MS calc: 511.26 ESI-MS 
found: 512.2110 [M+1], 534.1905 [M+Na] HPLC: 5.424  1H NMR (700 MHz, DMSO-d6) δ 13.56 
(s, 1H), 11.06 (s, 2H), 9.29 (s, 2H), 8.59 (d, J = 7.9 Hz, 2H), 8.21 (d, J = 1.5 Hz, 2H), 7.68 (d, J = 
8.1 Hz, 2H), 7.65 (s, 2H), 7.41 (d, J = 7.6 Hz, 4H), 7.33 (t, J = 7.6 Hz, 4H), 7.22 (t, J = 7.5 Hz, 
2H), 6.93 (d, J = 8.1 Hz, 2H), 6.71 – 6.64 (m, 1H), 6.27 (d, J = 15.5 Hz, 1H), 5.21 – 5.17 (m, 1H), 
3.05 (d, J = 5.6 Hz, 2H), 2.21 (s, 6H), 2.19 (s, 3H), 2.18 (s, 3H), 1.50 (d, J = 7.1 Hz, 3H). 13C 
NMR (176 MHz, dmso) δ 170.09, 166.24, 163.98, 145.47, 141.00, 140.66, 132.25, 128.68, 128.55, 
127.91, 127.30, 126.87, 126.48, 126.08, 125.81, 125.74, 125.61, 124.86, 124.52, 122.19, 117.61, 
112.99, 109.03, 62.41, 48.96, 25.82, 22.64, 14.44, 12.32, 9.77. 
(R)-2-oxo-N-(1-(m-tolyl)ethyl)indoline-5-carboxamide (148 RAR-12-63) 
To a round bottom flask were added 236.1 mg (1.33 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.200 mL (1.47 mmol) of 
(R)-1-(m-tolyl)ethan-1-amine, 0.300 mL (1.73 mmol) of DIPEA and 510.2 mg (1.33 mmol) of 
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HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 mL 
of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed 
with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography (0-15% 
DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 125.6 mg, 31%  
Molecular Formula: C18H18N2O2 ESI-MS calc: 294.14 ESI-MS found: 295.0167 [M+1]  HPLC: 
5.395 1H NMR (700 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.58 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 
Hz, 2H), 7.18 (p, J = 7.6 Hz, 4H), 7.02 (d, J = 7.3 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 5.11 (p, J = 
7.3 Hz, 1H), 2.28 (s, 3H), 1.44 (d, J = 7.0 Hz, 3H). 13C NMR (176 MHz, dmso) δ 176.62, 165.16, 
146.32, 145.07, 137.11, 128.06, 127.65, 127.48, 127.10, 126.66, 125.53, 123.51, 123.09, 108.36, 
48.29, 39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 38.22, 35.57, 22.34, 21.11. 
 
(R)-N-(1-(4-fluorophenyl)ethyl)-2-oxoindoline-5-carboxamide (149 RAR-12-74) 
To a round bottom flask were added 246.6 mg (1.41 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.200 mL (1.55 mmol) of 
(R)-1-(4-fluorophenyl)ethan-1-amine, 0.25 mL (1.41 mmol) of DIPEA and 667.1 mg (1.61 mmol) 
of HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 
mL of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was 
washed with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography 
(0-15% DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 315 mg, 71%  
Molecular Formula: C17H15FN2O2 ESI-MS calc: 298.11 ESI-MS found: 299.1216 [M+1]  HPLC: 
5.414 1H NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.62 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 7.5 
Hz, 2H), 7.43 – 7.38 (m, 2H), 7.16 – 7.08 (m, 2H), 6.87 – 6.82 (m, 1H), 5.14 (p, J = 7.2 Hz, 1H), 
3.53 (s, 2H), 1.45 (d, J = 7.1 Hz, 3H). 13C NMR (176 MHz, dmso) δ 176.84, 165.47, 160.34, 
146.46, 141.34, 128.06, 128.01, 127.77, 127.49, 125.69, 123.63, 114.99, 114.87, 108.55, 47.90, 
39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 38.33, 35.67, 22.35. 
 
(R)-2-oxo-N-(1-(pyridin-4-yl)ethyl)indoline-5-carboxamide (150 RAR-12-75) 
To a round bottom flask were added 248.1 mg (1.41 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.200 mL (1.55 mmol) of 
(R)-1-(pyridin-4-yl)ethan-1-amine, 0.25 mL (1.41 mmol) of DIPEA and 652.4 mg (1.61 mmol) of 
HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 mL 
of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed 
with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography (0-15% 
DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 200 mg, 48%  
Molecular Formula: C16H15N3O2 ESI-MS calc: 281.12 ESI-MS found: 282.1236 [M+1]  HPLC: 
2.378 1H NMR (700 MHz, DMSO-d6) δ 10.64 (s, 1H), 8.74 (dd, J = 7.6, 2.1 Hz, 1H), 8.55 – 8.52 
(m, 2H), 7.79 (dd, J = 7.5, 2.2 Hz, 2H), 7.45 – 7.42 (m, 2H), 7.08 (d, J = 2.3 Hz, 1H), 7.01 (s, 1H), 
6.89 – 6.85 (m, 1H), 5.14 (td, J = 7.3, 2.2 Hz, 1H), 3.55 (s, 2H), 3.46 – 3.41 (m, 3H), 1.47 (dd, J = 
7.2, 2.3 Hz, 3H), 1.07 – 1.03 (m, 3H). 13C NMR (176 MHz, dmso) δ 176.63, 165.65, 155.16, 
148.63, 146.56, 127.76, 127.03, 125.62, 123.57, 121.58, 108.43, 56.00, 47.92, 39.86, 39.74, 39.62, 
39.50, 39.38, 39.26, 39.14, 35.56, 21.45, 18.54. 
 
(R)-2-oxo-N-(1-(pyridin-2-yl)ethyl)indoline-5-carboxamide (151 RAR-12-78) 
To a round bottom flask were added 251.1 mg (1.41 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.200 mL (1.55 mmol) of 
(R)-1-(pyridin-2-yl)ethan-1-amine, 0.25 mL (1.41 mmol) of DIPEA and 625.1 mg (1.62 mmol) of 
146 
 
HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 mL 
of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed 
with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography (0-15% 
DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 165 mg, 39% 
Molecular Formula: C16H15N3O2 ESI-MS calc: 281.12 ESI-MS found: 282.1236 [M+1]  HPLC: 
2.111 1H NMR (700 MHz, DMSO-d6) δ 10.62 (d, J = 5.2 Hz, 1H), 8.63 (t, J = 6.6 Hz, 1H), 8.51 
(t, J = 5.3 Hz, 1H), 7.80 (d, J = 5.6 Hz, 2H), 7.74 (q, J = 7.0 Hz, 1H), 7.38 (t, J = 6.8 Hz, 1H), 7.24 
(q, J = 6.0 Hz, 1H), 6.86 (t, J = 6.7 Hz, 1H), 5.17 (p, J = 7.2 Hz, 1H), 3.54 (d, J = 5.2 Hz, 3H), 1.49 
(t, J = 6.4 Hz, 3H). 13C NMR (176 MHz, dmso) δ 177.27, 166.16, 163.50, 149.12, 137.26, 128.18, 
127.79, 126.11, 124.08, 122.46, 120.59, 108.98, 50.76, 40.22, 40.10, 39.98, 39.86, 39.74, 39.62, 
39.50, 36.07, 21.45. 
 
(R)-N-(1-(3-chlorophenyl)ethyl)-2-oxoindoline-5-carboxamide (152 RAR-12-86) 
To a round bottom flask were added 251.1 mg (1.41 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.200 mL (1.55 mmol) of 
(R)-1-(3-chlorophenyl)ethan-1-amine, 0.25 mL (1.41 mmol) of DIPEA and 717.7 mg (1.91 mmol) 
of HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 
mL of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was 
washed with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography 
(0-15% DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 423.3 mg, 91% 
Molecular Formula: C17H15ClN2O2 ESI-MS calc: 314.08 ESI-MS found: 315.0438 [M+1]  HPLC: 
5.730 1H NMR (700 MHz, DMSO-d6) δ 10.64 – 10.57 (m, 1H), 8.65 (dd, J = 7.5, 2.2 Hz, 1H), 
7.78 – 7.74 (m, 2H), 7.41 (t, J = 2.1 Hz, 1H), 7.33 (dt, J = 6.7, 1.8 Hz, 2H), 7.26 (dp, J = 6.4, 2.2 
Hz, 1H), 6.85 (dd, J = 8.1, 2.5 Hz, 1H), 5.15 – 5.06 (m, 1H), 3.53 (s, 2H), 1.45 – 1.42 (m, 3H). 
13C NMR (176 MHz, dmso) δ 176.91, 165.61, 148.09, 146.73, 133.15, 130.39, 127.97, 126.74, 
126.14, 125.88, 125.13, 123.78, 108.70, 56.27, 48.40, 40.12, 40.00, 39.88, 39.76, 39.64, 39.52, 
39.40, 35.83, 22.43, 18.80. 
 
(R)-2-oxo-N-(1-(p-tolyl)ethyl)indoline-5-carboxamide (153 RAR-12-90) 
To a round bottom flask were added 244.2 mg (1.41 mmol) of 2-oxoindoline-5-carboxylic acid, 
dissolved in 7 mL of dry DMF. To this dark red solution were added 0.220 mL (1.55 mmol) of 
(R)-1-(3-chlorophenyl)ethan-1-amine, 0.25 mL (1.41 mmol) of DIPEA and 622.1 mg (1.62 mmol) 
of HATU. The resultant dark red solution was allowed to stir at rt for 12 h, and then added 200 
mL of sat. Na2CO3 and extracted with EtOAc (3 x 100 mL). The combined organic layer was 
washed with brine (2 x 50 mL) and then dried over MgSO4. Purified by column chromatography 
(0-15% DCM/MeOH) to give the desired product as a strawberry pink solid. Yield: 300.8 mg, 69%  
Molecular Formula: C18H18N2O2 ESI-MS calc: 294.14 ESI-MS found: 317 [M+Na]  HPLC: 5.556 
1H NMR (700 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.57 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 
2H), 7.26 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 7.8 Hz, 2H), 6.85 (d, J = 8.0 Hz, 1H), 5.12 (p, J = 7.3 
Hz, 1H), 3.53 (s, 2H), 2.26 (s, 3H), 1.44 (d, J = 7.0 Hz, 3H). 13C NMR (176 MHz, dmso) δ 176.63, 
165.17, 146.30, 142.10, 135.44, 128.66, 127.64, 127.54, 125.93, 125.51, 123.51, 108.36, 48.03, 
39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 35.57, 22.29, 20.59. 
 
N-benzyl-2-oxoindoline-5-carboxamide (154, RAR-12-100) 
Prepared with protocol described in making 133. Yields a strawberry pink solid, 174.5 mg, 56% 
Molecular Formula: C16H14N2O2 ESI-MS calc: 266.11 ESI-MS found: 267.2180 [M+1]  HPLC: 
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4.822 1H NMR (700 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.87 (t, J = 6.1 Hz, 1H), 7.79 – 7.75 (m, 
2H), 7.34 – 7.28 (m, 5H), 7.23 (dt, J = 7.2, 4.3 Hz, 2H), 6.86 (d, J = 8.0 Hz, 1H), 4.46 (d, J = 5.9 
Hz, 2H), 3.53 (s, 2H). 13C NMR (176 MHz, dmso) δ 176.60, 165.95, 146.42, 139.88, 128.65, 
128.19, 128.12, 127.70, 127.59, 127.47, 127.29, 127.11, 126.61, 125.66, 123.45, 108.44, 47.80, 
45.00, 42.52, 39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 38.22, 35.57. 
(R)-N-(2-methyl-1-phenylpropyl)-2-oxoindoline-5-carboxamide (155, RAR-13-4) 
Synthesized using protocol described in 133. Yields a strawberry pink solid, 389.9 mg, quantitative 
yield. Molecular Formula: C19H20N2O2 ESI-MS calc: 308.15 ESI-MS found: 309.2172  HPLC: 
5.793 1H NMR (700 MHz, DMSO-d6) δ 10.44 (s, 1H), 8.37 (d, J = 8.9 Hz, 1H), 7.58 (dd, J = 10.7, 
2.9 Hz, 2H), 7.22 (d, J = 7.6 Hz, 2H), 7.12 (t, J = 7.5 Hz, 2H), 7.03 (t, J = 7.3 Hz, 1H), 6.68 (d, J 
= 8.0 Hz, 1H), 4.48 (t, J = 9.2 Hz, 1H), 3.36 (s, 2H), 1.06 (d, J = 6.4 Hz, 2H), 0.83 (d, J = 6.5 Hz, 
3H), 0.53 (d, J = 6.7 Hz, 3H). 13C NMR (176 MHz, dmso) δ 176.69, 165.65, 164.62, 162.32, 
146.32, 143.33, 128.02, 127.75, 127.70, 127.41, 126.61, 125.54, 123.53, 108.43, 59.92, 56.08, 
41.67, 39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 38.23, 35.78, 35.62, 32.55, 30.77, 20.09, 
19.90, 18.56. 
2-oxo-N-(3-phenyloxetan-3-yl)indoline-5-carboxamide (156, RAR-13-8) 
Synthesized using protocol described in 133. Yield a strawberry pink solid, 62.1 mg, 
31% Molecular Formula: C18H16N2O3 ESI-MS calc: 308.12 ESI-MS found: 309.1235  HPLC: 
4.601 1H NMR (700 MHz, DMSO-d6) δ 10.49 (d, J = 4.6 Hz, 1H), 9.16 (d, J = 4.6 Hz, 1H), 7.65 
– 7.60 (m, 2H), 7.38 – 7.34 (m, 2H), 7.22 – 7.18 (m, 2H), 7.10 (tdd, J = 7.3, 4.9, 2.2 Hz, 1H), 6.74 
– 6.70 (m, 1H), 4.82 (dd, J = 6.7, 4.8 Hz, 2H), 4.59 (dd, J = 6.7, 4.8 Hz, 2H), 3.38 (d, J = 4.7 Hz, 
2H). 13C NMR (176 MHz, dmso) δ 176.66, 165.18, 146.78, 143.10, 129.97, 128.28, 128.17, 
127.72, 126.91, 126.72, 126.06, 125.80, 125.41, 124.81, 123.53, 120.11, 108.72, 108.56, 81.89, 
58.27, 53.49, 39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 38.23, 35.58, 35.52, 30.66, 14.07. 
 
2-oxo-N-(2-phenylpropan-2-yl)indoline-5-carboxamide (157, RAR-13-12) 
Synthesized using protocol described in 133. Yields a strawberry pink solid, 210.8 mg, 48%. 
Molecular Formula: C18H18N2O2 ESI-MS calc: 294.14 ESI-MS found: 295.1456 [M+1], 317.1275 
[M+Na]   HPLC: 5.199 1H NMR (700 MHz, DMSO-d6) δ 10.60 (s, 1H), 8.23 (s, 1H), 7.74 (s, 
1H), 7.74 – 7.71 (m, 1H), 7.35 (d, J = 7.8 Hz, 2H), 7.26 (t, J = 7.7 Hz, 2H), 7.15 (t, J = 7.2 Hz, 
1H), 6.84 (d, J = 8.1 Hz, 1H), 3.53 (s, 2H), 1.65 (s, 6H). 13C NMR (176 MHz, dmso) δ 176.64, 
165.50, 148.19, 146.15, 128.51, 128.35, 127.82, 127.67, 125.59, 125.37, 124.81, 124.61, 123.65, 
108.26, 55.22, 39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 39.14, 35.59, 29.66. 
(R)-N-(1-(4-chlorophenyl)ethyl)-2-oxoindoline-5-carboxamide (158, RAR-13-16) 
Synthesized using protocol described in 133. Yields a strawberry pink solid, 471.0 mg, quantitative 
yield.  Molecular Formula: C17H15ClN2O2 ESI-MS calc: 314.08 ESI-MS found: 337.0717 
[M+Na]   HPLC: 5.682 1H NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.64 (d, J = 7.9 Hz, 1H), 
7.76 (d, J = 7.9 Hz, 2H), 7.42 – 7.34 (m, 4H), 6.85 (d, J = 8.1 Hz, 1H), 5.13 (p, J = 7.2 Hz, 1H), 
3.53 (s, 2H), 1.45 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, dmso) δ 176.61, 165.29, 146.40, 
144.17, 130.98, 128.09, 127.92, 127.67, 127.28, 125.55, 123.49, 108.37, 47.87, 40.00, 39.83, 




carboxamide (159 RAR-12-65) 
To a dried sealed tube were added 200 mg (0.679 mmol) of (148), 139.6 mg (0.815 mmol) of 3,5-
dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (6.0 
mL). To this solution were added 0.05 ml of piperidine and heated to reflux (95 °C) for 4 h. Once 
complete, cooled to room temperature and then filtered off the product as a lemon yellow solid. 
Yield: lemon yellow solid, 100 mg, 29.8 % Molecular Formula: C25H24N4O4 ESI-MS calc: 444.18 
ESI-MS found: 445.1862 [M+1]    HPLC: 7.732 1H NMR (700 MHz, DMSO-d6) δ 11.34 (s, 1H), 
8.58 (d, J = 8.0 Hz, 1H), 8.33 (d, J = 1.6 Hz, 1H), 7.78 (s, 1H), 7.76 (dd, J = 8.2, 1.6 Hz, 1H), 7.23 
– 7.18 (m, 3H), 7.03 (d, J = 6.1 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 5.16 (p, J = 7.2 Hz, 1H), 2.62 (s, 
3H), 2.57 (s, 3H), 2.30 (s, 3H), 1.49 (d, J = 7.0 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.83, 
165.49, 144.90, 141.26, 137.14, 136.75, 133.66, 128.34, 128.09, 127.51, 127.15, 126.74, 125.07, 
124.71, 124.39, 123.59, 123.17, 119.39, 118.96, 109.09, 48.36, 39.86, 39.74, 39.62, 39.50, 39.38, 
39.26, 39.14, 22.26, 21.11, 14.76, 11.21. 
(R,Z)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-N-(1-(4-fluorophenyl)ethyl)-2-
oxoindoline-5-carboxamide (160, RAR-12-76) 
To a dried sealed tube were added 128 mg (0.429 mmol) of (149), 101.3 mg (0.60 mmol) of 3,5-
dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (3.0 
mL). To this solution were added 0.05 ml of piperidine and heated to reflux (95 °C) for 4 h. Once 
complete, cooled to room temperature and then filtered off the product as an orange solid. Yield: 
orange solid, 96.3 mg, 50 % Molecular Formula: C24H21FN4O4 ESI-MS calc: 448.15 ESI-MS 
found: 449.1619 [M+1]   HPLC: 7.422  1H NMR (700 MHz, DMSO-d6) δ 11.37 (s, 1H), 8.64 (d, 
J = 7.8 Hz, 1H), 8.35 (d, J = 1.7 Hz, 1H), 7.83 (s, 1H), 7.76 (dd, J = 8.1, 1.7 Hz, 1H), 7.47 – 7.44 
(m, 2H), 7.18 – 7.14 (m, 2H), 6.97 (d, J = 8.1 Hz, 1H), 5.19 (p, J = 7.2 Hz, 1H), 2.65 (s, 3H), 2.60 
(s, 3H), 1.51 (d, J = 7.0 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.85, 165.62, 136.79, 133.69, 
128.31, 128.02, 127.97, 124.71, 123.71, 119.03, 114.88, 114.76, 50.22, 47.86, 39.86, 39.74, 39.62, 
39.50, 39.38, 39.26, 39.14, 22.26, 14.78, 11.22. 
(R,Z)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(pyridin-4-
yl)ethyl)indoline-5-carboxamide (161, RAR-12-77) 
To a dried sealed tube were added 100 mg (0.455 mmol) of (150), 77.1 mg (0.459 mmol) of 3,5-
dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (3.0 
mL). To this solution were added 0.05 ml of piperidine and heated to reflux (95 °C) for 4 h. Once 
complete, cooled to room temperature and then filtered off the product as a yellow solid. Yield: 
yellow solid, 48.0 mg, 31.3 % Molecular Formula: C23H21N5O4 ESI-MS calc: 431.16 ESI-MS 
found: 432.1656 [M+1]   HPLC: 5.496   1H NMR (700 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.73 (d, 
J = 7.6 Hz, 1H), 8.52 – 8.50 (m, 2H), 8.36 (d, J = 1.6 Hz, 1H), 7.82 (s, 1H), 7.77 (dd, J = 8.1, 1.6 
Hz, 1H), 7.40 (d, J = 5.2 Hz, 2H), 6.97 (d, J = 8.0 Hz, 1H), 5.15 (p, J = 7.3 Hz, 1H), 2.64 (s, 3H), 
2.59 (s, 3H), 1.51 (d, J = 7.1 Hz, 3H). 13C NMR (176 MHz, dmso) δ 170.11, 166.24, 153.97, 
149.80, 137.07, 135.63, 128.31, 127.80, 125.45, 124.98, 124.02, 121.55, 119.37, 109.42, 48.18, 




yl)ethyl)indoline-5-carboxamide (162, RAR-12-83) 
To a dried sealed tube were added 165 mg (0.587 mmol) of (151), 122.8 mg (0.762 mmol) of 3,5-
dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (3.0 
mL). To this solution were added 0.05 ml of piperidine and heated to reflux (95 °C) for 4 h. Once 
complete, cooled to room temperature and then filtered off the product as a yellow solid. Yield: 
yellow solid, 116 mg, 34 % Molecular Formula: C23H21N5O4 ESI-MS calc: 431.16 ESI-MS found: 
432.0558 [M+1]   HPLC: 5.49 1H NMR (700 MHz, DMSO-d6) δ 11.36 (d, J = 7.2 Hz, 1H), 8.65 
– 8.58 (m, 1H), 8.55 – 8.47 (m, 1H), 8.39 (t, J = 7.7 Hz, 1H), 7.78 (ddd, J = 33.0, 15.8, 7.2 Hz, 
3H), 7.42 (q, J = 10.5, 9.0 Hz, 1H), 7.25 (dd, J = 12.7, 6.8 Hz, 1H), 6.95 (d, J = 7.0 Hz, 1H), 5.22 
(q, J = 8.8, 8.0 Hz, 1H), 2.66 – 2.60 (m, 3H), 2.59 (s, 3H), 1.56 – 1.49 (m, 3H). 13C NMR (176 
MHz, dmso) δ 169.21, 165.90, 148.79, 136.83, 128.23, 124.86, 123.81, 120.44, 119.09, 109.32, 
58.91, 50.44, 40.00, 39.88, 39.76, 39.74, 39.64, 39.62, 39.52, 39.40, 39.28, 21.09, 11.38. 
(R,Z)-N-(1-(3-chlorophenyl)ethyl)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-2-
oxoindoline-5-carboxamide (163, RAR-12-87) 
To a dried sealed tube were added 242.2 mg (0.769 mmol) of (152), 150.1 mg (0.892 mmol) of 
3,5-dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (6.0 
mL). To this solution were added 0.05 ml of piperidine and heated to reflux (95 °C) for 4 h. Once 
complete, cooled to room temperature and then filtered off the product as an orange solid. Yield: 
orange solid, 46 mg, 16% Molecular Formula: C24H21ClN4O4 ESI-MS calc: 464.13 ESI-MS found: 
465.1318   HPLC: 7.699  1H NMR (700 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.68 (d, J = 7.8 Hz, 
1H), 8.36 (d, J = 1.6 Hz, 1H), 7.84 (s, 1H), 7.76 (dd, J = 8.2, 1.7 Hz, 1H), 7.46 (d, J = 2.1 Hz, 1H), 
7.37 (d, J = 6.6 Hz, 2H), 7.29 (dt, J = 6.7, 2.3 Hz, 1H), 6.97 (d, J = 8.1 Hz, 1H), 5.17 (p, J = 7.2 
Hz, 1H), 2.65 (s, 3H), 2.60 (s, 3H), 1.50 (d, J = 7.1 Hz, 3H). 13C NMR (176 MHz, dmso) δ 165.88, 
147.85, 144.31, 138.20, 130.27, 126.64, 126.10, 125.34, 125.04, 123.98, 119.28, 109.31, 102.54, 
48.41, 40.00, 39.88, 39.76, 39.64, 39.52, 39.40, 39.28, 22.27, 14.93. 
(R,Z)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(p-tolyl)ethyl)indoline-5-
carboxamide (164, RAR-12-91) 
To a dried sealed tube were added 253.9 mg (0.862 mmol) of (153), 140.9 mg (0.837 mmol) of 
3,5-dimethyl-4-nitro-1H-pyrrole-2-carbaldehyde, all of which were dissolved in abs. EtOH (3.0 
mL). To this solution were added 0.05 ml of piperidine and heated to reflux (95 °C) for 4 h. Once 
complete, cooled to room temperature and then filtered off the product as an orange solid. Yield: 
orange solid, 76.1 mg,  25% Molecular Formula: C25H24N4O4 ESI-MS calc: 444.18 ESI-MS found: 
445.1864 [M+1]   HPLC: 7.662  1H NMR (700 MHz, DMSO-d6) δ 9.73 (s, 1H), 8.57 (d, J = 8.2 
Hz, 2H), 8.35 (d, J = 1.7 Hz, 1H), 7.83 (s, 1H), 7.76 (dd, J = 8.1, 1.7 Hz, 2H), 7.30 (d, J = 7.8 Hz, 
3H), 7.14 (d, J = 7.9 Hz, 3H), 6.96 (d, J = 8.0 Hz, 2H), 5.17 (p, J = 7.2 Hz, 1H), 2.55 (d, J = 8.7 
Hz, 6H), 2.28 (s, 5H). 13C NMR (176 MHz, dmso) δ 170.11, 165.77, 155.70, 142.17, 141.51, 
137.04, 135.76, 135.76, 128.94, 126.27, 125.36, 119.23, 109.39, 52.91, 40.12, 40.00, 39.88, 39.76, 





Yield: orange solid, 150 mg, 55% Molecular Formula: C23H20N4O4 ESI-MS calc: 416.15 ESI-MS 
found: 417.2934, HPLC: 7.158, 1H NMR (700 MHz, DMSO-d6) δ 11.44 – 11.06 (m, 1H), 8.84 
(t, J = 6.1 Hz, 1H), 8.34 (s, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.69 (s, 1H), 7.34 (d, J = 5.6 Hz, 4H), 
7.25 (d, J = 6.6 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H), 4.52 (d, J = 5.7 Hz, 2H). 13C NMR (176 MHz, 
dmso) δ 169.75, 166.10, 141.33, 139.82, 136.69, 133.57, 128.23, 127.89, 127.37, 127.18, 126.67, 
124.95, 124.69, 124.44, 123.25, 119.29, 118.57, 109.16, 42.62, 39.86, 39.74, 39.62, 39.50, 39.38, 
39.26, 39.14, 14.73, 11.11. 
(R,Z)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-N-(2-methyl-1-phenylpropyl)-2-
oxoindoline-5-carboxamide (166, RAR-13-5) 
Synthesized using protocol described in 164. Yields an orange solid, 144.6 mg, 64.8% Molecular 
Formula: C26H26N4O4 ESI-MS calc: 458.20 ESI-MS found: 459.2109 HPLC: 7.896 1H NMR (700 
MHz, DMSO-d6) δ 11.32 (s, 1H), 8.56 (p, J = 9.3, 8.3 Hz, 1H), 8.29 (dq, J = 13.4, 7.5 Hz, 1H), 
7.88 – 7.63 (m, 2H), 7.48 – 7.28 (m, 4H), 7.22 (qd, J = 14.5, 9.4, 7.5 Hz, 1H), 6.94 (tt, J = 14.2, 
7.5 Hz, 1H), 4.79 – 4.64 (m, 1H), 2.64 – 2.58 (m, 3H), 2.58 (s, 3H), 1.05 (tt, J = 13.4, 8.0 Hz, 3H), 
0.75 (dp, J = 25.8, 6.7 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.69, 165.86, 143.12, 141.05, 
127.89, 127.29, 127.17, 126.47, 125.00, 124.61, 124.32, 123.62, 119.24, 119.05, 108.85, 59.80, 
39.74, 39.62, 39.50, 39.38, 39.26, 39.15, 39.03, 32.40, 19.97, 19.82, 14.64, 11.05. 
(Z)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-2-oxo-N-(3-phenyloxetan-3-yl)indoline-
5-carboxamide (167, RAR-13-9) 
Synthesized using protocol described in 164. Yields an orange solid, 47 mg, 42%. Molecular 
Formula: C25H22N4O5 ESI-MS calc: 458.16 ESI-MS found: 459.1656 HPLC: 6.923, 1H NMR (700 
MHz, DMSO-d6) δ 11.39 (s, 1H), 9.36 (s, 1H), 8.40 (d, J = 2.0 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 
7.81 – 7.77 (m, 1H), 7.59 – 7.55 (m, 2H), 7.40 (t, J = 7.8 Hz, 2H), 7.29 (t, J = 7.4 Hz, 1H), 6.99 
(dd, J = 8.4, 2.0 Hz, 1H), 5.04 (d, J = 6.7 Hz, 2H), 4.81 (d, J = 6.7 Hz, 2H), 2.63 (d, J = 2.0 Hz, 
3H), 2.58 (d, J = 2.1 Hz, 3H). 13C NMR (176 MHz, dmso) δ 169.85, 165.50, 142.99, 141.58, 
136.84, 133.69, 127.65, 127.44, 126.92, 125.26, 124.89, 124.72, 124.58, 123.78, 119.24, 109.26, 
81.88, 58.33, 14.77, 11.15. 
(Z)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-2-oxo-N-(2-phenylpropan-2-yl)indoline-
5-carboxamide (158, RAR-13-13) 
Synthesized using protocol described in 164. Yields an orange solid, 76.1 mg, 32.1%. Molecular 
Formula: C25H24N4O4 ESI-MS calc: 444.18 ESI-MS found:445.2680 [M+1]  HPLC: 7.713 1H 
NMR (700 MHz, DMSO-d6) δ 11.32 (s, 1H), 8.31 (d, J = 1.7 Hz, 1H), 8.25 (s, 1H), 7.80 (s, 1H), 
7.72 (dd, J = 8.0, 1.7 Hz, 1H), 7.42 – 7.39 (m, 2H), 7.28 (t, J = 7.8 Hz, 2H), 7.17 (t, J = 7.3 Hz, 
1H), 6.92 (d, J = 8.1 Hz, 1H), 2.61 (s, 3H), 2.57 (s, 3H), 1.70 (s, 6H). 13C NMR (176 MHz, dmso) 
δ 169.84, 165.70, 148.16, 141.11, 136.71, 133.63, 129.19, 127.83, 127.58, 125.62, 125.05, 124.73, 
124.69, 124.29, 123.61, 119.44, 119.02, 108.96, 55.31, 39.86, 39.74, 39.62, 39.50, 39.38, 39.26, 
39.14, 29.65, 14.76, 11.21. 
(R,Z)-N-(1-(4-chlorophenyl)ethyl)-3-((3,5-dimethyl-4-nitro-1H-pyrrol-2-yl)methylene)-2-
oxoindoline-5-carboxamide (159, RAR-13-17) 
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Synthesized using protocol described in 164. Yields an orange solid, 213.3 mg, 96%. Molecular 
Formula: C24H21ClN4O4 ESI-MS calc: 464.13 ESI-MS found: 465.1318 [M+1] HPLC: 7.795 1H 
NMR (500 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.65 (d, J = 7.8 Hz, 1H), 8.35 – 8.30 (m, 1H), 7.79 
(s, 1H), 7.75 (dd, J = 8.1, 1.7 Hz, 1H), 7.43 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.5 Hz, 3H), 6.94 (d, 
J = 8.1 Hz, 1H), 5.17 (p, J = 7.2 Hz, 1H), 2.62 (s, 3H), 2.57 (s, 3H), 1.49 (d, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, dmso) δ 169.83, 165.67, 144.05, 141.32, 136.76, 133.66, 131.02, 128.18, 128.10, 
128.00, 127.49, 125.11, 124.70, 124.41, 123.63, 119.35, 118.98, 109.10, 48.00, 40.00, 39.83, 
39.67, 39.50, 39.34, 39.17, 39.00, 22.07, 14.76, 11.21. 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(m-tolyl)ethyl)indoline-5-
carboxamide (168, RAR-12-68) 
To a flask were added 86.4 mg of (159), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 210.9 mg (14 equiv) of Zn powder and 2 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid. *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: red solid, 86.6 mg, 94% Molecular Formula: C25H26N4O2 ESI-
MS calc: 414.21 ESI-MS found: 415.2120 [M+1]   HPLC: 5.627 
 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(1-(4-fluorophenyl)ethyl)-2-
oxoindoline-5-carboxamide (169, RAR-12-79) 
To a flask were added 96.3 mg of (160), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 295 mg (14 equiv) of Zn powder and 2 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid. *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: red solid, 96 mg, 100% Molecular Formula: C24H23FN4O2 ESI-
MS calc: 418.18 ESI-MS found: 419.1938 [M+1]   HPLC: 5.713 
 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(pyridin-4-
yl)ethyl)indoline-5-carboxamide (170 RAR-12-80) 
To a flask were added 48.0 mg of (161), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 208 mg (14 equiv) of Zn powder and 2 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid. *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: red solid, 41.5 mg, 89% Molecular Formula: C23H23N5O2 ESI-





yl)ethyl)indoline-5-carboxamide (171, RAR-12-84) 
To a flask were added 73.9 mg of (162), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 289 mg (14 equiv) of Zn powder and 2 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid. *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: red solid, 73.8 mg, 100% Molecular Formula: C23H23N5O2 ESI-
MS calc: 401.19 ESI-MS found: 402.1450 [M+1]   HPLC: 3.920 
 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(1-(3-chlorophenyl)ethyl)-2-
oxoindoline-5-carboxamide (173, RAR-12-88) 
To a flask were added 46.0 mg of (163), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 170.1 mg (14 equiv) of Zn powder and 1.4 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid. *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: red solid, 40 mg, 95% Molecular Formula: C24H23ClN4O2 ESI-
MS calc: 434.15 ESI-MS found: 435.1569 [M+1]   HPLC: 5.556 
 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(p-tolyl)ethyl)indoline-5-
carboxamide (174 RAR-12-92) 
To a flask were added 76.1 mg of (164), dissolved in 5 mL of 2:1 EtOH/EtOAc. To this slurry 
were added 314.4 mg (14 equiv) of Zn powder and 2.0 mL (150 equiv) of AcOH. The turbid orange 
solution was allowed to stir at 50 C for 2 h. Once complete, the reaction was cooled to rt and then 
add EtOAc before basifying with sat. Na2CO3. The basified aqueous layer was extracted with 
EtOAc (3 x 30 mL) and then washed with water and brine (1 x 30 mL), respectively. The organic 
layer was dried over MgSO4 and then solvent was removed under pressure to give the desired 
product as a red solid. *Note: the free amine is very reactive, so it was moved forward without 
further characterization* Result: red solid, 220 mg, 100% Molecular Formula: C25H26N4O2 ESI-




Synthesized using protocol described in 168. Yields a red solid, 210 mg, quantitative yield. 
Molecular Formula: C23H22N4O2 ESI-MS calc: 386.17 ESI-MS found: 387.1810   HPLC: 5.129. 
 
(R,Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(2-methyl-1-phenylpropyl)-2-
oxoindoline-5-carboxamide (176, RAR-13-6) 
Synthesized using protocol described in 168. Yields a red solid, 220 mg, quantitative yield. 





yl)indoline-5-carboxamide (177, RAR-13-10) 
Synthesized using protocol described in 168. Yields a red solid, 20.6 mg, 47%. Molecular Formula: 
C25H24N4O3 ESI-MS calc: 428.18 ESI-MS found: 429.1494  HPLC: 4.710 
 
(Z)-3-((4-amino-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(2-phenylpropan-2-
yl)indoline-5-carboxamide (178, RAR-13-14) 
Synthesized using protocol described in 168. Yields a red solid, 307 mg, quantitative yield. 




oxoindoline-5-carboxamide (179, RAR-13-18) 
Synthesized using protocol described in 168. Yields a red solid, 36.1 mg, 48%. Molecular Formula: 
C24H23ClN4O2 ESI-MS calc: 434.15 ESI-MS found: 435.15612  HPLC: 5.398 
 
(R,Z)-3-((4-(2-cyanoacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-
phenylethyl)indoline-5-carboxamide (180, RAR-12-67) 
To a round bottom flask were added 20.2 mg of 141 (0.05 mmol), 6.7 mg (0.075 mmol) of 
cyanoacetic acid and 24.6 mg (0.1 mmol) of DMTMM. All materials were brought up in 2 mL of 
DMF, and the resulting solution was allowed to stir at rt for 12 h. Once complete, the reaction was 
quenched with Sat. NaCl, and extracting with EtOAc (3 x 50 mL). The organic layer was washed 
with sat. Na2CO3 and brine (1 x 50 mL) respectively and then dried over MgSO4. The solvent 
was removed under pressure, evaporating the material onto silica gel. Purified by column 
chromatography 5-100% Acetone/Hexanes. Flushed the column with 7N NH3 in MeOH to yield 
the final product as a bright orange solid. Result: orange solid, 10 mg, 43%  Molecular Formula: 
C27H25N5O3 ESI-MS calc: 467.20 ESI-MS found: 468.1297 HPLC: 6.100. 1H NMR (700 MHz, 
DMSO-d6) δ 13.51 (s, 1H), 11.08 (s, 1H), 9.52 (s, 1H), 8.60 (d, J = 8.2 Hz, 1H), 8.21 (d, J = 1.7 
Hz, 1H), 7.69 (dd, J = 8.1, 1.7 Hz, 1H), 7.65 (s, 1H), 7.41 (d, J = 7.7 Hz, 2H), 7.33 (t, J = 7.6 Hz, 
3H), 7.22 (t, J = 7.3 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 5.19 (p, J = 7.2 Hz, 1H), 3.88 (s, 2H), 2.20 
(dd, J = 12.9, 10.8 Hz, 6H), 1.50 (d, J = 7.1 Hz, H). 13C NMR (499 MHz, DMSO-d6) δ 170.92, 
130.6, 129.23, 128.8, 127.2, 126.2, 125.48, 123.25, 122.22, 118.36, 109.03, 50.20, 25.49, 22.99, 
12.52, 9.63 (derived from HSQC, so quaternary carbons are missing: 168.2, 167.5, 154.1, 120.1, 
144.8, 141.5)  
 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(m-
tolyl)ethyl)indoline-5-carboxamide (181 RAR-12-69) 
To a dried round bottom flask were added 86.6 mg of 168, (0.209 mmol) dissolved in 3 mL of 
THF. The yellow solution was cooled to 0 °C and 0.04 mL (0.30 mmol) of chloroacetylchloride 
was added dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, 
quenched with water and extracted with EtOAc. The solvent was removed, and the crude material 
was purified by prep plate (50% Acetone/Hexanes) collecting the major product. The desired 
product was rinsed off of silica gel and then the solvent was removed to give a bright yellow solid. 
The yellow solid was washed with DCM and sonicated to give a red solid. The red solid was then 
pulped in water:acetone (30:1) to give the final product. Result: red solid, 57.2 mg, 55%  Molecular 
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Formula: C27H27ClN4O3 ESI-MS calc: 490.18 ESI-MS found: 491.1133  HPLC: 6.68 1H NMR 
(500 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.07 (s, 1H), 9.53 (s, 1H), 8.56 (d, J = 8.1 Hz, 1H), 8.21 
(s, 1H), 7.74 – 7.62 (m, 2H), 7.24 – 7.15 (m, 4H), 7.03 (s, 1H), 6.93 (d, J = 8.0 Hz, 1H), 5.15 (s, 
1H), 4.26 (s, 2H), 2.30 (s, 3H), 2.20 (d, J = 8.9 Hz, 6H), 1.49 (d, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, dmso) δ 170.18, 169.06, 166.24, 165.84, 145.51, 140.80, 137.63, 132.18, 128.59, 128.10, 
127.62, 127.24, 126.26, 125.83, 124.93, 123.68, 121.47, 117.93, 113.45, 109.13, 48.80, 43.22, 
22.79, 21.62, 12.15, 9.70. 
 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(1-(4-
fluorophenyl)ethyl)-2-oxoindoline-5-carboxamide (182, RAR-12-81) 
To a dried round bottom flask were added 96.0 mg of 169, (0.23 mmol) dissolved in 4 mL of THF. 
The yellow solution was cooled to 0 °C and 0.02 mL (0.25 mmol) of chloroacetylchloride was 
added dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, 
quenched with water and extracted with EtOAc. The solvent was removed, and the crude material 
was purified by prep plate (50% Acetone/Hexanes) collecting the major product. The desired 
product was rinsed off of silica gel and then the solvent was removed to give a bright yellow solid. 
The yellow solid was washed with DCM and sonicated to give a red solid. The red solid was then 
pulped in water:acetone (30:1) to give the final product. Result: red solid, 46.5 mg, 41% Molecular 
Formula: C26H24FClN4O3 ESI-MS calc: 494.15 ESI-MS found: 495.0480 [M+1]  HPLC: 6.439 1H 
NMR (700 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.08 (s, 1H), 9.54 (s, 1H), 8.63 (d, J = 7.9 Hz, 1H), 
8.23 (d, J = 1.7 Hz, 1H), 7.68 (dd, J = 8.1, 1.8 Hz, 1H), 7.66 (s, 1H), 7.46 – 7.43 (m, 2H), 7.15 (tt, 
J = 9.9, 3.2 Hz, 3H), 6.93 (d, J = 8.2 Hz, 1H), 5.19 (p, J = 7.2 Hz, 1H), 4.28 – 4.26 (m, 4H), 2.20 
(d, J = 10.1 Hz, 6H), 1.50 (d, J = 6.9 Hz, 4H). 13C NMR (176 MHz, dmso) δ 170.20, 169.07, 
166.36, 165.86, 162.12, 160.75, 141.78, 141.76, 140.85, 132.22, 128.54, 128.49, 128.41, 128.02, 
127.42, 126.27, 125.87, 124.96, 124.70, 121.50, 117.90, 115.38, 115.26, 113.44, 109.15, 48.33, 
43.23, 41.97, 40.37, 40.25, 40.13, 40.01, 39.89, 39.77, 39.65, 36.07, 29.51, 22.78, 12.16, 9.72. 
 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(pyridin-4-
yl)ethyl)indoline-5-carboxamide (183, RAR-12-82) 
To a dried round bottom flask were added 41.5 mg of 170, (0.103 mmol) dissolved in 2 mL of 
THF. The yellow solution was cooled to 0 °C and 0.01 mL (0.103 mmol) of chloroacetylchloride 
was added dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, 
quenched with water and extracted with EtOAc. The solvent was removed, and the crude material 
was purified by prep plate (50% Acetone/Hexanes) collecting the major product as the desired 
product. Result: red solid, 6.3 mg, 13% Molecular Formula: C25H24ClN5O3 ESI-MS calc: 477.16 
ESI-MS found: 478.1734 [M+H]  HPLC: 4.363 1H NMR (700 MHz, DMSO-d6) δ 13.51 (s, 1H), 
11.15 (s, 1H), 10.56 (s, 1H), 9.86 (s, 1H), 8.73 (s, 1H), 8.48 (s, 2H), 7.75 (s, 1H), 7.72 (d, J = 7.9 
Hz, 1H), 7.34 (d, J = 7.6 Hz, 2H), 7.27 (s, 1H), 6.96 (d, J = 7.9 Hz, 1H), 5.33 (t, J = 7.0 Hz, 1H), 
4.27 (s, 2H), 2.21 (s, 6H), 1.50 (d, J = 7.8 Hz, 3H). 13C NMR (176 MHz, dmso) δ 168.53, 166.49, 
165.34, 154.01, 141.60, 140.65, 130.38, 129.30, 129.05, 127.97, 124.37, 123.04, 122.68, 121.09, 
119.53, 118.36, 108.73, 54.90, 42.72, 21.66, 10.38, 8.77. 
 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(pyridin-2-
yl)ethyl)indoline-5-carboxamide (184, RAR-12-85) 
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To a dried round bottom flask were added 73.8 mg of 171, (0.18 mmol) dissolved in 4 mL of THF. 
The yellow solution was cooled to 0 °C and 0.04 mL (0.50 mmol) of chloroacetylchloride was 
added dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, 
removed solvent under pressure and then added DCM to the dark red residue. The DCM solution 
was sonicated to give a dark red precipitate. The solid was filtered off and rinsed with THF and 
DCM to give the desired product as a dark red solid. Result: red solid, 37.1 mg, 42%  Molecular 
Formula: C25H24ClN5O3 ESI-MS calc: 477.16 ESI-MS found: 478.1547 [M+1]  HPLC: 4.743  1H 
NMR (700 MHz, DMSO-d6) δ 13.28 (t, J = 13.6 Hz, 1H), 11.02 (q, J = 7.5, 5.9 Hz, 1H), 9.86 (s, 
1H), 8.98 (d, J = 52.4 Hz, 1H), 8.57 (d, J = 9.4 Hz, 1H), 8.42 (d, J = 9.4 Hz, 1H), 8.26 (q, J = 9.9, 
9.4 Hz, 2H), 7.86 (d, J = 11.1 Hz, 1H), 7.64 (s, 2H), 7.58 (d, J = 9.2 Hz, 1H), 7.50 (dt, J = 27.4, 
8.6 Hz, 1H), 6.72 (p, J = 8.1 Hz, 1H), 5.23 – 5.16 (m, 1H), 4.03 (t, J = 8.6 Hz, 1H), 2.92 (d, J = 
16.9 Hz, 14H), 2.26 (d, J = 10.2 Hz, 7H), 2.17 (dt, J = 18.1, 8.8 Hz, 4H), 1.97 (q, J = 8.9 Hz, 2H), 
1.48 – 1.40 (m, 3H). 13C NMR (176 MHz, dmso) δ 169.75, 166.56, 165.36, 159.41, 145.67, 
142.08, 141.13, 140.72, 131.91, 128.62, 127.17, 126.78, 126.44, 125.11, 124.85, 124.26, 123.99, 
121.10, 118.54, 52.68, 42.73, 20.48, 11.23, 8.81. 
 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(1-(3-
chlorophenyl)ethyl)-2-oxoindoline-5-carboxamide (185, RAR-12-89) 
To a dried round bottom flask were added 40 mg of 172, (0.16 mmol) dissolved in 4 mL of THF. 
The yellow solution was cooled to 0 °C and 0.01 mL (0.18 mmol) of chloroacetylchloride was 
added dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, 
removed solvent under pressure and then added DCM to the dark red residue. The DCM solution 
was sonicated to give a dark red precipitate. The solid was filtered off and rinsed with THF and 
DCM to give the desired product as a dark red solid. Result: red solid, 23.4 mg, 28% Molecular 
Formula: C26H24Cl2N4O3 ESI-MS calc: 510.12 ESI-MS found: 511.1579 [M+1]  HPLC: 6.742 1H 
NMR (500 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.09 (s, 1H), 9.53 (s, 1H), 8.66 (d, J = 7.9 Hz, 1H), 
8.21 (d, J = 1.7 Hz, 1H), 7.68 (dd, J = 8.2, 1.7 Hz, 1H), 7.66 (s, 1H), 7.47 – 7.45 (m, 1H), 7.38 – 
7.36 (m, 2H), 7.29 (dq, J = 6.2, 2.2 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 5.17 (p, J = 7.2 Hz, 1H), 
4.26 (s, 2H), 2.20 (d, J = 8.6 Hz, 6H), 1.50 (d, J = 7.1 Hz, 4H). 13C NMR (126 MHz, dmso) δ 
169.51, 165.17, 147.64, 140.23, 132.71, 131.57, 129.96, 127.20, 126.77, 126.30, 125.79, 125.55, 
125.23, 124.73, 124.28, 120.82, 117.27, 112.71, 48.03, 42.55, 39.83, 39.67, 39.50, 39.33, 39.17, 
39.00, 38.83, 21.96, 11.48, 9.02. 
 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(1-(p-
tolyl)ethyl)indoline-5-carboxamide (186, RAR-12-93) 
To a dried round bottom flask were added 93 mg of 173, (0.19 mmol) dissolved in 5 mL of THF. 
The yellow solution was cooled to 0 °C and 0.1 mL (1.3 mmol) of chloroacetylchloride was added 
dropwise. The solution was allowed to stir at 0 °C for 30 mins. Once complete by TLC, removed 
solvent under pressure and then added DCM to the dark red residue. The DCM solution was 
sonicated to give a dark red precipitate. The solid was filtered off and rinsed with THF and DCM 
to give the desired product as a dark red solid. Result: red solid, 73.6 mg, 77% Molecular Formula: 
C27H27ClN4O3 ESI-MS calc: 490.18 ESI-MS found 473.05 [M-Cl]  HPLC: 6.625 1H NMR (500 
MHz, DMSO-d6) δ 13.51 (s, 1H), 11.06 (s, 1H), 9.52 (s, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.20 (s, 
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1H), 7.71 – 7.65 (m, 1H), 7.64 (s, 1H), 7.27 (t, J = 10.7 Hz, 4H), 7.12 (d, J = 7.8 Hz, 6H), 6.92 (d, 
J = 8.1 Hz, 1H), 5.18 – 5.12 (m, 2H), 2.26 (d, J = 3.9 Hz, 8H), 1.48 (d, J = 7.1 Hz, 5H).  
 
(Z)-3-((4-(3-chloro-2-hydroxypropanamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-
((R)-1-phenylethyl)indoline-5-carboxamide (187 RAR-12-95) 
To a round bottom flask were added 80 mg of 168 (0.20 mmol), 31.1 mg (0.26 mmol) of 3-chloro-
2-hydroxypropionic acid and 81.8 mg (0.32 mmol) of DMTMM. All materials were brought up in 
2 mL of DMF, and the resulting solution was allowed to stir at rt for 12 h. Once complete, the 
reaction was quenched with Sat. NaCl, and extracting with EtOAc (3 x 50 mL). The organic layer 
was washed with sat. Na2CO3 and brine (1 x 50 mL) respectively and then dried over MgSO4. 
The solvent was removed under pressure, evaporating the material onto silica gel. Purified by 
column chromatography 5-100% Acetone/Hexanes. Result: orange solid, 72.8 mg, 58% Molecular 
Formula: C27H27ClN4O4 ESI-MS calc: 506.17 ESI-MS found: 507.1809 [M+1], 540.2377 
[M+H+MeOH] HPLC: 6.043 1H NMR (700 MHz, DMSO-d6) δ 13.58 – 13.42 (m, 1H), 11.07 (d, 
J = 4.9 Hz, 1H), 8.60 (d, J = 8.1 Hz, 1H), 8.23 – 8.19 (m, 1H), 7.95 (s, 1H), 7.69 – 7.67 (m, 1H), 
7.64 (d, J = 5.9 Hz, 1H), 7.41 (d, J = 7.2 Hz, 2H), 7.33 (t, J = 7.1 Hz, 3H), 7.22 (t, J = 7.2 Hz, 1H), 
6.93 (dt, J = 8.2, 2.1 Hz, 1H), 5.19 (p, J = 7.3 Hz, 1H), 3.96 (d, J = 7.9 Hz, 1H), 3.74 (s, 1H), 2.21 
– 2.18 (m, 4H), 2.16 (s, 2H), 1.50 (d, J = 7.0 Hz, 3H). 13C NMR (176 MHz, dmso) δ 172.44, 
166.31, 162.74, 145.53, 128.63, 127.95, 126.94, 126.54, 125.88, 124.64, 121.80, 117.71, 115.92, 
109.07, 107.36, 55.41, 48.82, 22.73, 21.51, 9.74. 
(Z)-3-((3,5-dimethyl-4-(oxirane-2-carboxamido)-1H-pyrrol-2-yl)methylene)-2-oxo-N-((R)-1-
phenylethyl)indoline-5-carboxamide (188 RAR-12-96) 
To a flask were added 36.4 mg of RAR-12-95, and 47.2 mg of K2CO3. All materials were brought 
up in 3.0 mL of Acetone and then refluxed (60 C) for 30 mins. Cooled to rt and then checked by 
TLC, not complete, so run for another 60 mins. HPLC confirms still not done. MS looks like 
mostly the starting material. Heated up to 70 C for another 1 h, TLC shows it’s not complete. So 
added cat. KI and heated back up to 70 C for 45 mins. Cooled to rt and check again by TLC/HPLC. 
Not complete (even after o/n run --> 76% complete) Added 2 more equiv of KI and 1 mL of MeCN 
(to solubilize) and then heated back to 70 C, after 1 h, if not complete, work up and try to isolate. 
Quenched with water (1 x 30 mL) and then extracted with EtOAc (2 x 25 mL). Dried over Na2SO4 
and then purified by column chromatography 25-100% Acetone/Hexanes Collected F19-23 as the 
potential product and F24-31 as the starting material. Double check by MS before NMR Result: 
yellow residue, 3.0 mg, 6% Molecular Formula: C27H26ClN4O4 ESI-MS calc: 470.20 ESI-MS 
found: 471.2158  [M+1]    HPLC: 6.591 1H NMR (700 MHz, Acetone-d6) δ 13.62 (s, 1H), 10.01 
(s, 1H), 8.24 – 8.22 (m, 2H), 7.83 (d, J = 8.3 Hz, 1H), 7.75 (dt, J = 8.1, 2.2 Hz, 1H), 7.69 (s, 1H), 
7.46 (d, J = 8.0 Hz, 3H), 7.33 (t, J = 7.7 Hz, 3H), 7.23 (t, J = 7.3 Hz, 1H), 6.99 (dd, J = 8.3, 5.5 Hz, 
1H), 5.33 (q, J = 7.3 Hz, 2H), 3.91 (s, 2H), 3.79 (s, 2H), 2.30 (s, 2H), 2.25 (d, J = 2.7 Hz, 3H), 2.19 
(d, J = 5.5 Hz, 2H), 2.14 (d, J = 5.1 Hz, 3H), 1.56 (dd, J = 7.1, 1.3 Hz, 3H). 13C NMR (126 MHz, 
dmso) δ 171.84, 169.70, 167.77, 152.56, 145.07, 140.26, 132.32, 128.18, 127.58, 127.45, 126.50, 




phenylethyl)indoline-5-carboxamide (189 RAR-12-98) 
To a round bottom flask were added 83.7 mg of 142 (0.21 mmol), 60.1 mg (0.41 mmol) of 
bromoacetic acid and 100 mg (0.25 mmol) of DMTMM. All materials were brought up in 2 mL 
of DMF, and the resulting solution was allowed to stir at rt for 1.5 h. Once complete, the reaction 
was quenched with brine and then extracted with EtOAc (3 x 20 mL). The combined organic layer 
was dried over Na2SO4 and then solvent was removed under pressure to give a dark orange solid. 
The solid was then dissolved in DCM, and the resultant solution was sonicated to give a dark red 
precipitate. The solid was filtered off and rinsed with excess cold DCM to give the final product.  
Result: red solid, 42.9 mg, 39%. Molecular Formula: C26H25BrN4O3 ESI-MS calc: 520.11 ESI-MS 
found: 523.1164 HPLC: 6.397 1H NMR (700 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.08 (s, 1H), 
9.60 (s, 1H), 8.60 (d, J = 7.9 Hz, 1H), 8.21 (d, J = 1.6 Hz, 1H), 7.69 (dd, J = 8.1, 1.7 Hz, 1H), 7.65 
(s, 1H), 7.41 (d, J = 7.7 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 6.93 (d, J = 8.1 
Hz, 1H), 5.20 (p, J = 7.2 Hz, 1H), 4.03 (s, 2H), 2.20 (d, J = 10.4 Hz, 6H), 1.51 (d, J = 7.0 Hz, 3H). 
13C NMR (176 MHz, dmso) δ 169.68, 165.82, 165.54, 145.05, 140.30, 131.64, 128.15, 127.59, 
126.78, 126.47, 126.07, 125.76, 125.33, 124.44, 124.13, 121.01, 117.35, 112.95, 108.62, 48.34, 
29.33, 22.26, 11.61, 9.14. 
(Z)-N-benzyl-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxoindoline-
5-carboxamide (RAR-13-3, 273561, 190) 
Synthesized using protocol described in 143. Yields an orange solid, 18.2 mg, 21%. Molecular 
Formula: C25H23ClN4O3 ESI-MS calc: 462.15 ESI-MS found: 463.1529 [M+1] HPLC: 6.177. 1H 
NMR (700 MHz, DMSO-d6) δ 13.49 (s, 1H), 11.08 (s, 1H), 9.52 (s, 1H), 8.85 (dt, J = 12.4, 6.1 
Hz, 1H), 8.26 (d, J = 1.7 Hz, 1H), 7.78 (d, J = 9.4 Hz, 1H), 7.71 (dd, J = 8.2, 1.7 Hz, 1H), 7.64 (s, 
1H), 7.35 – 7.32 (m, 4H), 7.24 (tt, J = 6.2, 3.0 Hz, 2H), 6.94 (d, J = 8.1 Hz, 1H), 4.51 (d, J = 6.0 
Hz, 2H), 4.26 (s, 2H), 2.21 (s, 3H), 2.18 (s, 3H). 13C NMR (176 MHz, dmso) δ 170.18, 166.91, 
165.85, 140.89, 140.42, 132.22, 128.74, 128.72, 128.70, 127.98, 127.78, 127.68, 127.67, 127.62, 
127.38, 127.15, 126.21, 125.93, 124.95, 124.54, 123.95, 121.48, 117.63, 113.41, 109.28, 68.98, 
56.32, 43.22, 43.09, 43.03, 40.37, 40.25, 40.13, 40.01, 39.89, 39.77, 39.65, 36.08, 32.59, 30.08, 
12.14, 11.67, 9.92, 9.65. 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(2-methyl-1-
phenylpropyl)-2-oxoindoline-5-carboxamide (RAR-13-7, 273562, 191) 
Synthesized using protocol described in 143. Yields an orange solid, 5.5 mg, 5.8%. Molecular 
Formula: C28H29ClN4O3 ESI-MS calc: 504.19 ESI-MS found: 505.1997  HPLC: 6.803 1H NMR 
(700 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.06 (s, 1H), 9.52 (s, 1H), 8.53 (d, J = 8.9 Hz, 1H), 8.14 
(d, J = 1.6 Hz, 1H), 7.67 – 7.62 (m, 2H), 7.43 – 7.40 (m, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 
7.3 Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 4.69 (t, J = 9.2 Hz, 1H), 4.26 (s, 2H), 2.20 (d, J = 10.3 Hz, 
6H), 1.04 (d, J = 6.6 Hz, 4H), 0.73 (d, J = 6.7 Hz, 4H). 13C NMR (126 MHz, dmso) δ 170.14, 
166.69, 165.80, 151.43, 143.78, 140.68, 132.14, 128.47, 128.45, 127.89, 127.78, 127.38, 127.05, 




(3-phenyloxetan-3-yl)indoline-5-carboxamide (RAR-13-11, 273563, 192) 
Synthesized using the protocol described in 143 Yields a red solid, 5.0 mg, 21%. Molecular 
Formula: C27H25ClN4O4 ESI-MS calc: 504.16 ESI-MS found: 505.1619  HPLC: 5.332 1H NMR 
(700 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.28 (s, 1H), 9.54 (d, J = 13.2 Hz, 1H), 8.43 (s, 1H), 7.84 
(s, 2H), 7.77 (d, J = 13.4 Hz, 2H), 7.52 (t, J = 9.1 Hz, 4H), 7.39 (dt, J = 14.7, 7.8 Hz, 5H), 7.31 
(dd, J = 16.7, 7.7 Hz, 3H), 7.19 (s, 1H), 7.11 (s, 1H), 7.04 (s, 2H), 4.85 (d, J = 9.0 Hz, 2H), 4.45 
(t, J = 9.9 Hz, 2H), 4.27 (d, J = 3.1 Hz, 2H), 2.22 (d, J = 4.8 Hz, 6H). 13C NMR (126 MHz, dmso) 
δ 170.16, 167.57, 165.90, 154.45, 143.80, 130.21, 129.17, 129.09, 129.04, 128.64, 126.55, 126.07, 
125.78, 125.47, 125.31, 122.08, 121.39, 120.35, 115.60, 110.34, 78.59, 72.40, 43.21, 11.78, 9.23. 
(Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(2-
phenylpropan-2-yl)indoline-5-carboxamide (RAR-13-15, 273564, 193) 
Synthesized using the protocol described in 143. Yields a brown solid, 14.2 mg, 15%. Molecular 
Formula: C27H27ClN4O3 ESI-MS calc: 490.18 ESI-MS found: 491.1832 [M+1], 513.1656 
[M+Na]  HPLC: 6.63. 1H NMR (500 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.06 (s, 1H), 9.53 (s, 
1H), 8.24 (s, 1H), 8.19 (d, J = 1.8 Hz, 1H), 7.68 (s, 1H), 7.64 (dd, J = 8.1, 1.7 Hz, 1H), 7.40 (dd, J 
= 7.9, 1.8 Hz, 3H), 7.28 (t, J = 7.8 Hz, 2H), 7.16 (dd, J = 8.3, 6.3 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 
4.26 (s, 2H), 2.20 (d, J = 8.2 Hz, 6H), 1.69 (s, 6H). 13C NMR (126 MHz, dmso) δ 170.12, 166.37, 
165.75, 148.67, 143.56, 140.59, 132.03, 128.86, 128.24, 127.26, 126.00, 125.65, 125.11, 124.86, 
124.66, 121.37, 117.90, 108.94, 55.69, 43.14, 30.13, 12.07, 9.61. 
(R,Z)-3-((4-(2-chloroacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(1-(4-
chlorophenyl)ethyl)-2-oxoindoline-5-carboxamide (RAR-13-19, 273583, 194) 
Synthesized using the protocol described in 143. Yields a brown solid, 43.5 mg, 100%. Molecular 
Formula: C26H24Cl2N4O3 ESI-MS calc: 510.12 ESI-MS found: 511.12917 [M+1]  HPLC: 6.723. 
1H NMR (499 MHz, DMSO-d6) δ 13.52 (s, 1H), 11.08 (d, J = 7.8 Hz, 1H), 9.53 (s, 1H), 8.64 (dd, 
J = 7.9, 5.3 Hz, 2H), 8.20 (d, J = 1.5 Hz, 1H), 7.67 (dt, J = 8.0, 2.1 Hz, 2H), 7.65 (s, 1H), 7.44 – 
7.40 (m, 4H), 7.40 – 7.37 (m, 5H), 6.93 (d, J = 8.1 Hz, 1H), 5.16 (dq, J = 13.7, 7.0 Hz, 1H), 4.26 
(d, J = 2.8 Hz, 2H), 2.20 (d, J = 8.4 Hz, 6H), 1.49 (d, J = 7.1 Hz, 3H). 13C NMR (126 MHz, dmso) 
δ 170.31, 169.68, 165.92, 165.35, 144.15, 140.36, 131.73, 130.99, 128.11, 128.01, 127.44, 126.92, 
126.09, 125.76, 125.35, 124.44, 123.36, 122.09, 121.43, 120.99, 120.43, 117.37, 108.64, 55.81, 
42.72, 22.10, 11.65, 9.21. 
(R,Z)-3-((4-(2-bromoacetamido)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-N-(1-(4-
fluorophenyl)ethyl)-2-oxoindoline-5-carboxamide (195, RAR-13-26, CCG-359090) 
This material was prepared using the protocol described for 143. Yields a bright orange solid, 13.7 
mg, 23%. HRMS: 541.1106 [M+1, Br81], HPLC: 6.449. 1H NMR (700 MHz, DMSO-d6) δ 13.52 
(s, 1H), 11.08 (s, 1H), 9.60 (s, 1H), 8.61 (d, J = 8.1 Hz, 1H), 8.20 (s, 1H), 7.68 (d, J = 8.4 Hz, 1H), 
7.65 (s, 1H), 7.44 (t, J = 4.8 Hz, 2H), 7.17 – 7.13 (m, 2H), 6.93 (dd, J = 8.2, 2.5 Hz, 1H), 5.19 (q, 
J = 7.4 Hz, 1H), 4.26 (d, J = 2.4 Hz, 1H), 4.03 (d, J = 2.4 Hz, 1H), 2.22 – 2.18 (m, 6H), 1.51 – 1.48 
(m, 3H).  13C NMR (176 MHz, dmso) δ 170.07, 167.64, 166.24, 162.00, 155.00, 144.70, 140.72, 
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132.05, 129.71, 128.41, 127.92, 124.56, 122.76, 121.42, 117.77, 115.96, 115.26, 109.01, 48.19, 
29.73, 22.66, 12.01, 9.54. 
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Chapter 5. Future Directions in the Age of Covalent GRK5 Inhibitors 
5.1 Expanding the SAR of the Indolinone Scaffold Could Offer New Insights 
Herein, is described the current efforts towards making selective GRK5 inhibitors using a covalent 
strategy. It was proven that the indolinone scaffold, featured in CCG-273220, offers exceptional 
GRK5 affinity and selectivity. Additionally, the best pendants for the free phenyl ring, the benzylic 
position and the appropriate stereochemistry at the benzylic position were determined. These 
efforts are a strong start but there is still much that could be done. First, the SAR around the pyrrole 
linker and a combination of the SAR strategies for the other pendants has yet to be explored.  
 As this series has been developed to provide SAR around the phenyl ring and the benzylic 
positions, a combination strategy can be used to explore subtle synergistic effects. CCG-273563 
and CCG-273564 were designed to address the potential metabolic liability of the benzylic 
position. GRK5 seems to prefer para pendants on the phenyl ring (as seen in CCG-273441, CCG-
273443, and CCG-273583), thus by combining a benzylic pendant from CCG-273563 or CCG-
273564 and one of the para pendants a greater level of activity could be achieved (Figure 5.1). As 
the 4-fluoro and 4-pyridyl pendants (273441 and 273423 respectively) have the best level of 
activity, these pendants serve as a good starting point for the next SAR campaign. 
 To further expand the SAR of this series, the pyrrole linker can be explored to understand 
the importance of the pseudo-seven membered ring on activity and solubility. The initial lead 
 
Figure 5.1 Design analogues which demonstrate a combined strategy for blocking metabolism and maintaining high levels of 
affinity for GRK5. Additional analogues can be designed but are not shown.  
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compound, Sunitinib, contains this same pseudo-seven membered ring, and it has been suggested 
that this locked conformation leads to less isomerization, and more exposure to the active isomer 
of the compound.1,2 In order to validate this principal, other heterocycles could replace the pyrrole 
linker leading to either a loss of the pseudo-seven membered ring, or a weaker intramolecular 
interaction. Additionally, the 3-methyl and 5-methyl pendants can be removed from the pyrrole 
linker, as these too may be contributing to the overall locked conformation (Figure 5.2).3,4 This 
strategy provides a number of diverse new compounds which may not have a loss in activity, as 
our model suggests this linker is solvent exposed and therefore may not be critical to binding 
affinity. Such an SAR campaign would greatly expand the arsenal of GRK5 covalent selective 
compounds and facilitate elucidating the role of GRK5 in various disease states.  
  Perhaps one of the most interesting routes this project could take would be to explore 
reversibly covalent warheads. This idea was initially proposed in Chapter 2 but was not pursued 
due to the lack of potency of the initial pyrrolopyrimidine series. It is generally understood that 
the compounds carrying reversible covalent warheads need to have a high affinity for GRK5, as 
the experimental design dictates that such compounds undergo a “wash out” phase.5,6 With 
insufficient binding, the compounds could be washed out of the experiment before the covalent 
interaction can take place. However, the development of the indolinone scaffold offers a second 
chance at this avenue. So far, only one reversible covalent compound has been made, CCG-273240 
(GRK5 IC50 = 250 nM). In initial mass spectrometry experiments, this compound was found to be 
non-covalent. However, this result is inconclusive because it cannot be determined whether or not 
the covalent interaction has not happened, or whether it has happened and then the reversible 
 
Figure 5.2 Pseudo-seven membered ring shown in the structure on the left. This pseudo-ring is what confers 
conformational restriction and stability to the inhibitors. To the right, compounds designed with various heterocyclic 
linkers. Some linkers can maintain the pseudo-seven membered ring, while others no longer have the hydrogen bond 
donor which allows the formation of this pseudo ring. Additional inhibitors can be designed with the pendants used 
in developing the SAR campaign in Chapter 4.  
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disconnection has also occurred. In order to determine this, a wash-out experiment must be 
performed. As this wash-out experiment is highly dependent on the Kon rate of the compound, a 
longer incubation for the initial covalent interaction will be needed. From the experiments with 
CCG-273182, it can be assumed that the incubation time will need to be around 3 h.  
 Recently, there has been a large amount of work concerning how to make tunable reversible 
covalent inhibitors.7,8 It is envisioned that this work could be translated to the indolinone series. 
Taunton et. al. have been able to develop a series of reversible warheads, that have demonstrated 
the ability to bind, and then come off the target residue with an increased residence time. It is 
possible to make a series of indolinones that contain these warheads, and have the optimized 
pendants explored in the initial campaign (Chapter 4). These reversible warheads would offer an 
avenue to avoid the potentially toxic side reactions that could arise from the reactive chloroketone 
warhead. Additionally, as the turnover time of GRK5 is not known, having an inhibitor with 
tunable residence time will provide another avenue to adequate inhibitor exposure if the turnover 
of GRK5 proves to be shorter than 24 h.  Initially, there will have to be two classes of reversible 
warheads, as it is unknown whether an aliphatic or aromatic branch will be most beneficial for this 
series of inhibitors (Figure 5.3). Pleasingly, these compounds can be accessed through a common 
advanced intermediate, making rapid expansion of the series viable.  
 These new compounds can then be tested within the washout experiment parameters 
determined by Taunton et. al. to develop an understanding of how this strategy applies to GRK5 
inhibitors. For further ways to avoid metabolic liability, it is envisioned that the strategy applied 
 
Figure 5.3 Reversible covalent inhibitor, CCG-273240, and designed analogues. A variety of pendants will 
need to be explored to gather an understanding variability of residence times for these analogues. Pendants are 




to the indazole series, from which CCG-215022 is derived, can be applied to the indolinone series. 
In a new series of compounds, a fluorine walk can be performed around the indolinone ring, to 
limit metabolic liabilities on the core scaffold. The inclusion of the pendants from the initial SAR 
of the indazole series can further limit the metabolic liability of both the phenyl pendant and the 
benzylic position. However, metabolic stability cannot be so high as to prevent clearance of the 
compounds altogether. Rather, designed analogues must strike a balance between exposure and 
clearance to avoid cytotoxicity. As these inhibitors feature highly reactive warheads, limited 
cellular exposure is desired, as hitting multiple side targets can produce undesirable 
pharmacokinetic effects. Thus,  only 1-2 metabolic strategies should be applied to avoid high 
cellular exposure, while also ensuring the inhibitors are not rapidly cleared thereby limiting 
efficacy. 
 Ultimately, this new series can give rise to a new arsenal of GRK5 selective inhibitors that 
feature warheads of variable reactivity and residence time. Once this has been achieved, additional 
biological assays can be performed to better understand the role of GRK5 in multiple disease states. 
This initial work will set a template for further work on GRK5 and indeed other kinase targets for 
which isoform selectivity remains a challenge.   
5.2 Combining Linkers and Covalent Warheads can Rapidly Expand the Current Arsenal 
As was laid out in the previous section, there are numerous ways to tune the residence time of a 
targeted covalent inhibitor, using reversible covalent warheads. While this is a valid approach, 
there are ways to tune the residence time of a targeted covalent inhibitor (TCI) through the use of 
irreversible warheads. Indeed, there have been numerous examples of FDA approved TCIs since 
the 1960s (although some compounds were not known to covalent at the time of approval). Perhaps 
one of the most interesting ways to introduce new warheads and linkers to the indolinone scaffold 
 
Figure 5.4 New analogues which possess a linker with a covalent element already in place.  
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is to combine the two elements together to form one linker, with a covalent element present. 
Examples of this approach are chloro-heterocyles and vinyl-heterocycles. Both use a different type 
of covalent engagement (SNAr vs. Michael Addition, respectively), and have been used in various 
other examples of developing TCIs. In this case, the vinyl heterocycles offer the unique 
opportunity to tune the residence time of an irreversible covalent inhibitor.9 By making a few 
modifications to the current synthetic route, a larger variety of indolinone TCIs can be accessed 
quickly all of which would possess unique intellectual property (Figure 5.4). 
 Other approaches could include the issue of previously developed, but synthetically 
challenging warheads. As was demonstrated previously, the vinyl sulfone in CCG-273182 can 
form a covalent engagement in 3 h. It would be interesting to see if the reactivity of the vinyl 
warheads could be increased to produce a covalent interaction within 30 min. One of the ways that 
this could be achieved would be to use the vinyl propellene warhead, which has a highly strained 
1,1,1-propellane ring.10–12 A free cysteine, Cys474 in this case, could open this highly strained 
ring, and therefore satisfy the enthalpic needs of the system, producing a rapid irreversible covalent 
engagement.  
 Additionally, using 
the information that has 
already been published by 
Ullrich and co-workers,  
redesign of covalent 
warheads to include crucial 
pieces of architecture that 
have validated activity is 
feasible. Of the options, the 
addition of a terminal amine 
appears to be the most important to include within the linker. Indeed, as demonstrated by CCG-
271421, the terminal amine plays a crucial role in not only solubility of the compound, but also 
the activity, resulting in a low nanomolar compound. A terminal amine was included within this 
series of TCIs, see CCG-273221, but was not successful in retaining the level of activity seen in 
CCG-271421. This drop in potency is attributed to the ability of the highly flexible BI warhead to 
interact with the GRK5 P-loop.  However, it is possible that the construction of a more constrained, 
 
Figure 5.5 New enamine and sulfone warheads could be used to explore how  
to tune reactivity of a covalent warhead.  
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enamine Michael acceptor could regain that level of low anomolar activity while also increasing 
the solubility of the compound. Therefore, we propose the construction of enamine Michael 
acceptor linkers, with varying degrees of flexibility and varying levels of basicity (Figure 5.5). In 
these examples, both the original amide orientation and the reversed amide orientation are possible, 
allowing for exploration of the planar requirements for covalent action in this series. Additionally, 
the reactivity of each enamine will vary with either an electron sink (ketone) or an electron donor 
(amine) available in the γ-position.  
5.3 Biological Evaluation of GRK5 Inhibitors Can Clarify Role of GRK5 in Cardiovascular 
Disease 
Initial testing of these compounds indicates that GRK5 inhibitors do not affect cardiomyocyte 
contractility in the same fashion as GRK2 inhibitors. Rather, GRK5 inhibitors directly affect Ca2+ 
transience. As this is not a known function of GRK5, additional studies to understand how this 
relationship between calcium transience and GRK5 are needed.  
5.4 Biological Evaluation of GRK5 Inhibitors Can Provide New Treatments for Cancer, and 
Neurodegenerative Diseases 
In neurodegeneration, studies have shown that GRK5 hyperexpression is a hallmark of Parkinson’s 
Disease. Meanwhile, GRK5 hypoexpression has been found to be detrimental in Alzheimer’s 
Disease studies. Thus, the indolinone series can serve as an interesting probe for Parkinson’s 
Disease. The indolinone series has not yet been designed to accommodate a central nervous system 
target, however, it is entirely possible to determine the effect of GRK5 inhibition in ex vivo studies. 
There is literature available on the effects of GRK5 genetic knockout on Parkinson’s disease 
outcomes, and these probes provide an unexplored avenue for studying genetically unaltered 
systems to continue this work.13  
Additionally, GRK5 plays an important role in migration of cancer cells, and furthermore, 
could impact the utility of currently marked cancer therapies. Sommer et. al. have shown that 
GRK5 plays a special role in the migration of breast cancer cells.14 Indeed, Sommer and coworkers 
were able to show that genetic downregulation of GRK5 hinders the migration of these cancerous 
cells. Such data indicates that these indolinone derived compounds could be used to produce a 
similar result. This effect also indicates that there could exist a synergistic effect between GRK5 
inhibitors and standard-of-care breast cancer treatments. This does appear to be the case. Lagman 
et. al. have described the effect of genetic knockdown of GRK5 on the susceptibility of triple 
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negative breast cancer cells against paclitaxel. Lagman and co-workers found that when GRK5 is 
downregulated breast cancer cells are far more susceptible to paclitaxel.15 Therefore, it is 
envisioned that CCG-273463, CCG-271423 or CCG-359090, could be used to investigate whether 
a synergistic effect does occur when taken with paclitaxel.  
5.5 Concluding Remarks 
The initial intent of this project was to develop GRK5 inhibitors for the express purpose of 
investigating the role of GRK5 in cardiovascular disease, however, this project has grown to 
encompass several fields. The utility of selective GRK5 inhibitors spans from cardiovascular 
disease to neurodegenerative disease to cancer. As selective GRK5 inhibitors have been the 
missing piece in many biological studies in the past, it is fully expected these compounds will 
serve as useful probes in various systems to help undercover the underlying mechanism of several 
diseases. Meanwhile, this campaign serves as an excellent example of how to leverage a covalent 
strategy to achieve selectivity. Additionally, this work was able to establish a new covalent handle 
outside the kinase domain, Cys474, which was previously not utilized in the kinase drug discovery 
realm.  
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